

2025

Prescription Drug Guide

NC State Health Plan Formulary

List of covered drugs or "Drug List"

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN.

42

Formulary 25800

This formulary was updated on 08/01/2025. For more recent information or other questions, please contact the NC State Health Plan Humana Customer Care Team with any questions at 1-888-700-2263 or for TTY users, 711, or visit your.humana.com/ncshp.

Humana[®]



Welcome to Humana Group Medicare Plan!

Note to existing members: This Formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this Drug List (Formulary) refers to "we," "us", or "our," it means Humana. When it refers to "plan" or "our plan," it means Humana Group Medicare Plan.

This document includes a Drug List (formulary) for our plan which is current as of August 2025. For an updated Drug List (formulary), please contact us. Our contact information, along with the date we last updated the Drug List (formulary), appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1 of each year, and from time to time during the year.

What is the Humana formulary?

In this document, we use the terms Drug List and formulary to mean the same thing. A formulary is the entire list of covered drugs or medications selected by Humana. The terms formulary and Drug List may be used interchangeably throughout communications regarding changes to your pharmacy benefits. Humana Group Medicare Plan worked with a team of doctors and pharmacists to make a formulary that represents the prescription drugs we think you need for a quality treatment program. Humana Group Medicare Plan will generally cover the drugs listed in the formulary as long as the drug is medically necessary, the prescription is filled at a Humana Group Medicare Plan network pharmacy, and other plan rules are followed. For more information on how to fill your medications, please review your Evidence of Coverage.

Can the formulary change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the formulary during the year, move them to different cost sharing tiers, or add new restrictions. We must follow Medicare rules in making these changes. Updates to the formulary are posted monthly to our website here: your.humana.com/ncshp.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **Immediate substitutions of certain new versions of brand name drugs and original biological products.** We may immediately remove a drug on our formulary if we are replacing it with a certain new version of that drug that will appear on the same or lower cost-sharing tier and with the same or fewer restrictions. When we add a new version of a drug to our formulary, we may decide to keep the brand name drug or biological product on our formulary, but immediately move it to a different cost-sharing tier or add new restrictions.

We can make these immediate changes only if we are adding a new generic version of a brand name drug, or adding certain new biosimilar versions of an original biological product, that was already on the formulary (for example, adding an interchangeable biosimilar that can be substituted for an original biological product by a pharmacy without a new prescription).

If you are currently taking the brand name drug or biological product, we may not tell you in advance before we make an immediate change, but we will later provide you with information about the specific change(s) we have made.

If we make such a change, you or your prescriber can ask us to make an exception and continue to cover for you the drug that is being changed. For more information, see the section below titled "How do I request an exception to the Humana Formulary?"

Some of these drug types may be new to you. For more information, see the section below titled "What are

original biological products and how are they related to biosimilars?"

- **Drugs removed from the market.** If a drug is withdrawn from sale by the manufacturer or the Food and Drug Administration (FDA) determines to be withdrawn for safety or effectiveness reasons, we may immediately remove the drug from our formulary and later provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may remove a brand name drug from the formulary when adding a generic equivalent or remove an original biological product when adding a biosimilar. We may also apply new restrictions to the brand name drug or original biological product, or move it to a different cost-sharing tier, or both. We may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug, or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective. Alternatively, when a member requests a refill of the drug, they may receive a 30-day supply of the drug and notice of the change.

We will notify members who are affected by the following changes to the formulary:

- When a drug is removed from the formulary.
- When prior authorization, quantity limits, or step-therapy restrictions are added to a drug or made more restrictive.
- When a drug is moved to a higher cost sharing tier.

If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the drug you have been taking. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below titled "How do I request an exception to the Humana Formulary?"

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2025 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2025 coverage year except as described above. This means these drugs will remain available at the same cost sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the formulary for the new benefit year for any changes to drugs.

What if you are affected by a Drug List change?

We will notify you by mail at least 30 days before one of these changes happens or we will provide a 30-day refill of the affected medicine with notice of the change.

The enclosed formulary is current as of August 2025. To get updated information about the drugs covered by Humana please contact us. Our contact information appears on the front and back cover pages.

How do I use the Formulary?

There are two ways to find your drug in the formulary:

Medical condition

The formulary begins on page 11. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs that treat a heart condition are listed under the category “Cardiovascular Agents.” If you know what your drug is used for, look for the category name in the list that begins on page 11. Then look under the category name for your drug. The formulary also lists the Tier and Utilization Management Requirements for each drug (see page 6 for more information on Utilization Management Requirements).

Alphabetical listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 202. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to each drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of the drug in the first column of the list.

What are generic drugs?

Humana covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs work just as well as and usually cost less than brand name drugs. There are generic drug substitutes available for many brand name drugs. Generic drugs usually can be substituted for the brand name drug at the pharmacy without needing a new prescription, depending on state laws.

What are original biological products and how are they related to biosimilars?

On the formulary, when we refer to drugs, this could mean a drug or a biological product. Biological products are drugs that are more complex than typical drugs. Since biological products are more complex than typical drugs, instead of having a generic form, they have alternatives that are called biosimilars. Generally, biosimilars work just as well as the original biological product and may cost less. There are biosimilar alternatives for some original biological products. Some biosimilars are interchangeable biosimilars and, depending on state laws, may be substituted for the original biological product at the pharmacy without needing a new prescription, just like generic drugs can be substituted for brand name drugs.

- For discussion of drug types, please see the Evidence of Coverage, Chapter 5, Section 3.1, “The ‘Drug List’ tells which Part D drugs are covered.”

Prescription drugs are grouped into one of four tiers.

Humana Group Medicare Plan covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs cost less than brand-name drugs.

- **Tier 1 - Generic or Preferred Generic:** Generic or brand drugs that are available at the lowest cost share for the plan
- **Tier 2 - Preferred Brand:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 1 Generic or Preferred Generic, and at a lower cost to you than Tier 3 Non-Preferred Drug
- **Tier 3 - Non-Preferred Drug:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 2 Preferred Brand drug
- **Tier 4 - Specialty Tier:** Some injectables and other high-cost drugs

How much will I pay for covered drugs?

The Humana Group Medicare Plan pays part of the costs for your covered drugs and you pay part of the costs, too.

The amount of money you pay depends on:

- Which tier your drug is on
- Whether you fill your prescription at a network pharmacy
- Your current drug payment stage - please read your Evidence of Coverage (EOC) for more information

If you qualified for extra help with your drug costs, your costs may be different from those described above. Please refer to your Evidence of Coverage (EOC) or call NC State Health Plan Humana Customer Care to find out what your costs are.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization (PA):** Humana Group Medicare Plan requires you to get prior authorization for certain drugs. This means that you will need to get approval from Humana Group Medicare Plan before you fill your prescriptions. If you do not get approval, Humana Group Medicare Plan may not cover the drug.
- **Quantity Limits (QL):** For certain drugs, the Humana Group Medicare Plan limits the amount of the drug that is covered. The Humana Group Medicare Plan might limit how many refills you can get or how much of a drug you can get each time you fill your prescription. For example, if it is normally considered safe to take only one pill per day for a certain drug, we may limit coverage for your prescription to no more than one pill per day. Some drugs are limited to a 30-day supply regardless of tier placement.
- **Step Therapy (ST):** In some cases, the Humana Group Medicare Plan requires that you first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, the Humana Group Medicare Plan may not cover Drug B unless you try Drug A first. If Drug A does not work for you, the Humana Group Medicare Plan will then cover Drug B.
- **Part B versus Part D (BvsD):** Some drugs may be covered under Medicare Part B or Part D, depending upon the circumstances. Information may need to be submitted to Humana that describes the use and the place where you receive and take the drug so a determination can be made.

For drugs that need prior authorization or step therapy, or drugs that fall outside of quantity limits, your health care provider can fax information about your condition and need for those drugs to Humana Group Medicare Plan at **1-877-486-2621**. Representatives are available Monday - Friday, 8 a.m. - 8 p.m. (EST).

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 11. You can also get more information about the restrictions applied to specific covered drugs by visiting **your.humana.com/ncshp**. We have posted online documents that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask Humana to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section "**How do I request an exception to the Humana Formulary?**" on page 7 for information about how to request an exception.

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact NC State Health Plan Humana Customer Care and ask if your drug is covered. For more information, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you learn that Humana Group Medicare Plan does not cover your drug, you have two options:

- You can ask NC State Health Plan Humana Customer Care for a list of similar drugs that are covered by Humana Group Medicare Plan. When you receive the list, show it to your doctor and ask them to prescribe a similar drug that is covered by Humana Group Medicare Plan.
- You can ask Humana Group Medicare Plan to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the Humana Formulary?

You can ask the Humana Group Medicare Plan to make an exception to the coverage rules. There are several types of exceptions that you can ask us to make.

- **Formulary exception:** You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- **Utilization restriction exception:** You can ask us to waive a coverage restriction including prior authorization, step therapy, or a quantity limit on your drug. For example, for certain drugs, Humana Group Medicare Plan limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.
- **Tier exception:** You can ask us to cover a formulary drug at lower cost-sharing level unless the drug is on the specialty tier. If approved, this would lower the amount you must pay for your drug.

Generally, Humana Group Medicare Plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost sharing drug, or applying the restriction would not be as effective for you and/or would cause you to have adverse effects.

You or your prescriber should contact us to ask for a tiering, or formulary exception, including an exception to a coverage restriction. **When you request an exception, your prescriber will need to explain the medical reasons why you need the exception.**

Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can ask for an expedited (fast) decision if you believe, and we agree, that your health could be seriously harmed by waiting up to 72 hours for a decision. If we agree, or if your prescriber asks for a fast decision, we must give you a decision no later than 24 hours after we get your prescriber's supporting statement.

What can I do if my drug is not on the formulary or has a restriction?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but has a coverage restriction, such as prior authorization. You should talk to your prescriber about requesting a coverage decision to show that you meet the criteria for approval, switching to an alternative drug that we cover, or requesting a formulary exception so that we will cover the drug you take. While you and your doctor determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or has a coverage restriction, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30 day supply of

medication. If coverage is not approved, after your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug unless you have a prescription written for fewer days. (in which case we will allow multiple fills to provide up to a total of 31 days of a drug) while you pursue a formulary exception.

Throughout the plan year, your treatment setting (the place where you receive and take your medicine) may change. These changes include:

- Members who are discharged from a hospital or skilled-nursing facility to a home setting
- Members who are admitted to a hospital or skilled-nursing facility from a home setting
- Members who transfer from one skilled-nursing facility to another and use a different pharmacy
- Members who end their skilled-nursing facility Medicare Part A stay (where payments include all pharmacy charges) and who now need to use their Part D plan benefit
- Members who give up Hospice Status and go back to standard Medicare Part A and B coverage
- Members discharged from chronic psychiatric hospitals with highly individualized drug regimens

For these changes in treatment settings, Humana Group Medicare Plan will cover as much as a 31-day temporary supply of a Part D-covered drug when you fill your prescription at a pharmacy. If you change treatment settings multiple times within the same month, you may have to request an exception or prior authorization and receive approval for continued coverage of your drug. Humana Group Medicare Plan will review requests for continuation of therapy on a case-by-case basis understanding when you are on a stabilized drug regimen that, if changed, is known to have risks.

Transition extension

Humana Group Medicare Plan will consider on a case-by-case basis an extension of the transition period if your exception request or appeal has not been processed by the end of your initial transition period. We will continue to provide necessary drugs to you if your transition period is extended.

A Transition Policy is available on your.humana.com/ncshp, in the same area where the Prescription Drug Guides are displayed.

CenterWell Pharmacy™

You may fill your medicines at any network pharmacy. CenterWell Pharmacy – Humana's mail-delivery pharmacy is one option. To get started or learn more, visit CenterWellPharmacy.com. You can also call CenterWell Pharmacy at **1-844-222-2151 (TTY: 711)** Monday – Friday, 8 a.m. to 11 p.m. (EST), and Saturday, 8 a.m. to 6:30 p.m. (EST).

Other pharmacies are available in our network.

For More Information

For more detailed information about your Humana Group Medicare Plan prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about Humana Group Medicare Plan, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at **1-800-MEDICARE (1-800-633-4227)** 24 hours a day, seven days a week. **TTY** users should call **1-877-486-2048**. You can also visit **www.medicare.gov**.

Humana Group Medicare Plan Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by Humana Group Medicare Plan. If you have trouble finding your drug in the list, turn to the Index that begins on page 202.

Your plan has additional coverage of some drugs. These drugs are not normally covered under Medicare Part D and are not subject to the Medicare appeals process. These drugs are listed separately on page 199.

How to read your formulary

The first column of the chart lists categories of medical conditions in alphabetical order. The drug names are then listed in alphabetical order within each category. Brand-name drugs are CAPITALIZED and generic drugs are listed in lower-case italics. Next to the drug name or Utilization Management column, you may see an indicator to tell you about additional coverage information for that drug. You might see the following indicators:

\$0 - Most vaccines and diabetic supplies covered 100% with no member cost.

DL - Dispensing Limit; Drugs that may be limited to a 30 day supply, regardless of tier placement.

MO - Drugs that are typically available through mail-order. Please contact your mail-order pharmacy to make sure your drug is available.

LA - Limited Access; The health plan has authorized certain pharmacies to dispense this medicine, as it requires extra handling, doctor coordination or patient education. Please call the number on the back of your ID card for additional information.

CI - Covered insulin products; Part D insulin products covered by your plan. For more information on cost sharing for your covered insulin products, please refer to your Evidence of Coverage.

PDS - Preferred Diabetic Supplies; BD and HTL-Droplet are the preferred diabetic syringe and pen needle brands for the plan.

The second column lists the tier of the drug. See page 5 for more details on the drug tiers in your plan.

The third column shows the Utilization Management Requirements for the drug. Humana Group Medicare Plan may have special requirements for covering that drug. If the column is blank, then there are no utilization requirements for that drug. The supply for each drug is based on benefits and whether your health care provider prescribes a supply for 30, 60, or 90 days. The amount of any quantity limits will also be in this column (Example: "QL - 30 for 30 days" means you can only get 30 doses every 30 days). See page 6 for more information about these requirements.

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ANALGESICS		
acetaminophen-caff-dihydrocod 320.5-30-16 mg CAPSULE DL	1	QL(300 per 30 days)
acetaminophen-codeine 120 mg-12 mg /5 ml (5 ml), 120-12 mg/5 ml, 300 mg-30 mg /12.5 ml SOLUTION DL	1	QL(2700 per 30 days)
acetaminophen-codeine 300-15 mg TABLET DL	1	QL(390 per 30 days)
acetaminophen-codeine 300-30 mg TABLET DL	1	QL(360 per 30 days)
acetaminophen-codeine 300-60 mg TABLET DL	1	QL(180 per 30 days)
APADAZ 4.08-325 MG, 6.12-325 MG, 8.16-325 MG TABLET DL	3	
ARTHROTEC 50 50-200 MG-MCG TABLET, IR, DR, BIPHASIC MO	3	PA
ARTHROTEC 75 75-200 MG-MCG TABLET, IR, DR, BIPHASIC MO	3	PA
ascomp with codeine 30-50-325-40 mg CAPSULE DL	1	QL(360 per 30 days)
BELBUCA 150 MCG, 300 MCG, 450 MCG, 600 MCG, 75 MCG, 750 MCG, 900 MCG FILM DL	3	ST,QL(60 per 30 days)
benzhydrocodone-acetaminophen 4.08-325 mg, 6.12-325 mg, 8.16-325 mg TABLET DL	3	
BUPRENEX 0.3 MG/ML SOLUTION DL	3	QL(240 per 30 days)
buprenorphine 10 mcg/hour, 15 mcg/hour, 20 mcg/hour, 5 mcg/hour, 7.5 mcg/hour PATCH, WEEKLY DL	1	PA,QL(4 per 28 days)
buprenorphine hcl 0.3 mg/ml SYRINGE DL	1	QL(240 per 30 days)
butorphanol 1 mg/ml SOLUTION DL	1	QL(960 per 30 days)
butorphanol 10 mg/ml SPRAY, NON-AEROSOL DL	1	QL(5 per 28 days)
butorphanol 2 mg/ml SOLUTION DL	1	QL(480 per 30 days)
BUTRANS 10 MCG/HOUR, 15 MCG/HOUR, 20 MCG/HOUR, 5 MCG/HOUR, 7.5 MCG/HOUR PATCH, WEEKLY DL	3	PA,QL(4 per 28 days)
CALDOLOR 800 MG/200 ML (4 MG/ML) PIGGYBACK MO	3	
CALDOLOR 800 MG/8 ML (100 MG/ML) RECON SOLUTION MO	3	
CAMBIA 50 MG POWDER IN PACKET DL	4	ST,QL(9 per 30 days)
CELEBREX 100 MG, 200 MG, 400 MG, 50 MG CAPSULE MO	3	PA,QL(60 per 30 days)
celecoxib 100 mg, 200 mg CAPSULE MO	1	QL(60 per 30 days)
celecoxib 400 mg, 50 mg CAPSULE MO	1	QL(60 per 30 days)
codeine sulfate 15 mg, 30 mg TABLET DL	1	QL(360 per 30 days)
codeine sulfate 60 mg TABLET DL	1	QL(180 per 30 days)
codeine-butalbital-asa-caff 30-50-325-40 mg CAPSULE DL	1	QL(360 per 30 days)
CONZIP 100 MG, 200 MG, 300 MG CAPSULE, ER, BIPHASIC DL	3	ST,QL(30 per 30 days)
DAYPRO 600 MG TABLET MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DEMEROL 50 MG/ML SOLUTION DL	3	QL(720 per 30 days)
DEMEROL (PF) 100 MG/ML SYRINGE DL	3	QL(360 per 30 days)
DEMEROL (PF) 25 MG/ML SYRINGE DL	3	QL(1440 per 30 days)
DEMEROL (PF) 50 MG/ML SYRINGE DL	3	QL(720 per 30 days)
DEMEROL (PF) 75 MG/ML SYRINGE DL	3	QL(480 per 30 days)
diclofenac epolamine 1.3 % PATCH, 12 HR. MO	1	PA,QL(60 per 30 days)
diclofenac potassium 25 mg CAPSULE MO	3	ST,QL(120 per 30 days)
diclofenac potassium 25 mg TABLET DL	4	
diclofenac potassium 50 mg POWDER IN PACKET MO	3	ST,QL(9 per 30 days)
diclofenac potassium 50 mg TABLET MO	1	
diclofenac sodium 1 % GEL MO	1	QL(1000 per 30 days)
diclofenac sodium 1.5 % DROPS MO	1	PA,QL(300 per 30 days)
diclofenac sodium 100 mg TABLET, ER 24 HR. MO	1	
diclofenac sodium 20 mg/gram /actuation(2 %) SOLUTION IN METERED DOSE PUMP DL	4	PA,QL(224 per 28 days)
diclofenac sodium 25 mg, 50 mg TABLET, DR/EC MO	1	
diclofenac sodium 75 mg TABLET, DR/EC MO	1	
diclofenac-misoprostol 50-200 mg-mcg, 75-200 mg-mcg TABLET, IR, DR, BIPHASIC MO	1	
diflunisal 500 mg TABLET MO	1	
DILAUDID 1 MG/ML LIQUID DL	3	PA,QL(2400 per 30 days)
DILAUDID 2 MG, 4 MG TABLET DL	3	PA,QL(360 per 30 days)
DILAUDID 8 MG TABLET DL	3	PA,QL(240 per 30 days)
dolobid 250 mg TABLET DL	4	ST
DOLOBID 375 MG TABLET DL	4	ST
DUEXIS 800-26.6 MG TABLET DL	4	PA,QL(90 per 30 days)
DURAMORPH (PF) 0.5 MG/ML SOLUTION DL	3	BvsD,QL(7200 per 30 days)
DURAMORPH (PF) 1 MG/ML SOLUTION DL	3	BvsD,QL(3600 per 30 days)
ec-naproxen 500 mg TABLET, DR/EC MO	3	
endocet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg TABLET DL	1	QL(360 per 30 days)
etodolac 200 mg, 300 mg CAPSULE MO	1	
etodolac 400 mg, 500 mg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
etodolac 400 mg, 500 mg, 600 mg TABLET, ER 24 HR. MO	1	
FELDENE 10 MG, 20 MG CAPSULE MO	3	
fenoprofen 400 mg CAPSULE MO	1	ST
fenoprofen 600 mg TABLET MO	1	ST
fenopron 300 mg CAPSULE DL	4	ST
fentanyl 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour PATCH. 72 HR. DL	1	QL(20 per 30 days)
fentanyl citrate 1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg LOZENGE DL	4	PA,QL(120 per 30 days)
fentanyl citrate 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg TABLET, EFFERVESCENT DL	4	PA,QL(120 per 30 days)
fentanyl citrate 200 mcg LOZENGE DL	1	PA,QL(120 per 30 days)
fentanyl citrate (pf) 50 mcg/ml SOLUTION DL	1	BvsD,QL(720 per 30 days)
FENTORA 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG TABLET, EFFERVESCENT DL	4	PA,QL(120 per 30 days)
FLECTOR 1.3 % PATCH, 12 HR. MO	3	PA,QL(60 per 30 days)
flurbiprofen 100 mg TABLET MO	1	
hydrocodone bitartrate 10 mg, 15 mg, 20 mg, 30 mg, 40 mg CAPSULE, ER 12 HR. DL	1	ST,QL(90 per 30 days)
hydrocodone bitartrate 100 mg, 120 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg TABLET, ER 24 HR. DL	1	ST,QL(30 per 30 days)
hydrocodone bitartrate 50 mg CAPSULE, ER 12 HR. DL	1	ST,QL(120 per 30 days)
hydrocodone-acetaminophen 10-300 mg, 5-300 mg, 7.5-300 mg TABLET DL	1	QL(390 per 30 days)
hydrocodone-acetaminophen 10-300 mg/15 ml SOLUTION DL	4	QL(6000 per 30 days)
hydrocodone-acetaminophen 10-325 mg, 5-325 mg, 7.5-325 mg TABLET DL	1	QL(360 per 30 days)
hydrocodone-acetaminophen 10-325 mg/15 ml, 10-325 mg/15 ml(15 ml) SOLUTION DL	1	QL(2700 per 30 days)
hydrocodone-acetaminophen 2.5-325 mg TABLET DL	1	QL(360 per 30 days)
hydrocodone-acetaminophen 7.5-325 mg/15 ml SOLUTION DL	1	QL(5520 per 30 days)
hydrocodone-ibuprofen 10-200 mg, 5-200 mg, 7.5-200 mg TABLET DL	1	QL(150 per 30 days)
HYDROMORPHONE 0.25 MG/0.5 ML SYRINGE DL	1	BvsD
hydromorphone 0.5 mg/0.5 ml, 1 mg/ml SYRINGE DL	1	BvsD,QL(720 per 30 days)
hydromorphone 1 mg/ml LIQUID DL	1	QL(2400 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
hydromorphone 1 mg/ml SOLUTION DL	1	BvsD,QL(720 per 30 days)
hydromorphone 12 mg TABLET, ER 24 HR. DL	1	ST,QL(180 per 30 days)
hydromorphone 16 mg TABLET, ER 24 HR. DL	1	ST,QL(120 per 30 days)
hydromorphone 2 mg, 4 mg TABLET DL	1	QL(360 per 30 days)
hydromorphone 2 mg/ml SOLUTION DL	1	BvsD,QL(360 per 30 days)
hydromorphone 2 mg/ml SYRINGE DL	1	BvsD,QL(360 per 30 days)
hydromorphone 32 mg TABLET, ER 24 HR. DL	1	ST,QL(60 per 30 days)
hydromorphone 4 mg/ml SYRINGE DL	1	BvsD,QL(180 per 30 days)
hydromorphone 8 mg TABLET DL	1	QL(240 per 30 days)
hydromorphone 8 mg TABLET, ER 24 HR. DL	1	ST,QL(240 per 30 days)
hydromorphone (pf) 0.2 mg/ml, 1 mg/ml, 2 mg/ml SYRINGE DL	1	BvsD
hydromorphone (pf) 1 mg/ml SOLUTION DL	1	BvsD,QL(720 per 30 days)
hydromorphone (pf) 10 mg/ml SOLUTION DL	1	BvsD,QL(144 per 30 days)
hydromorphone (pf) 4 mg/ml SOLUTION DL	1	BvsD,QL(180 per 30 days)
HYSINGLA ER 100 MG, 120 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG TABLET, ER 24 HR. DL	3	ST,QL(30 per 30 days)
ibu 400 mg, 600 mg, 800 mg TABLET MO	1	
ibuprofen 100 mg/5 ml SUSPENSION MO	1	
ibuprofen 300 mg TABLET DL	4	ST
ibuprofen 400 mg TABLET MO	1	
ibuprofen 600 mg, 800 mg TABLET MO	1	
ibuprofen-famotidine 800-26.6 mg TABLET MO	1	PA,QL(90 per 30 days)
INDOCIN 25 MG/5 ML SUSPENSION DL	4	
INDOCIN 50 MG SUPPOSITORY MO	3	
indomethacin 25 mg, 50 mg CAPSULE MO	1	
indomethacin 25 mg/5 ml SUSPENSION DL	4	
indomethacin 50 mg SUPPOSITORY MO	1	
indomethacin 75 mg CAPSULE, ER MO	1	
indomethacin sodium 1 mg RECON SOLUTION MO	1	
INFUMORPH P/F 10 MG/ML SOLUTION DL	3	BvsD,QL(360 per 30 days)
INFUMORPH P/F 25 MG/ML SOLUTION DL	3	BvsD,QL(150 per 30 days)
ketoprofen 200 mg CAPSULE ER PELLETS 24 HR. MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ketoprofen 25 mg, 50 mg, 75 mg CAPSULE MO	1	ST
ketorolac 10 mg TABLET MO	1	QL(20 per 30 days)
ketorolac 15 mg/ml, 30 mg/ml, 30 mg/ml (1 ml), 60 mg/2 ml SOLUTION MO	1	
ketorolac 15 mg/ml, 30 mg/ml, 60 mg/2 ml SYRINGE MO	1	
ketorolac 15.75 mg/spray SPRAY, NON-AEROSOL DL	4	PA,QL(5 per 30 days)
kiprofen 25 mg CAPSULE MO	1	ST
levorphanol tartrate 2 mg TABLET DL	4	ST,QL(240 per 30 days)
levorphanol tartrate 3 mg TABLET DL	4	ST,QL(150 per 30 days)
LICART 1.3 % PATCH, 24 HR. MO	3	PA,QL(30 per 30 days)
LODINE 400 MG TABLET MO	3	PA
lofena 25 mg TABLET DL	4	
lurbipr 100 mg TABLET MO	1	
meclofenamate 100 mg, 50 mg CAPSULE MO	1	
mefenamic acid 250 mg CAPSULE MO	1	
meloxicam 15 mg TABLET MO	1	QL(30 per 30 days)
meloxicam 7.5 mg TABLET MO	1	QL(60 per 30 days)
meloxicam submicronized 10 mg, 5 mg CAPSULE MO	3	QL(30 per 30 days)
meperidine 50 mg TABLET DL	4	QL(480 per 30 days)
meperidine 50 mg/5 ml SOLUTION DL	1	QL(720 per 30 days)
meperidine (pf) 100 mg/ml SOLUTION DL	1	QL(360 per 30 days)
meperidine (pf) 25 mg/ml SOLUTION DL	1	QL(1440 per 30 days)
meperidine (pf) 50 mg/ml SOLUTION DL	1	QL(720 per 30 days)
methadone 10 mg TABLET DL	1	QL(240 per 30 days)
methadone 10 mg/5 ml SOLUTION DL	1	QL(1800 per 30 days)
methadone 10 mg/ml CONCENTRATE DL	1	QL(360 per 30 days)
methadone 10 mg/ml SOLUTION DL	1	QL(360 per 30 days)
methadone 5 mg TABLET DL	1	QL(480 per 30 days)
methadone 5 mg/5 ml SOLUTION DL	1	QL(3600 per 30 days)
methadone intensol 10 mg/ml CONCENTRATE DL	1	QL(360 per 30 days)
METHADOSE 10 MG/ML CONCENTRATE DL	3	QL(360 per 30 days)
mitigo (pf) 10 mg/ml SOLUTION DL	3	BvsD,QL(360 per 30 days)
mitigo (pf) 25 mg/ml SOLUTION DL	3	BvsD,QL(150 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>morphine 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg CAPSULE ER PELLETS</i> DL	1	ST,QL(60 per 30 days)
<i>morphine 10 mg/5 ml SOLUTION</i> DL	1	QL(2700 per 30 days)
<i>morphine 10 mg/ml SOLUTION</i> DL	1	BvsD,QL(360 per 30 days)
<i>morphine 10 mg/ml SYRINGE</i> DL	1	BvsD,QL(360 per 30 days)
<i>morphine 100 mg TABLET ER</i> DL	1	QL(180 per 30 days)
<i>morphine 120 mg, 60 mg, 75 mg, 90 mg CAPSULE ER MULTIPHASE 24 HR.</i> DL	1	ST,QL(60 per 30 days)
<i>morphine 15 mg, 30 mg TABLET</i> DL	1	QL(180 per 30 days)
<i>morphine 15 mg, 30 mg, 60 mg TABLET ER</i> DL	1	QL(120 per 30 days)
<i>morphine 2 mg/ml SOLUTION</i> DL	1	BvsD,QL(1800 per 30 days)
<i>morphine 2 mg/ml SYRINGE</i> DL	1	BvsD,QL(1800 per 30 days)
<i>morphine 2 mg/ml, 4 mg/ml, 5 mg/ml SYRINGE</i> DL	1	BvsD
<i>morphine 20 mg/5 ml (4 mg/ml) SOLUTION</i> DL	1	QL(1350 per 30 days)
<i>morphine 200 mg TABLET ER</i> DL	1	QL(90 per 30 days)
<i>morphine 30 mg, 45 mg CAPSULE ER MULTIPHASE 24 HR.</i> DL	1	ST,QL(30 per 30 days)
<i>morphine 4 mg/ml SOLUTION</i> DL	1	BvsD,QL(900 per 30 days)
<i>morphine 4 mg/ml SYRINGE</i> DL	1	BvsD,QL(900 per 30 days)
<i>morphine 5 mg/ml SOLUTION</i> DL	1	BvsD,QL(720 per 30 days)
<i>morphine 8 mg/ml SOLUTION</i> DL	1	BvsD,QL(450 per 30 days)
<i>morphine 8 mg/ml SYRINGE</i> DL	1	BvsD,QL(450 per 30 days)
<i>morphine (pf) 0.5 mg/ml SOLUTION</i> DL	1	BvsD,QL(7200 per 30 days)
<i>morphine (pf) 1 mg/ml SOLUTION</i> DL	1	BvsD,QL(3600 per 30 days)
<i>morphine (pf) 30 mg/30 ml (1 mg/ml) PATIENT CONTROL ANALGESIA SOLN</i> DL	1	BvsD,QL(3600 per 30 days)
<i>morphine concentrate 100 mg/5 ml (20 mg/ml) SOLUTION</i> DL	1	QL(540 per 30 days)
MS CONTIN 100 MG TABLET ER DL	3	PA,QL(180 per 30 days)
MS CONTIN 15 MG, 30 MG, 60 MG TABLET ER DL	3	PA,QL(120 per 30 days)
MS CONTIN 200 MG TABLET ER DL	3	PA,QL(90 per 30 days)
<i>nabumetone 500 mg, 750 mg TABLET</i> MO	1	
<i>nalbuphine 10 mg/ml SOLUTION</i> DL	1	QL(240 per 30 days)
<i>nalbuphine 20 mg/ml SOLUTION</i> DL	1	QL(120 per 30 days)
NALFON 600 MG TABLET MO	1	ST
<i>nalocet 2.5-300 mg TABLET</i> DL	4	PA,QL(360 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NAPRELAN CR 375 MG TABLET, ER 24 HR., MULTIPHASE MO	3	QL(120 per 30 days)
NAPRELAN CR 500 MG TABLET, ER 24 HR., MULTIPHASE MO	3	QL(90 per 30 days)
NAPRELAN CR 750 MG TABLET, ER 24 HR., MULTIPHASE MO	3	QL(60 per 30 days)
NAPROSYN 125 MG/5 ML SUSPENSION DL	4	PA
<i>naproxen 125 mg/5 ml SUSPENSION</i> MO	1	
<i>naproxen 250 mg, 375 mg TABLET</i> MO	1	
<i>naproxen 375 mg, 500 mg TABLET, DR/EC</i> MO	1	
<i>naproxen 500 mg TABLET</i> MO	1	
<i>naproxen sodium 275 mg, 550 mg TABLET</i> MO	1	
<i>naproxen sodium 375 mg TABLET, ER 24 HR., MULTIPHASE</i> MO	1	ST,QL(120 per 30 days)
<i>naproxen sodium 500 mg TABLET, ER 24 HR., MULTIPHASE</i> MO	1	ST,QL(90 per 30 days)
<i>naproxen sodium 750 mg TABLET, ER 24 HR., MULTIPHASE</i> MO	1	ST,QL(60 per 30 days)
<i>naproxen-esomeprazole 375-20 mg, 500-20 mg TABLET, IR, DR, BIPHASIC</i> DL	4	PA,QL(60 per 30 days)
NUCYNTA 100 MG, 50 MG, 75 MG TABLET DL	4	ST,QL(180 per 30 days)
NUCYNTA ER 100 MG, 150 MG, 200 MG, 250 MG TABLET, ER 12 HR. DL	4	ST,QL(60 per 30 days)
NUCYNTA ER 50 MG TABLET, ER 12 HR. DL	3	ST,QL(60 per 30 days)
OLINVYK 1 MG/ML SOLUTION DL	4	PA
OLINVYK 30 MG/30 ML (1 MG/ML) PATIENT CONTROL ANALGESIA SOLN DL	4	PA
<i>oxaprozin 600 mg TABLET</i> MO	1	
OXAYDO 5 MG, 7.5 MG TABLET, ORAL ONLY DL	4	PA,QL(360 per 30 days)
<i>oxycodone 10 mg, 15 mg, 5 mg TABLET</i> DL	1	QL(360 per 30 days)
<i>oxycodone 10 mg, 20 mg, 40 mg TABLET, ER 12 HR.</i> DL	3	ST,QL(90 per 30 days)
<i>oxycodone 10 mg, 5 mg TABLET, ORAL ONLY</i> DL	4	PA,QL(360 per 30 days)
<i>oxycodone 15 mg, 30 mg TABLET, ORAL ONLY</i> DL	4	PA,QL(180 per 30 days)
<i>oxycodone 20 mg, 30 mg TABLET</i> DL	1	QL(360 per 30 days)
<i>oxycodone 20 mg/ml CONCENTRATE</i> DL	1	QL(270 per 30 days)
<i>oxycodone 5 mg CAPSULE</i> DL	1	QL(360 per 30 days)
<i>oxycodone 5 mg/5 ml SOLUTION</i> DL	1	QL(5400 per 30 days)
<i>oxycodone 80 mg TABLET, ER 12 HR.</i> DL	3	ST,QL(120 per 30 days)
<i>oxycodone-acetaminophen 10-300 mg, 5-300 mg, 7.5-300 mg TABLET</i> DL	4	PA,QL(390 per 30 days)
<i>oxycodone-acetaminophen 10-300 mg/5 ml SOLUTION</i> DL	4	PA,QL(900 per 30 days)
<i>oxycodone-acetaminophen 10-325 mg, 5-325 mg, 7.5-325 mg TABLET</i> DL	1	QL(360 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>oxycodone-acetaminophen 2.5-300 mg TABLET</i> DL	1	PA,QL(360 per 30 days)
<i>oxycodone-acetaminophen 2.5-325 mg TABLET</i> DL	1	QL(360 per 30 days)
<i>oxycodone-acetaminophen 5-325 mg/5 ml SOLUTION</i> DL	1	QL(1800 per 30 days)
OXYCONTIN 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG TABLET, ER 12 HR. DL	3	ST,QL(90 per 30 days)
OXYCONTIN 80 MG TABLET, ER 12 HR. DL	3	ST,QL(120 per 30 days)
<i>oxymorphone 10 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg TABLET, ER 12 HR.</i> DL	1	ST,QL(60 per 30 days)
<i>oxymorphone 10 mg, 5 mg TABLET</i> DL	1	QL(360 per 30 days)
<i>oxymorphone 40 mg TABLET, ER 12 HR.</i> DL	4	ST,QL(60 per 30 days)
PENNSAID 2 % SOLUTION IN PACKET DL	4	PA
PENNSAID 20 MG/GRAM /ACTUATION(2 %) SOLUTION IN METERED DOSE PUMP DL	4	PA,QL(224 per 28 days)
<i>pentazocine-naloxone 50-0.5 mg TABLET</i> DL	1	QL(360 per 30 days)
PERCOCET 10-325 MG, 5-325 MG, 7.5-325 MG TABLET DL	4	PA,QL(360 per 30 days)
PERCOCET 2.5-325 MG TABLET DL	1	PA,QL(360 per 30 days)
<i>piroxicam 10 mg, 20 mg CAPSULE</i> MO	1	
<i>primlev 10-300 mg, 5-300 mg, 7.5-300 mg TABLET</i> DL	4	PA,QL(390 per 30 days)
<i>prolate 10-300 mg, 5-300 mg, 7.5-300 mg TABLET</i> DL	4	PA,QL(390 per 30 days)
PROLATE 10-300 MG/5 ML SOLUTION DL	4	PA,QL(900 per 30 days)
QDOLO 5 MG/ML SOLUTION DL	4	QL(2400 per 30 days)
RELAFEN DS 1,000 MG TABLET DL	4	ST,QL(60 per 30 days)
ROXICODONE 15 MG TABLET DL	3	PA,QL(360 per 30 days)
ROXICODONE 30 MG TABLET DL	4	PA,QL(360 per 30 days)
ROXYBOND 10 MG, 5 MG TABLET, ORAL ONLY DL	4	PA,QL(360 per 30 days)
ROXYBOND 15 MG, 30 MG TABLET, ORAL ONLY DL	4	PA,QL(180 per 30 days)
SEGLENTIS 44-56 MG TABLET DL	3	PA,QL(120 per 30 days)
SPRIX 15.75 MG/SPRAY SPRAY, NON-AEROSOL DL	4	PA,QL(5 per 30 days)
<i>sulindac 150 mg, 200 mg TABLET</i> MO	1	
<i>tolectin 600 600 mg TABLET</i> MO	1	
<i>tolmetin 400 mg CAPSULE</i> MO	1	
<i>tolmetin 600 mg TABLET</i> MO	1	
<i>tramadol 100 mg TABLET</i> DL	1	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
tramadol 100 mg, 200 mg, 300 mg CAPSULE, ER, BIPHASIC DL	1	ST,QL(30 per 30 days)
tramadol 100 mg, 200 mg, 300 mg TABLET, ER 24 HR. DL	1	ST,QL(30 per 30 days)
tramadol 100 mg, 200 mg, 300 mg TABLET, ER 24 HR., MULTIPHASE DL	1	ST,QL(30 per 30 days)
tramadol 25 mg TABLET DL	1	QL(180 per 30 days)
tramadol 5 mg/ml SOLUTION DL	4	QL(2400 per 30 days)
tramadol 50 mg TABLET DL	1	QL(240 per 30 days)
tramadol 75 mg TABLET DL	1	QL(150 per 30 days)
tramadol-acetaminophen 37.5-325 mg TABLET DL	1	QL(240 per 30 days)
TREZIX 320.5-30-16 MG CAPSULE DL	1	QL(300 per 30 days)
VIMOVO 375-20 MG, 500-20 MG TABLET, IR, DR, BIPHASIC DL	4	PA,QL(60 per 30 days)
VIVLODEX 10 MG, 5 MG CAPSULE MO	3	QL(30 per 30 days)
XIFYRM 30 MG/ML SOLUTION MO	3	
XTAMPZA ER 13.5 MG, 18 MG, 27 MG, 36 MG, 9 MG CAPSULE ER SPRINKLE 12 HR. DL	3	ST,QL(60 per 30 days)
ZIPSOR 25 MG CAPSULE DL	4	ST,QL(120 per 30 days)
ZORVOLEX 18 MG, 35 MG CAPSULE MO	3	ST,QL(90 per 30 days)
ANESTHETICS		
bupivacaine (pf) 0.25 % (2.5 mg/ml), 0.5 % (5 mg/ml), 0.75 % (7.5 mg/ml) SOLUTION MO	1	
bupivacaine hcl 0.25 % (2.5 mg/ml), 0.5 % (5 mg/ml) SOLUTION MO	1	
bupivacaine liposome (pf) 1.3 % (13.3 mg/ml) SUSPENSION MO	1	
bupivacaine-dextrose-water(pf) 0.75 % (7.5 mg/ml) SOLUTION MO	1	
bupivacaine-epinephrine 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION MO	1	
bupivacaine-epinephrine (pf) 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION MO	1	
CARBOCAINE WITH NEO-COBEFRIN 2 % -1:20,000 CARTRIDGE MO	1	
chloroprocaine (pf) 20 mg/ml (2 %), 30 mg/ml (3 %) SOLUTION MO	1	
CLOROTEKAL (PF) 10 MG/ML (1 %) SOLUTION MO	3	
dermacinrx lidocan 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
EXPAREL (PF) 1.3 % (13.3 MG/ML) SUSPENSION MO	3	
glydo 2 % JELLY IN APPLICATOR MO	1	
lidocaine 5 % ADHESIVE PATCH, MEDICATED MO	1	PA,QL(90 per 30 days)
lidocaine 5 % OINTMENT MO	1	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
lidocaine (pf) 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %), 40 mg/ml (4 %), 5 mg/ml (0.5 %) SOLUTION MO	1	
lidocaine hcl 10 mg/ml (1 %), 2 %, 20 mg/ml (2 %), 4 %, 4 % (40 mg/ml), 5 mg/ml (0.5 %) SOLUTION MO	1	
lidocaine hcl 2 % JELLY MO	1	
lidocaine hcl 2 % JELLY IN APPLICATOR MO	1	
lidocaine viscous 2 % SOLUTION MO	1	
lidocaine-epinephrine 0.5 %-1:200,000, 1 %-1:100,000, 2 %-1:100,000 SOLUTION MO	1	
lidocaine-epinephrine bit 2 %-1:100,000, 2 %-1:50,000 CARTRIDGE MO	1	
lidocaine-prilocaine 2.5-2.5 % CREAM MO	1	
lidocan iii 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
lidocan iv 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
lidocan v 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
LIDODERM 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
lignospan standard 2 %-1:100,000 CARTRIDGE MO	1	
MARCAINE 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) SOLUTION MO	3	
MARCAINE (PF) 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML), 0.75 % (7.5 MG/ML) SOLUTION MO	3	
MARCAINE SPINAL (PF) 0.75 % (7.5 MG/ML) SOLUTION MO	3	
MARCAINE-EPINEPHRINE 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION MO	3	
marcaine-epinephrine 0.5 %-1:200,000 CARTRIDGE MO	1	
MARCAINE-EPINEPHRINE (PF) 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION MO	3	
NAROPIN (PF) 10 MG/ML (1 %), 2 MG/ML (0.2 %), 5 MG/ML (0.5 %), 7.5 MG/ML (0.75 %) SOLUTION MO	3	
NESACAINE 10 MG/ML (1 %), 20 MG/ML (2 %) SOLUTION MO	3	
NESACAINE-MPF 20 MG/ML (2 %), 30 MG/ML (3 %) SOLUTION MO	3	
PLIAGLIS 7-7 % CREAM MO	3	
polocaine 1 % (10 mg/ml), 2 % SOLUTION MO	1	
polocaine-mpf 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %) SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ropivacaine (pf) 10 mg/ml (1 %), 2 mg/ml (0.2 %), 5 mg/ml (0.5 %), 7.5 mg/ml (0.75 %) SOLUTION MO	1	
SENSORCAINE 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) SOLUTION MO	1	
sensorcaine-epinephrine 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION MO	1	
SENSORCAINE-MPF 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML), 0.75 % (7.5 MG/ML) SOLUTION MO	1	
sensorcaine-mpf 0.25 % (2.5 mg/ml), 0.5 % (5 mg/ml), 0.75 % (7.5 mg/ml) SOLUTION MO	1	
sensorcaine-mpf spinal 0.75 % (7.5 mg/ml) SOLUTION MO	1	
sensorcaine-mpf/epinephrine 0.25 %-1:200,000 SOLUTION MO	1	
SENSORCAINE-MPF/EPINEPHRINE 0.5 %-1:200,000, 0.75 %-1:200,000 SOLUTION MO	1	
vivacaine 0.5 %-1:200,000 CARTRIDGE MO	1	
ZTLIDO 1.8 % ADHESIVE PATCH, MEDICATED MO	3	PA,QL(90 per 30 days)
ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS		
acamprosate 333 mg TABLET, DR/EC MO	1	
buprenorphine hcl 2 mg, 8 mg SUBLINGUAL TABLET MO	1	QL(90 per 30 days)
buprenorphine-naloxone 12-3 mg FILM MO	1	QL(60 per 30 days)
buprenorphine-naloxone 2-0.5 mg, 4-1 mg, 8-2 mg FILM MO	1	QL(90 per 30 days)
buprenorphine-naloxone 2-0.5 mg, 8-2 mg SUBLINGUAL TABLET MO	1	QL(90 per 30 days)
bupropion hcl (smoking deter) 150 mg TABLET, ER 12 HR. MO	1	QL(90 per 30 days)
CHANTIX 0.5 MG, 1 MG TABLET MO	3	PA,QL(56 per 28 days)
CHANTIX CONTINUING MONTH BOX 1 MG TABLET MO	3	PA,QL(56 per 28 days)
CHANTIX STARTING MONTH BOX 0.5 MG (11)- 1 MG (42) TABLET, DOSE PACK MO	3	PA,QL(53 per 28 days)
disulfiram 250 mg, 500 mg TABLET MO	1	
KLOXXADO 8 MG/ACTUATION SPRAY, NON-AEROSOL MO	2	QL(2 per 30 days)
lofexidine 0.18 mg TABLET DL	4	PA,QL(224 per 365 days)
LUCEMYRA 0.18 MG TABLET DL	4	PA,QL(224 per 365 days)
nalmefene 1 mg/ml SOLUTION MO	1	
naloxone 0.4 mg/ml SOLUTION MO	1	
naloxone 0.4 mg/ml, 1 mg/ml SYRINGE MO	1	
naloxone 4 mg/actuation SPRAY, NON-AEROSOL MO	2	QL(2 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>naltrexone 50 mg TABLET</i> MO	1	
NARCAN 4 MG/ACTUATION SPRAY, NON-AEROSOL MO	3	PA,QL(2 per 30 days)
NICOTROL 10 MG CARTRIDGE MO	3	
NICOTROL NS 10 MG/ML SPRAY, NON-AEROSOL MO	3	
OPVEE 2.7 MG/ACTUATION SPRAY, NON-AEROSOL MO	2	QL(2 per 30 days)
SUBOXONE 12-3 MG FILM MO	3	PA,QL(60 per 30 days)
SUBOXONE 2-0.5 MG, 4-1 MG, 8-2 MG FILM MO	3	PA,QL(90 per 30 days)
<i>varenicline tartrate 0.5 mg (11)- 1 mg (42) TABLET, DOSE PACK</i> MO	1	QL(53 per 28 days)
<i>varenicline tartrate 0.5 mg, 1 mg TABLET</i> MO	1	QL(56 per 28 days)
VIVITROL 380 MG SUSPENSION, ER, RECON DL	4	QL(1 per 28 days)
ZIMHI 5 MG/0.5 ML SYRINGE MO	3	PA,QL(1 per 30 days)
ZUBSOLV 0.7-0.18 MG, 1.4-0.36 MG, 2.9-0.71 MG, 5.7-1.4 MG SUBLINGUAL TABLET MO	1	QL(90 per 30 days)
ZUBSOLV 11.4-2.9 MG SUBLINGUAL TABLET MO	1	QL(30 per 30 days)
ZUBSOLV 8.6-2.1 MG SUBLINGUAL TABLET MO	1	QL(60 per 30 days)
ANTIBACTERIALS		
<i>acetic acid 2 % SOLUTION</i> MO	1	
ACTICLATE 150 MG TABLET DL	4	ST,QL(30 per 30 days)
ACTICLATE 75 MG TABLET DL	4	ST,QL(60 per 30 days)
<i>amikacin 1,000 mg/4 ml, 500 mg/2 ml SOLUTION</i> MO	1	
<i>amoxicillin 125 mg, 250 mg CHEWABLE TABLET</i> MO	1	
<i>amoxicillin 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>amoxicillin 250 mg CAPSULE</i> MO	1	
<i>amoxicillin 500 mg CAPSULE</i> MO	1	
<i>amoxicillin 500 mg TABLET</i> MO	1	
<i>amoxicillin 875 mg TABLET</i> MO	1	
<i>amoxicillin-pot clavulanate 1,000-62.5 mg TABLET, ER 12 HR.</i> MO	1	
<i>amoxicillin-pot clavulanate 200-28.5 mg, 400-57 mg CHEWABLE TABLET</i> MO	1	
<i>amoxicillin-pot clavulanate 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>amoxicillin-pot clavulanate 250-125 mg, 500-125 mg TABLET</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
amoxicillin-pot clavulanate 875-125 mg TABLET MO	1	
ampicillin 500 mg CAPSULE MO	1	
ampicillin sodium 1 gram, 10 gram, 125 mg, 2 gram, 250 mg, 500 mg RECON SOLUTION MO	1	
ampicillin-sulbactam 1.5 gram, 15 gram, 3 gram RECON SOLUTION MO	1	
ARIKAYCE 590 MG/8.4 ML SUSPENSION FOR NEBULIZATION DL	4	PA,QL(235.2 per 28 days)
AUGMENTIN 125-31.25 MG/5 ML, 250-62.5 MG/5 ML SUSPENSION FOR RECONSTITUTION DL	4	
AUGMENTIN 500-125 MG TABLET MO	3	PA
AUGMENTIN ES-600 600-42.9 MG/5 ML SUSPENSION FOR RECONSTITUTION MO	3	
AUGMENTIN XR 1,000-62.5 MG TABLET, ER 12 HR. MO	3	
AVELOX IN NACL (ISO-OSMOTIC) 400 MG/250 ML PIGGYBACK MO	3	PA
avidoxy 100 mg TABLET MO	1	ST
AVYCAZ 2.5 GRAM RECON SOLUTION DL	4	
AZACTAM 1 GRAM, 2 GRAM RECON SOLUTION MO	3	PA
azithromycin 1 gram PACKET MO	1	
azithromycin 100 mg/5 ml, 200 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
azithromycin 250 mg TABLET MO	1	
azithromycin 500 mg RECON SOLUTION MO	1	
azithromycin 500 mg, 600 mg TABLET MO	1	
aztreonam 1 gram, 2 gram RECON SOLUTION MO	1	
bacitracin 50,000 unit RECON SOLUTION MO	1	
BACTRIM 400-80 MG TABLET MO	3	
BACTRIM DS 800-160 MG TABLET MO	3	
BAXDELA 300 MG RECON SOLUTION DL	4	QL(28 per 14 days)
BAXDELA 450 MG TABLET DL	4	QL(28 per 14 days)
BETHKIS 300 MG/4 ML SOLUTION FOR NEBULIZATION DL	4	PA
BICILLIN C-R 1,200,000 UNIT/ 2 ML(600K/600K), 1,200,000 UNIT/ 2 ML(900K/300K) SYRINGE MO	3	
BICILLIN L-A 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML SYRINGE MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ceftazidime 1 gram, 2 gram, 6 gram RECON SOLUTION MO	1	
cefuroxime sodium 1.5 gram, 7.5 gram, 750 mg RECON SOLUTION MO	1	
cefuroxime axetil 250 mg, 500 mg TABLET MO	1	
ceftriaxone in dextrose,iso-os 1 gram/50 ml, 2 gram/50 ml PIGGYBACK MO	1	
ceftriaxone 1 gram, 10 gram, 100 gram, 2 gram, 250 mg, 500 mg RECON SOLUTION MO	1	
cefprozil 250 mg, 500 mg TABLET MO	1	
cefprozil 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cefpodoxime 100 mg/5 ml, 50 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cefpodoxime 100 mg, 200 mg TABLET MO	1	
cefoxitin in dextrose, iso-osm 1 gram/50 ml, 2 gram/50 ml PIGGYBACK MO	1	
cefoxitin 1 gram, 10 gram, 2 gram RECON SOLUTION MO	1	
cefotetan 1 gram, 10 gram, 2 gram RECON SOLUTION MO	1	
cefixime 400 mg CAPSULE MO	1	
cefixime 100 mg/5 ml, 200 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cefepime in dextrose,iso-osm 1 gram/50 ml, 2 gram/100 ml PIGGYBACK MO	3	
cefepime in dextrose 5 % 1 gram/50 ml, 2 gram/50 ml PIGGYBACK MO	1	
cefepime 1 gram, 2 gram RECON SOLUTION MO	1	
cefdinir 300 mg CAPSULE MO	1	
cefdinir 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
CEFAZOLIN 2 GRAM, 3 GRAM RECON SOLUTION MO	1	
cefazolin in dextrose (iso-os) 1 gram/50 ml, 2 gram/100 ml, 2 gram/50 ml, 3 gram/50 ml PIGGYBACK MO	1	
cefazolin 1 gram, 10 gram, 2 gram, 3 gram, 500 mg RECON SOLUTION MO	1	
cefadroxil 500 mg CAPSULE MO	1	
cefadroxil 250 mg/5 ml, 500 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cefadroxil 1 gram TABLET MO	1	
ceftazidime 1 gram, 2 gram, 6 gram RECON SOLUTION MO	1	
cefprozil 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cefprozil 250 mg, 500 mg TABLET MO	1	
ceftazidime 1 gram, 2 gram, 6 gram RECON SOLUTION MO	1	
ceftriaxone 1 gram, 10 gram, 100 gram, 2 gram, 250 mg, 500 mg RECON SOLUTION MO	1	
ceftriaxone in dextrose,iso-os 1 gram/50 ml, 2 gram/50 ml PIGGYBACK MO	1	
cefuroxime axetil 250 mg, 500 mg TABLET MO	1	
cefuroxime sodium 1.5 gram, 7.5 gram, 750 mg RECON SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>cephalexin 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>cephalexin 250 mg, 500 mg TABLET</i> MO	1	
<i>cephalexin 250 mg, 750 mg CAPSULE</i> MO	1	
<i>cephalexin 500 mg CAPSULE</i> MO	1	
<i>chloramphenicol sod succinate 1 gram RECON SOLUTION</i> MO	1	
<i>CIPRO 250 MG, 500 MG TABLET</i> MO	3	
<i>CIPRO 250 MG/5 ML, 500 MG/5 ML SUSPENSION, MICROCAPSULE RECON</i> MO	3	
<i>ciprofloxacin 250 mg/5 ml, 500 mg/5 ml SUSPENSION, MICROCAPSULE RECON</i> MO	1	
<i>ciprofloxacin hcl 100 mg, 250 mg, 750 mg TABLET</i> MO	1	
<i>ciprofloxacin hcl 500 mg TABLET</i> MO	1	
<i>ciprofloxacin in 5 % dextrose 200 mg/100 ml, 400 mg/200 ml PIGGYBACK</i> MO	1	
<i>CLAFORAN 1 GRAM, 10 GRAM, 2 GRAM RECON SOLUTION</i> MO	3	
<i>clarithromycin 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>clarithromycin 250 mg, 500 mg TABLET</i> MO	1	
<i>clarithromycin 500 mg TABLET, ER 24 HR.</i> MO	1	
<i>CLEOCIN 100 MG SUPPOSITORY</i> MO	3	
<i>CLEOCIN 150 MG/ML SOLUTION</i> MO	1	
<i>CLEOCIN 2 % CREAM</i> MO	3	PA
<i>CLEOCIN HCL 150 MG, 300 MG, 75 MG CAPSULE</i> MO	3	
<i>CLEOCIN PEDIATRIC 75 MG/5 ML RECON SOLUTION</i> MO	1	
<i>clindamycin hcl 150 mg, 300 mg, 75 mg CAPSULE</i> MO	1	
<i>clindamycin in 0.9 % sod chlor 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml PIGGYBACK</i> MO	1	
<i>clindamycin in 5 % dextrose 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml PIGGYBACK</i> MO	1	
<i>clindamycin palmitate hcl 75 mg/5 ml RECON SOLUTION</i> MO	1	
<i>clindamycin pediatric 75 mg/5 ml RECON SOLUTION</i> MO	1	
<i>clindamycin phosphate 150 mg/ml SOLUTION</i> MO	1	
<i>clindamycin phosphate 2 % CREAM</i> MO	1	
<i>CLINDESSE 2 % CREAM, ER</i> MO	3	
<i>colistin (colistimethate na) 150 mg RECON SOLUTION</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
COLY-MYCIN M PARENTERAL 150 MG RECON SOLUTION DL	4	
CUBICIN RF 500 MG RECON SOLUTION DL	4	
DALVANCE 500 MG SOLUTION DL	4	QL(4 per 28 days)
<i>daptomycin 350 mg RECON SOLUTION</i> MO	1	
<i>daptomycin 500 mg RECON SOLUTION</i> DL	4	
<i>daptomycin in 0.9 % sod chlor 1,000 mg/100 ml, 350 mg/50 ml, 500 mg/50 ml, 700 mg/100 ml PIGGYBACK</i> MO	3	
<i>demeclocycline 150 mg TABLET</i> MO	1	QL(240 per 30 days)
<i>demeclocycline 300 mg TABLET</i> MO	1	QL(120 per 30 days)
<i>dicloxacillin 250 mg, 500 mg CAPSULE</i> MO	1	
DIFICID 200 MG TABLET DL	4	
DIFICID 40 MG/ML SUSPENSION FOR RECONSTITUTION DL	4	
DORYX 200 MG TABLET, DR/EC MO	3	ST,QL(30 per 30 days)
DORYX 50 MG TABLET, DR/EC MO	3	ST,QL(60 per 30 days)
DORYX 80 MG TABLET, DR/EC DL	4	ST,QL(60 per 30 days)
DORYX MPC 120 MG TABLET, DR/EC MO	3	ST,QL(60 per 30 days)
DORYX MPC 60 MG TABLET, DR/EC DL	4	ST,QL(60 per 30 days)
<i>doxy-100 100 mg RECON SOLUTION</i> MO	1	
<i>doxycycline hyclate 100 mg CAPSULE</i> MO	1	
<i>doxycycline hyclate 100 mg RECON SOLUTION</i> MO	1	
<i>doxycycline hyclate 100 mg TABLET</i> MO	1	
<i>doxycycline hyclate 100 mg TABLET, DR/EC</i> MO	1	ST,QL(90 per 30 days)
<i>doxycycline hyclate 150 mg TABLET</i> MO	1	ST,QL(30 per 30 days)
<i>doxycycline hyclate 150 mg, 50 mg, 75 mg TABLET, DR/EC</i> MO	1	ST,QL(60 per 30 days)
<i>doxycycline hyclate 20 mg TABLET</i> MO	1	
<i>doxycycline hyclate 200 mg TABLET, DR/EC</i> MO	1	ST,QL(30 per 30 days)
<i>doxycycline hyclate 50 mg CAPSULE</i> MO	1	
<i>doxycycline hyclate 50 mg TABLET</i> MO	1	ST,QL(180 per 30 days)
<i>doxycycline hyclate 75 mg TABLET</i> MO	1	ST,QL(60 per 30 days)
<i>doxycycline hyclate 80 mg TABLET, DR/EC</i> DL	4	ST,QL(60 per 30 days)
<i>doxycycline monohydrate 100 mg, 150 mg, 50 mg, 75 mg TABLET</i> MO	1	
<i>doxycycline monohydrate 100 mg, 50 mg CAPSULE</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>doxycycline monohydrate 150 mg CAPSULE</i> MO	1	QL(30 per 30 days)
<i>doxycycline monohydrate 25 mg/5 ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>doxycycline monohydrate 40 mg CAPSULE, IR/DR, BIPHASIC</i> MO	1	ST,QL(30 per 30 days)
<i>doxycycline monohydrate 75 mg CAPSULE</i> MO	1	QL(60 per 30 days)
E.E.S. 400 400 MG TABLET MO	1	
E.E.S. GRANULES 200 MG/5 ML SUSPENSION FOR RECONSTITUTION MO	3	
EMBLAVEO 2 GRAM RECON SOLUTION DL	4	
EMROSI 40 MG CAPSULE, IR/ER, BIPHASIC DL	4	PA,QL(30 per 30 days)
<i>ertapenem 1 gram RECON SOLUTION</i> MO	1	
ERY-TAB 250 MG, 333 MG, 500 MG TABLET, DR/EC MO	1	
ERYPED 200 200 MG/5 ML SUSPENSION FOR RECONSTITUTION MO	3	
ERYPED 400 400 MG/5 ML SUSPENSION FOR RECONSTITUTION DL	4	
ERYTHROCIN 500 MG RECON SOLUTION MO	1	
ERYTHROCIN (AS STEARATE) 250 MG TABLET MO	1	
<i>erythromycin 250 mg CAPSULE, DR/EC</i> MO	1	
<i>erythromycin 250 mg, 333 mg, 500 mg TABLET, DR/EC</i> MO	1	
<i>erythromycin 250 mg, 500 mg TABLET</i> MO	1	
<i>erythromycin ethylsuccinate 200 mg/5 ml, 400 mg/5 ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>erythromycin ethylsuccinate 400 mg TABLET</i> MO	1	
<i>erythromycin lactobionate 500 mg RECON SOLUTION</i> DL	4	
FETROJA 1 GRAM RECON SOLUTION DL	4	QL(84 per 14 days)
<i>fidaxomicin 200 mg TABLET</i> DL	4	
FIRVANQ 25 MG/ML, 50 MG/ML RECON SOLUTION MO	3	
FLAGYL 375 MG CAPSULE MO	3	QL(320 per 30 days)
<i>fosfomycin tromethamine 3 gram PACKET</i> MO	1	
FURADANTIN 25 MG/5 ML SUSPENSION MO	3	
<i>gentamicin 0.1 % CREAM</i> MO	1	
<i>gentamicin 0.1 % OINTMENT</i> MO	1	
<i>gentamicin 40 mg/ml SOLUTION</i> MO	1	
<i>gentamicin in nacl (iso-osm) 100 mg/100 ml, 100 mg/50 ml, 120 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml PIGGYBACK</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
gentamicin sulfate (ped) (pf) 20 mg/2 ml SOLUTION MO	1	
HIPREX 1 GRAM TABLET MO	3	PA
HUMATIN 250 MG CAPSULE DL	4	
imipenem-cilastatin 250 mg, 500 mg RECON SOLUTION MO	1	
KIMYRSA 1,200 MG RECON SOLUTION DL	4	QL(1 per 30 days)
KITABIS PAK 300 MG/5 ML SOLUTION FOR NEBULIZATION DL	4	PA
KLARON 10 % SUSPENSION MO	3	QL(118 per 30 days)
levofloxacin 25 mg/ml, 250 mg/10 ml SOLUTION MO	1	
levofloxacin 250 mg, 750 mg TABLET MO	1	
levofloxacin 500 mg TABLET MO	1	
levofloxacin in d5w 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml PIGGYBACK MO	1	
LINCOCIN 300 MG/ML SOLUTION MO	3	
lincomycin 300 mg/ml SOLUTION MO	1	
linezolid 100 mg/5 ml SUSPENSION FOR RECONSTITUTION DL	4	QL(1800 per 30 days)
linezolid 600 mg TABLET MO	1	QL(60 per 30 days)
linezolid in dextrose 5% 600 mg/300 ml PIGGYBACK MO	1	
linezolid-0.9% sodium chloride 600 mg/300 ml PARENTERAL SOLUTION MO	1	
MACROBID 100 MG CAPSULE MO	3	
MACRODANTIN 100 MG, 25 MG, 50 MG CAPSULE MO	3	
meropenem 1 gram, 500 mg RECON SOLUTION MO	1	
meropenem-0.9% sodium chloride 1 gram/50 ml, 500 mg/50 ml PIGGYBACK MO	1	
methenamine hippurate 1 gram TABLET MO	1	
METRO I.V. 500 MG/100 ML PIGGYBACK MO	3	
METROCREAM 0.75 % CREAM MO	3	PA
METROGEL 1 % GEL MO	3	ST
METROLOTION 0.75 % LOTION MO	3	PA
metronidazole 0.75 % CREAM MO	1	
metronidazole 0.75 % LOTION MO	1	
metronidazole 0.75 %, 0.75 % (37.5mg/5 gram), 1 %, 1.3 % (65 mg/5 gram) GEL MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
metronidazole 1 % GEL WITH PUMP MO	1	
metronidazole 125 mg, 250 mg, 500 mg TABLET MO	1	
metronidazole 375 mg CAPSULE MO	1	QL(320 per 30 days)
metronidazole in nacl (iso-os) 500 mg/100 ml PIGGYBACK MO	1	
MINOCIN 100 MG RECON SOLUTION DL	4	PA
minocycline 100 mg, 50 mg, 75 mg CAPSULE MO	1	
minocycline 100 mg, 50 mg, 75 mg TABLET MO	1	
minocycline 105 mg, 115 mg, 135 mg, 45 mg, 55 mg, 65 mg, 80 mg, 90 mg TABLET, ER 24 HR. MO	1	ST,QL(30 per 30 days)
mondoxyne nl 100 mg CAPSULE MO	1	
mondoxyne nl 75 mg CAPSULE MO	1	ST,QL(60 per 30 days)
morgidox 50 mg CAPSULE MO	1	ST
moxifloxacin 400 mg TABLET MO	1	
moxifloxacin-sod.ace,sul-water 400 mg/250 ml PIGGYBACK MO	1	
moxifloxacin-sod.chloride(iso) 400 mg/250 ml PIGGYBACK MO	1	
nafcillin 1 gram, 10 gram, 2 gram RECON SOLUTION MO	1	
nafcillin in dextrose iso-osm 1 gram/50 ml, 2 gram/100 ml PIGGYBACK DL	4	
neomycin 500 mg TABLET MO	1	
nitrofurantoin 25 mg/5 ml, 50 mg/5 ml SUSPENSION DL	4	
nitrofurantoin macrocrystal 100 mg, 25 mg, 50 mg CAPSULE MO	1	
nitrofurantoin monohyd/m-cryst 100 mg CAPSULE MO	1	
NORITATE 1 % CREAM DL	4	ST,QL(60 per 30 days)
NUZYRA 100 MG RECON SOLUTION DL	4	
NUZYRA 150 MG TABLET DL	4	QL(30 per 14 days)
ofloxacin 300 mg, 400 mg TABLET MO	1	
ORACEA 40 MG CAPSULE, IR/DR, BIPHASIC MO	3	ST,QL(30 per 30 days)
ORBACTIV 400 MG RECON SOLUTION DL	4	QL(3 per 28 days)
oxacillin 1 gram, 10 gram, 2 gram RECON SOLUTION MO	1	
oxacillin in dextrose(iso-osm) 1 gram/50 ml, 2 gram/50 ml PIGGYBACK MO	3	
penicillin g pot in dextrose 2 million unit/50 ml, 3 million unit/50 ml PIGGYBACK MO	3	
penicillin g potassium 20 million unit, 5 million unit RECON SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
penicillin g sodium 5 million unit RECON SOLUTION MO	1	
penicillin v potassium 125 mg/5 ml, 250 mg/5 ml RECON SOLUTION MO	1	
penicillin v potassium 250 mg, 500 mg TABLET MO	1	
pfizerpen-g 20 million unit, 5 million unit RECON SOLUTION MO	1	
piperacillin-tazobactam 13.5 gram, 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram RECON SOLUTION MO	1	
polymyxin b sulfate 500,000 unit RECON SOLUTION MO	1	
PRIMAXIN IV 500 MG RECON SOLUTION MO	3	
PRIMSOL 50 MG/5 ML SOLUTION MO	3	
RECARBRIO 1.25 GRAM RECON SOLUTION DL	4	
rosadan 0.75 % CREAM MO	1	ST
rosadan 0.75 % GEL MO	1	ST
SEYSARA 100 MG, 150 MG, 60 MG TABLET DL	4	ST,QL(30 per 30 days)
SIVEXTRO 200 MG RECON SOLUTION DL	4	QL(6 per 28 days)
SIVEXTRO 200 MG TABLET DL	4	QL(6 per 28 days)
SOLODYN 105 MG, 115 MG, 55 MG, 65 MG, 80 MG TABLET, ER 24 HR. DL	4	ST,QL(30 per 30 days)
SOLOSEC 2 GRAM DR GRANULES IN PACKET MO	3	PA
streptomycin 1 gram RECON SOLUTION DL	4	
sulfacetamide sodium 10 % OINTMENT MO	1	
sulfacetamide sodium (acne) 10 % SUSPENSION MO	1	QL(118 per 30 days)
sulfadiazine 500 mg TABLET MO	1	
sulfamethoxazole-trimethoprim 200-40 mg/5 ml SUSPENSION MO	1	
sulfamethoxazole-trimethoprim 400-80 mg TABLET MO	1	
sulfamethoxazole-trimethoprim 400-80 mg/5 ml SOLUTION MO	1	
sulfamethoxazole-trimethoprim 800-160 mg TABLET MO	1	
TARGADOX 50 MG TABLET MO	1	ST,QL(180 per 30 days)
tazicef 1 gram, 2 gram, 6 gram RECON SOLUTION MO	1	
TEFLARO 400 MG, 600 MG RECON SOLUTION DL	4	
tetracycline 250 mg, 500 mg CAPSULE MO	1	
tetracycline 250 mg, 500 mg TABLET DL	4	
tigecycline 50 mg RECON SOLUTION DL	4	
tinidazole 250 mg, 500 mg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TOBI 300 MG/5 ML SOLUTION FOR NEBULIZATION DL	4	PA
tobramycin 300 mg/4 ml SOLUTION FOR NEBULIZATION DL	4	PA
tobramycin in 0.225 % nacl 300 mg/5 ml SOLUTION FOR NEBULIZATION DL	4	BvsD
tobramycin sulfate 1.2 gram RECON SOLUTION DL	4	
tobramycin sulfate 10 mg/ml, 40 mg/ml SOLUTION MO	1	
trimethoprim 100 mg TABLET MO	1	
TYGACIL 50 MG RECON SOLUTION DL	4	
UNASYN 1.5 GRAM, 15 GRAM, 3 GRAM RECON SOLUTION MO	3	
VABOMERE 2 GRAM RECON SOLUTION DL	4	QL(84 per 14 days)
VANCOGIN 125 MG CAPSULE MO	3	PA,QL(120 per 30 days)
VANCOGIN 250 MG CAPSULE DL	4	PA,QL(240 per 30 days)
vancomycin 1,000 mg, 1.25 gram, 1.5 gram, 10 gram, 25 mg/ml, 5 gram, 50 mg/ml, 500 mg, 750 mg RECON SOLUTION MO	1	
vancomycin 1.75 gram, 2 gram RECON SOLUTION MO	3	
vancomycin 125 mg CAPSULE MO	1	QL(120 per 30 days)
vancomycin 250 mg CAPSULE MO	1	QL(240 per 30 days)
vancomycin in 0.9 % sodium chl 1 gram/200 ml, 500 mg/100 ml, 750 mg/150 ml PIGGYBACK MO	3	
vancomycin in dextrose 5 % 1 gram/200 ml, 500 mg/100 ml, 750 mg/150 ml PIGGYBACK MO	3	
VANCOMYCIN IN DEXTROSE 5 % 1.25 GRAM/250 ML, 1.5 GRAM/300 ML PIGGYBACK MO	3	
vancomycin-diluent combo no.1 1 gram/200 ml, 1.25 gram/250 ml, 1.5 gram/300 ml, 1.75 gram/350 ml, 2 gram/400 ml, 500 mg/100 ml, 750 mg/150 ml PIGGYBACK MO	3	
VANDAZOLE 0.75 % (37.5MG/5 GRAM) GEL MO	3	
VIBATIV 750 MG RECON SOLUTION DL	4	
VIBRAMYCIN 100 MG CAPSULE MO	3	
XACDURO 1 GRAM-1 GRAM (0.5 GRAM X 2) RECON SOLUTION	4	
XACIATO 2 % GEL MO	3	
XERAVA 100 MG, 50 MG RECON SOLUTION MO	3	
XIMINO 135 MG, 90 MG CAPSULE, ER 24 HR. DL	3	ST,QL(30 per 30 days)
XIMINO 45 MG CAPSULE, ER 24 HR. MO	3	ST,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZEMDRI 50 MG/ML SOLUTION DL	4	
ZERBAXA 1.5 GRAM RECON SOLUTION DL	4	
ZEVERTA 667 MG RECON SOLUTION DL	4	
ZITHROMAX 1 GRAM PACKET MO	3	
ZITHROMAX 100 MG/5 ML, 200 MG/5 ML SUSPENSION FOR RECONSTITUTION MO	3	
ZITHROMAX 250 MG, 500 MG TABLET MO	3	
ZITHROMAX 500 MG RECON SOLUTION MO	3	
ZITHROMAX TRI-PAK 500 MG TABLET MO	3	
ZITHROMAX Z-PAK 250 MG TABLET MO	3	
ZOSYN IN DEXTROSE (ISO-OSM) 2.25 GRAM/50 ML, 3.375 GRAM/50 ML, 4.5 GRAM/100 ML PIGGYBACK MO	3	
ZYVOX 100 MG/5 ML SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(1800 per 30 days)
ZYVOX 200 MG/100 ML, 600 MG/300 ML PIGGYBACK MO	3	
ZYVOX 600 MG TABLET DL	4	PA,QL(60 per 30 days)
ANTICONVULSANTS		
APTIOM 200 MG, 400 MG TABLET	4	PA,QL(30 per 30 days)
APTIOM 600 MG, 800 MG TABLET	4	PA,QL(60 per 30 days)
BANZEL 200 MG TABLET DL	4	PA,QL(480 per 30 days)
BANZEL 40 MG/ML SUSPENSION DL	4	PA,QL(2760 per 30 days)
BANZEL 400 MG TABLET DL	4	PA,QL(240 per 30 days)
BRIVIACT 10 MG, 100 MG, 25 MG, 50 MG, 75 MG TABLET	4	PA,QL(60 per 30 days)
BRIVIACT 10 MG/ML SOLUTION	4	PA,QL(600 per 30 days)
BRIVIACT 50 MG/5 ML SOLUTION	4	PA
carbamazepine 100 mg, 200 mg CHEWABLE TABLET MO	1	
carbamazepine 100 mg, 200 mg, 300 mg CAPSULE ER MULTIPHASE 12 HR. MO	1	
carbamazepine 100 mg, 200 mg, 400 mg TABLET, ER 12 HR. MO	1	
carbamazepine 100 mg/5 ml, 100 mg/5 ml (5 ml), 200 mg/10 ml SUSPENSION MO	1	
carbamazepine 200 mg TABLET MO	1	
CARBATROL 100 MG, 200 MG, 300 MG CAPSULE ER MULTIPHASE 12 HR. MO	3	
CELONTIN 300 MG CAPSULE MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CEREBYX 100 MG PE/2 ML, 500 MG PE/10 ML SOLUTION MO	3	
<i>clobazam 10 mg, 20 mg</i> TABLET DL	1	PA
<i>clobazam 2.5 mg/ml</i> SUSPENSION DL	1	PA
DEPAKOTE 125 MG, 250 MG, 500 MG TABLET, DR/EC MO	3	
DEPAKOTE ER 250 MG, 500 MG TABLET, ER 24 HR. MO	3	
DEPAKOTE SPRINKLES 125 MG CAPSULE, DR SPRINKLE MO	3	
DIACOMIT 250 MG, 500 MG CAPSULE DL	4	PA,QL(180 per 30 days)
DIACOMIT 250 MG, 500 MG POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
DIASTAT 2.5 MG KIT DL	3	PA
DIASTAT ACUDIAL 12.5-15-17.5-20 MG, 5-7.5-10 MG KIT DL	3	PA
<i>diazepam 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg</i> KIT DL	1	
DILANTIN 30 MG CAPSULE MO	1	
DILANTIN EXTENDED 100 MG CAPSULE MO	1	
DILANTIN INFATABS 50 MG CHEWABLE TABLET MO	1	
DILANTIN-125 125 MG/5 ML SUSPENSION MO	3	
<i>divalproex 125 mg</i> CAPSULE, DR SPRINKLE MO	1	
<i>divalproex 125 mg, 250 mg, 500 mg</i> TABLET, DR/EC MO	1	
<i>divalproex 250 mg, 500 mg</i> TABLET, ER 24 HR. MO	1	
ELEPSIA XR 1,000 MG, 1,500 MG TABLET, ER 24 HR. DL	4	QL(60 per 30 days)
EPIDIOLEX 100 MG/ML SOLUTION DL	4	PA
<i>epitol 200 mg</i> TABLET MO	1	
EPRONTIA 25 MG/ML SOLUTION MO	3	PA,QL(480 per 30 days)
EQUETRO 100 MG, 200 MG, 300 MG CAPSULE ER MULTIPHASE 12 HR. MO	3	PA
<i>eslicarbazepine 200 mg, 400 mg</i> TABLET DL	4	PA,QL(30 per 30 days)
<i>eslicarbazepine 600 mg, 800 mg</i> TABLET DL	4	PA,QL(60 per 30 days)
<i>ethosuximide 250 mg</i> CAPSULE MO	1	
<i>ethosuximide 250 mg/5 ml</i> SOLUTION MO	1	
<i>felbamate 400 mg, 600 mg</i> TABLET MO	1	
<i>felbamate 600 mg/5 ml</i> SUSPENSION MO	1	
FELBATOL 400 MG, 600 MG TABLET DL	4	PA
FELBATOL 600 MG/5 ML SUSPENSION DL	4	PA
FINTEPLA 2.2 MG/ML SOLUTION DL,LA	4	PA,QL(360 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml SOLUTION</i> MO	1	
FYCOMPA 0.5 MG/ML SUSPENSION	4	PA,QL(680 per 28 days)
FYCOMPA 10 MG, 12 MG, 4 MG, 6 MG, 8 MG TABLET	4	PA,QL(30 per 30 days)
FYCOMPA 2 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>gabapentin 100 mg, 300 mg, 400 mg CAPSULE</i> MO	1	QL(270 per 30 days)
<i>gabapentin 250 mg/5 ml, 250 mg/5 ml (5 ml), 300 mg/6 ml (6 ml) SOLUTION</i> MO	1	QL(2250 per 30 days)
<i>gabapentin 600 mg, 800 mg TABLET</i> MO	1	QL(180 per 30 days)
GABARONE 100 MG, 400 MG TABLET DL	4	QL(270 per 30 days)
KEPPRA 1,000 MG, 500 MG, 750 MG TABLET	4	PA
KEPPRA 100 MG/ML, 500 MG/5 ML SOLUTION	4	PA
KEPPRA 250 MG TABLET MO	3	PA
KEPPRA XR 500 MG TABLET, ER 24 HR.	4	PA,QL(180 per 30 days)
KEPPRA XR 750 MG TABLET, ER 24 HR.	4	PA,QL(120 per 30 days)
<i>lacosamide 10 mg/ml SOLUTION</i> MO	1	QL(1395 per 30 days)
<i>lacosamide 100 mg, 150 mg, 200 mg, 50 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>lacosamide 200 mg/20 ml SOLUTION</i> DL	4	
LAMICTAL 100 MG, 150 MG, 200 MG, 25 MG TABLET	4	
LAMICTAL 25 MG, 5 MG TABLET, CHEWABLE DISPERSIBLE	4	
LAMICTAL ODT 100 MG, 200 MG, 25 MG, 50 MG TABLET, DISINTEGRATING	4	
LAMICTAL ODT STARTER (BLUE) 25 MG (21) -50 MG (7) TABLET, DISINTEGRATING,DOSE PK	4	
LAMICTAL ODT STARTER (GREEN) 50 MG (42) -100 MG (14) TABLET, DISINTEGRATING,DOSE PK	4	
LAMICTAL ODT STARTER (ORANGE) 25 MG(14)-50 MG (14)-100 MG (7) TABLET, DISINTEGRATING,DOSE PK	4	
LAMICTAL STARTER (BLUE) KIT 25 MG (35) TABLET, DOSE PACK MO	3	
LAMICTAL STARTER (GREEN) KIT 25 MG (84) -100 MG (14) TABLET, DOSE PACK MO	3	
LAMICTAL STARTER (ORANGE) KIT 25 MG (42) -100 MG (7) TABLET, DOSE PACK MO	3	
LAMICTAL XR 100 MG, 200 MG, 25 MG, 250 MG, 300 MG, 50 MG TABLET, ER 24 HR.	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LAMICTAL XR STARTER (BLUE) 25 MG (21) -50 MG (7) TABLET, ER, DOSE PACK MO	3	
LAMICTAL XR STARTER (GREEN) 50 MG(14)-100MG (14)-200 MG (7) TABLET, ER, DOSE PACK MO	3	
LAMICTAL XR STARTER (ORANGE) 25MG (14)-50 MG (14)-100MG (7) TABLET, ER, DOSE PACK MO	3	
lamotrigine 100 mg, 150 mg, 200 mg, 25 mg TABLET MO	1	
lamotrigine 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg TABLET, ER 24 HR. MO	1	
lamotrigine 100 mg, 200 mg, 25 mg, 50 mg TABLET, DISINTEGRATING MO	1	
lamotrigine 25 mg (21) -50 mg (7), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg (42) -100 mg (14) TABLET, DISINTEGRATING,DOSE PK MO	1	
lamotrigine 25 mg (35), 25 mg (42) -100 mg (7), 25 mg (84) -100 mg (14) TABLET, DOSE PACK MO	1	
lamotrigine 25 mg, 5 mg TABLET, CHEWABLE DISPERSIBLE MO	1	
levetiracetam 1,000 mg, 250 mg, 750 mg TABLET MO	1	
levetiracetam 100 mg/ml, 500 mg/5 ml SOLUTION MO	1	
levetiracetam 250 mg TABLET FOR SUSPENSION MO	3	ST,QL(360 per 30 days)
levetiracetam 500 mg TABLET MO	1	
levetiracetam 500 mg TABLET, ER 24 HR. MO	1	QL(180 per 30 days)
levetiracetam 500 mg/5 ml (5 ml) SOLUTION MO	1	QL(900 per 30 days)
levetiracetam 750 mg TABLET, ER 24 HR. MO	1	QL(120 per 30 days)
levetiracetam in nacl (iso-os) 1,000 mg/100 ml, 1,500 mg/100 ml, 500 mg/100 ml PIGGYBACK MO	1	
LIBERVANT 10 MG, 12.5 MG, 15 MG, 5 MG, 7.5 MG FILM DL	4	QL(10 per 30 days)
methsuximide 300 mg CAPSULE MO	1	
MOTPOLY XR 100 MG, 150 MG, 200 MG CAPSULE, ER 24 HR. DL	4	PA,QL(60 per 30 days)
MYSOLINE 250 MG, 50 MG TABLET DL	4	PA
NAYZILAM 5 MG/SPRAY (0.1 ML) SPRAY, NON-AEROSOL DL	3	QL(10 per 30 days)
NEURONTIN 100 MG, 300 MG, 400 MG CAPSULE MO	3	PA,QL(270 per 30 days)
NEURONTIN 250 MG/5 ML SOLUTION MO	3	PA,QL(2250 per 30 days)
NEURONTIN 600 MG, 800 MG TABLET	4	PA,QL(180 per 30 days)
ONFI 10 MG, 20 MG TABLET DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ONFI 2.5 MG/ML SUSPENSION DL	4	PA
oxcarbazepine 150 mg, 300 mg, 600 mg TABLET MO	1	
oxcarbazepine 150 mg, 300 mg, 600 mg TABLET, ER 24 HR. MO	1	ST
oxcarbazepine 300 mg/5 ml (60 mg/ml) SUSPENSION MO	1	
OXTELLAR XR 150 MG, 300 MG TABLET, ER 24 HR. MO	3	ST
OXTELLAR XR 600 MG TABLET, ER 24 HR.	4	ST
pentobarbital sodium 50 mg/ml SOLUTION MO	1	
perampanel 10 mg, 12 mg, 4 mg, 6 mg, 8 mg TABLET	4	PA,QL(30 per 30 days)
perampanel 2 mg TABLET MO	1	PA,QL(30 per 30 days)
phenobarbital 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg TABLET MO	1	QL(90 per 30 days)
phenobarbital 15 mg, 60 mg TABLET MO	1	QL(120 per 30 days)
phenobarbital 20 mg/5 ml (4 mg/ml) ELIXIR MO	1	QL(1500 per 30 days)
phenobarbital 30 mg TABLET MO	1	QL(300 per 30 days)
phenobarbital sodium 130 mg/ml, 65 mg/ml SOLUTION DL	4	
PHENYTEK 200 MG, 300 MG CAPSULE MO	1	
phenytoin 100 mg/4 ml, 125 mg/5 ml SUSPENSION MO	1	
phenytoin 50 mg CHEWABLE TABLET MO	1	
phenytoin sodium 50 mg/ml SOLUTION MO	1	
phenytoin sodium 50 mg/ml SYRINGE MO	1	
phenytoin sodium extended 100 mg, 200 mg, 300 mg CAPSULE MO	1	
primidone 125 mg, 250 mg, 50 mg TABLET MO	1	
QUDEXY XR 100 MG, 50 MG CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(30 per 30 days)
QUDEXY XR 150 MG, 200 MG CAPSULE ER SPRINKLE 24 HR. DL	4	PA,QL(60 per 30 days)
QUDEXY XR 25 MG CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(90 per 30 days)
roweepra 500 mg TABLET MO	1	
roweepra xr 500 mg TABLET, ER 24 HR. MO	1	QL(180 per 30 days)
roweepra xr 750 mg TABLET, ER 24 HR. MO	1	QL(120 per 30 days)
rufinamide 200 mg TABLET MO	1	PA,QL(480 per 30 days)
rufinamide 40 mg/ml SUSPENSION MO	1	PA,QL(2760 per 30 days)
rufinamide 400 mg TABLET MO	1	PA,QL(240 per 30 days)
SABRIL 500 MG POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
SABRIL 500 MG TABLET DL	4	PA,QL(180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SEZABY 100 MG RECON SOLUTION DL	4	
SPRITAM 1,000 MG TABLET FOR SUSPENSION MO	3	ST,QL(90 per 30 days)
SPRITAM 250 MG TABLET FOR SUSPENSION MO	3	ST,QL(360 per 30 days)
SPRITAM 500 MG TABLET FOR SUSPENSION MO	3	ST,QL(180 per 30 days)
SPRITAM 750 MG TABLET FOR SUSPENSION MO	3	ST,QL(120 per 30 days)
subvenite 100 mg, 150 mg, 200 mg, 25 mg TABLET MO	1	
subvenite starter (blue) kit 25 mg (35) TABLET, DOSE PACK MO	1	
subvenite starter (green) kit 25 mg (84) -100 mg (14) TABLET, DOSE PACK MO	1	
subvenite starter (orange) kit 25 mg (42) -100 mg (7) TABLET, DOSE PACK MO	1	
SYMPAZAN 10 MG, 20 MG, 5 MG FILM DL	4	PA,QL(60 per 30 days)
TEGRETOL 100 MG/5 ML SUSPENSION MO	3	
TEGRETOL 200 MG TABLET MO	3	
TEGRETOL XR 100 MG, 200 MG, 400 MG TABLET, ER 12 HR. MO	3	
tiagabine 12 mg, 16 mg, 2 mg, 4 mg TABLET MO	1	
TOPAMAX 100 MG, 200 MG, 50 MG TABLET	4	QL(120 per 30 days)
TOPAMAX 15 MG, 25 MG CAPSULE, SPRINKLE	4	
TOPAMAX 25 MG TABLET MO	3	QL(90 per 30 days)
topiramate 100 mg, 200 mg, 50 mg TABLET MO	1	QL(120 per 30 days)
topiramate 100 mg, 50 mg CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(30 per 30 days)
topiramate 100 mg, 50 mg CAPSULE, ER 24 HR. MO	1	PA,QL(30 per 30 days)
topiramate 15 mg, 25 mg, 50 mg CAPSULE, SPRINKLE MO	1	
topiramate 150 mg, 200 mg CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(60 per 30 days)
topiramate 200 mg CAPSULE, ER 24 HR. MO	1	PA,QL(60 per 30 days)
topiramate 25 mg CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(90 per 30 days)
topiramate 25 mg CAPSULE, ER 24 HR. MO	1	PA,QL(90 per 30 days)
topiramate 25 mg TABLET MO	1	QL(90 per 30 days)
topiramate 25 mg/ml SOLUTION MO	1	PA,QL(480 per 30 days)
TRILEPTAL 150 MG TABLET MO	3	PA
TRILEPTAL 300 MG, 600 MG TABLET	4	PA
TRILEPTAL 300 MG/5 ML (60 MG/ML) SUSPENSION	4	PA
TROKENDI XR 100 MG CAPSULE, ER 24 HR.	4	PA,QL(30 per 30 days)
TROKENDI XR 200 MG CAPSULE, ER 24 HR.	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TROKENDI XR 25 MG CAPSULE, ER 24 HR. MO	3	PA,QL(90 per 30 days)
TROKENDI XR 50 MG CAPSULE, ER 24 HR. MO	3	PA,QL(30 per 30 days)
valproate sodium 500 mg/5 ml (100 mg/ml) SOLUTION MO	1	
valproic acid 250 mg CAPSULE MO	1	
valproic acid (as sodium salt) 250 mg/5 ml, 250 mg/5 ml (5 ml), 500 mg/10 ml (10 ml) SOLUTION MO	1	
VALTOCO 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) SPRAY, NON-AEROSOL DL	4	QL(10 per 30 days)
vigabatrin 500 mg POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
vigabatrin 500 mg TABLET DL	4	PA,QL(180 per 30 days)
vigadrone 500 mg POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
vigadrone 500 mg TABLET DL	4	PA,QL(180 per 30 days)
VIGAFYDE 100 MG/ML SOLUTION DL	4	PA,QL(600 per 25 days)
vigpoder 500 mg POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
VIMPAT 10 MG/ML SOLUTION DL	4	PA,QL(1395 per 30 days)
VIMPAT 100 MG, 150 MG, 200 MG TABLET DL	4	PA,QL(60 per 30 days)
VIMPAT 200 MG/20 ML SOLUTION DL	4	PA
VIMPAT 50 MG TABLET MO	3	PA,QL(60 per 30 days)
XCOPRI 100 MG, 25 MG, 50 MG TABLET DL	4	PA,QL(30 per 30 days)
XCOPRI 150 MG, 200 MG TABLET DL	4	PA,QL(60 per 30 days)
XCOPRI MAINTENANCE PACK 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) TABLET DL	4	PA,QL(56 per 28 days)
XCOPRI TITRATION PACK 12.5 MG (14)- 25 MG (14) TABLET, DOSE PACK MO	3	PA,QL(28 per 28 days)
XCOPRI TITRATION PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) TABLET, DOSE PACK DL	4	PA,QL(28 per 28 days)
ZARONTIN 250 MG CAPSULE MO	3	
ZARONTIN 250 MG/5 ML SOLUTION MO	1	
ZONEGRAN 100 MG, 25 MG CAPSULE	4	PA
ZONISADE 100 MG/5 ML SUSPENSION MO	3	PA,QL(900 per 30 days)
zonisamide 100 mg, 25 mg, 50 mg CAPSULE MO	1	
ZTALMY 50 MG/ML SUSPENSION DL	4	PA,QL(1080 per 30 days)
ANTIDEMENTIA AGENTS		
ADLARITY 10 MG/24 HOUR, 5 MG/24 HOUR PATCH, WEEKLY MO	3	ST,QL(4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ARICEPT 10 MG TABLET MO	3	PA,QL(60 per 30 days)
ARICEPT 23 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
donepezil 10 mg TABLET MO	1	QL(60 per 30 days)
donepezil 10 mg, 5 mg TABLET, DISINTEGRATING MO	1	QL(30 per 30 days)
donepezil 23 mg TABLET MO	1	QL(30 per 30 days)
donepezil 5 mg TABLET MO	1	QL(30 per 30 days)
ergoloid 1 mg TABLET MO	1	
EXELON PATCH 13.3 MG/24 HOUR, 4.6 MG/24 HOUR, 9.5 MG/24 HOUR PATCH, 24 HR. MO	3	PA,QL(30 per 30 days)
galantamine 12 mg, 4 mg, 8 mg TABLET MO	1	QL(60 per 30 days)
galantamine 16 mg, 24 mg, 8 mg CAPSULE ER PELLETS 24 HR. MO	1	QL(30 per 30 days)
galantamine 4 mg/ml SOLUTION MO	1	QL(200 per 30 days)
memantine 10 mg, 5 mg TABLET MO	1	PA,QL(60 per 30 days)
memantine 14 mg, 21 mg, 28 mg, 7 mg CAPSULE ER SPRINKLE 24 HR. MO	1	PA,QL(30 per 30 days)
memantine 2 mg/ml SOLUTION MO	1	PA,QL(360 per 30 days)
memantine 5-10 mg TABLET, DOSE PACK MO	1	PA,QL(98 per 30 days)
NAMENDA 10 MG TABLET MO	3	PA,QL(60 per 30 days)
NAMENDA TITRATION PAK 5-10 MG TABLET, DOSE PACK MO	3	PA,QL(98 per 30 days)
NAMENDA XR 14 MG, 21 MG, 28 MG, 7 MG CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(30 per 30 days)
NAMENDA XR 7-14-21-28 MG CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(28 per 28 days)
NAMZARIC 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG CAPSULE ER SPRINKLE 24 HR. MO	2	QL(30 per 30 days)
NAMZARIC 7/14/21/28 MG-10 MG CAPSULE ER SPRINKLE 24 HR. MO	2	QL(28 per 28 days)
rivastigmine 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour PATCH, 24 HR. MO	1	QL(30 per 30 days)
rivastigmine tartrate 1.5 mg, 3 mg CAPSULE MO	1	QL(90 per 30 days)
rivastigmine tartrate 4.5 mg, 6 mg CAPSULE MO	1	QL(60 per 30 days)
ZUNVEYL 10 MG, 15 MG, 5 MG TABLET, DR/EC MO	3	PA,QL(60 per 30 days)
ANTIDEPRESSANTS		
amitriptyline 10 mg, 100 mg, 150 mg, 50 mg, 75 mg TABLET MO	1	
amitriptyline 25 mg TABLET MO	1	
amitriptyline-chlordiazepoxide 12.5-5 mg, 25-10 mg TABLET DL	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
amoxapine 100 mg, 150 mg, 25 mg, 50 mg TABLET MO	1	
ANAFRANIL 25 MG, 50 MG, 75 MG CAPSULE DL	4	
APLENZIN 174 MG, 348 MG, 522 MG TABLET, ER 24 HR.	4	ST,QL(30 per 30 days)
AUVELITY 45-105 MG TABLET, IR/ER, BIPHASIC MO	3	PA,QL(60 per 30 days)
bupropion hcl 100 mg TABLET, SR 12 HR. MO	1	QL(120 per 30 days)
bupropion hcl 100 mg, 75 mg TABLET MO	1	QL(180 per 30 days)
bupropion hcl 150 mg TABLET, ER 24 HR. MO	1	QL(90 per 30 days)
bupropion hcl 150 mg TABLET, SR 12 HR. MO	1	QL(90 per 30 days)
bupropion hcl 200 mg TABLET, SR 12 HR. MO	1	QL(60 per 30 days)
bupropion hcl 300 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
bupropion hcl 450 mg TABLET, ER 24 HR. MO	1	ST,QL(30 per 30 days)
CELEXA 10 MG, 40 MG TABLET MO	3	PA,QL(30 per 30 days)
CELEXA 20 MG TABLET MO	3	PA,QL(60 per 30 days)
citalopram 10 mg, 40 mg TABLET MO	1	QL(30 per 30 days)
citalopram 10 mg/5 ml SOLUTION MO	1	
citalopram 20 mg TABLET MO	1	QL(60 per 30 days)
CITALOPRAM 30 MG CAPSULE MO	3	QL(30 per 30 days)
clomipramine 25 mg, 50 mg, 75 mg CAPSULE MO	1	
desipramine 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg TABLET MO	1	
desvenlafaxine 100 mg, 50 mg TABLET, ER 24 HR. MO	3	ST,QL(30 per 30 days)
desvenlafaxine succinate 100 mg, 25 mg, 50 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
EFFEXOR XR 150 MG CAPSULE, ER 24 HR. MO	3	PA,QL(60 per 30 days)
EFFEXOR XR 37.5 MG, 75 MG CAPSULE, ER 24 HR. MO	3	PA,QL(90 per 30 days)
EMSAM 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR PATCH, 24 HR.	4	PA,QL(30 per 30 days)
escitalopram oxalate 10 mg TABLET MO	1	QL(45 per 30 days)
escitalopram oxalate 20 mg, 5 mg TABLET MO	1	QL(30 per 30 days)
escitalopram oxalate 5 mg/5 ml SOLUTION MO	1	QL(600 per 30 days)
FETZIMA 120 MG, 20 MG, 40 MG, 80 MG CAPSULE, ER 24 HR. MO	3	PA,QL(30 per 30 days)
FETZIMA 20 MG (2)- 40 MG (26) CAPSULE, ER 24 HR. MO	3	PA,QL(28 per 28 days)
fluoxetine 10 mg CAPSULE MO	1	QL(60 per 30 days)
fluoxetine 10 mg TABLET MO	1	QL(240 per 30 days)
fluoxetine 20 mg CAPSULE MO	1	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
fluoxetine 20 mg TABLET MO	1	QL(120 per 30 days)
fluoxetine 20 mg/5 ml (4 mg/ml) SOLUTION MO	1	
fluoxetine 40 mg CAPSULE MO	1	QL(60 per 30 days)
fluoxetine 60 mg TABLET MO	1	QL(30 per 30 days)
fluoxetine 90 mg CAPSULE, DR/EC MO	1	QL(4 per 28 days)
fluvoxamine 100 mg, 150 mg CAPSULE, ER 24 HR. MO	1	QL(60 per 30 days)
fluvoxamine 100 mg, 25 mg, 50 mg TABLET MO	1	QL(90 per 30 days)
FORFIVO XL 450 MG TABLET, ER 24 HR. MO	3	ST,QL(30 per 30 days)
imipramine hcl 10 mg, 25 mg, 50 mg TABLET MO	1	
imipramine pamoate 100 mg, 125 mg, 150 mg, 75 mg CAPSULE MO	1	
LEXAPRO 10 MG TABLET MO	3	PA,QL(45 per 30 days)
LEXAPRO 20 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
MARPLAN 10 MG TABLET MO	3	
mirtazapine 15 mg, 30 mg, 45 mg TABLET, DISINTEGRATING MO	1	QL(30 per 30 days)
mirtazapine 15 mg, 30 mg, 7.5 mg TABLET MO	1	
mirtazapine 45 mg TABLET MO	1	
NARDIL 15 MG TABLET MO	3	
nefazodone 100 mg, 150 mg, 200 mg, 250 mg, 50 mg TABLET MO	1	
NORPRAMIN 10 MG, 25 MG TABLET MO	3	
nortriptyline 10 mg, 25 mg, 50 mg, 75 mg CAPSULE MO	1	
nortriptyline 10 mg/5 ml SOLUTION MO	1	
olanzapine-fluoxetine 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg CAPSULE MO	1	QL(30 per 30 days)
PAMELOR 10 MG, 25 MG, 50 MG, 75 MG CAPSULE DL	4	
PARNATE 10 MG TABLET DL	4	
paroxetine hcl 10 mg, 20 mg TABLET MO	1	QL(30 per 30 days)
paroxetine hcl 10 mg/5 ml SUSPENSION MO	1	
paroxetine hcl 12.5 mg, 37.5 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
paroxetine hcl 25 mg TABLET, ER 24 HR. MO	1	QL(90 per 30 days)
paroxetine hcl 30 mg, 40 mg TABLET MO	1	QL(60 per 30 days)
paroxetine mesylate(menop.sym) 7.5 mg CAPSULE MO	1	QL(30 per 30 days)
PAXIL 10 MG, 20 MG TABLET MO	3	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PAXIL 10 MG/5 ML SUSPENSION MO	3	PA
PAXIL 30 MG, 40 MG TABLET MO	3	QL(60 per 30 days)
PAXIL CR 12.5 MG, 37.5 MG TABLET, ER 24 HR. MO	3	QL(60 per 30 days)
PAXIL CR 25 MG TABLET, ER 24 HR. MO	3	QL(90 per 30 days)
<i>perphenazine-amitriptyline 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg</i> TABLET MO	1	
<i>phenelzine 15 mg</i> TABLET MO	1	
PRISTIQ 100 MG, 25 MG, 50 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
<i>protriptyline 10 mg, 5 mg</i> TABLET MO	1	
PROZAC 10 MG, 40 MG CAPSULE	4	PA,QL(60 per 30 days)
PROZAC 20 MG CAPSULE	4	PA,QL(120 per 30 days)
RALDESY 10 MG/ML SOLUTION DL	4	
REMERON 15 MG, 30 MG TABLET MO	3	
REMERON SOLTAB 15 MG, 30 MG, 45 MG TABLET, DISINTEGRATING MO	3	QL(30 per 30 days)
<i>sertraline 100 mg</i> TABLET MO	1	QL(60 per 30 days)
SERTRALINE 150 MG, 200 MG CAPSULE MO	3	QL(30 per 30 days)
<i>sertraline 150 mg, 200 mg</i> CAPSULE MO	3	QL(30 per 30 days)
<i>sertraline 20 mg/ml</i> CONCENTRATE MO	1	
<i>sertraline 25 mg, 50 mg</i> TABLET MO	1	QL(90 per 30 days)
SYMBYAX 3-25 MG, 6-25 MG CAPSULE MO	3	PA,QL(30 per 30 days)
<i>tranylcypromine 10 mg</i> TABLET MO	1	
<i>trazodone 100 mg, 150 mg, 50 mg</i> TABLET MO	1	
<i>trazodone 300 mg</i> TABLET MO	1	
<i>trimipramine 100 mg, 25 mg, 50 mg</i> CAPSULE MO	1	
TRINTELLIX 10 MG, 20 MG, 5 MG TABLET MO	3	ST,QL(30 per 30 days)
<i>venlafaxine 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> TABLET MO	1	
<i>venlafaxine 150 mg</i> CAPSULE, ER 24 HR. MO	1	QL(60 per 30 days)
<i>venlafaxine 150 mg, 225 mg, 37.5 mg</i> TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
<i>venlafaxine 37.5 mg</i> CAPSULE, ER 24 HR. MO	1	QL(90 per 30 days)
<i>venlafaxine 75 mg</i> CAPSULE, ER 24 HR. MO	1	QL(90 per 30 days)
<i>venlafaxine 75 mg</i> TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
VENLAFAXINE BESYLATE 112.5 MG TABLET, ER 24 HR. MO	3	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VIIBRYD 10 MG, 20 MG, 40 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>vilazodone 10 mg, 20 mg, 40 mg TABLET MO</i>	1	PA,QL(30 per 30 days)
WELLBUTRIN SR 100 MG TABLET, SR 12 HR. MO	3	PA,QL(120 per 30 days)
WELLBUTRIN SR 150 MG TABLET, SR 12 HR. MO	3	PA,QL(90 per 30 days)
WELLBUTRIN SR 200 MG TABLET, SR 12 HR. MO	3	PA,QL(60 per 30 days)
WELLBUTRIN XL 150 MG TABLET, ER 24 HR.	4	PA,QL(90 per 30 days)
WELLBUTRIN XL 300 MG TABLET, ER 24 HR.	4	PA,QL(60 per 30 days)
ZOLOFT 100 MG TABLET MO	3	PA,QL(60 per 30 days)
ZOLOFT 20 MG/ML CONCENTRATE MO	3	PA
ZOLOFT 25 MG, 50 MG TABLET MO	3	PA,QL(90 per 30 days)
ZULRESSO 5 MG/ML SOLUTION DL	4	PA,QL(100 per 365 days)
ZURZUVAE 20 MG, 25 MG CAPSULE DL	4	PA,QL(28 per 365 days)
ZURZUVAE 30 MG CAPSULE DL	4	PA,QL(14 per 365 days)
ANTIEMETICS		
AKYNZEO (FOSNETUPITANT) 235 MG-0.25 MG/20 ML SOLUTION DL	4	PA,QL(80 per 28 days)
AKYNZEO (FOSNETUPITANT) 235-0.25 MG RECON SOLUTION DL	4	PA,QL(4 per 28 days)
AKYNZEO (NETUPITANT) 300-0.5 MG CAPSULE MO	3	PA
ANTIVERT 25 MG CHEWABLE TABLET MO	3	
ANTIVERT 50 MG TABLET MO	3	
ANZEMET 50 MG TABLET MO	3	BvsD,QL(4 per 28 days)
APONVIE 32 MG/4.4 ML (7.2 MG/ML) EMULSION MO	3	
<i>aprepitant 125 mg (1)- 80 mg (2) CAPSULE, DOSE PACK MO</i>	1	BvsD
<i>aprepitant 125 mg, 40 mg CAPSULE MO</i>	1	BvsD,QL(2 per 28 days)
<i>aprepitant 80 mg CAPSULE MO</i>	1	BvsD,QL(4 per 28 days)
BONJESTA 20-20 MG TABLET, IR, DR, BIPHASIC MO	3	QL(60 per 30 days)
CINVANTI 130 MG/18 ML (7.2 MG/ML) EMULSION MO	3	PA,QL(36 per 28 days)
COMPAZINE 10 MG, 5 MG TABLET MO	3	BvsD
COMPAZINE 25 MG SUPPOSITORY MO	1	
<i>compro 25 mg SUPPOSITORY MO</i>	1	
DICLEGIS 10-10 MG TABLET, DR/EC MO	3	QL(120 per 30 days)
<i>dimenhydrinate 50 mg/ml SOLUTION MO</i>	1	
<i>doxylamine-pyridoxine (vit b6) 10-10 mg TABLET, DR/EC MO</i>	1	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>dronabinol 10 mg, 2.5 mg, 5 mg CAPSULE</i> MO	1	BvsD,QL(120 per 30 days)
EMEND 125 MG (1)- 80 MG (2) CAPSULE, DOSE PACK MO	3	BvsD
EMEND 125 MG (25 MG/ ML FINAL CONC.) SUSPENSION FOR RECONSTITUTION MO	3	BvsD,QL(3 per 28 days)
EMEND 80 MG CAPSULE MO	3	BvsD,QL(4 per 28 days)
EMEND (FOSAPREPITANT) 150 MG RECON SOLUTION MO	3	PA
FOCINVEZ 150 MG/50 ML (3 MG/ML) SOLUTION MO	3	PA
<i>fosaprepitant 150 mg RECON SOLUTION</i> MO	1	PA
GIMOTI 15 MG/SPRAY SPRAY WITH PUMP DL	4	PA,QL(9.8 per 28 days)
<i>granisetron (pf) 1 mg/ml (1 ml), 100 mcg/ml SOLUTION</i> MO	1	
<i>granisetron hcl 1 mg TABLET</i> MO	1	BvsD,QL(28 per 28 days)
<i>granisetron hcl 1 mg/ml, 1 mg/ml (1 ml) SOLUTION</i> MO	1	
MARINOL 10 MG, 2.5 MG, 5 MG CAPSULE DL	4	BvsD,QL(120 per 30 days)
<i>meclizine 12.5 mg TABLET</i> MO	1	
<i>meclizine 25 mg TABLET</i> MO	1	
<i>meclizine 50 mg TABLET</i> MO	3	
<i>metoclopramide hcl 10 mg, 5 mg TABLET</i> MO	1	
<i>metoclopramide hcl 5 mg/5 ml, 5 mg/ml SOLUTION</i> MO	1	
<i>metoclopramide hcl 5 mg/ml SYRINGE</i> MO	1	
<i>ondansetron 16 mg TABLET, DISINTEGRATING</i> DL	4	BvsD
<i>ondansetron 4 mg TABLET, DISINTEGRATING</i> MO	1	BvsD
<i>ondansetron 8 mg TABLET, DISINTEGRATING</i> MO	1	BvsD
<i>ondansetron hcl 2 mg/ml SOLUTION</i> MO	1	
<i>ondansetron hcl 4 mg TABLET</i> MO	1	BvsD
<i>ondansetron hcl 4 mg/5 ml SOLUTION</i> MO	1	BvsD,QL(450 per 30 days)
<i>ondansetron hcl 8 mg TABLET</i> MO	1	BvsD
<i>ondansetron hcl (pf) 4 mg/2 ml SOLUTION</i> MO	1	
<i>ondansetron hcl (pf) 4 mg/2 ml SYRINGE</i> MO	1	
PHENERGAN 25 MG/ML, 50 MG/ML SOLUTION MO	1	
<i>prochlorperazine 25 mg SUPPOSITORY</i> MO	1	
<i>prochlorperazine edisylate 10 mg/2 ml (5 mg/ml), 5 mg/ml SOLUTION</i> MO	1	
<i>prochlorperazine maleate 10 mg, 5 mg TABLET</i> MO	1	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>promethazine 12.5 mg, 25 mg, 50 mg SUPPOSITORY</i> MO	1	
<i>promethazine 12.5 mg, 50 mg TABLET</i> MO	1	
<i>promethazine 25 mg TABLET</i> MO	1	
<i>promethazine 25 mg/ml, 50 mg/ml SOLUTION</i> MO	1	
<i>promethazine 6.25 mg/5 ml SYRUP</i> MO	1	
<i>promethegan 12.5 mg, 25 mg, 50 mg SUPPOSITORY</i> MO	1	
REGLAN 10 MG, 5 MG TABLET MO	3	
SANCUSO 3.1 MG/24 HOUR PATCH, WEEKLY DL	4	PA,QL(4 per 30 days)
<i>scopolamine base 1 mg over 3 days PATCH, 3 DAY</i> MO	1	QL(10 per 30 days)
TIGAN 100 MG/ML SOLUTION MO	3	
TRANSDERM-SCOP 1 MG OVER 3 DAYS PATCH, 3 DAY MO	3	QL(10 per 30 days)
<i>trimethobenzamide 300 mg CAPSULE</i> MO	1	BvsD
VARUBI 90 MG TABLET MO	3	PA
ANTIFUNGALS		
ABELCET 5 MG/ML SUSPENSION MO	3	BvsD
AMBISOME 50 MG SUSPENSION FOR RECONSTITUTION DL	4	BvsD
<i>amphotericin b 50 mg RECON SOLUTION</i> MO	1	BvsD
<i>amphotericin b liposome 50 mg SUSPENSION FOR RECONSTITUTION</i> DL	4	BvsD
ANCOBON 250 MG, 500 MG CAPSULE MO	3	
CANCIDAS 50 MG, 70 MG RECON SOLUTION DL	4	PA
<i>caspofungin 50 mg, 70 mg RECON SOLUTION</i> MO	1	
<i>ciclodan 8 % SOLUTION</i> MO	1	QL(13.2 per 30 days)
<i>ciclopirox 0.77 % CREAM</i> MO	1	QL(90 per 30 days)
<i>ciclopirox 0.77 % GEL</i> MO	1	QL(100 per 30 days)
<i>ciclopirox 0.77 % SUSPENSION</i> MO	1	QL(60 per 30 days)
<i>ciclopirox 1 % SHAMPOO</i> MO	1	QL(120 per 30 days)
<i>ciclopirox 8 % SOLUTION</i> MO	1	QL(13.2 per 30 days)
<i>clotrimazole 1 % CREAM</i> MO	1	
<i>clotrimazole 1 % SOLUTION</i> MO	1	
<i>clotrimazole 10 mg TROCHE</i> MO	1	
<i>clotrimazole-betamethasone 1-0.05 % CREAM</i> MO	1	QL(180 per 30 days)
<i>clotrimazole-betamethasone 1-0.05 % LOTION</i> MO	1	QL(90 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CRESEMBA 186 MG, 74.5 MG CAPSULE DL	4	PA
CRESEMBA 372 MG RECON SOLUTION DL	4	PA
DIFLUCAN 100 MG, 200 MG TABLET MO	3	PA
DIFLUCAN 40 MG/ML SUSPENSION FOR RECONSTITUTION DL	4	PA
<i>econazole nitrate 1 % CREAM</i> MO	1	PA,QL(85 per 30 days)
ERAXIS(WATER DILUENT) 100 MG, 50 MG RECON SOLUTION DL	4	
ERTACZO 2 % CREAM DL	4	QL(60 per 30 days)
EXELDERM 1 % CREAM	4	ST
EXELDERM 1 % SOLUTION	4	ST,QL(60 per 30 days)
EXTINA 2 % FOAM MO	3	QL(100 per 30 days)
<i>fluconazole 10 mg/ml, 40 mg/ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>fluconazole 100 mg, 200 mg, 50 mg TABLET</i> MO	1	
<i>fluconazole 150 mg TABLET</i> MO	1	
<i>fluconazole in nacl (iso-osm) 100 mg/50 ml, 200 mg/100 ml, 400 mg/200 ml PIGGYBACK</i> MO	1	
<i>flucytosine 250 mg, 500 mg CAPSULE</i> DL	4	
FULVICIN P/G 165 MG TABLET DL	4	
<i>griseofulvin microsize 125 mg/5 ml SUSPENSION</i> MO	1	
<i>griseofulvin microsize 500 mg TABLET</i> MO	1	
<i>griseofulvin ultramicrosize 125 mg, 250 mg TABLET</i> MO	1	
<i>griseofulvin ultramicrosize 165 mg TABLET</i> DL	4	
<i>gynazole-1 2 % CREAM</i> MO	1	
<i>itraconazole 10 mg/ml SOLUTION</i> DL	4	
<i>itraconazole 100 mg CAPSULE</i> MO	1	QL(120 per 30 days)
JUBLIA 10 % SOLUTION W/APPLICATOR DL	4	PA,QL(4 per 28 days)
<i>ketoconazole 2 % CREAM</i> MO	1	QL(60 per 30 days)
<i>ketoconazole 2 % FOAM</i> MO	1	QL(100 per 30 days)
<i>ketoconazole 2 % SHAMPOO</i> MO	1	QL(120 per 30 days)
<i>ketoconazole 200 mg TABLET</i> MO	1	PA
<i>ketodan 2 % FOAM</i> MO	1	QL(100 per 30 days)
<i>klayesta 100,000 unit/gram POWDER</i> MO	1	PA
LOPROX 1 % SHAMPOO MO	3	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LOPROX (AS OLAMINE) 0.77 % CREAM MO	3	PA,QL(90 per 30 days)
LOPROX (AS OLAMINE) 0.77 % SUSPENSION MO	3	PA,QL(60 per 30 days)
<i>luliconazole</i> 1 % CREAM MO	1	ST,QL(60 per 28 days)
LUZU 1 % CREAM MO	3	ST,QL(60 per 28 days)
MENTAX 1 % CREAM MO	3	QL(30 per 30 days)
<i>micafungin</i> 100 mg, 50 mg RECON SOLUTION MO	1	
MICAFUNGIN IN 0.9 % SODIUM CHL 100 MG/100 ML, 150 MG/150 ML, 50 MG/50 ML PIGGYBACK DL	4	
<i>micafungin</i> in 0.9 % sodium chl 150 mg/150 ml PIGGYBACK DL	4	
<i>miconazole</i> nitrate-zinc ox-pet 0.25-15-81.35 % OINTMENT MO	1	
<i>miconazole</i> -3 200 mg SUPPOSITORY MO	1	
MYCAMINE 100 MG, 50 MG RECON SOLUTION DL	4	
<i>naftifine</i> 1 % CREAM MO	1	ST,QL(90 per 30 days)
<i>naftifine</i> 2 % CREAM MO	1	ST,QL(120 per 30 days)
<i>naftifine</i> 2 % GEL MO	1	ST,QL(120 per 30 days)
NAFTIN 1 % GEL MO	3	ST,QL(90 per 30 days)
NAFTIN 2 % GEL MO	3	ST,QL(120 per 30 days)
NOXAFIL 100 MG TABLET, DR/EC DL	4	PA
NOXAFIL 200 MG/5 ML (40 MG/ML) SUSPENSION DL	4	PA,QL(840 per 28 days)
NOXAFIL 300 MG SUSPENSION, DR FOR RECON DL	4	PA,QL(32 per 30 days)
NOXAFIL 300 MG/16.7 ML SOLUTION DL	4	PA
<i>nyamyc</i> 100,000 unit/gram POWDER MO	1	PA
<i>nystatin</i> 100,000 unit/gram CREAM MO	1	
<i>nystatin</i> 100,000 unit/gram OINTMENT MO	1	
<i>nystatin</i> 100,000 unit/gram POWDER MO	1	PA
<i>nystatin</i> 100,000 unit/ml SUSPENSION MO	1	
<i>nystatin</i> 500,000 unit TABLET MO	1	
<i>nystatin-triamcinolone</i> 100,000-0.1 unit/g-% CREAM MO	1	
<i>nystatin-triamcinolone</i> 100,000-0.1 unit/gram-% OINTMENT MO	1	
<i>nystop</i> 100,000 unit/gram POWDER MO	1	PA
<i>oxiconazole</i> 1 % CREAM MO	1	PA,QL(60 per 30 days)
OXISTAT 1 % LOTION MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
posaconazole 100 mg TABLET, DR/EC DL	4	PA
posaconazole 200 mg/5 ml (40 mg/ml) SUSPENSION DL	4	PA,QL(840 per 28 days)
posaconazole 300 mg/16.7 ml SOLUTION DL	4	PA
REZZAYO 200 MG RECON SOLUTION DL	4	PA
SPORANOX 10 MG/ML SOLUTION DL	4	
SPORANOX 100 MG CAPSULE MO	3	PA,QL(120 per 30 days)
tavaborole 5 % SOLUTION W/APPLICATOR MO	1	PA,QL(10 per 30 days)
terbinafine hcl 250 mg TABLET MO	1	
terconazole 0.4 %, 0.8 % CREAM MO	1	
terconazole 80 mg SUPPOSITORY MO	1	
TOLSURA 65 MG CAPSULE, SOLID DISPERSION DL	4	PA,QL(120 per 30 days)
VFEND 200 MG, 50 MG TABLET MO	3	PA,QL(120 per 30 days)
VFEND 200 MG/5 ML (40 MG/ML) SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(400 per 30 days)
VFEND IV 200 MG RECON SOLUTION MO	3	PA
VIVJOA 150 MG CAPSULE MO	3	PA
voriconazole 200 mg RECON SOLUTION MO	1	PA
voriconazole 200 mg, 50 mg TABLET MO	1	PA,QL(120 per 30 days)
voriconazole 200 mg/5 ml (40 mg/ml) SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(400 per 30 days)
voriconazole-hpbc 200 mg RECON SOLUTION MO	1	PA
VUSION 0.25-15-81.35 % OINTMENT MO	3	
XOLEGEL 2 % GEL MO	3	
ANTIGOUT AGENTS		
allopurinol 100 mg, 300 mg TABLET MO	1	
allopurinol 200 mg TABLET MO	3	
allopurinol sodium 500 mg RECON SOLUTION MO	1	
ALOPRIM 500 MG RECON SOLUTION MO	3	
colchicine 0.6 mg CAPSULE MO	1	PA
colchicine 0.6 mg TABLET MO	1	QL(120 per 30 days)
COLCRYS 0.6 MG TABLET MO	3	PA,QL(120 per 30 days)
DUZALLO 200-200 MG, 200-300 MG TABLET MO	3	PA,QL(30 per 30 days)
febuxostat 40 mg, 80 mg TABLET MO	1	ST,QL(30 per 30 days)
GLOPERBA 0.6 MG/5 ML SOLUTION MO	3	PA,QL(300 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MITIGARE 0.6 MG CAPSULE MO	3	PA
<i>probenecid</i> 500 mg TABLET MO	1	
<i>probenecid-colchicine</i> 500-0.5 mg TABLET MO	1	
ULORIC 40 MG, 80 MG TABLET MO	3	ST,QL(30 per 30 days)
ZYLOPRIM 100 MG TABLET MO	3	
ANTIMIGRAINE AGENTS		
AIMOVIG AUTOINJECTOR 140 MG/ML AUTO-INJECTOR MO	3	PA,QL(1 per 28 days)
AIMOVIG AUTOINJECTOR 70 MG/ML AUTO-INJECTOR MO	3	PA,QL(2 per 28 days)
AJOVY AUTOINJECTOR 225 MG/1.5 ML AUTO-INJECTOR MO	3	PA,QL(1.5 per 28 days)
AJOVY SYRINGE 225 MG/1.5 ML SYRINGE MO	3	PA,QL(1.5 per 28 days)
<i>almotriptan malate</i> 12.5 mg, 6.25 mg TABLET MO	1	ST,QL(9 per 30 days)
<i>dihydroergotamine</i> 0.5 mg/pump act. (4 mg/ml) SPRAY, NON-AEROSOL DL	4	PA,QL(8 per 30 days)
<i>dihydroergotamine</i> 1 mg/ml SOLUTION DL	4	PA
<i>eletriptan</i> 20 mg, 40 mg TABLET MO	1	ST,QL(9 per 30 days)
EMGALITY PEN 120 MG/ML PEN INJECTOR MO	3	PA,QL(2 per 30 days)
EMGALITY SYRINGE 120 MG/ML SYRINGE MO	3	PA,QL(2 per 30 days)
EMGALITY SYRINGE 300 MG/3 ML (100 MG/ML X 3) SYRINGE MO	3	PA,QL(3 per 30 days)
ERGOMAR 2 MG SUBLINGUAL TABLET DL	4	QL(20 per 28 days)
<i>ergotamine-caffeine</i> 1-100 mg TABLET MO	1	QL(40 per 30 days)
FROVA 2.5 MG TABLET DL	4	ST,QL(12 per 30 days)
<i>frovatriptan</i> 2.5 mg TABLET MO	1	ST,QL(12 per 30 days)
IMITREX 100 MG TABLET DL	4	PA,QL(9 per 30 days)
IMITREX 20 MG/ACTUATION, 5 MG/ACTUATION SPRAY, NON-AEROSOL MO	3	PA,QL(12 per 30 days)
IMITREX 25 MG, 50 MG TABLET MO	3	PA,QL(9 per 30 days)
IMITREX STATDOSE PEN 4 MG/0.5 ML, 6 MG/0.5 ML PEN INJECTOR MO	3	PA,QL(6 per 30 days)
IMITREX STATDOSE REFILL 4 MG/0.5 ML, 6 MG/0.5 ML CARTRIDGE DL	4	PA,QL(6 per 30 days)
MAXALT 10 MG TABLET MO	3	PA,QL(12 per 30 days)
MAXALT-MLT 10 MG TABLET, DISINTEGRATING MO	3	PA,QL(12 per 30 days)
<i>migergot</i> 2-100 mg SUPPOSITORY DL	4	QL(20 per 28 days)
MIGRANAL 0.5 MG/PUMP ACT. (4 MG/ML) SPRAY, NON-AEROSOL DL	4	QL(8 per 30 days)
<i>naratriptan</i> 1 mg, 2.5 mg TABLET MO	1	QL(9 per 30 days)
NURTEC ODT 75 MG TABLET, DISINTEGRATING	4	PA,QL(18 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ONZETRA XSAIL 11 MG AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(16 per 30 days)
QULIPTA 10 MG, 30 MG, 60 MG TABLET MO	3	PA,QL(30 per 30 days)
RELPAK 20 MG, 40 MG TABLET DL	4	ST,QL(9 per 30 days)
REYVOW 100 MG TABLET MO	3	PA,QL(8 per 30 days)
REYVOW 50 MG TABLET MO	3	PA,QL(4 per 30 days)
<i>rizatriptan 10 mg, 5 mg TABLET</i> MO	1	QL(12 per 30 days)
<i>rizatriptan 10 mg, 5 mg TABLET, DISINTEGRATING</i> MO	1	QL(12 per 30 days)
<i>sumatriptan 20 mg/actuation, 5 mg/actuation SPRAY, NON-AEROSOL</i> MO	1	QL(12 per 30 days)
<i>sumatriptan succinate 100 mg, 25 mg, 50 mg TABLET</i> MO	1	QL(9 per 30 days)
<i>sumatriptan succinate 4 mg/0.5 ml, 6 mg/0.5 ml CARTRIDGE</i> MO	3	QL(6 per 30 days)
<i>sumatriptan succinate 4 mg/0.5 ml, 6 mg/0.5 ml PEN INJECTOR</i> MO	1	QL(6 per 30 days)
<i>sumatriptan succinate 6 mg/0.5 ml SOLUTION</i> MO	1	QL(6 per 30 days)
<i>sumatriptan succinate 6 mg/0.5 ml SYRINGE</i> MO	1	QL(6 per 30 days)
<i>sumatriptan-naproxen 85-500 mg TABLET</i> MO	1	ST,QL(18 per 30 days)
SYMBRAVO 10-20 MG TABLET DL	4	ST,QL(9 per 30 days)
TOSYMRA 10 MG/ACTUATION SPRAY, NON-AEROSOL MO	3	ST,QL(12 per 30 days)
TREXIMET 85-500 MG TABLET DL	4	ST,QL(18 per 30 days)
TRUDHESA 0.725 MG/PUMP ACT. (4 MG/ML) SPRAY, NON-AEROSOL DL	4	PA,QL(8 per 30 days)
UBRELVY 100 MG, 50 MG TABLET MO	2	PA,QL(16 per 30 days)
VYEPTI 100 MG/ML SOLUTION MO	3	PA,QL(3 per 90 days)
ZAVZPRET 10 MG/ACTUATION SPRAY, NON-AEROSOL DL	4	PA,QL(8 per 30 days)
ZEMBRACE SYMTOUCH 3 MG/0.5 ML PEN INJECTOR DL	4	ST,QL(6 per 30 days)
<i>zolmitriptan 2.5 mg TABLET</i> MO	1	ST,QL(9 per 30 days)
<i>zolmitriptan 2.5 mg TABLET, DISINTEGRATING</i> MO	1	ST,QL(9 per 30 days)
<i>zolmitriptan 2.5 mg, 5 mg SPRAY, NON-AEROSOL</i> MO	1	ST,QL(12 per 30 days)
<i>zolmitriptan 5 mg TABLET</i> MO	1	ST,QL(6 per 30 days)
<i>zolmitriptan 5 mg TABLET, DISINTEGRATING</i> MO	1	ST,QL(6 per 30 days)
<i>zomig 2.5 mg TABLET</i> MO	3	ST,QL(9 per 30 days)
ZOMIG 2.5 MG, 5 MG SPRAY, NON-AEROSOL MO	3	ST,QL(12 per 30 days)
<i>zomig 5 mg TABLET</i> MO	3	ST,QL(6 per 30 days)
ANTIMYASTHENIC AGENTS		
MESTINON 60 MG TABLET	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MESTINON 60 MG/5 ML SYRUP	4	
MESTINON TIMESPAN 180 MG TABLET ER	4	PA
<i>pyridostigmine bromide 180 mg TABLET ER</i> MO	1	
<i>pyridostigmine bromide 30 mg, 60 mg TABLET</i> MO	1	
<i>pyridostigmine bromide 60 mg/5 ml SYRUP</i> MO	1	
REGONOL 5 MG/ML SOLUTION MO	3	
VYVGART 20 MG/ML SOLUTION DL	4	PA
VYVGART HYTRULO 1,000 MG-10,000 UNIT/5 ML SYRINGE DL	4	PA,QL(20 per 28 days)
VYVGART HYTRULO 1,008 MG-11,200 UNIT/5.6 ML SOLUTION DL	4	PA,QL(22.4 per 28 days)
ANTIMYCOBACTERIALS		
<i>cycloserine 250 mg CAPSULE</i> DL	4	
<i>dapsone 100 mg, 25 mg TABLET</i> MO	1	
<i>ethambutol 100 mg, 400 mg TABLET</i> MO	1	
<i>isoniazid 100 mg, 300 mg TABLET</i> MO	1	
<i>isoniazid 100 mg/ml, 50 mg/5 ml SOLUTION</i> MO	1	
MYAMBUTOL 400 MG TABLET MO	3	
MYCOBUTIN 150 MG CAPSULE MO	3	
PRETOMANID 200 MG TABLET MO	3	PA,QL(30 per 30 days)
PRIFTIN 150 MG TABLET MO	3	
<i>pyrazinamide 500 mg TABLET</i> MO	1	
<i>rifabutin 150 mg CAPSULE</i> MO	1	
RIFADIN 600 MG RECON SOLUTION MO	3	
<i>rifampin 150 mg, 300 mg CAPSULE</i> MO	1	
<i>rifampin 600 mg RECON SOLUTION</i> MO	1	
SIRTURO 100 MG, 20 MG TABLET DL	4	PA
TRECTOR 250 MG TABLET MO	3	
ANTINEOPLASTICS		
<i>abiraterone 250 mg TABLET</i> DL	4	PA,QL(120 per 30 days)
<i>abiraterone 500 mg TABLET</i> DL	4	PA,QL(60 per 30 days)
<i>abirtega 250 mg TABLET</i> MO	1	PA,QL(120 per 30 days)
ABRAXANE 100 MG SUSPENSION FOR RECONSTITUTION DL	4	PA
ADCETRIS 50 MG RECON SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ADRIAMYCIN 50 MG RECON SOLUTION MO	1	BvsD
<i>adrucil 2.5 gram/50 ml SOLUTION</i> MO	1	BvsD
AFINITOR 10 MG, 2.5 MG, 5 MG, 7.5 MG TABLET DL	4	PA,QL(30 per 30 days)
AFINITOR DISPERZ 2 MG, 3 MG, 5 MG TABLET FOR SUSPENSION DL	4	PA
AKEEGA 100-500 MG, 50-500 MG TABLET DL	4	PA,QL(60 per 30 days)
ALECENSA 150 MG CAPSULE DL	4	PA,QL(240 per 30 days)
ALIMTA 100 MG, 500 MG RECON SOLUTION DL	4	PA
ALIQOPA 60 MG RECON SOLUTION DL	4	PA,QL(3 per 28 days)
ALUNBRIG 180 MG, 90 MG TABLET DL	4	PA,QL(30 per 30 days)
ALUNBRIG 30 MG TABLET DL	4	PA,QL(180 per 30 days)
ALUNBRIG 90 MG (7)- 180 MG (23) TABLET, DOSE PACK DL	4	PA,QL(30 per 30 days)
ALYMSYS 25 MG/ML SOLUTION DL	4	PA
<i>anastrozole 1 mg TABLET</i> MO	1	QL(30 per 30 days)
ANKTIVA 400 MCG/0.4 ML SOLUTION DL	4	PA
ARIMIDEX 1 MG TABLET DL	4	PA,QL(30 per 30 days)
AROMASIN 25 MG TABLET DL	4	PA,QL(60 per 30 days)
ARRANON 250 MG/50 ML SOLUTION DL	4	
<i>arsenic trioxide 1 mg/ml, 2 mg/ml SOLUTION</i> DL	4	PA
ASPARLAS 750 UNIT/ML SOLUTION DL	4	PA
AUGTYRO 160 MG CAPSULE DL	4	PA,QL(60 per 30 days)
AUGTYRO 40 MG CAPSULE DL	4	PA,QL(240 per 30 days)
AVASTIN 25 MG/ML SOLUTION DL	4	PA
AVMAPKI-FAKZYNJA 0.8-200 MG COMBO PACK DL	4	PA,QL(66 per 28 days)
AXTLE 100 MG, 500 MG RECON SOLUTION DL	4	PA
AYVAKIT 100 MG, 200 MG, 25 MG, 300 MG, 50 MG TABLET DL	4	PA,QL(30 per 30 days)
<i>azacitidine 100 mg RECON SOLUTION</i> DL	4	PA
BALVERSA 3 MG TABLET DL	4	PA,QL(90 per 30 days)
BALVERSA 4 MG TABLET DL	4	PA,QL(60 per 30 days)
BALVERSA 5 MG TABLET DL	4	PA,QL(30 per 30 days)
BAVENCIO 20 MG/ML SOLUTION DL	4	PA
BELEODAQ 500 MG RECON SOLUTION DL	4	PA
<i>bendamustine 100 mg, 25 mg RECON SOLUTION</i> DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>bendamustine 25 mg/ml SOLUTION</i> DL	4	PA
BENDEKA 25 MG/ML SOLUTION DL	4	PA
BESPONSA 0.9 MG (0.25 MG/ML INITIAL) RECON SOLUTION DL	4	PA
<i>bexarotene 1 % GEL</i> DL	4	PA,QL(240 per 30 days)
<i>bexarotene 75 mg CAPSULE</i> DL	4	PA,QL(300 per 30 days)
<i>bicalutamide 50 mg TABLET</i> MO	1	QL(30 per 30 days)
BICNU 100 MG RECON SOLUTION MO	3	
BIZENGRI 375 MG/18.75 ML (20 MG/ML) SOLUTION DL	4	PA,QL(75 per 28 days)
<i>bleomycin 15 unit, 30 unit RECON SOLUTION</i> MO	1	BvsD
BORTEZOMIB 1 MG, 2.5 MG RECON SOLUTION DL	4	PA
<i>bortezomib 3.5 mg RECON SOLUTION</i> DL	4	PA
BORUZU 2.5 MG/ML SOLUTION DL	4	PA
BOSULIF 100 MG CAPSULE DL	4	PA,QL(180 per 30 days)
BOSULIF 100 MG TABLET DL	4	PA,QL(120 per 30 days)
BOSULIF 400 MG, 500 MG TABLET DL	4	PA,QL(30 per 30 days)
BOSULIF 50 MG CAPSULE DL	4	PA,QL(360 per 30 days)
BRAFTOVI 75 MG CAPSULE DL	4	PA,QL(180 per 30 days)
BRUKINSA 80 MG CAPSULE DL	4	PA,QL(120 per 30 days)
<i>busulfan 60 mg/10 ml SOLUTION</i> MO	1	
BUSULFEX 60 MG/10 ML SOLUTION MO	3	
CABOMETYX 20 MG, 40 MG, 60 MG TABLET DL	4	PA,QL(30 per 30 days)
CALQUENCE (ACALABRUTINIB MAL) 100 MG TABLET DL	4	PA,QL(60 per 30 days)
CAMPTOSAR 100 MG/5 ML, 300 MG/15 ML, 40 MG/2 ML SOLUTION DL	4	
CAPRELSA 100 MG TABLET DL,LA	4	PA,QL(60 per 30 days)
CAPRELSA 300 MG TABLET DL,LA	4	PA,QL(30 per 30 days)
<i>carboplatin 10 mg/ml SOLUTION</i> MO	1	
<i>carmustine 100 mg RECON SOLUTION</i> MO	1	
CASODEX 50 MG TABLET DL	4	QL(30 per 30 days)
<i>cisplatin 1 mg/ml SOLUTION</i> MO	1	
<i>cladribine 10 mg/10 ml SOLUTION</i> DL	4	BvsD
<i>clofarabine 1 mg/ml SOLUTION</i> DL	4	
CLOLAR 1 MG/ML SOLUTION DL	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
COLUMVI 1 MG/ML SOLUTION DL	4	PA
COMETRIQ 100 MG/DAY(80 MG X1-20 MG X1) CAPSULE DL	4	PA,QL(56 per 28 days)
COMETRIQ 140 MG/DAY(80 MG X1-20 MG X3) CAPSULE DL	4	PA,QL(112 per 28 days)
COMETRIQ 60 MG/DAY (20 MG X 3/DAY) CAPSULE DL	4	PA,QL(84 per 28 days)
COPIKTRA 15 MG, 25 MG CAPSULE DL	4	PA,QL(56 per 28 days)
COSMEGEN 0.5 MG RECON SOLUTION DL	4	
COTELLIC 20 MG TABLET DL	4	PA,QL(63 per 28 days)
<i>cyclophosphamide 1 gram, 2 gram, 500 mg RECON SOLUTION MO</i>	1	BvsD
CYCLOPHOSPHAMIDE 100 MG/ML, 200 MG/ML SOLUTION MO	1	BvsD
<i>cyclophosphamide 200 mg/ml SOLUTION MO</i>	1	BvsD
<i>cyclophosphamide 25 mg, 50 mg CAPSULE MO</i>	1	BvsD
<i>cyclophosphamide 25 mg, 50 mg TABLET MO</i>	1	BvsD
<i>cyclophosphamide 500 mg/ml SOLUTION DL</i>	4	BvsD
CYRAMZA 10 MG/ML SOLUTION DL	4	PA
<i>cytarabine 20 mg/ml SOLUTION MO</i>	1	BvsD
<i>cytarabine (pf) 100 mg/5 ml (20 mg/ml), 2 gram/20 ml (100 mg/ml), 20 mg/ml SOLUTION MO</i>	1	BvsD
<i>dacarbazine 100 mg, 200 mg RECON SOLUTION MO</i>	1	
<i>dactinomycin 0.5 mg RECON SOLUTION DL</i>	4	
DANYELZA 4 MG/ML SOLUTION DL	4	PA,QL(120 per 28 days)
DANZITEN 71 MG, 95 MG TABLET DL	4	PA,QL(120 per 30 days)
DARZALEX 20 MG/ML SOLUTION DL	4	PA
DARZALEX FASPRO 1,800 MG-30,000 UNIT/15 ML SOLUTION DL	4	PA
<i>dasatinib 100 mg, 50 mg, 70 mg, 80 mg TABLET DL</i>	4	PA,QL(60 per 30 days)
<i>dasatinib 140 mg TABLET DL</i>	4	PA,QL(30 per 30 days)
<i>dasatinib 20 mg TABLET DL</i>	4	PA,QL(90 per 30 days)
DATROWAY 100 MG RECON SOLUTION DL	4	PA
<i>daunorubicin 5 mg/ml SOLUTION MO</i>	1	
DAURISMO 100 MG TABLET DL	4	PA,QL(30 per 30 days)
DAURISMO 25 MG TABLET DL	4	PA,QL(60 per 30 days)
<i>decitabine 50 mg RECON SOLUTION DL</i>	4	PA
<i>dexrazoxane hcl 250 mg, 500 mg RECON SOLUTION MO</i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
docetaxel 160 mg/16 ml (10 mg/ml), 160 mg/8 ml (20 mg/ml), 20 mg/2 ml (10 mg/ml), 20 mg/ml (1 ml), 80 mg/4 ml (20 mg/ml), 80 mg/8 ml (10 mg/ml) SOLUTION MO	1	
DOCIVYX 160 MG/16 ML (10 MG/ML), 20 MG/2 ML (10 MG/ML), 80 MG/8 ML (10 MG/ML) SOLUTION DL	4	
DOXIL 2 MG/ML SUSPENSION DL	4	PA
doxorubicin 10 mg, 50 mg RECON SOLUTION MO	1	BvsD
doxorubicin 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml SOLUTION MO	1	BvsD
doxorubicin, peg-liposomal 2 mg/ml SUSPENSION DL	4	PA
ELAHERE 5 MG/ML SOLUTION DL	4	PA
ELITEK 1.5 MG, 7.5 MG RECON SOLUTION DL	4	PA
ELLEENCE 200 MG/100 ML, 50 MG/25 ML SOLUTION DL	4	
ELREXFIO 40 MG/ML SOLUTION DL	4	PA
ELZONRIS 1,000 MCG/ML SOLUTION DL	4	PA,QL(10 per 21 days)
EMCYT 140 MG CAPSULE DL	4	
EMPLICITI 300 MG, 400 MG RECON SOLUTION DL	4	PA
EMRELIS 100 MG, 20 MG RECON SOLUTION DL	4	PA
ENHERTU 100 MG RECON SOLUTION DL	4	PA
epirubicin 200 mg/100 ml, 50 mg/25 ml SOLUTION MO	1	
EPKINLY 4 MG/0.8 ML, 48 MG/0.8 ML SOLUTION DL	4	PA
ERBITUX 100 MG/50 ML, 200 MG/100 ML SOLUTION DL	4	PA
eribulin 1 mg/2 ml (0.5 mg/ml) SOLUTION DL	4	
ERIVEDGE 150 MG CAPSULE DL	4	PA,QL(28 per 28 days)
ERLEADA 240 MG TABLET DL	4	PA,QL(30 per 30 days)
ERLEADA 60 MG TABLET DL	4	PA,QL(120 per 30 days)
erlotinib 100 mg, 150 mg TABLET DL	4	PA,QL(30 per 30 days)
erlotinib 25 mg TABLET DL	4	PA,QL(90 per 30 days)
ETOPOPHOS 100 MG RECON SOLUTION MO	3	
etoposide 20 mg/ml SOLUTION MO	1	
EULEXIN 125 MG CAPSULE DL	4	PA
everolimus (antineoplastic) 10 mg, 2.5 mg, 5 mg, 7.5 mg TABLET DL	4	PA,QL(30 per 30 days)
everolimus (antineoplastic) 2 mg, 3 mg, 5 mg TABLET FOR SUSPENSION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EVOMELA 50 MG RECON SOLUTION DL	4	
exemestane 25 mg TABLET MO	1	QL(60 per 30 days)
EXKIVITY 40 MG CAPSULE DL	4	PA,QL(120 per 30 days)
FARESTON 60 MG TABLET DL	4	QL(30 per 30 days)
FASLODEX 250 MG/5 ML SYRINGE DL	4	PA,QL(30 per 30 days)
FEMARA 2.5 MG TABLET MO	3	PA,QL(30 per 30 days)
flouxuridine 0.5 gram RECON SOLUTION MO	1	BvsD
fludarabine 50 mg RECON SOLUTION MO	1	
fludarabine 50 mg/2 ml SOLUTION DL	4	
fluorouracil 1 gram/20 ml, 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml SOLUTION MO	1	BvsD
FOLOTYN 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML) SOLUTION DL	4	PA
FOTIVDA 0.89 MG, 1.34 MG CAPSULE DL	4	PA,QL(21 per 28 days)
FRINDOVYX 500 MG/ML SOLUTION DL	4	BvsD
FRUZAQLA 1 MG CAPSULE DL	4	PA,QL(84 per 28 days)
FRUZAQLA 5 MG CAPSULE DL	4	PA,QL(21 per 28 days)
fulvestrant 250 mg/5 ml SYRINGE MO	1	PA,QL(30 per 30 days)
FUSILEV 50 MG RECON SOLUTION DL	4	PA
FYARRO 100 MG SUSPENSION FOR RECONSTITUTION DL	4	PA
GAVRETO 100 MG CAPSULE DL,LA	4	PA,QL(120 per 30 days)
GAZYVA 1,000 MG/40 ML SOLUTION DL	4	PA,QL(120 per 28 days)
gefitinib 250 mg TABLET DL	4	PA
gemcitabine 1 gram, 2 gram, 200 mg RECON SOLUTION MO	1	
gemcitabine 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml) SOLUTION MO	1	
GILOTRIF 20 MG, 30 MG, 40 MG TABLET DL,LA	4	PA,QL(30 per 30 days)
GLEEVEC 100 MG TABLET DL	4	PA,QL(90 per 30 days)
GLEEVEC 400 MG TABLET DL	4	PA,QL(60 per 30 days)
GLEOSTINE 10 MG CAPSULE MO	3	PA
GLEOSTINE 100 MG CAPSULE DL	4	PA
GLEOSTINE 40 MG CAPSULE	4	PA
GOMEKLI 1 MG TABLET FOR SUSPENSION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GOMEKLI 1 MG, 2 MG CAPSULE DL	4	PA
GRAFAPEX 1 GRAM, 5 GRAM RECON SOLUTION DL	4	
HALAVEN 1 MG/2 ML (0.5 MG/ML) SOLUTION DL	4	
HERCEPTIN 150 MG RECON SOLUTION DL	4	PA
HERCEPTIN HYLECTA 600 MG-10,000 UNIT/5 ML SOLUTION DL	4	PA,QL(5 per 21 days)
HERZUMA 150 MG, 420 MG RECON SOLUTION DL	4	PA
HYCANTIN 4 MG RECON SOLUTION DL	4	
HYDREA 500 MG CAPSULE MO	3	
<i>hydroxyurea 500 mg CAPSULE MO</i>	1	
IBRANCE 100 MG, 125 MG, 75 MG CAPSULE DL	4	PA,QL(21 per 28 days)
IBRANCE 100 MG, 125 MG, 75 MG TABLET DL	4	PA,QL(21 per 28 days)
IBTROZI 200 MG CAPSULE DL	4	PA,QL(90 per 30 days)
ICLUSIG 10 MG, 30 MG, 45 MG TABLET DL	4	PA,QL(30 per 30 days)
ICLUSIG 15 MG TABLET DL	4	PA,QL(60 per 30 days)
IDAMYCIN PFS 1 MG/ML SOLUTION DL	4	
<i>idarubicin 1 mg/ml SOLUTION DL</i>	4	
IDHIFA 100 MG, 50 MG TABLET DL	4	PA,QL(30 per 30 days)
IFEX 1 GRAM, 3 GRAM RECON SOLUTION MO	3	
<i>ifosfamide 1 gram, 3 gram RECON SOLUTION MO</i>	1	
<i>ifosfamide 1 gram/20 ml, 3 gram/60 ml SOLUTION MO</i>	1	
<i>imatinib 100 mg TABLET DL</i>	4	PA,QL(90 per 30 days)
<i>imatinib 400 mg TABLET DL</i>	4	PA,QL(60 per 30 days)
IMBRUVICA 140 MG CAPSULE DL	4	PA,QL(120 per 30 days)
IMBRUVICA 420 MG TABLET DL	4	PA,QL(28 per 28 days)
IMBRUVICA 70 MG CAPSULE DL	4	PA,QL(28 per 28 days)
IMBRUVICA 70 MG/ML SUSPENSION DL	4	PA
IMDELLTRA 1 MG, 10 MG RECON SOLUTION DL	4	PA
IMFINZI 50 MG/ML SOLUTION DL	4	PA
IMJUDO 20 MG/ML SOLUTION DL	4	PA
IMKELDI 80 MG/ML SOLUTION DL	4	PA,QL(300 per 30 days)
IMLYGIC 10EXP6 (1 MILLION) PFU/ML SUSPENSION DL	4	PA,QL(4 per 365 days)
IMLYGIC 10EXP8 (100 MILLION) PFU/ML SUSPENSION DL	4	PA,QL(8 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INFUGEM 1,200 MG/120 ML (10 MG/ML), 1,300 MG/130 ML (10 MG/ML), 1,400 MG/140 ML (10 MG/ML), 1,500 MG/150 ML (10 MG/ML), 1,600 MG/160 ML (10 MG/ML), 1,700 MG/170 ML (10 MG/ML), 1,800 MG/180 ML (10 MG/ML), 1,900 MG/190 ML (10 MG/ML), 2,000 MG/200 ML (10 MG/ML), 2,200 MG/220 ML (10 MG/ML) PIGGYBACK DL	4	
INLYTA 1 MG TABLET DL	4	PA,QL(180 per 30 days)
INLYTA 5 MG TABLET DL	4	PA,QL(120 per 30 days)
INQOVI 35-100 MG TABLET DL	4	PA,QL(5 per 28 days)
INREBIC 100 MG CAPSULE DL	4	PA,QL(120 per 30 days)
IRESSA 250 MG TABLET DL	4	PA
<i>irinotecan</i> 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml SOLUTION MO	1	
ISTODAX 10 MG/2 ML RECON SOLUTION DL	4	PA
ITOVEBI 3 MG TABLET DL	4	PA,QL(56 per 28 days)
ITOVEBI 9 MG TABLET DL	4	PA,QL(28 per 28 days)
IVRA 90 MG/ML SOLUTION DL	4	
IWILFIN 192 MG TABLET DL	4	PA,QL(240 per 30 days)
IXEMPRA 15 MG, 45 MG RECON SOLUTION DL	4	PA
JAKAFI 10 MG, 15 MG, 20 MG, 25 MG, 5 MG TABLET DL	4	PA,QL(60 per 30 days)
JAYPIRCA 100 MG, 50 MG TABLET DL	4	PA,QL(90 per 30 days)
JEMPERLI 50 MG/ML SOLUTION	4	PA,QL(20 per 42 days)
JEVTANA 10 MG/ML (FIRST DILUTION) SOLUTION DL	4	PA
KADCYLA 100 MG, 160 MG RECON SOLUTION DL	4	PA
KANJINTI 150 MG, 420 MG RECON SOLUTION DL	4	PA
KEYTRUDA 25 MG/ML SOLUTION DL	4	PA
KHAPZORY 175 MG, 300 MG RECON SOLUTION DL	4	PA
KIMMTRAK 100 MCG/0.5 ML SOLUTION DL	4	PA
KISQALI 200 MG/DAY (200 MG X 1) TABLET DL	4	PA,QL(21 per 28 days)
KISQALI 400 MG/DAY (200 MG X 2) TABLET DL	4	PA,QL(42 per 28 days)
KISQALI 600 MG/DAY (200 MG X 3) TABLET DL	4	PA,QL(63 per 28 days)
KISQALI FEMARA CO-PACK 200 MG/DAY(200 MG X 1)-2.5 MG TABLET DL	4	PA,QL(49 per 28 days)
KISQALI FEMARA CO-PACK 400 MG/DAY(200 MG X 2)-2.5 MG TABLET DL	4	PA,QL(70 per 28 days)
KISQALI FEMARA CO-PACK 600 MG/DAY(200 MG X 3)-2.5 MG TABLET DL	4	PA,QL(91 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
KOSELUGO 10 MG CAPSULE DL	4	PA,QL(240 per 30 days)
KOSELUGO 25 MG CAPSULE DL	4	PA,QL(120 per 30 days)
KRAZATI 200 MG TABLET DL	4	PA,QL(180 per 30 days)
KYPROLIS 10 MG RECON SOLUTION DL	4	PA,QL(6 per 28 days)
KYPROLIS 30 MG RECON SOLUTION DL	4	PA,QL(3 per 28 days)
KYPROLIS 60 MG RECON SOLUTION DL	4	PA,QL(12 per 28 days)
<i>lapatinib</i> 250 mg TABLET DL	4	PA,QL(180 per 30 days)
LAZCLUZE 240 MG TABLET DL	4	PA,QL(30 per 30 days)
LAZCLUZE 80 MG TABLET DL	4	PA,QL(60 per 30 days)
<i>lenalidomide</i> 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg CAPSULE DL	4	PA,QL(28 per 28 days)
LENVIMA 10 MG/DAY (10 MG X 1), 4 MG CAPSULE DL	4	PA,QL(30 per 30 days)
LENVIMA 12 MG/DAY (4 MG X 3), 18 MG/DAY (10 MG X 1-4 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1) CAPSULE DL	4	PA,QL(90 per 30 days)
LENVIMA 14 MG/DAY(10 MG X 1-4 MG X 1), 20 MG/DAY (10 MG X 2), 8 MG/DAY (4 MG X 2) CAPSULE DL	4	PA,QL(60 per 30 days)
<i>letrozole</i> 2.5 mg TABLET MO	1	QL(30 per 30 days)
<i>leucovorin calcium</i> 10 mg, 15 mg, 25 mg, 5 mg TABLET MO	1	
<i>leucovorin calcium</i> 10 mg/ml SOLUTION MO	1	
<i>leucovorin calcium</i> 100 mg, 200 mg, 350 mg, 50 mg, 500 mg RECON SOLUTION MO	1	
LEUKERAN 2 MG TABLET DL	4	
<i>levoleucovorin calcium</i> 10 mg/ml SOLUTION MO	1	PA
<i>levoleucovorin calcium</i> 50 mg RECON SOLUTION MO	1	PA
LEVULAN 20 % SOLUTION MO	3	
LIBTAYO 50 MG/ML SOLUTION DL	4	PA,QL(7 per 21 days)
LONSURF 15-6.14 MG TABLET DL	4	PA,QL(100 per 30 days)
LONSURF 20-8.19 MG TABLET DL	4	PA,QL(80 per 30 days)
LOQTORZI 240 MG/6 ML (40 MG/ML) SOLUTION DL	4	PA
LORBRENA 100 MG TABLET DL	4	PA,QL(30 per 30 days)
LORBRENA 25 MG TABLET DL	4	PA,QL(90 per 30 days)
LUMAKRAS 120 MG TABLET DL	4	PA,QL(240 per 30 days)
LUMAKRAS 240 MG TABLET DL	4	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LUMAKRAS 320 MG TABLET DL	4	PA,QL(90 per 30 days)
LUNSUMIO 1 MG/ML SOLUTION DL	4	PA
LYNOZYFIC 2 MG/ML, 20 MG/ML SOLUTION DL	4	PA
LYNPARZA 100 MG, 150 MG TABLET DL	4	PA,QL(120 per 30 days)
LYSODREN 500 MG TABLET DL	4	
LYTGOBI 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) TABLET DL	4	PA,QL(140 per 28 days)
MARGENZA 25 MG/ML SOLUTION DL	4	PA
MATULANE 50 MG CAPSULE DL	4	
MEKINIST 0.05 MG/ML RECON SOLUTION DL	4	PA,QL(1170 per 28 days)
MEKINIST 0.5 MG TABLET DL	4	PA,QL(120 per 30 days)
MEKINIST 2 MG TABLET DL	4	PA,QL(30 per 30 days)
MEKTOVI 15 MG TABLET DL	4	PA,QL(180 per 30 days)
<i>melfalan 2 mg TABLET MO</i>	1	BvsD
<i>melfalan hcl 50 mg RECON SOLUTION MO</i>	1	
<i>mercaptopurine 20 mg/ml SUSPENSION DL</i>	4	
<i>mercaptopurine 50 mg TABLET MO</i>	1	
<i>mesna 100 mg/ml SOLUTION MO</i>	1	
<i>mesna 400 mg TABLET DL</i>	4	
MESNEX 100 MG/ML SOLUTION DL	4	
MESNEX 400 MG TABLET DL	4	
<i>mitomycin 20 mg, 40 mg, 5 mg RECON SOLUTION DL</i>	4	
<i>mitoxantrone 2 mg/ml CONCENTRATE MO</i>	1	
MUTAMYCIN 20 MG, 40 MG, 5 MG RECON SOLUTION DL	4	
MVASI 25 MG/ML SOLUTION DL	4	PA
MYLOTARG 4.5 MG (1 MG/ML INITIAL CONC) RECON SOLUTION DL	4	PA
<i>nelarabine 250 mg/50 ml SOLUTION DL</i>	4	
NERLYNX 40 MG TABLET DL	4	PA,QL(180 per 30 days)
NEXAVAR 200 MG TABLET DL	4	PA,QL(120 per 30 days)
NILANDRON 150 MG TABLET DL	4	PA,QL(60 per 30 days)
<i>nilotinib hcl 150 mg, 200 mg, 50 mg CAPSULE DL</i>	4	PA,QL(120 per 30 days)
<i>nilotinib tartrate 150 mg, 200 mg, 50 mg CAPSULE DL</i>	4	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>nilutamide 150 mg TABLET</i> DL	4	QL(60 per 30 days)
NINLARO 2.3 MG, 3 MG, 4 MG CAPSULE DL	4	PA,QL(3 per 28 days)
NIPENT 10 MG RECON SOLUTION DL	4	
NUBEQA 300 MG TABLET DL	4	PA,QL(120 per 30 days)
ODOMZO 200 MG CAPSULE DL	4	PA,QL(30 per 30 days)
OGIVRI 150 MG, 420 MG RECON SOLUTION DL	4	PA
OGSIVEO 100 MG, 150 MG TABLET DL	4	PA,QL(60 per 30 days)
OGSIVEO 50 MG TABLET DL	4	PA,QL(180 per 30 days)
OJEMDA 25 MG/ML SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(96 per 28 days)
OJEMDA 400 MG/WEEK (100 MG X 4) TABLET DL	4	PA,QL(16 per 28 days)
OJEMDA 500 MG/WEEK (100 MG X 5) TABLET DL	4	PA,QL(20 per 28 days)
OJEMDA 600 MG/WEEK (100 MG X 6) TABLET DL	4	PA,QL(24 per 28 days)
OJJAARA 100 MG, 150 MG, 200 MG TABLET DL	4	PA,QL(30 per 30 days)
ONCASPAR 750 UNIT/ML SOLUTION DL	4	PA
ONIVYDE 4.3 MG/ML DISPERSION DL	4	PA
ONTRUZANT 150 MG, 420 MG RECON SOLUTION DL	4	PA
ONUREG 200 MG, 300 MG TABLET DL	4	PA,QL(14 per 28 days)
OPDIVO 100 MG/10 ML SOLUTION DL	4	PA,QL(40 per 28 days)
OPDIVO 120 MG/12 ML, 240 MG/24 ML SOLUTION DL	4	PA,QL(48 per 28 days)
OPDIVO 40 MG/4 ML SOLUTION DL	4	PA,QL(16 per 28 days)
OPDIVO QVANTIG 600 MG-10,000 UNIT/5 ML SOLUTION DL	4	PA,QL(10 per 28 days)
OPDUALAG 240-80 MG/20 ML SOLUTION DL	4	PA,QL(40 per 28 days)
ORGOVYX 120 MG TABLET DL	4	PA,QL(32 per 30 days)
ORSERDU 345 MG TABLET DL	4	PA,QL(30 per 30 days)
ORSERDU 86 MG TABLET DL	4	PA,QL(90 per 30 days)
<i>oxaliplatin 100 mg, 50 mg RECON SOLUTION</i> MO	1	
<i>oxaliplatin 100 mg/20 ml, 200 mg/40 ml, 50 mg/10 ml (5 mg/ml) SOLUTION</i> MO	1	
<i>paclitaxel 6 mg/ml CONCENTRATE</i> MO	1	
<i>paclitaxel protein-bound 100 mg SUSPENSION FOR RECONSTITUTION</i> DL	4	PA
PADCEV 20 MG RECON SOLUTION DL	4	PA,QL(21 per 28 days)
PADCEV 30 MG RECON SOLUTION DL	4	PA,QL(15 per 28 days)
PANRETIN 0.1 % GEL DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>paraplatin 10 mg/ml SOLUTION</i> MO	1	
<i>pazopanib 200 mg TABLET</i> DL	4	PA,QL(120 per 30 days)
PEDMARK 12.5 GRAM/100ML (125 MG/ML) SOLUTION DL	4	PA
PEMAZYRE 13.5 MG, 4.5 MG, 9 MG TABLET DL	4	PA,QL(28 per 28 days)
<i>pemetrexed 1 gram, 100 mg, 500 mg RECON SOLUTION</i> DL	4	PA
<i>pemetrexed 25 mg/ml SOLUTION</i> DL	4	PA,QL(120 per 21 days)
<i>pemetrexed disodium 1,000 mg, 100 mg, 500 mg, 750 mg RECON SOLUTION</i> DL	4	PA
<i>pemetrexed disodium 25 mg/ml SOLUTION</i> DL	4	PA
PEMRYDI RTU 10 MG/ML SOLUTION DL	4	PA
PERJETA 420 MG/14 ML (30 MG/ML) SOLUTION DL	4	PA
PHESGO 1,200 MG-600MG- 30000 UNIT/15ML SOLUTION DL	4	PA,QL(15 per 21 days)
PHESGO 600 MG-600 MG- 20000 UNIT/10ML SOLUTION DL	4	PA,QL(10 per 21 days)
PIQRAY 200 MG/DAY (200 MG X 1) TABLET DL	4	PA,QL(28 per 28 days)
PIQRAY 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) TABLET DL	4	PA,QL(56 per 28 days)
POLIVY 140 MG RECON SOLUTION DL	4	PA,QL(2 per 21 days)
POLIVY 30 MG RECON SOLUTION DL	4	PA,QL(8 per 21 days)
POMALYST 1 MG, 2 MG, 3 MG, 4 MG CAPSULE DL	4	PA,QL(21 per 28 days)
PORTRAZZA 800 MG/50 ML (16 MG/ML) SOLUTION DL	4	PA,QL(100 per 21 days)
POTELIGEO 4 MG/ML SOLUTION DL	4	PA
<i>pralatrexate 20 mg/ml (1 ml), 40 mg/2 ml (20 mg/ml) SOLUTION</i> DL	4	PA
PURIXAN 20 MG/ML SUSPENSION DL	4	
QINLOCK 50 MG TABLET DL	4	PA,QL(90 per 30 days)
RETEVMO 120 MG, 160 MG, 80 MG TABLET DL	4	PA,QL(60 per 30 days)
RETEVMO 40 MG CAPSULE DL	4	PA,QL(180 per 30 days)
RETEVMO 40 MG TABLET DL	4	PA,QL(90 per 30 days)
RETEVMO 80 MG CAPSULE DL	4	PA,QL(120 per 30 days)
REVUFORJ 110 MG, 160 MG, 25 MG TABLET DL	4	PA
REZLIDHIA 150 MG CAPSULE DL	4	PA,QL(60 per 30 days)
RIABNI 10 MG/ML SOLUTION DL	4	PA
RITUXAN 10 MG/ML CONCENTRATE DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RITUXAN HYCELA 1400 MG/11.7 ML (120 MG/ML) SOLUTION DL	4	PA,QL(46.8 per 28 days)
RITUXAN HYCELA 1600 MG/13.4 ML (120 MG/ML) SOLUTION DL	4	PA,QL(13.4 per 28 days)
<i>romidepsin 10 mg/2 ml RECON SOLUTION</i> DL	4	PA
ROMIDEPSIN 5 MG/ML SOLUTION DL	4	PA
ROMVIMZA 14 MG, 20 MG, 30 MG CAPSULE DL	4	PA
ROZLYTREK 100 MG CAPSULE DL	4	PA,QL(150 per 30 days)
ROZLYTREK 200 MG CAPSULE DL	4	PA,QL(90 per 30 days)
ROZLYTREK 50 MG PELLETS IN PACKET DL	4	PA,QL(360 per 30 days)
RUBRACA 200 MG, 250 MG, 300 MG TABLET DL	4	PA,QL(120 per 30 days)
RUXIENCE 10 MG/ML SOLUTION DL	4	PA
RYBREVANT 50 MG/ML SOLUTION DL	4	PA,QL(784 per 365 days)
RYDAPT 25 MG CAPSULE DL	4	PA,QL(224 per 28 days)
RYLAZE 10 MG/0.5 ML SOLUTION DL	4	PA
RYTELO 188 MG, 47 MG RECON SOLUTION DL	4	PA
SARCLISA 20 MG/ML SOLUTION DL	4	PA
SCEMBLIX 100 MG TABLET DL	4	PA,QL(120 per 30 days)
SCEMBLIX 20 MG TABLET DL	4	PA,QL(60 per 30 days)
SCEMBLIX 40 MG TABLET DL	4	PA,QL(300 per 30 days)
SOLTAMOX 20 MG/10 ML SOLUTION DL	4	
<i>sorafenib 200 mg TABLET</i> DL	4	PA,QL(120 per 30 days)
SPRYCEL 100 MG, 50 MG, 70 MG, 80 MG TABLET DL	4	PA,QL(60 per 30 days)
SPRYCEL 140 MG TABLET DL	4	PA,QL(30 per 30 days)
SPRYCEL 20 MG TABLET DL	4	PA,QL(90 per 30 days)
STIVARGA 40 MG TABLET DL	4	PA,QL(84 per 28 days)
<i>sunitinib malate 12.5 mg, 25 mg, 37.5 mg, 50 mg CAPSULE</i> DL	4	PA,QL(28 per 28 days)
SUTENT 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE DL	4	PA,QL(28 per 28 days)
SYNRIBO 3.5 MG RECON SOLUTION DL	4	PA
TABLOID 40 MG TABLET MO	3	
TABRECTA 150 MG, 200 MG TABLET DL	4	PA,QL(112 per 28 days)
TAFINLAR 10 MG TABLET FOR SUSPENSION DL	4	PA,QL(840 per 28 days)
TAFINLAR 50 MG CAPSULE DL	4	PA,QL(180 per 30 days)
TAFINLAR 75 MG CAPSULE DL	4	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TAGRISSO 40 MG, 80 MG TABLET DL	4	PA,QL(30 per 30 days)
TALVEY 2 MG/ML, 40 MG/ML SOLUTION DL	4	PA
TALZENNA 0.1 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG CAPSULE DL	4	PA,QL(30 per 30 days)
TALZENNA 0.25 MG CAPSULE DL	4	PA,QL(90 per 30 days)
<i>tamoxifen 10 mg, 20 mg TABLET MO</i>	1	
TARCEVA 100 MG, 150 MG TABLET DL	4	PA,QL(30 per 30 days)
TARCEVA 25 MG TABLET DL	4	PA,QL(90 per 30 days)
TARGRETIN 1 % GEL DL	4	PA,QL(240 per 30 days)
TARGRETIN 75 MG CAPSULE DL	4	PA,QL(300 per 30 days)
TASIGNA 150 MG, 200 MG, 50 MG CAPSULE DL	4	PA,QL(120 per 30 days)
TAZVERIK 200 MG TABLET DL	4	PA,QL(240 per 30 days)
TECENTRIQ 1,200 MG/20 ML (60 MG/ML) SOLUTION DL	4	PA,QL(20 per 21 days)
TECENTRIQ 840 MG/14 ML (60 MG/ML) SOLUTION DL	4	PA,QL(28 per 28 days)
TECENTRIQ HYBREZA 1,875 MG-30,000 UNIT/15 ML SOLUTION DL	4	PA,QL(15 per 21 days)
TECVAYLI 10 MG/ML, 90 MG/ML SOLUTION DL	4	PA
TEMODAR 100 MG RECON SOLUTION DL	4	PA,QL(27 per 30 days)
<i>temsirolimus 30 mg/3 ml (10 mg/ml) (first) RECON SOLUTION DL</i>	4	PA,QL(8 per 28 days)
TEPADINA 100 MG, 15 MG RECON SOLUTION DL	4	
TEPMETKO 225 MG TABLET DL	4	PA,QL(60 per 30 days)
TEPYLUTE 10 MG/ML SOLUTION DL	4	
TEVIMBRA 10 MG/ML SOLUTION DL	4	PA,QL(20 per 21 days)
THALOMID 100 MG, 200 MG, 50 MG CAPSULE DL	4	PA,QL(30 per 30 days)
THALOMID 150 MG CAPSULE DL	4	PA,QL(60 per 30 days)
<i>thiotepa 100 mg RECON SOLUTION DL</i>	4	
<i>thiotepa 15 mg RECON SOLUTION MO</i>	1	
TIBSOVO 250 MG TABLET DL	4	PA,QL(60 per 30 days)
TIVDAK 40 MG RECON SOLUTION DL	4	PA,QL(5 per 21 days)
<i>topotecan 4 mg RECON SOLUTION MO</i>	1	
<i>topotecan 4 mg/4 ml (1 mg/ml) SOLUTION MO</i>	1	
<i>toremifene 60 mg TABLET</i>	4	QL(30 per 30 days)
TORISEL 30 MG/3 ML (10 MG/ML) (FIRST) RECON SOLUTION DL	4	PA,QL(8 per 28 days)
torpenz 10 mg, 2.5 mg, 5 mg, 7.5 mg TABLET DL	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TRAZIMERA 150 MG RECON SOLUTION DL	4	PA
TRAZIMERA 420 MG RECON SOLUTION DL	4	PA
TREANDA 100 MG, 25 MG RECON SOLUTION DL	4	PA
<i>tretinoin (antineoplastic) 10 mg CAPSULE</i> DL	4	
TRISENOX 2 MG/ML SOLUTION DL	4	PA
TRODELVY 180 MG RECON SOLUTION DL	4	PA
TRUQAP 160 MG, 200 MG TABLET DL	4	PA,QL(64 per 28 days)
TRUXIMA 10 MG/ML SOLUTION DL	4	PA
TUKYSA 150 MG TABLET DL	4	PA,QL(120 per 30 days)
TUKYSA 50 MG TABLET DL	4	PA,QL(300 per 30 days)
TURALIO 125 MG CAPSULE DL,LA	4	PA,QL(120 per 30 days)
TYKERB 250 MG TABLET DL	4	PA,QL(180 per 30 days)
UNITUXIN 3.5 MG/ML SOLUTION DL	4	PA
VALCHLOR 0.016 % GEL DL	4	PA,QL(60 per 28 days)
<i>valrubicin 40 mg/ml SOLUTION</i> DL	4	PA,QL(80 per 28 days)
VALSTAR 40 MG/ML SOLUTION DL	4	PA,QL(80 per 28 days)
VANFLYTA 17.7 MG, 26.5 MG TABLET DL	4	PA,QL(56 per 28 days)
VECTIBIX 100 MG/5 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML) SOLUTION DL	4	PA
VEGZELMA 25 MG/ML SOLUTION DL	4	PA
VELCADE 3.5 MG RECON SOLUTION DL	4	PA
VENCLEXTA 10 MG TABLET MO	2	PA,QL(56 per 28 days)
VENCLEXTA 100 MG TABLET DL	4	PA,QL(180 per 30 days)
VENCLEXTA 50 MG TABLET MO	2	PA,QL(28 per 28 days)
VENCLEXTA STARTING PACK 10 MG-50 MG- 100 MG TABLET, DOSE PACK DL	4	PA,QL(42 per 28 days)
VERZENIO 100 MG, 150 MG, 200 MG, 50 MG TABLET DL	4	PA,QL(60 per 30 days)
VIDAZA 100 MG RECON SOLUTION DL	4	PA
<i>vinblastine 1 mg/ml SOLUTION</i> MO	1	BvsD
<i>vincasar pfs 1 mg/ml, 2 mg/2 ml SOLUTION</i> MO	1	BvsD
<i>vincristine 1 mg/ml, 2 mg/2 ml SOLUTION</i> MO	1	BvsD
<i>vinorelbine 10 mg/ml, 50 mg/5 ml SOLUTION</i> MO	1	
VITRAKVI 100 MG CAPSULE DL	4	PA,QL(60 per 30 days)
VITRAKVI 20 MG/ML SOLUTION DL	4	PA,QL(300 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VITRAKVI 25 MG CAPSULE DL	4	PA,QL(180 per 30 days)
VIZIMPRO 15 MG, 30 MG, 45 MG TABLET DL	4	PA,QL(30 per 30 days)
VONJO 100 MG CAPSULE DL	4	PA,QL(120 per 30 days)
VORANIGO 10 MG TABLET DL	4	PA,QL(60 per 30 days)
VORANIGO 40 MG TABLET DL	4	PA,QL(30 per 30 days)
VOTRIENT 200 MG TABLET DL	4	PA,QL(120 per 30 days)
VYLOY 100 MG, 300 MG RECON SOLUTION DL	4	PA
VYXEOS 44-100 MG RECON SOLUTION DL	4	PA
XALKORI 150 MG PELLETT DL	4	PA,QL(180 per 30 days)
XALKORI 20 MG PELLETT DL	4	PA,QL(120 per 30 days)
XALKORI 200 MG, 250 MG CAPSULE DL	4	PA,QL(120 per 30 days)
XALKORI 50 MG PELLETT DL	4	PA,QL(240 per 30 days)
XOSPATA 40 MG TABLET DL	4	PA,QL(90 per 30 days)
XPOVIO 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2) TABLET DL	4	PA,QL(8 per 28 days)
XPOVIO 40 MG/WEEK (10 MG X 4) TABLET DL	4	PA,QL(16 per 28 days)
XPOVIO 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) TABLET DL	4	PA,QL(4 per 28 days)
XPOVIO 60MG TWICE WEEK (120 MG/WEEK) TABLET DL	4	PA,QL(24 per 28 days)
XPOVIO 80MG TWICE WEEK (160 MG/WEEK) TABLET DL	4	PA,QL(32 per 28 days)
XTANDI 40 MG CAPSULE DL	4	PA,QL(120 per 30 days)
XTANDI 40 MG TABLET DL	4	PA,QL(120 per 30 days)
XTANDI 80 MG TABLET DL	4	PA,QL(60 per 30 days)
YERVOY 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) SOLUTION DL	4	PA
YONDELIS 1 MG RECON SOLUTION DL	4	PA
YONSA 125 MG TABLET DL	4	PA,QL(120 per 30 days)
ZALTRAP 100 MG/4 ML (25 MG/ML), 200 MG/8 ML (25 MG/ML) SOLUTION DL	4	PA
ZANOSAR 1 GRAM RECON SOLUTION MO	3	
ZEJULA 100 MG CAPSULE DL	4	PA,QL(90 per 30 days)
ZEJULA 100 MG, 200 MG, 300 MG TABLET DL	4	PA,QL(30 per 30 days)
ZELBORAF 240 MG TABLET DL	4	PA,QL(240 per 30 days)
ZEPZELCA 4 MG RECON SOLUTION DL	4	PA
ZIIHERA 300 MG RECON SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZIRABEV 25 MG/ML SOLUTION DL	4	PA
ZOLINZA 100 MG CAPSULE DL	4	PA,QL(120 per 30 days)
ZYDELIG 100 MG, 150 MG TABLET DL	4	PA,QL(60 per 30 days)
ZYKADIA 150 MG TABLET DL	4	PA,QL(150 per 30 days)
ZYNLONTA 10 MG RECON SOLUTION DL	4	PA
ZYNYZ 500 MG/20 ML SOLUTION DL	4	PA,QL(20 per 28 days)
ZYTIGA 250 MG TABLET DL	4	PA,QL(120 per 30 days)
ZYTIGA 500 MG TABLET DL	4	PA,QL(60 per 30 days)
ANTIPARASITICS		
<i>albendazole 200 mg TABLET MO</i>	1	
<i>atovaquone 750 mg/5 ml SUSPENSION MO</i>	1	
<i>atovaquone-proguanil 250-100 mg, 62.5-25 mg TABLET MO</i>	1	
BILTRICIDE 600 MG TABLET DL	4	PA
<i>chloroquine phosphate 250 mg, 500 mg TABLET MO</i>	1	
COARTEM 20-120 MG TABLET MO	3	QL(24 per 30 days)
DARAPRIM 25 MG TABLET DL	4	PA,QL(90 per 30 days)
EGATEN 250 MG TABLET MO	3	
<i>emverm 100 mg CHEWABLE TABLET DL</i>	4	
<i>hydroxychloroquine 100 mg, 300 mg, 400 mg TABLET MO</i>	1	
<i>hydroxychloroquine 200 mg TABLET MO</i>	1	
IMPAVIDO 50 MG CAPSULE DL	4	QL(84 per 28 days)
<i>ivermectin 3 mg, 6 mg TABLET MO</i>	1	
KRINTAFEL 150 MG TABLET MO	3	QL(4 per 180 days)
LAMPIT 120 MG, 30 MG TABLET MO	3	
MALARONE 250-100 MG TABLET MO	3	PA
MALARONE PEDIATRIC 62.5-25 MG TABLET MO	3	PA
<i>mefloquine 250 mg TABLET MO</i>	1	
MEPRON 750 MG/5 ML SUSPENSION DL	4	
NEBUPENT 300 MG RECON SOLUTION MO	3	BvsD
<i>nitazoxanide 500 mg TABLET DL</i>	4	
PENTAM 300 MG RECON SOLUTION MO	3	
<i>pentamidine 300 mg RECON SOLUTION MO</i>	1	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
pentamidine 300 mg RECON SOLUTION MO	1	
PLAQUENIL 200 MG TABLET MO	3	PA
praziquantel 600 mg TABLET MO	1	
primaquine 26.3 mg (15 mg base) TABLET MO	1	
pyrimethamine 25 mg TABLET DL	4	QL(90 per 30 days)
quinine sulfate 324 mg CAPSULE MO	1	PA,QL(42 per 7 days)
SOVUNA 200 MG, 300 MG TABLET MO	3	
STROMEKTOL 3 MG TABLET MO	3	PA
ANTIPARKINSON AGENTS		
amantadine hcl 100 mg CAPSULE MO	1	
amantadine hcl 100 mg TABLET MO	1	
amantadine hcl 50 mg/5 ml SOLUTION MO	1	
APOKYN 10 MG/ML CARTRIDGE DL	4	PA,QL(84 per 28 days)
apomorphine 10 mg/ml CARTRIDGE DL	4	PA,QL(84 per 28 days)
AZILECT 0.5 MG, 1 MG TABLET DL	4	PA,QL(30 per 30 days)
benztropine 0.5 mg, 1 mg, 2 mg TABLET MO	1	
benztropine 1 mg/ml SOLUTION MO	1	
bromocriptine 2.5 mg TABLET MO	1	
bromocriptine 5 mg CAPSULE MO	1	QL(600 per 30 days)
carbidopa 25 mg TABLET MO	1	
carbidopa-levodopa 10-100 mg, 25-100 mg, 25-250 mg TABLET, DISINTEGRATING MO	1	
carbidopa-levodopa 10-100 mg, 25-250 mg TABLET MO	1	
carbidopa-levodopa 25-100 mg TABLET MO	1	
carbidopa-levodopa 25-100 mg, 50-200 mg TABLET ER MO	1	
carbidopa-levodopa-entacapone 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg TABLET MO	1	
COMTAN 200 MG TABLET MO	3	PA,QL(300 per 30 days)
CREXONT 35-140 MG, 52.5-210 MG, 70-280 MG, 87.5-350 MG CAPSULE, IR/ER, BIPHASIC MO	3	ST,QL(180 per 30 days)
DHIVY 25-100 MG TABLET MO	3	
DUOPA 4.63-20 MG/ML INTESTINAL PUMP SUSPENSION DL	4	PA,QL(2800 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>entacapone</i> 200 mg TABLET MO	1	QL(300 per 30 days)
GOCOVRI 137 MG CAPSULE, ER 24 HR.	4	PA,QL(60 per 30 days)
GOCOVRI 68.5 MG CAPSULE, ER 24 HR.	4	PA,QL(30 per 30 days)
INBRIJA 42 MG CAPSULE DL	4	PA,QL(300 per 30 days)
INBRIJA 42 MG CAPSULE, W/INHALATION DEVICE DL	4	PA,QL(300 per 30 days)
LODOSYN 25 MG TABLET DL	4	PA
MIRAPEX ER 0.375 MG, 0.75 MG, 1.5 MG, 2.25 MG, 3 MG, 3.75 MG, 4.5 MG TABLET, ER 24 HR. MO	3	ST,QL(30 per 30 days)
NEUPRO 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR PATCH, 24 HR. MO	3	ST,QL(30 per 30 days)
NOURIANZ 20 MG, 40 MG TABLET DL	4	PA,QL(30 per 30 days)
ONAPGO 4.9 MG/ ML CARTRIDGE DL	4	PA,QL(600 per 30 days)
ONGENTYS 25 MG, 50 MG CAPSULE MO	3	PA,QL(30 per 30 days)
OSMOLEX ER 129 MG, 193 MG, 258 MG TABLET, IR/ER 24 HR., BIPHASIC MO	3	PA,QL(30 per 30 days)
OSMOLEX ER 322 MG/DAY(129 MG X1-193MG X1) TABLET, IR/ER 24 HR., BIPHASIC MO	3	PA,QL(60 per 30 days)
PARLODEL 2.5 MG TABLET MO	3	PA
PARLODEL 5 MG CAPSULE MO	3	PA,QL(600 per 30 days)
<i>pramipexole</i> 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg TABLET MO	1	
<i>pramipexole</i> 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg TABLET, ER 24 HR. MO	1	ST,QL(30 per 30 days)
<i>rasagiline</i> 0.5 mg, 1 mg TABLET MO	1	QL(30 per 30 days)
<i>ropinirole</i> 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg TABLET MO	1	
<i>ropinirole</i> 12 mg, 2 mg, 4 mg, 6 mg, 8 mg TABLET, ER 24 HR. MO	1	ST,QL(90 per 30 days)
RYTARY 23.75-95 MG, 48.75-195 MG CAPSULE, ER MO	3	ST,QL(360 per 30 days)
RYTARY 36.25-145 MG CAPSULE, ER MO	3	ST,QL(270 per 30 days)
RYTARY 61.25-245 MG CAPSULE, ER MO	3	ST,QL(300 per 30 days)
<i>selegiline hcl</i> 5 mg CAPSULE MO	1	
<i>selegiline hcl</i> 5 mg TABLET MO	1	
SINEMET 10-100 MG, 25-100 MG TABLET MO	3	PA
STALEVO 100 25-100-200 MG TABLET DL	4	PA
STALEVO 125 31.25-125-200 MG TABLET DL	4	PA
STALEVO 150 37.5-150-200 MG TABLET DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
STALEVO 200 50-200-200 MG TABLET DL	4	PA
STALEVO 50 12.5-50-200 MG TABLET DL	4	PA
STALEVO 75 18.75-75-200 MG TABLET DL	4	PA
TASMAR 100 MG TABLET DL	4	PA
<i>tolcapone 100 mg TABLET DL</i>	4	PA
<i>trihexyphenidyl 0.4 mg/ml ELIXIR MO</i>	1	
<i>trihexyphenidyl 2 mg, 5 mg TABLET MO</i>	1	
VYALEV 12-240 MG/ML SOLUTION DL	4	PA
XADAGO 100 MG, 50 MG TABLET	4	PA,QL(30 per 30 days)
ZELAPAR 1.25 MG TABLET, DISINTEGRATING DL	4	
ANTIPSYCHOTICS		
ABILIFY 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET MO	3	PA
ABILIFY ASIMTUFIG 720 MG/2.4 ML SUSPENSION, ER, SYRINGE	4	QL(2.4 per 56 days)
ABILIFY ASIMTUFIG 960 MG/3.2 ML SUSPENSION, ER, SYRINGE	4	QL(3.2 per 56 days)
ABILIFY MAINTENA 300 MG, 400 MG SUSPENSION, ER, RECON DL	4	QL(1 per 28 days)
ABILIFY MAINTENA 300 MG, 400 MG SUSPENSION, ER, SYRINGE DL	4	QL(1 per 28 days)
ABILIFY MYCITE MAINTENANCE KIT 10 MG TABLET WITH SENSOR AND STRIP DL	4	PA,QL(30 per 30 days)
ABILIFY MYCITE MAINTENANCE KIT 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET WITH SENSOR AND STRIP DL	4	PA,QL(30 per 30 days)
ABILIFY MYCITE STARTER KIT 10 MG TABLET W/SENSOR AND STRIP, POD DL	4	PA,QL(30 per 30 days)
ABILIFY MYCITE STARTER KIT 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET W/SENSOR AND STRIP, POD DL	4	PA,QL(30 per 30 days)
<i>aripiprazole 1 mg/ml SOLUTION MO</i>	1	QL(750 per 30 days)
<i>aripiprazole 10 mg, 15 mg TABLET, DISINTEGRATING MO</i>	1	QL(60 per 30 days)
<i>aripiprazole 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg TABLET MO</i>	1	
ARISTADA 1,064 MG/3.9 ML SUSPENSION, ER, SYRINGE	4	QL(3.9 per 56 days)
ARISTADA 441 MG/1.6 ML SUSPENSION, ER, SYRINGE	4	QL(1.6 per 28 days)
ARISTADA 662 MG/2.4 ML SUSPENSION, ER, SYRINGE	4	QL(2.4 per 28 days)
ARISTADA 882 MG/3.2 ML SUSPENSION, ER, SYRINGE	4	QL(3.2 per 28 days)
ARISTADA INITIO 675 MG/2.4 ML SUSPENSION, ER, SYRINGE	4	QL(2.4 per 42 days)
<i>asenapine maleate 10 mg, 2.5 mg, 5 mg SUBLINGUAL TABLET MO</i>	1	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CAPLYTA 10.5 MG, 21 MG CAPSULE DL	4	PA,QL(30 per 30 days)
CAPLYTA 42 MG CAPSULE	4	PA,QL(30 per 30 days)
chlorpromazine 10 mg, 25 mg TABLET MO	1	BvsD
chlorpromazine 100 mg, 200 mg, 50 mg TABLET MO	1	
chlorpromazine 100 mg/ml, 30 mg/ml CONCENTRATE MO	1	
chlorpromazine 25 mg/ml SOLUTION MO	1	
clozapine 100 mg TABLET MO	1	QL(270 per 30 days)
clozapine 100 mg TABLET, DISINTEGRATING MO	1	PA,QL(270 per 30 days)
clozapine 12.5 mg TABLET, DISINTEGRATING MO	1	PA
clozapine 150 mg TABLET, DISINTEGRATING MO	1	PA,QL(180 per 30 days)
clozapine 200 mg TABLET MO	1	QL(135 per 30 days)
clozapine 200 mg TABLET, DISINTEGRATING MO	1	PA,QL(135 per 30 days)
clozapine 25 mg TABLET MO	1	QL(1080 per 30 days)
clozapine 25 mg TABLET, DISINTEGRATING MO	1	PA,QL(1080 per 30 days)
clozapine 50 mg TABLET MO	1	
CLOZARIL 100 MG TABLET DL	4	QL(270 per 30 days)
CLOZARIL 200 MG TABLET DL	4	QL(135 per 30 days)
CLOZARIL 25 MG TABLET DL	4	QL(1080 per 30 days)
CLOZARIL 50 MG TABLET DL	4	
droperidol 2.5 mg/ml SOLUTION MO	1	
FANAPT 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET DL	4	PA,QL(60 per 30 days)
FANAPT TITRATION PACK A 1MG(2)-2MG(2)- 4MG(2)-6MG(2) TABLET, DOSE PACK MO	3	PA,QL(56 per 28 days)
FANAPT TITRATION PACK B 1 MG(6)-2MG(2)- 6 MG(2)-8 MG(2) TABLET, DOSE PACK MO	3	PA,QL(56 per 28 days)
FANAPT TITRATION PACK C 1 MG(4)-2 MG(2) -6 MG (2) TABLET, DOSE PACK MO	3	PA,QL(56 per 28 days)
fluphenazine decanoate 25 mg/ml SOLUTION MO	1	
fluphenazine hcl 1 mg, 10 mg, 2.5 mg, 5 mg TABLET MO	1	
fluphenazine hcl 2.5 mg/5 ml ELIXIR MO	1	
fluphenazine hcl 2.5 mg/ml SOLUTION MO	1	
fluphenazine hcl 5 mg/ml CONCENTRATE MO	1	
GEODON 20 MG, 40 MG, 60 MG, 80 MG CAPSULE DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GEODON 20 MG/ML (FINAL CONC.) RECON SOLUTION MO	3	PA
HALDOL DECANOATE 100 MG/ML, 50 MG/ML SOLUTION MO	3	PA
<i>haloperidol 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg TABLET MO</i>	1	
<i>haloperidol decanoate 100 mg/ml, 50 mg/ml SOLUTION MO</i>	1	
<i>haloperidol lactate 2 mg/ml CONCENTRATE MO</i>	1	
<i>haloperidol lactate 5 mg/ml SOLUTION MO</i>	1	
<i>haloperidol lactate 5 mg/ml SYRINGE MO</i>	1	
INVEGA 1.5 MG TABLET, ER 24 HR. DL	4	PA,QL(30 per 30 days)
INVEGA 3 MG, 9 MG TABLET, ER 24 HR. DL	4	PA,QL(30 per 30 days)
INVEGA 6 MG TABLET, ER 24 HR. DL	4	PA,QL(60 per 30 days)
INVEGA HAFYERA 1,092 MG/3.5 ML SYRINGE	4	QL(3.5 per 180 days)
INVEGA HAFYERA 1,560 MG/5 ML SYRINGE	4	QL(5 per 180 days)
INVEGA SUSTENNA 117 MG/0.75 ML, 234 MG/1.5 ML, 78 MG/0.5 ML SYRINGE DL	4	QL(1.5 per 28 days)
INVEGA SUSTENNA 156 MG/ML SYRINGE DL	4	QL(1 per 28 days)
INVEGA SUSTENNA 39 MG/0.25 ML SYRINGE MO	3	QL(1.5 per 28 days)
INVEGA TRINZA 273 MG/0.88 ML SYRINGE	4	QL(0.88 per 90 days)
INVEGA TRINZA 410 MG/1.32 ML SYRINGE	4	QL(1.32 per 90 days)
INVEGA TRINZA 546 MG/1.75 ML SYRINGE	4	QL(1.75 per 90 days)
INVEGA TRINZA 819 MG/2.63 ML SYRINGE	4	QL(2.63 per 90 days)
LATUDA 120 MG, 20 MG, 40 MG, 60 MG TABLET	4	PA,QL(30 per 30 days)
LATUDA 80 MG TABLET	4	PA,QL(60 per 30 days)
<i>loxapine succinate 10 mg, 25 mg, 5 mg, 50 mg CAPSULE MO</i>	1	
<i>lurasidone 120 mg, 20 mg, 40 mg, 60 mg TABLET MO</i>	1	QL(30 per 30 days)
<i>lurasidone 80 mg TABLET MO</i>	1	QL(60 per 30 days)
LYBALVI 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG TABLET DL	4	PA,QL(30 per 30 days)
<i>molindone 10 mg TABLET MO</i>	1	PA,QL(240 per 30 days)
<i>molindone 25 mg TABLET MO</i>	1	PA,QL(270 per 30 days)
<i>molindone 5 mg TABLET MO</i>	1	PA,QL(360 per 30 days)
NUPLAZID 10 MG TABLET DL	4	PA,QL(30 per 30 days)
NUPLAZID 34 MG CAPSULE DL	4	PA,QL(30 per 30 days)
<i>olanzapine 10 mg RECON SOLUTION MO</i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
olanzapine 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg TABLET MO	1	
olanzapine 10 mg, 5 mg TABLET, DISINTEGRATING MO	1	QL(30 per 30 days)
olanzapine 15 mg, 20 mg TABLET, DISINTEGRATING MO	1	QL(60 per 30 days)
OPIPZA 10 MG FILM DL	4	PA,QL(90 per 30 days)
OPIPZA 2 MG FILM DL	4	PA,QL(30 per 30 days)
OPIPZA 5 MG FILM DL	4	PA,QL(180 per 30 days)
paliperidone 1.5 mg, 3 mg, 9 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
paliperidone 6 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
perphenazine 16 mg, 2 mg, 4 mg, 8 mg TABLET MO	1	
PERSERIS 120 MG, 90 MG SUSPENSION, ER, SYRINGE DL	4	QL(1 per 28 days)
pimozide 1 mg, 2 mg TABLET MO	1	
quetiapine 100 mg TABLET MO	1	QL(90 per 30 days)
quetiapine 150 mg TABLET MO	1	QL(30 per 30 days)
quetiapine 150 mg TABLET, ER 24 HR. MO	1	QL(90 per 30 days)
quetiapine 200 mg TABLET MO	1	QL(120 per 30 days)
quetiapine 200 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
quetiapine 25 mg, 50 mg TABLET MO	1	QL(120 per 30 days)
quetiapine 300 mg, 400 mg TABLET MO	1	QL(60 per 30 days)
quetiapine 300 mg, 400 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
quetiapine 50 mg TABLET, ER 24 HR. MO	1	QL(120 per 30 days)
REXULTI 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG TABLET DL	4	PA,QL(30 per 30 days)
RISPERDAL 0.5 MG TABLET MO	3	QL(120 per 30 days)
RISPERDAL 1 MG, 2 MG TABLET MO	3	QL(60 per 30 days)
RISPERDAL 1 MG/ML SOLUTION DL	4	
RISPERDAL 3 MG, 4 MG TABLET DL	4	QL(60 per 30 days)
RISPERDAL CONSTA 12.5 MG/2 ML, 25 MG/2 ML SUSPENSION, ER, RECON MO	3	QL(2 per 28 days)
RISPERDAL CONSTA 37.5 MG/2 ML, 50 MG/2 ML SUSPENSION, ER, RECON DL	4	QL(2 per 28 days)
risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg TABLET MO	1	QL(60 per 30 days)
risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg TABLET, DISINTEGRATING MO	1	ST,QL(60 per 30 days)
risperidone 0.5 mg TABLET MO	1	QL(120 per 30 days)
risperidone 0.5 mg TABLET, DISINTEGRATING MO	1	ST,QL(120 per 30 days)
risperidone 1 mg/ml SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SAPHRIS 10 MG, 2.5 MG, 5 MG SUBLINGUAL TABLET DL	4	PA,QL(60 per 30 days)
SECUADO 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR PATCH, 24 HR. DL	4	PA,QL(30 per 30 days)
SEROQUEL 100 MG TABLET MO	3	QL(90 per 30 days)
SEROQUEL 200 MG, 25 MG, 50 MG TABLET MO	3	QL(120 per 30 days)
SEROQUEL 300 MG, 400 MG TABLET MO	3	QL(60 per 30 days)
SEROQUEL XR 150 MG TABLET, ER 24 HR. MO	3	PA,QL(90 per 30 days)
SEROQUEL XR 200 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
SEROQUEL XR 300 MG, 400 MG TABLET, ER 24 HR. MO	3	PA,QL(60 per 30 days)
SEROQUEL XR 50 MG TABLET, ER 24 HR. MO	3	PA,QL(120 per 30 days)
SEROQUEL XR 50 MG(3)-200 MG (1)-300 MG(11) TABLET, ER 24 HR., DOSE PACK MO	3	PA,QL(15 per 30 days)
thioridazine 10 mg, 100 mg, 25 mg, 50 mg TABLET MO	1	
thiothixene 1 mg, 10 mg, 2 mg, 5 mg CAPSULE MO	1	
trifluoperazine 1 mg, 10 mg, 2 mg, 5 mg TABLET MO	1	
UZEDY 100 MG/0.28 ML SUSPENSION, ER, SYRINGE DL	4	QL(0.28 per 28 days)
UZEDY 125 MG/0.35 ML SUSPENSION, ER, SYRINGE DL	4	QL(0.35 per 28 days)
UZEDY 150 MG/0.42 ML SUSPENSION, ER, SYRINGE	4	QL(0.42 per 56 days)
UZEDY 200 MG/0.56 ML SUSPENSION, ER, SYRINGE	4	QL(0.56 per 56 days)
UZEDY 250 MG/0.7 ML SUSPENSION, ER, SYRINGE	4	QL(0.7 per 56 days)
UZEDY 50 MG/0.14 ML SUSPENSION, ER, SYRINGE DL	4	QL(0.14 per 28 days)
UZEDY 75 MG/0.21 ML SUSPENSION, ER, SYRINGE DL	4	QL(0.21 per 28 days)
VERSACLOZ 50 MG/ML SUSPENSION DL	4	PA,QL(540 per 30 days)
VRAYLAR 1.5 MG (1)- 3 MG (6) CAPSULE, DOSE PACK MO	3	PA
VRAYLAR 1.5 MG, 3 MG, 4.5 MG, 6 MG CAPSULE	4	PA,QL(30 per 30 days)
ziprasidone hcl 20 mg, 40 mg, 60 mg, 80 mg CAPSULE MO	1	
ziprasidone mesylate 20 mg/ml (final conc.) RECON SOLUTION MO	1	
ZYPREXA 10 MG RECON SOLUTION MO	3	
ZYPREXA 10 MG, 15 MG, 2.5 MG, 20 MG, 5 MG, 7.5 MG TABLET	4	
ZYPREXA RELPREVV 210 MG SUSPENSION FOR RECONSTITUTION MO	3	QL(4 per 28 days)
ZYPREXA RELPREVV 300 MG SUSPENSION FOR RECONSTITUTION	4	QL(2 per 28 days)
ZYPREXA RELPREVV 405 MG SUSPENSION FOR RECONSTITUTION	4	QL(1 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZYPREXA ZYDIS 10 MG TABLET, DISINTEGRATING	4	QL(30 per 30 days)
ZYPREXA ZYDIS 15 MG, 20 MG TABLET, DISINTEGRATING	4	QL(60 per 30 days)
ZYPREXA ZYDIS 5 MG TABLET, DISINTEGRATING MO	3	QL(30 per 30 days)
ANTISPASTICITY AGENTS		
baclofen 10 mg TABLET MO	1	
baclofen 10 mg/5 ml (2 mg/ml), 5 mg/5 ml SOLUTION DL	4	
baclofen 15 mg, 20 mg TABLET MO	1	
baclofen 25 mg/5 ml (5 mg/ml) SUSPENSION DL	4	QL(480 per 30 days)
baclofen 5 mg TABLET MO	1	QL(90 per 30 days)
DANTRIUM 20 MG RECON SOLUTION MO	3	
DANTRIUM 25 MG CAPSULE MO	3	
dantrolene 100 mg, 25 mg, 50 mg CAPSULE MO	1	
dantrolene 20 mg RECON SOLUTION MO	1	
FLEQSUVY 25 MG/5 ML (5 MG/ML) SUSPENSION DL	4	QL(480 per 30 days)
LYVISPAH 10 MG, 20 MG GRANULES IN PACKET MO	3	ST,QL(120 per 30 days)
LYVISPAH 5 MG GRANULES IN PACKET MO	3	ST,QL(270 per 30 days)
OZOBAX 5 MG/5 ML SOLUTION DL	4	
OZOBAX DS 10 MG/5 ML (2 MG/ML) SOLUTION DL	4	
revonto 20 mg RECON SOLUTION MO	1	
tizanidine 2 mg, 4 mg TABLET MO	1	
tizanidine 2 mg, 4 mg, 6 mg CAPSULE MO	1	ST
ZANAFLEX 2 MG, 4 MG, 6 MG CAPSULE MO	3	ST
ZANAFLEX 4 MG TABLET MO	3	ST
ANTIVIRALS		
abacavir 20 mg/ml SOLUTION MO	1	QL(960 per 30 days)
abacavir 300 mg TABLET MO	1	QL(60 per 30 days)
abacavir-lamivudine 600-300 mg TABLET MO	1	QL(30 per 30 days)
acyclovir 200 mg CAPSULE MO	1	
acyclovir 200 mg/5 ml (5 ml) SUSPENSION DL	4	
acyclovir 200 mg/5 ml SUSPENSION MO	1	
acyclovir 400 mg, 800 mg TABLET MO	1	
acyclovir 5 % CREAM MO	3	PA,QL(5 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>acyclovir 5 % OINTMENT</i> MO	1	PA,QL(30 per 30 days)
<i>acyclovir sodium 50 mg/ml SOLUTION</i> MO	1	BvsD
<i>adefovir 10 mg TABLET</i> MO	1	
APTIVUS 250 MG CAPSULE DL	4	QL(120 per 30 days)
<i>atazanavir 150 mg, 200 mg CAPSULE</i> MO	1	QL(60 per 30 days)
<i>atazanavir 300 mg CAPSULE</i> MO	1	QL(30 per 30 days)
ATRIPLA 600-200-300 MG TABLET DL	4	QL(30 per 30 days)
BARACLUDE 0.05 MG/ML SOLUTION DL	4	QL(630 per 30 days)
BARACLUDE 0.5 MG, 1 MG TABLET DL	4	PA,QL(30 per 30 days)
BIKTARVY 30-120-15 MG, 50-200-25 MG TABLET DL	4	QL(30 per 30 days)
CABENUVA 400 MG/2 ML- 600 MG/2 ML, 600 MG/3 ML- 900 MG/3 ML SUSPENSION, ER DL	4	QL(50 per 365 days)
<i>cidofovir 75 mg/ml SOLUTION</i> DL	4	
CIMDUO 300-300 MG TABLET DL	4	QL(30 per 30 days)
COMBIVIR 150-300 MG TABLET DL	4	QL(60 per 30 days)
COMPLERA 200-25-300 MG TABLET DL	4	QL(30 per 30 days)
<i>darunavir 600 mg TABLET</i> DL	4	QL(60 per 30 days)
<i>darunavir 800 mg TABLET</i> DL	4	QL(30 per 30 days)
DELSTRIGO 100-300-300 MG TABLET DL	4	QL(30 per 30 days)
DENAVIR 1 % CREAM MO	3	PA
DESCOVY 120-15 MG, 200-25 MG TABLET DL	4	QL(30 per 30 days)
<i>didanosine 250 mg, 400 mg CAPSULE, DR/EC</i> MO	1	QL(30 per 30 days)
DOVATO 50-300 MG TABLET DL	4	QL(30 per 30 days)
EDURANT 25 MG TABLET DL	4	QL(30 per 30 days)
EDURANT PED 2.5 MG TABLET FOR SUSPENSION DL	4	QL(180 per 30 days)
<i>efavirenz 200 mg CAPSULE</i> MO	1	QL(120 per 30 days)
<i>efavirenz 50 mg CAPSULE</i> MO	1	QL(480 per 30 days)
<i>efavirenz 600 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>efavirenz-emtricitabin-tenofov 600-200-300 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>efavirenz-lamivu-tenofov disop 400-300-300 mg, 600-300-300 mg TABLET</i> DL	4	QL(30 per 30 days)
<i>emtricitabine-tenofov 200-25-300 mg TABLET</i> DL	4	QL(30 per 30 days)
<i>emtricitabine 200 mg CAPSULE</i> MO	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
emtricitabine-tenofovir (tdf) 100-150 mg, 133-200 mg, 167-250 mg, 200-300 mg TABLET MO	1	QL(30 per 30 days)
EMTRIVA 10 MG/ML SOLUTION MO	3	QL(680 per 28 days)
EMTRIVA 200 MG CAPSULE MO	3	QL(30 per 30 days)
entecavir 0.5 mg, 1 mg TABLET MO	1	QL(30 per 30 days)
EPCLUSA 150-37.5 MG PELLETS IN PACKET DL	4	PA,QL(28 per 28 days)
EPCLUSA 200-50 MG PELLETS IN PACKET DL	4	PA,QL(56 per 28 days)
EPCLUSA 200-50 MG, 400-100 MG TABLET DL	4	PA,QL(28 per 28 days)
EPIVIR 10 MG/ML SOLUTION MO	3	QL(900 per 30 days)
EPIVIR 150 MG TABLET MO	3	QL(60 per 30 days)
EPIVIR 300 MG TABLET MO	3	QL(30 per 30 days)
EPZICOM 600-300 MG TABLET DL	4	QL(30 per 30 days)
etravirine 100 mg TABLET DL	4	QL(120 per 30 days)
etravirine 200 mg TABLET DL	4	QL(60 per 30 days)
EVOTAZ 300-150 MG TABLET DL	4	QL(30 per 30 days)
famciclovir 125 mg, 250 mg, 500 mg TABLET MO	1	QL(90 per 30 days)
FLUMADINE 100 MG TABLET MO	3	
fosamprenavir 700 mg TABLET DL	4	QL(120 per 30 days)
foscarnet 24 mg/ml SOLUTION MO	1	BvsD
FUZEON 90 MG RECON SOLUTION DL	4	QL(60 per 30 days)
ganciclovir sodium 50 mg/ml SOLUTION MO	1	BvsD
ganciclovir sodium 500 mg RECON SOLUTION MO	1	BvsD
GENVOYA 150-150-200-10 MG TABLET DL	4	QL(30 per 30 days)
HARVONI 33.75-150 MG PELLETS IN PACKET DL	4	PA,QL(28 per 28 days)
HARVONI 45-200 MG PELLETS IN PACKET DL	4	PA,QL(56 per 28 days)
HARVONI 45-200 MG, 90-400 MG TABLET DL	4	PA,QL(28 per 28 days)
HEPSERA 10 MG TABLET DL	4	
INTELENCE 100 MG TABLET DL	4	QL(120 per 30 days)
INTELENCE 200 MG TABLET DL	4	QL(60 per 30 days)
INTELENCE 25 MG TABLET MO	3	QL(120 per 30 days)
ISENTRESS 100 MG CHEWABLE TABLET DL	4	QL(180 per 30 days)
ISENTRESS 100 MG POWDER IN PACKET MO	3	QL(300 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ISENTRESS 25 MG CHEWABLE TABLET MO	2	QL(180 per 30 days)
ISENTRESS 400 MG TABLET DL	4	QL(120 per 30 days)
ISENTRESS HD 600 MG TABLET DL	4	QL(60 per 30 days)
JULUCA 50-25 MG TABLET DL	4	QL(30 per 30 days)
KALETRA 100-25 MG TABLET MO	3	QL(300 per 30 days)
KALETRA 200-50 MG TABLET MO	3	QL(150 per 30 days)
KALETRA 400-100 MG/5 ML SOLUTION DL	4	
lamivudine 10 mg/ml SOLUTION MO	1	QL(900 per 30 days)
lamivudine 100 mg TABLET MO	1	QL(90 per 30 days)
lamivudine 150 mg TABLET MO	1	QL(60 per 30 days)
lamivudine 300 mg TABLET MO	1	QL(30 per 30 days)
lamivudine-zidovudine 150-300 mg TABLET MO	1	QL(60 per 30 days)
ledipasvir-sofosbuvir 90-400 mg TABLET DL	4	PA,QL(28 per 28 days)
LEXIVA 50 MG/ML SUSPENSION MO	3	QL(1575 per 28 days)
LEXIVA 700 MG TABLET DL	4	QL(120 per 30 days)
LIVTENCITY 200 MG TABLET DL	4	PA,QL(120 per 30 days)
lopinavir-ritonavir 100-25 mg TABLET MO	1	QL(300 per 30 days)
lopinavir-ritonavir 200-50 mg TABLET MO	1	QL(150 per 30 days)
lopinavir-ritonavir 400-100 mg/5 ml SOLUTION MO	1	
maraviroc 150 mg TABLET DL	4	QL(240 per 30 days)
maraviroc 300 mg TABLET DL	4	QL(120 per 30 days)
MAVYRET 100-40 MG TABLET DL	4	PA,QL(84 per 28 days)
MAVYRET 50-20 MG PELLETS IN PACKET DL	4	PA,QL(150 per 30 days)
nevirapine 100 mg TABLET, ER 24 HR. MO	1	QL(120 per 30 days)
nevirapine 200 mg TABLET MO	1	QL(60 per 30 days)
nevirapine 400 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
nevirapine 50 mg/5 ml SUSPENSION MO	1	QL(1200 per 30 days)
NORVIR 100 MG CAPSULE MO	3	QL(360 per 30 days)
NORVIR 100 MG POWDER IN PACKET MO	3	QL(360 per 30 days)
NORVIR 100 MG TABLET MO	3	QL(360 per 30 days)
ODEFSEY 200-25-25 MG TABLET DL	4	QL(30 per 30 days)
oseltamivir 30 mg CAPSULE MO	1	QL(224 per 365 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
oseltamivir 45 mg, 75 mg CAPSULE MO	1	QL(112 per 365 days)
oseltamivir 6 mg/ml SUSPENSION FOR RECONSTITUTION MO	1	QL(1440 per 365 days)
PAXLOVID 150 MG (10)- 100 MG (10) TABLET, DOSE PACK MO	2	QL(40 per 10 days)
PAXLOVID 150 MG (6)- 100 MG (5) TABLET, DOSE PACK MO	2	QL(22 per 10 days)
PAXLOVID 300 MG (150 MG X 2)-100 MG TABLET, DOSE PACK MO	2	QL(60 per 10 days)
penciclovir 1 % CREAM MO	1	PA
PIFELTRO 100 MG TABLET DL	4	QL(60 per 30 days)
PREVYMIS 120 MG, 20 MG PELLETS IN PACKET DL	4	PA,QL(120 per 30 days)
PREVYMIS 240 MG TABLET DL	4	PA,QL(28 per 28 days)
PREVYMIS 240 MG/12 ML SOLUTION DL	4	PA,QL(336 per 28 days)
PREVYMIS 480 MG TABLET DL	4	PA
PREVYMIS 480 MG/24 ML SOLUTION DL	4	PA,QL(672 per 28 days)
PREZCOBIX 800-150 MG-MG TABLET DL	4	QL(30 per 30 days)
PREZISTA 100 MG/ML SUSPENSION DL	4	QL(360 per 30 days)
PREZISTA 150 MG TABLET DL	4	QL(240 per 30 days)
PREZISTA 600 MG TABLET DL	4	QL(60 per 30 days)
PREZISTA 75 MG TABLET MO	3	QL(480 per 30 days)
PREZISTA 800 MG TABLET DL	4	QL(30 per 30 days)
RELENZA DISKHALER 5 MG/ACTUATION BLISTER WITH DEVICE MO	3	QL(60 per 180 days)
RETROVIR 10 MG/ML SOLUTION MO	3	
RETROVIR 10 MG/ML SYRUP MO	3	QL(1680 per 28 days)
RETROVIR 100 MG CAPSULE MO	3	QL(180 per 30 days)
REYATAZ 200 MG CAPSULE DL	4	QL(60 per 30 days)
REYATAZ 300 MG CAPSULE DL	4	QL(30 per 30 days)
REYATAZ 50 MG POWDER IN PACKET MO	3	
ribavirin 200 mg CAPSULE MO	1	
ribavirin 200 mg TABLET MO	1	
rimantadine 100 mg TABLET MO	1	
ritonavir 100 mg TABLET MO	1	QL(360 per 30 days)
RUKOBIA 600 MG TABLET, ER 12 HR. DL	4	QL(60 per 30 days)
SELZENTRY 150 MG TABLET DL	4	QL(240 per 30 days)
SELZENTRY 20 MG/ML SOLUTION DL	4	QL(1800 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SELZENTRY 25 MG TABLET MO	3	QL(240 per 30 days)
SELZENTRY 300 MG, 75 MG TABLET DL	4	QL(120 per 30 days)
SOVALDI 150 MG PELLETS IN PACKET DL	4	PA,QL(28 per 28 days)
SOVALDI 200 MG PELLETS IN PACKET DL	4	PA,QL(56 per 28 days)
SOVALDI 200 MG, 400 MG TABLET DL	4	PA,QL(28 per 28 days)
<i>stavudine 15 mg, 20 mg CAPSULE</i> MO	1	QL(120 per 30 days)
<i>stavudine 30 mg, 40 mg CAPSULE</i> MO	1	QL(60 per 30 days)
STRIBILD 150-150-200-300 MG TABLET DL	4	QL(30 per 30 days)
SUNLENCA 300 MG TABLET DL	4	QL(10 per 365 days)
SUNLENCA 309 MG/ML SOLUTION	4	QL(9 per 365 days)
SYMFI 600-300-300 MG TABLET DL	4	QL(30 per 30 days)
SYMFI LO 400-300-300 MG TABLET DL	4	QL(30 per 30 days)
SYMTUZA 800-150-200-10 MG TABLET DL	4	QL(30 per 30 days)
TAMIFLU 30 MG CAPSULE MO	3	PA,QL(224 per 365 days)
TAMIFLU 45 MG, 75 MG CAPSULE MO	3	PA,QL(112 per 365 days)
TAMIFLU 6 MG/ML SUSPENSION FOR RECONSTITUTION MO	3	PA,QL(1440 per 365 days)
<i>tenofovir disoproxil fumarate 300 mg TABLET</i> MO	1	QL(30 per 30 days)
TIVICAY 10 MG TABLET MO	3	QL(60 per 30 days)
TIVICAY 25 MG, 50 MG TABLET DL	4	QL(60 per 30 days)
TIVICAY PD 5 MG TABLET FOR SUSPENSION DL	4	QL(180 per 30 days)
TRIUMEQ 600-50-300 MG TABLET DL	4	QL(30 per 30 days)
TRIUMEQ PD 60-5-30 MG TABLET FOR SUSPENSION MO	3	QL(180 per 30 days)
TRIZIVIR 300-150-300 MG TABLET DL	4	QL(60 per 30 days)
TROGARZO 200 MG/1.33 ML (150 MG/ML) SOLUTION DL	4	
TRUVADA 100-150 MG, 133-200 MG, 167-250 MG, 200-300 MG TABLET DL	4	QL(30 per 30 days)
TYBOST 150 MG TABLET MO	2	QL(30 per 30 days)
<i>valacyclovir 1 gram, 500 mg TABLET</i> MO	1	
VALCYTE 450 MG TABLET DL	4	PA,QL(120 per 30 days)
VALCYTE 50 MG/ML RECON SOLUTION DL	4	PA,QL(1056 per 30 days)
<i>valganciclovir 450 mg TABLET</i> MO	1	QL(120 per 30 days)
<i>valganciclovir 50 mg/ml RECON SOLUTION</i> DL	4	QL(1056 per 30 days)
VALTREX 1 GRAM, 500 MG TABLET MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VEMLIDY 25 MG TABLET DL	4	QL(30 per 30 days)
VIRACEPT 250 MG TABLET DL	4	QL(300 per 30 days)
VIRACEPT 625 MG TABLET DL	4	QL(120 per 30 days)
VIREAD 150 MG, 200 MG, 250 MG, 300 MG TABLET DL	4	QL(30 per 30 days)
VIREAD 40 MG/SCOOP (40 MG/GRAM) POWDER DL	4	QL(240 per 30 days)
VOCABRIA 30 MG TABLET DL	4	QL(30 per 30 days)
VOSEVI 400-100-100 MG TABLET DL	4	PA,QL(28 per 28 days)
XERESE 5-1 % CREAM DL	4	QL(5 per 30 days)
XOFLUZA 20 MG, 40 MG, 80 MG TABLET MO	3	
ZEPATIER 50-100 MG TABLET DL	4	PA,QL(28 per 28 days)
ZIAGEN 20 MG/ML SOLUTION MO	3	QL(960 per 30 days)
ZIAGEN 300 MG TABLET MO	3	QL(60 per 30 days)
zidovudine 10 mg/ml SYRUP MO	1	QL(1680 per 28 days)
zidovudine 100 mg CAPSULE MO	1	QL(180 per 30 days)
zidovudine 300 mg TABLET MO	1	QL(60 per 30 days)
ZIRGAN 0.15 % GEL MO	3	QL(5 per 30 days)
ZOVIRAX 200 MG/5 ML SUSPENSION MO	3	PA
ZOVIRAX 5 % CREAM MO	3	PA,QL(5 per 30 days)
ZOVIRAX 5 % OINTMENT MO	3	PA,QL(30 per 30 days)
ANXIOLYTICS		
alprazolam 0.25 mg, 0.5 mg, 1 mg TABLET DL	1	QL(120 per 30 days)
alprazolam 0.25 mg, 0.5 mg, 1 mg, 2 mg TABLET, DISINTEGRATING DL	1	
alprazolam 0.5 mg, 1 mg, 2 mg, 3 mg TABLET, ER 24 HR. DL	1	QL(60 per 30 days)
alprazolam 2 mg TABLET DL	1	QL(150 per 30 days)
alprazolam intensol 1 mg/ml CONCENTRATE DL	1	
ATIVAN 0.5 MG, 1 MG TABLET DL	4	PA,QL(90 per 30 days)
ATIVAN 2 MG TABLET DL	4	PA,QL(150 per 30 days)
ATIVAN 2 MG/ML, 4 MG/ML SOLUTION DL	3	PA
BUCAPSOL 10 MG, 15 MG, 7.5 MG CAPSULE DL	4	
bupirone 10 mg, 5 mg TABLET MO	1	
bupirone 15 mg, 30 mg, 7.5 mg TABLET MO	1	
chlordiazepoxide hcl 10 mg, 25 mg, 5 mg CAPSULE DL	1	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg TABLET, DISINTEGRATING DL	1	
clonazepam 0.5 mg, 1 mg TABLET DL	1	
clonazepam 2 mg TABLET DL	1	
clorazepate dipotassium 15 mg, 3.75 mg, 7.5 mg TABLET DL	1	
diazepam 10 mg TABLET DL	1	QL(120 per 30 days)
diazepam 2 mg TABLET DL	1	QL(90 per 30 days)
diazepam 5 mg TABLET DL	1	QL(90 per 30 days)
diazepam 5 mg/5 ml (1 mg/ml), 5 mg/5 ml (1 mg/ml, 5 ml) SOLUTION DL	1	QL(1200 per 30 days)
diazepam 5 mg/ml CONCENTRATE DL	1	QL(240 per 30 days)
diazepam 5 mg/ml SOLUTION DL	1	
diazepam 5 mg/ml SYRINGE DL	1	
diazepam intensol 5 mg/ml CONCENTRATE DL	1	QL(240 per 30 days)
doxepin 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg CAPSULE MO	1	
doxepin 10 mg/ml CONCENTRATE MO	1	
hydroxyzine hcl 10 mg, 50 mg TABLET MO	1	
hydroxyzine hcl 10 mg/5 ml, 25 mg/ml, 50 mg/ml SOLUTION MO	1	
hydroxyzine hcl 25 mg TABLET MO	1	
KLONOPIN 0.5 MG, 1 MG, 2 MG TABLET DL	3	PA
lorazepam 0.5 mg, 1 mg TABLET DL	1	QL(90 per 30 days)
lorazepam 2 mg TABLET DL	1	QL(150 per 30 days)
lorazepam 2 mg/ml CONCENTRATE DL	1	QL(150 per 30 days)
lorazepam 2 mg/ml SYRINGE DL	1	
lorazepam 2 mg/ml, 4 mg/ml SOLUTION DL	1	
lorazepam intensol 2 mg/ml CONCENTRATE DL	1	QL(150 per 30 days)
LOREEV XR 1 MG CAPSULE, ER 24 HR. DL	4	PA,QL(210 per 30 days)
LOREEV XR 1.5 MG, 2 MG CAPSULE, ER 24 HR. DL	4	PA,QL(150 per 30 days)
LOREEV XR 3 MG CAPSULE, ER 24 HR. DL	4	PA,QL(90 per 30 days)
meprobamate 200 mg, 400 mg TABLET MO	1	
oxazepam 10 mg, 15 mg, 30 mg CAPSULE DL	1	
VALIUM 10 MG TABLET DL	3	PA,QL(120 per 30 days)
VALIUM 2 MG, 5 MG TABLET DL	3	PA,QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
XANAX 0.25 MG, 0.5 MG, 1 MG TABLET DL	3	PA,QL(120 per 30 days)
XANAX 2 MG TABLET DL	3	PA,QL(150 per 30 days)
XANAX XR 0.5 MG, 1 MG, 2 MG, 3 MG TABLET, ER 24 HR. DL	3	PA,QL(60 per 30 days)
BIPOLAR AGENTS		
<i>lithium carbonate 150 mg, 300 mg, 600 mg CAPSULE</i> MO	1	
<i>lithium carbonate 300 mg TABLET</i> MO	1	
<i>lithium carbonate 300 mg, 450 mg TABLET ER</i> MO	1	
<i>lithium citrate 8 meq/5 ml SOLUTION</i> MO	1	
LITHOBID 300 MG TABLET ER MO	3	
BLOOD GLUCOSE REGULATORS		
<i>acarbose 100 mg, 25 mg, 50 mg TABLET</i> MO	1	
ACTOPLUS MET 15-850 MG TABLET MO	3	PA,QL(90 per 30 days)
ACTOS 15 MG, 30 MG, 45 MG TABLET MO	3	PA,QL(30 per 30 days)
ADMELOG SOLOSTAR U-100 INSULIN 100 UNIT/ML INSULIN PEN CI,MO	3	ST
ADMELOG U-100 INSULIN LISPRO 100 UNIT/ML SOLUTION CI,MO	3	ST
AFREZZA 12 UNIT CARTRIDGE WITH INHALER CI	4	PA,QL(90 per 30 days)
AFREZZA 4 UNIT (90)/ 8 UNIT (90), 4 UNIT/8 UNIT/ 12 UNIT (60), 8 UNIT (90)/ 12 UNIT (90) CARTRIDGE WITH INHALER CI	4	PA,QL(180 per 30 days)
AFREZZA 4 UNIT, 8 UNIT CARTRIDGE WITH INHALER CI,MO	3	PA,QL(90 per 30 days)
APIDRA SOLOSTAR U-100 INSULIN 100 UNIT/ML INSULIN PEN CI,MO	3	ST
APIDRA U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	3	ST
BAQSIMI 3 MG/ACTUATION SPRAY, NON-AEROSOL MO	2	
BASAGLAR KWIKPEN U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
BASAGLAR TEMPO PEN(U-100)INSLN 100 UNIT/ML (3 ML) INSULIN PEN, SENSOR CI,MO	3	PA
BRYNOVIN 25 MG/ML SOLUTION MO	3	PA,QL(120 per 30 days)
BYDUREON BCISE 2 MG/0.85 ML AUTO-INJECTOR MO	3	PA,QL(3.4 per 28 days)
BYETTA 10 MCG/DOSE(250 MCG/ML) 2.4 ML, 5 MCG/DOSE (250 MCG/ML) 1.2 ML PEN INJECTOR MO	3	PA,QL(2.4 per 30 days)
CYCLOSET 0.8 MG TABLET MO	3	ST,QL(180 per 30 days)
<i>diazoxide 50 mg/ml SUSPENSION</i> DL	4	
DUETACT 30-2 MG, 30-4 MG TABLET MO	3	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
exenatide 10 mcg/dose(250 mcg/ml) 2.4 ml, 5 mcg/dose (250 mcg/ml) 1.2 ml PEN INJECTOR MO	1	PA,QL(2.4 per 30 days)
FARXIGA 10 MG, 5 MG TABLET MO	3	QL(30 per 30 days)
FIASP FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
FIASP PENFILL U-100 INSULIN 100 UNIT/ML (3 ML) CARTRIDGE CI,MO	2	
FIASP U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
glimepiride 1 mg, 3 mg TABLET MO	1	
glimepiride 2 mg, 4 mg TABLET MO	1	
glipizide 10 mg, 2.5 mg, 5 mg TABLET, ER 24 HR. MO	1	
glipizide 10 mg, 5 mg TABLET MO	1	
glipizide 2.5 mg TABLET MO	1	
glipizide-metformin 2.5-250 mg, 2.5-500 mg, 5-500 mg TABLET MO	1	
GLUCAGEN HYPOKIT 1 MG RECON SOLUTION MO	3	ST
GLUCAGON (HCL) EMERGENCY KIT 1 MG RECON SOLUTION MO	3	ST
glucagon emergency kit (human) 1 mg RECON SOLUTION MO	3	ST
GLUCAGON EMERGENCY KIT (HUMAN) 1 MG RECON SOLUTION MO	3	ST
GLUCOTROL XL 10 MG, 2.5 MG, 5 MG TABLET, ER 24 HR. MO	3	
GLUMETZA 1,000 MG TABLET, GAST. RETENTION 24 HR. DL	4	ST,QL(60 per 30 days)
GLUMETZA 500 MG TABLET, GAST. RETENTION 24 HR. DL	4	ST,QL(120 per 30 days)
glyburide 1.25 mg, 2.5 mg, 5 mg TABLET MO	1	
glyburide micronized 1.5 mg, 3 mg, 6 mg TABLET MO	1	
glyburide-metformin 1.25-250 mg, 2.5-500 mg, 5-500 mg TABLET MO	1	
GLYNASE 1.5 MG, 3 MG, 6 MG TABLET MO	3	
GLYXAMBI 10-5 MG, 25-5 MG TABLET MO	2	QL(30 per 30 days)
GVOKE 1 MG/0.2 ML SOLUTION MO	3	ST
GVOKE HYPOPEN 1-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML AUTO-INJECTOR MO	3	ST
GVOKE HYPOPEN 2-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML AUTO-INJECTOR MO	3	ST
GVOKE PFS 1-PACK SYRINGE 0.5 MG/0.1 ML, 1 MG/0.2 ML SYRINGE MO	3	ST
GVOKE PFS 2-PACK SYRINGE 0.5 MG/0.1 ML, 1 MG/0.2 ML SYRINGE MO	3	ST
HUMALOG JUNIOR KWIKPEN U-100 100 UNIT/ML INSULIN PEN, HALF-UNIT CI,MO	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HUMALOG KWIKPEN INSULIN 100 UNIT/ML, 200 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
HUMALOG MIX 50-50 INSULN U-100 100 UNIT/ML (50-50) SUSPENSION CI,MO	2	
HUMALOG MIX 50-50 KWIKPEN 100 UNIT/ML (50-50) INSULIN PEN CI,MO	2	
HUMALOG MIX 75-25 KWIKPEN 100 UNIT/ML (75-25) INSULIN PEN CI,MO	2	
HUMALOG MIX 75-25(U-100)INSULN 100 UNIT/ML (75-25) SUSPENSION CI,MO	2	
HUMALOG TEMPO PEN(U-100)INSULN 100 UNIT/ML INSULIN PEN, SENSOR CI,MO	3	ST
HUMALOG U-100 INSULIN 100 UNIT/ML CARTRIDGE CI,MO	2	
HUMALOG U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
HUMULIN 70/30 U-100 INSULIN 100 UNIT/ML (70-30) SUSPENSION CI,MO	2	
HUMULIN 70/30 U-100 KWIKPEN 100 UNIT/ML (70-30) INSULIN PEN CI,MO	2	
HUMULIN N NPH INSULIN KWIKPEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
HUMULIN N NPH U-100 INSULIN 100 UNIT/ML SUSPENSION CI,MO	2	
HUMULIN R REGULAR U-100 INSULN 100 UNIT/ML SOLUTION CI,MO	2	
HUMULIN R U-500 (CONC) INSULIN 500 UNIT/ML SOLUTION CI	4	
HUMULIN R U-500 (CONC) KWIKPEN 500 UNIT/ML (3 ML) INSULIN PEN CI	4	
INSULIN ASP PRT-INSULIN ASPART 100 UNIT/ML (70-30) INSULIN PEN CI,MO	2	
INSULIN ASP PRT-INSULIN ASPART 100 UNIT/ML (70-30) SOLUTION CI,MO	2	
INSULIN ASPART U-100 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
INSULIN ASPART U-100 100 UNIT/ML CARTRIDGE CI,MO	2	
INSULIN ASPART U-100 100 UNIT/ML SOLUTION CI,MO	2	
INSULIN DEGLUDEC 100 UNIT/ML (3 ML), 200 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
INSULIN DEGLUDEC 100 UNIT/ML SOLUTION CI,MO	3	PA
INSULIN GLARGINE 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
INSULIN GLARGINE 100 UNIT/ML SOLUTION CI,MO	3	PA
INSULIN GLARGINE U-300 CONC 300 UNIT/ML (1.5 ML), 300 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
INSULIN GLARGINE-YFGN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
INSULIN GLARGINE-YFGN 100 UNIT/ML SOLUTION CI,MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INSULIN LISPRO 100 UNIT/ML INSULIN PEN CI,MO	2	
INSULIN LISPRO 100 UNIT/ML INSULIN PEN, HALF-UNIT CI,MO	2	
INSULIN LISPRO 100 UNIT/ML SOLUTION CI,MO	2	
INSULIN LISPRO PROTAMIN-LISPRO 100 UNIT/ML (75-25) INSULIN PEN CI,MO	2	
INVOKAMET 150-1,000 MG, 150-500 MG, 50-1,000 MG, 50-500 MG TABLET MO	2	QL(60 per 30 days)
INVOKAMET XR 150-1,000 MG, 150-500 MG, 50-1,000 MG, 50-500 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(60 per 30 days)
INVOKANA 100 MG, 300 MG TABLET MO	2	QL(30 per 30 days)
JANUMET 50-1,000 MG, 50-500 MG TABLET MO	2	QL(60 per 30 days)
JANUMET XR 100-1,000 MG TABLET, ER 24 HR., MULTIPHASE MO	2	QL(30 per 30 days)
JANUMET XR 50-1,000 MG, 50-500 MG TABLET, ER 24 HR., MULTIPHASE MO	2	QL(60 per 30 days)
JANUVIA 100 MG, 25 MG, 50 MG TABLET MO	2	QL(30 per 30 days)
JARDIANCE 10 MG, 25 MG TABLET MO	2	QL(30 per 30 days)
JENTADUETO 2.5-1,000 MG, 2.5-500 MG TABLET MO	2	QL(60 per 30 days)
JENTADUETO 2.5-850 MG TABLET MO	2	QL(60 per 30 days)
JENTADUETO XR 2.5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(60 per 30 days)
JENTADUETO XR 5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(30 per 30 days)
KAZANO 12.5-1,000 MG, 12.5-500 MG TABLET MO	3	PA,QL(60 per 30 days)
LANTUS SOLOSTAR U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
LANTUS U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
LEVEMIR FLEXPEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
LEVEMIR U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	3	PA
<i>liraglutide 0.6 mg/0.1 ml (18 mg/3 ml) PEN INJECTOR</i> MO	3	PA,QL(9 per 30 days)
LYUMJEV KWIKPEN U-100 INSULIN 100 UNIT/ML INSULIN PEN CI,MO	2	
LYUMJEV KWIKPEN U-200 INSULIN 200 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
LYUMJEV TEMPO PEN(U-100)INSULN 100 UNIT/ML INSULIN PEN, SENSOR CI,MO	3	ST
LYUMJEV U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
MERILOG 100 UNIT/ML SOLUTION CI,MO	3	ST
MERILOG SOLOSTAR 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	ST
<i>metformin 1,000 mg TABLET, ER 24 HR.</i> MO	3	ST,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
metformin 1,000 mg TABLET, GAST. RETENTION 24 HR.	4	ST,QL(60 per 30 days)
metformin 1,000 mg, 500 mg TABLET MO	1	
metformin 500 mg TABLET, ER 24 HR. MO	1	QL(120 per 30 days)
metformin 500 mg TABLET, ER 24 HR. MO	3	ST,QL(150 per 30 days)
metformin 500 mg TABLET, GAST. RETENTION 24 HR.	4	ST,QL(120 per 30 days)
metformin 500 mg/5 ml SOLUTION MO	1	QL(750 per 30 days)
metformin 625 mg TABLET DL	4	ST,QL(120 per 30 days)
metformin 750 mg TABLET DL	4	ST
metformin 750 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
metformin 850 mg TABLET MO	1	
miglitol 100 mg, 25 mg, 50 mg TABLET MO	1	
MOUNJARO 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML PEN INJECTOR MO	2	PA,QL(2 per 28 days)
nateglinide 120 mg, 60 mg TABLET MO	1	
NESINA 12.5 MG, 25 MG, 6.25 MG TABLET MO	3	PA,QL(30 per 30 days)
NOVOLIN 70-30 FLEXPEN U-100 100 UNIT/ML (70-30) INSULIN PEN CI,MO	2	
NOVOLIN 70/30 U-100 INSULIN 100 UNIT/ML (70-30) SUSPENSION CI,MO	2	
NOVOLIN N FLEXPEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
NOVOLIN N NPH U-100 INSULIN 100 UNIT/ML SUSPENSION CI,MO	2	
NOVOLIN R FLEXPEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
NOVOLIN R REGULAR U100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
NOVOLOG FLEXPEN U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
NOVOLOG MIX 70-30 U-100 INSULN 100 UNIT/ML (70-30) SOLUTION CI,MO	2	
NOVOLOG MIX 70-30FLEXPEN U-100 100 UNIT/ML (70-30) INSULIN PEN CI,MO	2	
NOVOLOG PENFILL U-100 INSULIN 100 UNIT/ML CARTRIDGE CI,MO	2	
NOVOLOG U-100 INSULIN ASPART 100 UNIT/ML SOLUTION CI,MO	2	
OSENI 12.5-30 MG, 25-15 MG, 25-30 MG, 25-45 MG TABLET MO	3	PA,QL(30 per 30 days)
OZEMPIC 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) PEN INJECTOR MO	2	PA,QL(3 per 28 days)
pioglitazone 15 mg, 45 mg TABLET MO	1	QL(30 per 30 days)
pioglitazone 30 mg TABLET MO	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
pioglitazone-glimepiride 30-2 mg, 30-4 mg TABLET MO	1	QL(30 per 30 days)
pioglitazone-metformin 15-500 mg, 15-850 mg TABLET MO	1	QL(90 per 30 days)
PRECOSE 100 MG, 25 MG, 50 MG TABLET MO	3	
PROGLYCEM 50 MG/ML SUSPENSION DL	4	PA
QTERN 10-5 MG, 5-5 MG TABLET MO	3	PA,QL(30 per 30 days)
repaglinide 0.5 mg, 1 mg, 2 mg TABLET MO	1	
REZVOGLAR KWIKPEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
RIOMET 500 MG/5 ML SOLUTION MO	3	QL(750 per 30 days)
RYBELSUS 14 MG, 3 MG, 7 MG TABLET MO	2	PA,QL(30 per 30 days)
saxagliptin 2.5 mg, 5 mg TABLET MO	1	QL(30 per 30 days)
saxagliptin-metformin 2.5-1,000 mg TABLET, ER 24 HR., MULTIPHASE MO	1	QL(60 per 30 days)
saxagliptin-metformin 5-1,000 mg, 5-500 mg TABLET, ER 24 HR., MULTIPHASE MO	1	QL(30 per 30 days)
SEGLUROMET 2.5-1,000 MG, 2.5-500 MG, 7.5-1,000 MG, 7.5-500 MG TABLET MO	3	PA,QL(60 per 30 days)
SEMGLEE(INSULIN GLARG-YFGN)PEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
SEMGLEE(INSULIN GLARGINE-YFGN) 100 UNIT/ML SOLUTION CI,MO	3	PA
sitagliptin 100 mg, 25 mg, 50 mg TABLET MO	3	PA,QL(30 per 30 days)
sitagliptin-metformin 100-1,000 mg TABLET, ER 24 HR., MULTIPHASE MO	1	PA,QL(30 per 30 days)
sitagliptin-metformin 50-1,000 mg, 50-500 mg TABLET MO	3	PA,QL(60 per 30 days)
sitagliptin-metformin 50-1,000 mg, 50-500 mg TABLET, ER 24 HR., MULTIPHASE MO	1	PA,QL(60 per 30 days)
SOLIQUA 100/33 100 UNIT-33 MCG/ML INSULIN PEN CI,MO	2	QL(15 per 24 days)
STEGLATRO 15 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
STEGLUJAN 15-100 MG, 5-100 MG TABLET MO	3	PA,QL(30 per 30 days)
SYMLINPEN 120 2,700 MCG/2.7 ML PEN INJECTOR	4	QL(10.8 per 30 days)
SYMLINPEN 60 1,500 MCG/1.5 ML PEN INJECTOR	4	QL(10.5 per 28 days)
SYNJARDY 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG TABLET MO	2	QL(60 per 30 days)
SYNJARDY XR 10-1,000 MG, 25-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(30 per 30 days)
SYNJARDY XR 12.5-1,000 MG, 5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(60 per 30 days)
TOUJEO MAX U-300 SOLOSTAR 300 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TOUJEO SOLOSTAR U-300 INSULIN 300 UNIT/ML (1.5 ML) INSULIN PEN CI,MO	2	
TRADJENTA 5 MG TABLET MO	2	QL(30 per 30 days)
TRESIBA FLEXTOUCH U-100 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
TRESIBA FLEXTOUCH U-200 200 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
TRESIBA U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
TRIJARDY XR 10-5-1,000 MG, 25-5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(30 per 30 days)
TRIJARDY XR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(60 per 30 days)
TRULICITY 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML PEN INJECTOR MO	2	PA,QL(2 per 28 days)
VICTOZA 2-PAK 0.6 MG/0.1 ML (18 MG/3 ML) PEN INJECTOR MO	3	PA,QL(9 per 30 days)
VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) PEN INJECTOR MO	3	PA,QL(9 per 30 days)
XIGDUO XR 10-1,000 MG, 10-500 MG, 5-500 MG TABLET, IR/ER 24 HR., BIPHASIC MO	3	QL(30 per 30 days)
XIGDUO XR 2.5-1,000 MG, 5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	3	QL(60 per 30 days)
XULTOPHY 100/3.6 100 UNIT-3.6 MG /ML (3 ML) INSULIN PEN CI,MO	3	PA,QL(15 per 30 days)
ZEGALOGUE AUTOINJECTOR 0.6 MG/0.6 ML AUTO-INJECTOR MO	2	
ZEGALOGUE SYRINGE 0.6 MG/0.6 ML SYRINGE MO	2	
ZITUVIMET 50-1,000 MG, 50-500 MG TABLET MO	3	PA,QL(60 per 30 days)
ZITUVIMET XR 100-1,000 MG TABLET, ER 24 HR., MULTIPHASE MO	3	PA,QL(30 per 30 days)
ZITUVIMET XR 50-1,000 MG, 50-500 MG TABLET, ER 24 HR., MULTIPHASE MO	3	PA,QL(60 per 30 days)
ZITUVIO 100 MG, 25 MG, 50 MG TABLET MO	3	PA,QL(30 per 30 days)
BLOOD PRODUCTS AND MODIFIERS		
ADZYNMA 1,500 (+/-) UNIT, 500 (+/-) UNIT KIT DL	4	PA
AGGRASTAT CONCENTRATE 250 MCG/ML CONCENTRATE MO	3	
AGGRASTAT IN SODIUM CHLORIDE 12.5 MG/250 ML (50 MCG/ML), 5 MG/100 ML (50 MCG/ML) SOLUTION MO	3	
AGRYLIN 0.5 MG CAPSULE MO	3	PA
ALVAIZ 18 MG, 9 MG TABLET DL	4	PA,QL(30 per 30 days)
ALVAIZ 36 MG, 54 MG TABLET DL	4	PA,QL(60 per 30 days)
<i>aminocaproic acid 1,000 mg TABLET DL</i>	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
aminocaproic acid 250 mg/ml, 250 mg/ml (25 %) SOLUTION MO	1	
aminocaproic acid 500 mg TABLET MO	1	
anagrelide 0.5 mg, 1 mg CAPSULE MO	1	
ARANESP (IN POLYSORBATE) 10 MCG/0.4 ML, 40 MCG/0.4 ML SYRINGE MO	3	PA,QL(1.6 per 30 days)
ARANESP (IN POLYSORBATE) 100 MCG/0.5 ML SYRINGE DL	4	PA,QL(2 per 30 days)
ARANESP (IN POLYSORBATE) 100 MCG/ML, 200 MCG/ML, 60 MCG/ML SOLUTION DL	4	PA,QL(4 per 30 days)
ARANESP (IN POLYSORBATE) 150 MCG/0.3 ML SYRINGE DL	4	PA,QL(1.2 per 30 days)
ARANESP (IN POLYSORBATE) 200 MCG/0.4 ML SYRINGE DL	4	PA,QL(1.6 per 30 days)
ARANESP (IN POLYSORBATE) 25 MCG/0.42 ML SYRINGE MO	3	PA,QL(1.68 per 30 days)
ARANESP (IN POLYSORBATE) 25 MCG/ML, 40 MCG/ML SOLUTION MO	3	PA,QL(4 per 30 days)
ARANESP (IN POLYSORBATE) 300 MCG/0.6 ML SYRINGE DL	4	PA,QL(2.4 per 30 days)
ARANESP (IN POLYSORBATE) 500 MCG/ML SYRINGE DL	4	PA,QL(4 per 30 days)
ARANESP (IN POLYSORBATE) 60 MCG/0.3 ML SYRINGE MO	3	PA,QL(1.2 per 30 days)
ARIXTRA 10 MG/0.8 ML SYRINGE DL	4	PA,QL(24 per 30 days)
ARIXTRA 2.5 MG/0.5 ML SYRINGE DL	4	PA,QL(15 per 30 days)
ARIXTRA 5 MG/0.4 ML SYRINGE DL	4	PA,QL(12 per 30 days)
ARIXTRA 7.5 MG/0.6 ML SYRINGE DL	4	PA,QL(18 per 30 days)
aspirin-dipyridamole 25-200 mg CAPSULE ER MULTIPHASE 12 HR. MO	1	ST,QL(60 per 30 days)
BRILINTA 60 MG, 90 MG TABLET MO	2	QL(60 per 30 days)
CABLIVI 11 MG KIT DL	4	PA,QL(30 per 30 days)
cilostazol 100 mg, 50 mg TABLET MO	1	
clopidogrel 300 mg TABLET MO	1	
clopidogrel 75 mg TABLET MO	1	QL(30 per 30 days)
CYKLOKAPRON 1,000 MG/10 ML (100 MG/ML) SOLUTION DL	4	PA
dabigatran etexilate 110 mg, 150 mg, 75 mg CAPSULE MO	1	QL(60 per 30 days)
dipyridamole 25 mg, 50 mg, 75 mg TABLET MO	1	
DOPTELET (10 TAB PACK) 20 MG TABLET DL	4	PA,QL(60 per 30 days)
DOPTELET (15 TAB PACK) 20 MG TABLET DL	4	PA,QL(60 per 30 days)
DOPTELET (30 TAB PACK) 20 MG TABLET DL	4	PA,QL(60 per 30 days)
EFFIENT 10 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
ELIQUIS 2.5 MG TABLET MO	2	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ELIQUIS 5 MG TABLET MO	2	QL(74 per 30 days)
ELIQUIS DVT-PE TREAT 30D START 5 MG (74 TABS) TABLET, DOSE PACK MO	2	QL(74 per 30 days)
enoxaparin 100 mg/ml, 120 mg/0.8 ml, 150 mg/ml, 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml SYRINGE MO	1	
enoxaparin 300 mg/3 ml SOLUTION MO	1	
EPOGEN 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML SOLUTION MO	3	PA,QL(14 per 30 days)
EPOGEN 20,000 UNIT/2 ML SOLUTION MO	3	PA,QL(28 per 30 days)
eptifibatide 0.75 mg/ml, 2 mg/ml SOLUTION MO	1	
fondaparinux 10 mg/0.8 ml SYRINGE DL	4	QL(24 per 30 days)
fondaparinux 2.5 mg/0.5 ml SYRINGE DL	4	QL(15 per 30 days)
fondaparinux 5 mg/0.4 ml SYRINGE DL	4	QL(12 per 30 days)
fondaparinux 7.5 mg/0.6 ml SYRINGE DL	4	QL(18 per 30 days)
FRAGMIN 10,000 ANTI-XA UNIT/ML SYRINGE DL	4	QL(30 per 30 days)
FRAGMIN 12,500 ANTI-XA UNIT/0.5 ML SYRINGE DL	4	QL(15 per 30 days)
FRAGMIN 15,000 ANTI-XA UNIT/0.6 ML SYRINGE DL	4	QL(18 per 30 days)
FRAGMIN 18,000 ANTI-XA UNIT/0.72 ML SYRINGE DL	4	QL(21.6 per 30 days)
FRAGMIN 2,500 ANTI-XA UNIT/0.2 ML, 5,000 ANTI-XA UNIT/0.2 ML SYRINGE DL	4	QL(6 per 30 days)
FRAGMIN 2,500 ANTI-XA UNIT/ML SOLUTION DL	4	QL(120 per 30 days)
FRAGMIN 25,000 ANTI-XA UNIT/ML SOLUTION DL	4	QL(22.8 per 30 days)
FRAGMIN 7,500 ANTI-XA UNIT/0.3 ML SYRINGE DL	4	QL(9 per 30 days)
FULPHILA 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
FYLNETRA 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
GRANIX 300 MCG/0.5 ML SYRINGE DL	4	PA,QL(7 per 28 days)
GRANIX 300 MCG/ML SOLUTION DL	4	PA,QL(14 per 28 days)
GRANIX 480 MCG/0.8 ML SYRINGE DL	4	PA,QL(11.2 per 28 days)
GRANIX 480 MCG/1.6 ML SOLUTION DL	4	PA,QL(22.4 per 28 days)
heparin (porcine) 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml SOLUTION MO	1	
heparin (porcine) 5,000 unit/ml (1 ml) CARTRIDGE MO	1	
heparin (porcine) 5,000 unit/ml SYRINGE MO	1	
heparin, porcine (pf) 1,000 unit/ml, 5,000 unit/0.5 ml SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>heparin, porcine (pf) 5,000 unit/0.5 ml, 5,000 unit/ml SYRINGE</i> MO	1	
<i>jantoven 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg TABLET</i> MO	1	
KENGREAL 50 MG RECON SOLUTION DL	4	
LEUKINE 250 MCG RECON SOLUTION DL	4	PA
LOVENOX 100 MG/ML, 120 MG/0.8 ML, 150 MG/ML, 30 MG/0.3 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML SYRINGE DL	4	PA
LOVENOX 300 MG/3 ML SOLUTION DL	4	PA
MIRCERA 100 MCG/0.3 ML SYRINGE	4	PA,QL(1.2 per 28 days)
MIRCERA 120 MCG/0.3 ML SYRINGE DL	4	PA,QL(0.9 per 28 days)
MIRCERA 150 MCG/0.3 ML, 200 MCG/0.3 ML, 30 MCG/0.3 ML SYRINGE	4	PA,QL(0.6 per 28 days)
MIRCERA 50 MCG/0.3 ML, 75 MCG/0.3 ML SYRINGE	4	PA,QL(0.9 per 28 days)
MOZOBIL 24 MG/1.2 ML (20 MG/ML) SOLUTION DL	4	PA,QL(9.6 per 30 days)
MULPLETA 3 MG TABLET DL	4	PA
NEULASTA 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
NEULASTA ONPRO 6 MG/0.6 ML SYRINGE W/WEARABLE INJECTOR DL	4	PA,QL(1.2 per 28 days)
NEUPOGEN 300 MCG/0.5 ML SYRINGE DL	4	PA,QL(7 per 30 days)
NEUPOGEN 300 MCG/ML SOLUTION DL	4	PA,QL(14 per 30 days)
NEUPOGEN 480 MCG/0.8 ML SYRINGE DL	4	PA,QL(11.2 per 30 days)
NEUPOGEN 480 MCG/1.6 ML SOLUTION DL	4	PA,QL(22.4 per 30 days)
NIVESTYM 300 MCG/0.5 ML SYRINGE DL	4	PA,QL(7 per 30 days)
NIVESTYM 300 MCG/ML SOLUTION DL	4	PA,QL(14 per 30 days)
NIVESTYM 480 MCG/0.8 ML SYRINGE DL	4	PA,QL(11.2 per 30 days)
NIVESTYM 480 MCG/1.6 ML SOLUTION DL	4	PA,QL(22.4 per 30 days)
NYVEPRIA 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
PLAVIX 75 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>plerixafor 24 mg/1.2 ml (20 mg/ml) SOLUTION</i> DL	4	PA,QL(9.6 per 30 days)
PRADAXA 110 MG, 150 MG, 75 MG CAPSULE MO	3	QL(60 per 30 days)
PRADAXA 110 MG, 30 MG, 40 MG, 50 MG PELLETS IN PACKET DL	4	PA,QL(120 per 30 days)
PRADAXA 150 MG, 20 MG PELLETS IN PACKET DL	4	PA,QL(60 per 30 days)
<i>prasugrel hcl 10 mg, 5 mg TABLET</i> MO	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROCRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML SOLUTION MO	3	PA,QL(14 per 30 days)
PROCRIT 20,000 UNIT/2 ML SOLUTION MO	3	PA,QL(28 per 30 days)
PROCRIT 20,000 UNIT/ML, 40,000 UNIT/ML SOLUTION DL	4	PA,QL(14 per 30 days)
PROMACTA 12.5 MG POWDER IN PACKET DL	4	PA,QL(360 per 30 days)
PROMACTA 12.5 MG, 25 MG TABLET DL	4	PA,QL(30 per 30 days)
PROMACTA 25 MG POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
PROMACTA 50 MG TABLET DL	4	PA,QL(90 per 30 days)
PROMACTA 75 MG TABLET DL	4	PA,QL(60 per 30 days)
REBLOZYL 25 MG, 75 MG RECON SOLUTION DL	4	PA
RELEUKO 300 MCG/0.5 ML SYRINGE DL	4	PA,QL(7 per 30 days)
RELEUKO 300 MCG/ML SOLUTION DL	4	PA,QL(14 per 30 days)
RELEUKO 480 MCG/0.8 ML SYRINGE DL	4	PA,QL(11.2 per 30 days)
RELEUKO 480 MCG/1.6 ML SOLUTION DL	4	PA,QL(22.4 per 30 days)
RETACRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML SOLUTION MO	3	PA,QL(14 per 30 days)
RETACRIT 40,000 UNIT/ML SOLUTION DL	4	PA,QL(14 per 30 days)
RIASTAP 1 GRAM (900MG-1,300MG) RECON SOLUTION MO	3	
<i>rivaroxaban 1 mg/ml SUSPENSION FOR RECONSTITUTION</i> MO	1	ST,QL(600 per 30 days)
<i>rivaroxaban 2.5 mg TABLET</i> MO	1	QL(60 per 30 days)
ROLVEDON 13.2 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
RYZNEUTA 20 MG/ML SYRINGE DL	4	PA,QL(2 per 28 days)
SAVAYSA 15 MG, 30 MG, 60 MG TABLET MO	3	PA,QL(30 per 30 days)
STIMUFEND 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
TAVALISSE 100 MG, 150 MG TABLET DL	4	PA,QL(60 per 30 days)
<i>ticagrelor 60 mg, 90 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>tirofiban-0.9% sodium chloride 12.5 mg/250 ml (50 mcg/ml), 5 mg/100 ml (50 mcg/ml) SOLUTION</i> MO	1	
<i>tranexamic acid 1,000 mg/10 ml (100 mg/ml) SOLUTION</i> MO	1	PA
<i>tranexamic acid 650 mg TABLET</i> MO	1	QL(30 per 5 days)
UDENYCA 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
UDENYCA AUTOINJECTOR 6 MG/0.6 ML AUTO-INJECTOR DL	4	PA,QL(1.2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
UDENYCA ONBODY 6 MG/0.6 ML SYRINGE W/WEARABLE INJECTOR DL	4	PA,QL(1.2 per 28 days)
warfarin 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 6 mg, 7.5 mg TABLET MO	1	
warfarin 5 mg TABLET MO	1	
XARELTO 1 MG/ML SUSPENSION FOR RECONSTITUTION MO	2	ST,QL(600 per 30 days)
XARELTO 10 MG, 20 MG TABLET MO	2	QL(30 per 30 days)
XARELTO 15 MG, 2.5 MG TABLET MO	2	QL(60 per 30 days)
XARELTO DVT-PE TREAT 30D START 15 MG (42)- 20 MG (9) TABLET, DOSE PACK MO	2	QL(51 per 30 days)
XOLREMDI 100 MG CAPSULE DL	4	PA,QL(120 per 30 days)
ZARXIO 300 MCG/0.5 ML SYRINGE DL	4	PA,QL(7 per 30 days)
ZARXIO 480 MCG/0.8 ML SYRINGE DL	4	PA,QL(11.2 per 30 days)
ZIEXTENZO 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
CARDIOVASCULAR AGENTS		
ACCUPRIL 10 MG, 20 MG, 40 MG, 5 MG TABLET MO	3	
ACCURETIC 10-12.5 MG, 20-12.5 MG, 20-25 MG TABLET MO	3	
acebutolol 200 mg, 400 mg CAPSULE MO	1	
acetazolamide 125 mg, 250 mg TABLET MO	1	
acetazolamide 500 mg CAPSULE, ER MO	1	
acetazolamide sodium 500 mg RECON SOLUTION MO	1	
adenosine 3 mg/ml SOLUTION MO	1	
adenosine 3 mg/ml SYRINGE MO	1	
ADRENALIN IN 0.9 % SOD CHLOR 4 MG/250 ML (16 MCG/ML), 5 MG/250 ML (20 MCG/ML), 8 MG/250 ML (32 MCG/ML) SOLUTION MO	3	
ALDACTONE 100 MG, 25 MG, 50 MG TABLET MO	3	
aliskiren 150 mg, 300 mg TABLET MO	1	QL(30 per 30 days)
ALTACE 1.25 MG, 10 MG, 2.5 MG, 5 MG CAPSULE MO	3	PA
ALTOPREV 20 MG, 40 MG, 60 MG TABLET, ER 24 HR. DL	4	ST,QL(30 per 30 days)
amiloride 5 mg TABLET MO	1	
amiloride-hydrochlorothiazide 5-50 mg TABLET MO	1	
amiodarone 100 mg, 400 mg TABLET MO	1	
amiodarone 150 mg/3 ml SYRINGE MO	1	
amiodarone 200 mg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
amiodarone 50 mg/ml SOLUTION MO	1	
amlodipine 10 mg, 2.5 mg, 5 mg TABLET MO	1	
amlodipine-atorvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg TABLET MO	1	QL(30 per 30 days)
amlodipine-benazepril 10-20 mg, 2.5-10 mg, 5-10 mg, 5-20 mg CAPSULE MO	1	QL(60 per 30 days)
amlodipine-benazepril 10-40 mg, 5-40 mg CAPSULE MO	1	QL(30 per 30 days)
amlodipine-olmesartan 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg TABLET MO	1	QL(30 per 30 days)
amlodipine-valsartan 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg TABLET MO	1	QL(30 per 30 days)
amlodipine-valsartan-hcthiazid 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg TABLET MO	1	QL(30 per 30 days)
ARBLI 10 MG/ML SUSPENSION DL	4	ST,QL(300 per 30 days)
ASPRUZYO SPRINKLE 1,000 MG, 500 MG ER GRANULES, PACKET MO	3	QL(60 per 30 days)
ATACAND 16 MG, 4 MG, 8 MG TABLET MO	3	PA,QL(60 per 30 days)
ATACAND 32 MG TABLET MO	3	PA,QL(30 per 30 days)
ATACAND HCT 16-12.5 MG, 32-12.5 MG, 32-25 MG TABLET MO	3	PA,QL(30 per 30 days)
atenolol 100 mg TABLET MO	1	
atenolol 25 mg, 50 mg TABLET MO	1	
atenolol-chlorthalidone 100-25 mg, 50-25 mg TABLET MO	1	
ATORVALIQ 20 MG/5 ML (4 MG/ML) SUSPENSION MO	3	ST,QL(600 per 30 days)
atorvastatin 10 mg, 20 mg, 40 mg, 80 mg TABLET MO	1	
AVALIDE 150-12.5 MG TABLET MO	3	PA,QL(60 per 30 days)
AVALIDE 300-12.5 MG TABLET MO	3	PA,QL(30 per 30 days)
AVAPRO 150 MG, 300 MG, 75 MG TABLET MO	3	PA,QL(30 per 30 days)
AZOR 10-20 MG, 10-40 MG, 5-20 MG, 5-40 MG TABLET MO	3	PA,QL(30 per 30 days)
benazepril 10 mg, 20 mg, 40 mg, 5 mg TABLET MO	1	
benazepril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg TABLET MO	1	
BENICAR 20 MG, 40 MG TABLET MO	3	PA,QL(30 per 30 days)
BENICAR 5 MG TABLET MO	3	PA,QL(60 per 30 days)
BENICAR HCT 20-12.5 MG, 40-12.5 MG, 40-25 MG TABLET MO	3	PA,QL(30 per 30 days)
BETAPACE 120 MG, 160 MG, 240 MG, 80 MG TABLET DL	4	PA
BETAPACE AF 120 MG, 160 MG, 80 MG TABLET DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>betaxolol 10 mg, 20 mg TABLET</i> MO	1	
BIDIL 20-37.5 MG TABLET MO	3	PA,QL(180 per 30 days)
BIORPHEN 0.1 MG/ML SOLUTION MO	3	
<i>bisoprolol fumarate 10 mg, 2.5 mg, 5 mg TABLET</i> MO	1	
<i>bisoprolol-hydrochlorothiazide 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg TABLET</i> MO	1	
BREVIBLOC 100 MG/10 ML (10 MG/ML) SOLUTION MO	3	
BREVIBLOC IN NACL (ISO-OSM) 2,000 MG/100 ML, 2,500 MG/250 ML (10 MG/ML) PARENTERAL SOLUTION MO	3	
<i>bumetanide 0.25 mg/ml SOLUTION</i> MO	1	
<i>bumetanide 0.5 mg, 2 mg TABLET</i> MO	1	
<i>bumetanide 1 mg TABLET</i> MO	1	
BYSTOLIC 10 MG TABLET MO	3	PA,QL(120 per 30 days)
BYSTOLIC 2.5 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
BYSTOLIC 20 MG TABLET MO	3	PA,QL(60 per 30 days)
CADUET 10-10 MG, 10-20 MG, 10-40 MG, 10-80 MG, 5-10 MG, 5-20 MG, 5-40 MG, 5-80 MG TABLET MO	3	PA,QL(30 per 30 days)
CALAN SR 120 MG TABLET ER MO	3	
CAMZYOS 10 MG, 15 MG, 2.5 MG, 5 MG CAPSULE DL	4	PA,QL(30 per 30 days)
<i>candesartan 16 mg, 4 mg, 8 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>candesartan 32 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>candesartan-hydrochlorothiazid 16-12.5 mg, 32-12.5 mg, 32-25 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>captopril 100 mg, 12.5 mg, 25 mg, 50 mg TABLET</i> MO	1	
<i>captopril-hydrochlorothiazide 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg TABLET</i> MO	1	
CARDIZEM 120 MG, 30 MG, 60 MG TABLET MO	3	
CARDIZEM CD 120 MG, 180 MG, 240 MG CAPSULE, ER 24 HR. DL	4	PA,QL(60 per 30 days)
CARDIZEM CD 300 MG, 360 MG CAPSULE, ER 24 HR. DL	4	PA,QL(30 per 30 days)
CARDIZEM LA 120 MG, 300 MG, 360 MG, 420 MG TABLET, ER 24 HR. MO	3	QL(30 per 30 days)
CARDIZEM LA 180 MG, 240 MG TABLET, ER 24 HR. MO	3	QL(60 per 30 days)
CARDURA 1 MG, 2 MG, 4 MG, 8 MG TABLET MO	3	
CARDURA XL 4 MG, 8 MG TABLET, ER 24 HR. MO	3	QL(30 per 30 days)
CAROSPIR 25 MG/5 ML SUSPENSION MO	3	PA,QL(450 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
cartia xt 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR. MO	1	QL(60 per 30 days)
cartia xt 300 mg CAPSULE, ER 24 HR. MO	1	QL(30 per 30 days)
carvedilol 12.5 mg, 25 mg, 3.125 mg, 6.25 mg TABLET MO	1	
carvedilol phosphate 10 mg, 20 mg, 40 mg, 80 mg CAPSULE ER MULTIPHASE 24 HR. MO	1	QL(30 per 30 days)
chlorothiazide sodium 500 mg RECON SOLUTION MO	1	
chlorthalidone 25 mg TABLET MO	1	
chlorthalidone 50 mg TABLET MO	1	
cholestyramine (with sugar) 4 gram POWDER MO	1	
cholestyramine (with sugar) 4 gram POWDER IN PACKET MO	1	
cholestyramine light 4 gram POWDER MO	1	
cholestyramine light 4 gram POWDER IN PACKET MO	1	
CLEVIPREX 25 MG/50 ML, 50 MG/100 ML EMULSION MO	3	
clonidine 0.1 mg/24 hr, 0.2 mg/24 hr, 0.3 mg/24 hr PATCH, WEEKLY MO	1	QL(4 per 28 days)
clonidine hcl 0.1 mg TABLET MO	1	
clonidine hcl 0.17 mg TABLET, ER 24 HR. DL	4	PA,QL(90 per 30 days)
clonidine hcl 0.2 mg, 0.3 mg TABLET MO	1	
colesevelam 3.75 gram POWDER IN PACKET MO	1	QL(30 per 30 days)
colesevelam 625 mg TABLET MO	1	QL(180 per 30 days)
COLESTID 1 GRAM TABLET MO	3	
COLESTID 5 GRAM GRANULES MO	3	QL(1000 per 30 days)
COLESTID 5 GRAM PACKET MO	3	
COLESTID FLAVORED 7.5 GRAM PACKET MO	3	
colestipol 1 gram TABLET MO	1	
colestipol 5 gram GRANULES MO	1	QL(1000 per 30 days)
colestipol 5 gram PACKET MO	1	
COREG 12.5 MG, 25 MG, 3.125 MG, 6.25 MG TABLET MO	3	PA
COREG CR 10 MG, 20 MG, 40 MG, 80 MG CAPSULE ER MULTIPHASE 24 HR. MO	3	PA,QL(30 per 30 days)
CORGARD 20 MG, 40 MG TABLET MO	3	PA
CORLANOR 5 MG, 7.5 MG TABLET MO	3	PA,QL(60 per 30 days)
CORLANOR 5 MG/5 ML SOLUTION MO	3	PA,QL(560 per 28 days)
CORLOPAM 10 MG/ML SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CORVERT 0.1 MG/ML SOLUTION MO	3	
COZAAR 100 MG, 25 MG, 50 MG TABLET MO	3	PA,QL(60 per 30 days)
CRESTOR 10 MG, 20 MG, 40 MG, 5 MG TABLET MO	3	PA
DEMSEER 250 MG CAPSULE DL	4	
DIBENZYLIN 10 MG CAPSULE DL	4	
digitek 125 mcg (0.125 mg), 250 mcg (0.25 mg) TABLET MO	1	QL(30 per 30 days)
digoxin 125 mcg (0.125 mg), 250 mcg (0.25 mg), 62.5 mcg (0.0625 mg) TABLET MO	1	QL(30 per 30 days)
digoxin 250 mcg/ml (0.25 mg/ml), 50 mcg/ml (0.05 mg/ml) SOLUTION MO	1	
dilt-xr 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR. MO	1	QL(60 per 30 days)
diltiazem hcl 100 mg RECON SOLUTION MO	1	
diltiazem hcl 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR. MO	1	QL(60 per 30 days)
diltiazem hcl 120 mg, 30 mg, 60 mg, 90 mg TABLET MO	1	
diltiazem hcl 120 mg, 300 mg, 360 mg, 420 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
diltiazem hcl 120 mg, 60 mg, 90 mg CAPSULE, ER 12 HR. MO	1	
diltiazem hcl 180 mg, 240 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
diltiazem hcl 300 mg, 360 mg, 420 mg CAPSULE, ER 24 HR. MO	1	QL(30 per 30 days)
diltiazem hcl 5 mg/ml SOLUTION MO	1	
DIOVAN 160 MG, 320 MG, 40 MG, 80 MG TABLET MO	3	PA,QL(60 per 30 days)
DIOVAN HCT 160-12.5 MG, 160-25 MG, 320-12.5 MG, 320-25 MG, 80-12.5 MG TABLET MO	3	PA,QL(30 per 30 days)
disopyramide phosphate 100 mg, 150 mg CAPSULE MO	1	
DIURIL 250 MG/5 ML SUSPENSION MO	3	
dobutamine 250 mg/20 ml (12.5 mg/ml) SOLUTION MO	1	BvsD
dobutamine in d5w 1,000 mg/250 ml (4,000 mcg/ml), 250 mg/250 ml (1 mg/ml), 500 mg/250 ml (2,000 mcg/ml) PARENTERAL SOLUTION MO	1	BvsD
dofetilide 125 mcg, 250 mcg, 500 mcg CAPSULE MO	1	
dopamine 200 mg/5 ml (40 mg/ml), 400 mg/10 ml (40 mg/ml), 400 mg/5 ml (80 mg/ml), 800 mg/5 ml (160 mg/ml) SOLUTION MO	1	BvsD
dopamine in 5 % dextrose 200 mg/250 ml (800 mcg/ml), 400 mg/250 ml (1,600 mcg/ml), 400 mg/500 ml (800 mcg/ml), 800 mg/250 ml (3,200 mcg/ml), 800 mg/500 ml (1,600 mcg/ml) SOLUTION MO	1	BvsD
doxazosin 1 mg, 2 mg, 4 mg, 8 mg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>droxidopa</i> 100 mg, 200 mg CAPSULE MO	1	PA,QL(90 per 30 days)
<i>droxidopa</i> 300 mg CAPSULE MO	1	PA,QL(180 per 30 days)
DYRENIUM 100 MG, 50 MG CAPSULE MO	3	
EDARBI 40 MG, 80 MG TABLET MO	3	ST,QL(30 per 30 days)
EDARBYCLOR 40-12.5 MG, 40-25 MG TABLET MO	3	ST,QL(30 per 30 days)
EDECIN 25 MG TABLET DL	4	QL(480 per 30 days)
<i>enalapril maleate</i> 1 mg/ml SOLUTION MO	1	
<i>enalapril maleate</i> 10 mg, 2.5 mg, 20 mg, 5 mg TABLET MO	1	
<i>enalapril-hydrochlorothiazide</i> 10-25 mg, 5-12.5 mg TABLET MO	1	
<i>enalaprilat</i> 1.25 mg/ml SOLUTION MO	1	
ENTRESTO 24-26 MG, 49-51 MG, 97-103 MG TABLET MO	2	QL(60 per 30 days)
ENTRESTO SPRINKLE 15-16 MG, 6-6 MG PELLETT MO	2	QL(240 per 30 days)
EPANED 1 MG/ML SOLUTION DL	4	
<i>epineph bitart in 0.9% sod chl</i> 16 mg/250 ml (64 mcg/ml) SOLUTION MO	3	
<i>eplerenone</i> 25 mg, 50 mg TABLET MO	1	PA
<i>eprosartan</i> 600 mg TABLET MO	1	QL(60 per 30 days)
<i>esmolol</i> 100 mg/10 ml (10 mg/ml) SOLUTION MO	1	
<i>esmolol in nacl (iso-osm)</i> 2,000 mg/100 ml, 2,500 mg/250 ml (10 mg/ml) PARENTERAL SOLUTION MO	1	
<i>ethacrynate sodium</i> 50 mg RECON SOLUTION MO	1	
<i>ethacrynic acid</i> 25 mg TABLET MO	1	QL(480 per 30 days)
EVKEEZA 150 MG/ML SOLUTION DL	4	PA
EXFORGE 10-160 MG, 10-320 MG, 5-160 MG, 5-320 MG TABLET MO	3	PA,QL(30 per 30 days)
EXFORGE HCT 10-160-12.5 MG, 10-160-25 MG, 10-320-25 MG, 5-160-12.5 MG, 5-160-25 MG TABLET MO	3	PA,QL(30 per 30 days)
EZALLOR SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG CAPSULE, SPRINKLE MO	3	ST,QL(30 per 30 days)
<i>ezetimibe</i> 10 mg TABLET MO	1	QL(30 per 30 days)
<i>ezetimibe-rosuvastatin</i> 10-5 mg TABLET MO	3	ST,QL(30 per 30 days)
<i>ezetimibe-simvastatin</i> 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg TABLET MO	1	QL(30 per 30 days)
<i>felodipine</i> 10 mg, 2.5 mg, 5 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
<i>fenofibrate</i> 120 mg TABLET MO	1	QL(30 per 30 days)
<i>fenofibrate</i> 150 mg CAPSULE MO	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>fenofibrate 160 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>fenofibrate 40 mg, 54 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>fenofibrate 50 mg CAPSULE</i> MO	1	QL(60 per 30 days)
<i>fenofibrate micronized 130 mg, 43 mg CAPSULE</i> MO	1	ST,QL(30 per 30 days)
<i>fenofibrate micronized 134 mg, 200 mg CAPSULE</i> MO	1	QL(30 per 30 days)
<i>fenofibrate micronized 67 mg CAPSULE</i> MO	1	QL(60 per 30 days)
<i>fenofibrate micronized 90 mg CAPSULE</i> MO	3	QL(30 per 30 days)
<i>fenofibrate nanocrystallized 145 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>fenofibrate nanocrystallized 48 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>fenofibric acid 105 mg, 35 mg TABLET</i> MO	2	QL(30 per 30 days)
<i>fenofibric acid (choline) 135 mg, 45 mg CAPSULE, DR/EC</i> MO	1	QL(30 per 30 days)
FENOGLIDE 120 MG TABLET MO	3	QL(30 per 30 days)
FENOGLIDE 40 MG TABLET MO	3	QL(60 per 30 days)
FIBRICOR 105 MG, 35 MG TABLET MO	3	QL(30 per 30 days)
<i>flecainide 100 mg, 150 mg, 50 mg TABLET</i> MO	1	
FLOLIPID 20 MG/5 ML (4 MG/ML), 40 MG/5 ML (8 MG/ML) SUSPENSION MO	3	ST,QL(150 per 30 days)
<i>fluvastatin 20 mg, 40 mg CAPSULE</i> MO	1	ST,QL(60 per 30 days)
<i>fluvastatin 80 mg TABLET, ER 24 HR.</i> MO	1	ST,QL(30 per 30 days)
<i>fosinopril 10 mg, 20 mg, 40 mg TABLET</i> MO	1	
<i>fosinopril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg TABLET</i> MO	1	
FUROSCIX 80 MG/10 ML KIT MO	3	PA
<i>furosemide 10 mg/ml, 40 mg/5 ml (8 mg/ml) SOLUTION</i> MO	1	
<i>furosemide 20 mg, 40 mg TABLET</i> MO	1	
<i>furosemide 80 mg TABLET</i> MO	1	
<i>gemfibrozil 600 mg TABLET</i> MO	1	QL(60 per 30 days)
GONITRO 400 MCG POWDER IN PACKET MO	3	
<i>guanfacine 1 mg, 2 mg TABLET</i> MO	1	
HEMANGEOL 4.28 MG/ML SOLUTION MO	3	
HEMICLOR 12.5 MG TABLET MO	3	
<i>hydralazine 10 mg, 100 mg TABLET</i> MO	1	
<i>hydralazine 20 mg/ml SOLUTION</i> MO	1	
<i>hydralazine 25 mg, 50 mg TABLET</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
hydrochlorothiazide 12.5 mg CAPSULE MO	1	
hydrochlorothiazide 12.5 mg, 25 mg TABLET MO	1	
hydrochlorothiazide 50 mg TABLET MO	1	
HYZAAR 100-12.5 MG, 100-25 MG, 50-12.5 MG TABLET MO	3	PA,QL(60 per 30 days)
ibutilide fumarate 0.1 mg/ml SOLUTION MO	1	
IMMPHENTIV 0.1 MG/ML SOLUTION MO	3	
indapamide 1.25 mg, 2.5 mg TABLET MO	1	
INDERAL LA 120 MG, 160 MG, 60 MG, 80 MG CAPSULE, ER 24 HR. DL	4	PA
INNOPRAN XL 120 MG, 80 MG CAPSULE, ER 24 HR.	4	
INPEFA 200 MG, 400 MG TABLET MO	3	PA,QL(30 per 30 days)
INSPIRA 25 MG, 50 MG TABLET MO	3	PA
INZIRQO 10 MG/ML SUSPENSION FOR RECONSTITUTION MO	3	
irbesartan 150 mg, 300 mg, 75 mg TABLET MO	1	QL(30 per 30 days)
irbesartan-hydrochlorothiazide 150-12.5 mg TABLET MO	1	QL(60 per 30 days)
irbesartan-hydrochlorothiazide 300-12.5 mg TABLET MO	1	QL(30 per 30 days)
ISORDIL 40 MG TABLET DL	4	
ISORDIL TITRADOSE 5 MG TABLET DL	4	PA
isosorbide dinitrate 10 mg, 20 mg, 30 mg, 40 mg, 5 mg TABLET MO	1	
isosorbide mononitrate 10 mg, 20 mg TABLET MO	1	
isosorbide mononitrate 120 mg TABLET, ER 24 HR. MO	1	
isosorbide mononitrate 30 mg, 60 mg TABLET, ER 24 HR. MO	1	
isosorbide-hydralazine 20-37.5 mg TABLET MO	1	QL(180 per 30 days)
isradipine 2.5 mg, 5 mg CAPSULE MO	1	
ISUPREL 0.2 MG/ML SOLUTION MO	3	
ivabradine 5 mg, 7.5 mg TABLET MO	1	PA,QL(60 per 30 days)
JUXTAPID 10 MG, 30 MG, 5 MG CAPSULE DL	4	PA,QL(28 per 28 days)
JUXTAPID 20 MG CAPSULE DL	4	PA,QL(84 per 28 days)
KAPSPARGO SPRINKLE 100 MG, 25 MG, 50 MG CAPSULE ER SPRINKLE 24 HR. MO	3	ST,QL(30 per 30 days)
KAPSPARGO SPRINKLE 200 MG CAPSULE ER SPRINKLE 24 HR. MO	3	ST,QL(60 per 30 days)
KATERZIA 1 MG/ML SUSPENSION MO	3	ST,QL(300 per 30 days)
KERENDIA 10 MG, 20 MG TABLET MO	2	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
KERENDIA 40 MG TABLET MO	2	PA,QL(30 per 30 days)
<i>labetalol</i> 100 mg, 200 mg, 300 mg, 400 mg TABLET MO	1	
<i>labetalol</i> 5 mg/ml SOLUTION MO	1	
LABELALOL IN DEXTROSE,ISO-OSM 1 MG/ML SOLUTION MO	1	
LABELALOL IN NACL (ISO-OSMOT) 1 MG/ ML SOLUTION MO	1	
LANOXIN 125 MCG (0.125 MG), 250 MCG (0.25 MG), 62.5 MCG (0.0625 MG) TABLET MO	3	QL(30 per 30 days)
LANOXIN 250 MCG/ML (0.25 MG/ML), 500 MCG/2 ML (0.5 MG/2 ML) SOLUTION MO	3	
LANOXIN PEDIATRIC 100 MCG/ML (0.1 MG/ML) SOLUTION MO	3	
LASIX 20 MG, 40 MG, 80 MG TABLET MO	3	
LEQVIO 284 MG/1.5 ML SYRINGE	4	PA,QL(4.5 per 365 days)
LESCOL XL 80 MG TABLET, ER 24 HR. MO	3	ST,QL(30 per 30 days)
LEVOPHED (BITARTRATE) 1 MG/ML SOLUTION MO	3	
<i>lidocaine</i> (pf) 20 mg/ml (2 %) SOLUTION MO	1	
<i>lidocaine</i> in 5 % dextrose (pf) 4 mg/ml (0.4 %), 8 mg/ml (0.8 %) PARENTERAL SOLUTION MO	1	
LIPITOR 10 MG, 20 MG, 40 MG, 80 MG TABLET MO	3	PA
LIPOFEN 150 MG CAPSULE MO	3	QL(30 per 30 days)
LIPOFEN 50 MG CAPSULE MO	3	QL(60 per 30 days)
<i>lisinopril</i> 10 mg, 2.5 mg, 20 mg, 40 mg, 5 mg TABLET MO	1	
<i>lisinopril</i> 30 mg TABLET MO	1	
<i>lisinopril-hydrochlorothiazide</i> 10-12.5 mg, 20-12.5 mg, 20-25 mg TABLET MO	1	
LIVALO 1 MG, 2 MG, 4 MG TABLET MO	3	ST,QL(30 per 30 days)
LODOCO 0.5 MG TABLET MO	3	PA,QL(30 per 30 days)
LOPID 600 MG TABLET MO	3	PA,QL(60 per 30 days)
LOPRESSOR 10 MG/ML SOLUTION MO	3	
LOPRESSOR 100 MG, 50 MG TABLET MO	3	
<i>losartan</i> 100 mg, 25 mg, 50 mg TABLET MO	1	QL(60 per 30 days)
<i>losartan-hydrochlorothiazide</i> 100-12.5 mg, 100-25 mg, 50-12.5 mg TABLET MO	1	QL(60 per 30 days)
LOTENSIN 10 MG, 20 MG, 40 MG TABLET MO	3	
LOTENSIN HCT 10-12.5 MG, 20-12.5 MG, 20-25 MG TABLET MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LOTREL 10-20 MG, 5-10 MG, 5-20 MG CAPSULE MO	3	PA,QL(60 per 30 days)
LOTREL 10-40 MG CAPSULE MO	3	PA,QL(30 per 30 days)
lovastatin 10 mg, 20 mg, 40 mg TABLET MO	1	
LOVAZA 1 GRAM CAPSULE MO	3	PA,QL(120 per 30 days)
lovaza 1 gram CAPSULE MO	3	PA,QL(120 per 30 days)
mannitol 20 % 20 % PARENTERAL SOLUTION MO	1	
mannitol 25 % 25 % SOLUTION MO	1	
matzim la 180 mg, 240 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
matzim la 300 mg, 360 mg, 420 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
MAXZIDE 75-50 MG TABLET MO	3	PA
MAXZIDE-25MG 37.5-25 MG TABLET MO	3	PA
methyl dopa 250 mg, 500 mg TABLET MO	1	
methyl dopa-hydrochlorothiazide 250-15 mg, 250-25 mg TABLET MO	1	
methyl dopate 250 mg/5 ml SOLUTION MO	1	
metolazone 10 mg, 2.5 mg, 5 mg TABLET MO	1	
metoprolol succinate 100 mg, 25 mg, 50 mg TABLET, ER 24 HR. MO	1	
metoprolol succinate 200 mg TABLET, ER 24 HR. MO	1	
metoprolol ta-hydrochlorothiaz 100-25 mg, 100-50 mg, 50-25 mg TABLET MO	1	
metoprolol tartrate 100 mg, 25 mg, 50 mg TABLET MO	1	
metoprolol tartrate 37.5 mg, 75 mg TABLET MO	1	
metoprolol tartrate 5 mg/5 ml SOLUTION MO	1	
metyrosine 250 mg CAPSULE DL	4	
mexiletine 150 mg, 200 mg, 250 mg CAPSULE MO	1	
MICARDIS 20 MG, 40 MG TABLET MO	3	PA,QL(30 per 30 days)
MICARDIS 80 MG TABLET MO	3	PA,QL(60 per 30 days)
MICARDIS HCT 40-12.5 MG, 80-25 MG TABLET MO	3	PA,QL(30 per 30 days)
MICARDIS HCT 80-12.5 MG TABLET MO	3	PA,QL(60 per 30 days)
midodrine 10 mg, 2.5 mg, 5 mg TABLET MO	1	
milrinone 1 mg/ml SOLUTION MO	1	BvsD
milrinone in 5 % dextrose 20 mg/100 ml (200 mcg/ml), 40 mg/200 ml (200 mcg/ml) PIGGYBACK MO	1	BvsD
MINIPRESS 1 MG, 2 MG, 5 MG CAPSULE MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>minoxidil 10 mg, 2.5 mg TABLET</i> MO	1	
<i>moexipril 15 mg, 7.5 mg TABLET</i> MO	1	
MULTAQ 400 MG TABLET MO	2	QL(60 per 30 days)
<i>nadolol 20 mg, 40 mg, 80 mg TABLET</i> MO	1	
<i>nebivolol 10 mg TABLET</i> MO	1	QL(120 per 30 days)
<i>nebivolol 2.5 mg, 5 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>nebivolol 20 mg TABLET</i> MO	1	QL(60 per 30 days)
NEXICLON XR 0.17 MG TABLET, ER 24 HR. DL	4	PA,QL(90 per 30 days)
NEXLETOL 180 MG TABLET MO	3	PA,QL(30 per 30 days)
NEXLIZET 180-10 MG TABLET MO	3	PA,QL(30 per 30 days)
NEXTERONE 150 MG/100 ML (1.5 MG/ML), 360 MG/200 ML (1.8 MG/ML) SOLUTION MO	3	
<i>niacin 1,000 mg, 500 mg, 750 mg TABLET, ER 24 HR.</i> MO	1	
<i>niacin 500 mg TABLET</i> MO	1	
<i>niacor 500 mg TABLET</i> MO	1	
<i>nicardipine 20 mg, 30 mg CAPSULE</i> MO	1	
<i>nicardipine 25 mg/10 ml SOLUTION</i> MO	1	
<i>nifedipine 10 mg, 20 mg CAPSULE</i> MO	1	
<i>nifedipine 30 mg, 60 mg, 90 mg TABLET ER</i> MO	1	QL(60 per 30 days)
<i>nifedipine 30 mg, 60 mg, 90 mg TABLET, ER 24 HR.</i> MO	1	QL(60 per 30 days)
<i>nimodipine 30 mg CAPSULE</i> MO	1	
<i>nimodipine 60 mg/20 ml SOLUTION</i> DL	4	QL(2838 per 28 days)
<i>nisoldipine 17 mg, 20 mg, 34 mg, 40 mg, 8.5 mg TABLET, ER 24 HR.</i> MO	1	QL(30 per 30 days)
<i>nisoldipine 25.5 mg, 30 mg TABLET, ER 24 HR.</i> MO	1	QL(60 per 30 days)
NITRO-BID 2 % OINTMENT MO	1	
NITRO-DUR 0.1 MG/HR, 0.4 MG/HR PATCH, 24 HR. MO	3	
NITRO-DUR 0.2 MG/HR, 0.3 MG/HR, 0.6 MG/HR, 0.8 MG/HR PATCH, 24 HR.	4	
<i>nitroglycerin 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr PATCH, 24 HR.</i> MO	1	
<i>nitroglycerin 0.3 mg, 0.6 mg SUBLINGUAL TABLET</i> MO	1	
<i>nitroglycerin 0.4 mg SUBLINGUAL TABLET</i> MO	1	
<i>nitroglycerin 2 % OINTMENT</i> MO	1	
<i>nitroglycerin 400 mcg/spray SPRAY, NON-AEROSOL</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>nitroglycerin 50 mg/10 ml (5 mg/ml) SOLUTION</i> MO	1	
<i>nitroglycerin in 5 % dextrose 100 mg/250 ml (400 mcg/ml), 25 mg/250 ml (100 mcg/ml), 50 mg/250 ml (200 mcg/ml) SOLUTION</i> MO	1	
NITROLINGUAL 400 MCG/SPRAY SPRAY, NON-AEROSOL MO	3	
NITROSTAT 0.3 MG, 0.4 MG, 0.6 MG SUBLINGUAL TABLET MO	2	
<i>norepinephrine bitartrate 1 mg/ml SOLUTION</i> MO	1	
NORLIQVA 1 MG/ML SOLUTION DL	4	ST,QL(300 per 30 days)
NORPACE 100 MG, 150 MG CAPSULE MO	3	
NORPACE CR 100 MG, 150 MG CAPSULE, ER MO	3	
NORTHERA 100 MG, 200 MG CAPSULE DL	4	PA,QL(90 per 30 days)
NORTHERA 300 MG CAPSULE DL	4	PA,QL(180 per 30 days)
NORVASC 10 MG, 2.5 MG, 5 MG TABLET MO	3	PA
NYMALIZE 30 MG/5 ML SYRINGE DL	4	QL(630 per 28 days)
NYMALIZE 60 MG/10 ML SOLUTION DL	4	QL(1260 per 28 days)
NYMALIZE 60 MG/10 ML SYRINGE DL	4	QL(1260 per 28 days)
<i>olmesartan 20 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>olmesartan 40 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>olmesartan 5 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>olmesartan-amlodipin-hcthiazyd 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>olmesartan-hydrochlorothiazide 20-12.5 mg, 40-12.5 mg, 40-25 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>omega-3 acid ethyl esters 1 gram CAPSULE</i> MO	1	QL(120 per 30 days)
OSMITROL 10 % 10 % PARENTERAL SOLUTION MO	3	
OSMITROL 15 % 15 % PARENTERAL SOLUTION MO	3	
OSMITROL 20 % 20 % PARENTERAL SOLUTION MO	3	
OSMITROL 5 % 5 % PARENTERAL SOLUTION MO	3	
PACERONE 100 MG, 400 MG TABLET MO	1	
<i>pacerone 200 mg TABLET</i> MO	1	
<i>pentoxifylline 400 mg TABLET ER</i> MO	1	
<i>perindopril erbumine 2 mg, 4 mg, 8 mg TABLET</i> MO	1	
<i>phenoxybenzamine 10 mg CAPSULE</i> DL	4	
<i>phenylephrine hcl 10 mg/ml SOLUTION</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>pindolol 10 mg, 5 mg TABLET</i> MO	1	
<i>pitavastatin calcium 1 mg, 2 mg, 4 mg TABLET</i> MO	1	ST,QL(30 per 30 days)
PRALUENT PEN 150 MG/ML, 75 MG/ML PEN INJECTOR MO	3	PA,QL(2 per 28 days)
<i>pravastatin 10 mg, 80 mg TABLET</i> MO	1	
<i>pravastatin 20 mg, 40 mg TABLET</i> MO	1	
<i>prazosin 1 mg, 2 mg, 5 mg CAPSULE</i> MO	1	
<i>prevalite 4 gram POWDER</i> MO	1	
<i>prevalite 4 gram POWDER IN PACKET</i> MO	1	
<i>procainamide 100 mg/ml, 500 mg/ml SOLUTION</i> MO	1	
PROCARDIA XL 30 MG, 60 MG, 90 MG TABLET, ER 24 HR. MO	3	PA,QL(60 per 30 days)
<i>propafenone 150 mg, 225 mg, 300 mg TABLET</i> MO	1	
<i>propafenone 225 mg, 325 mg, 425 mg CAPSULE, ER 12 HR.</i> MO	1	
<i>propranolol 1 mg/ml, 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml) SOLUTION</i> MO	1	
<i>propranolol 10 mg, 20 mg, 40 mg, 60 mg, 80 mg TABLET</i> MO	1	
<i>propranolol 120 mg, 160 mg, 60 mg, 80 mg CAPSULE, ER 24 HR.</i> MO	1	
<i>propranolol-hydrochlorothiazid 40-25 mg, 80-25 mg TABLET</i> MO	1	
QBRELIS 1 MG/ML SOLUTION DL	4	QL(1200 per 30 days)
QUESTRAN 4 GRAM POWDER MO	1	
QUESTRAN 4 GRAM POWDER IN PACKET MO	1	
QUESTRAN LIGHT 4 GRAM POWDER MO	1	
<i>quinapril 10 mg, 20 mg, 40 mg, 5 mg TABLET</i> MO	1	
<i>quinapril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg, 20-25 mg TABLET</i> MO	1	
<i>quinidine gluconate 324 mg TABLET ER</i> MO	1	
<i>quinidine sulfate 200 mg, 300 mg TABLET</i> MO	1	
<i>ramipril 1.25 mg, 10 mg, 2.5 mg, 5 mg CAPSULE</i> MO	1	
<i>ranolazine 1,000 mg, 500 mg TABLET, ER 12 HR.</i> MO	1	QL(120 per 30 days)
REPATHA PUSHTRONEX 420 MG/3.5 ML WEARABLE INJECTOR MO	2	PA,QL(3.5 per 28 days)
REPATHA SURECLICK 140 MG/ML PEN INJECTOR MO	2	PA,QL(3 per 28 days)
REPATHA SYRINGE 140 MG/ML SYRINGE MO	2	PA,QL(3 per 28 days)
<i>rosuvastatin 10 mg, 20 mg, 40 mg, 5 mg TABLET</i> MO	1	
RYTHMOL SR 225 MG, 325 MG, 425 MG CAPSULE, ER 12 HR. MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>simvastatin 10 mg, 20 mg, 40 mg TABLET</i> MO	1	
<i>simvastatin 5 mg, 80 mg TABLET</i> MO	1	
SOAANZ 20 MG, 40 MG, 60 MG TABLET MO	3	ST
SODIUM EDECRIN 50 MG RECON SOLUTION MO	3	
<i>sorine 120 mg, 160 mg, 240 mg, 80 mg TABLET</i> MO	1	
<i>sotalol 120 mg, 160 mg, 240 mg, 80 mg TABLET</i> MO	1	
<i>sotalol af 120 mg, 160 mg, 80 mg TABLET</i> MO	1	
SOTYLIZE 5 MG/ML SOLUTION MO	3	
<i>spironolacton-hydrochlorothiaz 25-25 mg TABLET</i> MO	1	
<i>spironolactone 100 mg TABLET</i> MO	1	
<i>spironolactone 25 mg, 50 mg TABLET</i> MO	1	
<i>spironolactone 25 mg/5 ml SUSPENSION</i> MO	3	PA,QL(450 per 30 days)
SULAR 17 MG, 34 MG, 8.5 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
<i>taztia xt 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR.</i> MO	1	QL(60 per 30 days)
<i>taztia xt 300 mg, 360 mg CAPSULE, ER 24 HR.</i> MO	1	QL(30 per 30 days)
TEKTURNA 150 MG, 300 MG TABLET MO	3	PA,QL(30 per 30 days)
TEKTURNA HCT 150-12.5 MG, 150-25 MG, 300-12.5 MG, 300-25 MG TABLET MO	3	ST,QL(30 per 30 days)
<i>telmisartan 20 mg, 40 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>telmisartan 80 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>telmisartan-amlodipine 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>telmisartan-hydrochlorothiazid 40-12.5 mg, 80-25 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>telmisartan-hydrochlorothiazid 80-12.5 mg TABLET</i> MO	1	QL(60 per 30 days)
TENORETIC 100 100-25 MG TABLET MO	3	
TENORETIC 50 50-25 MG TABLET MO	3	PA
TENORMIN 100 MG, 25 MG, 50 MG TABLET MO	3	PA
<i>terazosin 1 mg, 10 mg, 2 mg, 5 mg CAPSULE</i> MO	1	
TEZRULY 1 MG/ML SOLUTION DL	4	PA,QL(600 per 30 days)
THALITONE 15 MG TABLET MO	3	
<i>tiadylt er 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR.</i> MO	1	QL(60 per 30 days)
<i>tiadylt er 300 mg, 360 mg, 420 mg CAPSULE, ER 24 HR.</i> MO	1	QL(30 per 30 days)
TIAZAC 120 MG, 180 MG, 240 MG CAPSULE, ER 24 HR. MO	3	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TIAZAC 300 MG, 360 MG, 420 MG CAPSULE, ER 24 HR. MO	3	QL(30 per 30 days)
TIKOSYN 125 MCG, 250 MCG, 500 MCG CAPSULE MO	3	PA
<i>timolol maleate 10 mg, 20 mg, 5 mg TABLET</i> MO	1	
TOPROL XL 100 MG, 200 MG, 25 MG, 50 MG TABLET, ER 24 HR. MO	3	
<i>torseamide 10 mg, 100 mg, 5 mg TABLET</i> MO	1	
<i>torseamide 20 mg TABLET</i> MO	1	
<i>trandolapril 1 mg, 2 mg, 4 mg TABLET</i> MO	1	
<i>trandolapril-verapamil 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg TABLET, IR/ER 24 HR., BIPHASIC</i> MO	1	
<i>triamterene 100 mg, 50 mg CAPSULE</i> MO	1	
<i>triamterene-hydrochlorothiazid 37.5-25 mg CAPSULE</i> MO	1	
<i>triamterene-hydrochlorothiazid 37.5-25 mg TABLET</i> MO	1	
<i>triamterene-hydrochlorothiazid 75-50 mg TABLET</i> MO	1	
TRIBENZOR 20-5-12.5 MG, 40-10-12.5 MG, 40-10-25 MG, 40-5-12.5 MG, 40-5-25 MG TABLET MO	3	PA,QL(30 per 30 days)
TRICOR 145 MG TABLET MO	3	PA,QL(30 per 30 days)
TRICOR 48 MG TABLET MO	3	PA,QL(60 per 30 days)
TRILIPIX 135 MG, 45 MG CAPSULE, DR/EC MO	3	PA,QL(30 per 30 days)
TRYNGOLZA 80 MG/0.8 ML AUTO-INJECTOR DL	4	PA,QL(0.8 per 28 days)
TRYVIO 12.5 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>valsartan 160 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>valsartan 320 mg, 40 mg, 80 mg TABLET</i> MO	1	QL(60 per 30 days)
VALSARTAN 4 MG/ML SOLUTION DL	4	ST,QL(2400 per 30 days)
<i>valsartan 4 mg/ml SOLUTION</i> DL	4	ST,QL(2400 per 30 days)
<i>valsartan-hydrochlorothiazide 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg TABLET</i> MO	1	QL(30 per 30 days)
VASCEPA 0.5 GRAM CAPSULE MO	2	QL(240 per 30 days)
VASCEPA 1 GRAM CAPSULE MO	2	QL(120 per 30 days)
VASERETIC 10-25 MG TABLET MO	3	
VASOTEC 10 MG, 2.5 MG, 20 MG, 5 MG TABLET DL	4	PA
<i>vecamyl 2.5 mg TABLET</i> DL	4	QL(300 per 30 days)
<i>verapamil 100 mg, 120 mg, 180 mg, 200 mg, 240 mg, 300 mg, 360 mg CAPSULE ER PELLETS 24 HR.</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
verapamil 120 mg, 180 mg, 240 mg TABLET ER MO	1	
verapamil 120 mg, 40 mg, 80 mg TABLET MO	1	
verapamil 2.5 mg/ml SOLUTION MO	1	
verapamil 2.5 mg/ml SYRINGE MO	1	
VERELAN PM 100 MG, 200 MG, 300 MG CAPSULE ER PELLETS 24 HR. MO	3	PA
VERQUVO 10 MG, 2.5 MG, 5 MG TABLET MO	2	PA,QL(30 per 30 days)
VYTORIN 10-10 10-10 MG TABLET MO	3	PA,QL(30 per 30 days)
VYTORIN 10-20 10-20 MG TABLET MO	3	PA,QL(30 per 30 days)
VYTORIN 10-40 10-40 MG TABLET MO	3	PA,QL(30 per 30 days)
VYTORIN 10-80 10-80 MG TABLET MO	3	PA,QL(30 per 30 days)
WELCHOL 3.75 GRAM POWDER IN PACKET MO	3	QL(30 per 30 days)
WELCHOL 625 MG TABLET MO	3	QL(180 per 30 days)
ZESTORETIC 10-12.5 MG, 20-12.5 MG, 20-25 MG TABLET MO	3	
ZESTRIL 10 MG, 2.5 MG, 20 MG, 30 MG, 40 MG, 5 MG TABLET MO	3	PA
ZETIA 10 MG TABLET MO	3	PA,QL(30 per 30 days)
ZIAC 10-6.25 MG, 2.5-6.25 MG, 5-6.25 MG TABLET MO	3	PA
ZOCOR 10 MG, 20 MG, 40 MG TABLET MO	3	PA
ZYPITAMAG 2 MG, 4 MG TABLET MO	2	ST,QL(30 per 30 days)
CENTRAL NERVOUS SYSTEM AGENTS		
ADDERALL 10 MG, 12.5 MG, 15 MG, 20 MG, 5 MG, 7.5 MG TABLET MO	1	PA,QL(90 per 30 days)
ADDERALL 30 MG TABLET MO	1	PA,QL(60 per 30 days)
ADDERALL XR 10 MG, 15 MG, 5 MG CAPSULE, ER 24 HR. MO	3	PA,QL(30 per 30 days)
ADDERALL XR 20 MG, 25 MG, 30 MG CAPSULE, ER 24 HR. MO	3	PA,QL(60 per 30 days)
ADZENYS XR-ODT 12.5 MG, 15.7 MG, 18.8 MG, 3.1 MG, 6.3 MG, 9.4 MG TABLET, DISINTEGRATING ER BIPH MO	3	QL(30 per 30 days)
amphetamine sulfate 10 mg, 5 mg TABLET MO	1	QL(90 per 30 days)
AMPYRA 10 MG TABLET, ER 12 HR. DL	4	PA,QL(60 per 30 days)
APTENSIO XR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG CAPSULE, ER SPRINKLE, BIPHASIC MO	3	QL(30 per 30 days)
atomoxetine 10 mg, 18 mg, 25 mg, 40 mg CAPSULE MO	1	QL(60 per 30 days)
atomoxetine 100 mg, 60 mg, 80 mg CAPSULE MO	1	QL(30 per 30 days)
AUBAGIO 14 MG, 7 MG TABLET DL	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AUSTEDO 12 MG, 9 MG TABLET DL	4	PA,QL(120 per 30 days)
AUSTEDO 6 MG TABLET DL	4	PA,QL(60 per 30 days)
AUSTEDO XR 12 MG, 6 MG TABLET, ER 24 HR. DL	4	PA,QL(90 per 30 days)
AUSTEDO XR 18 MG, 30 MG, 36 MG, 42 MG, 48 MG TABLET, ER 24 HR. DL	4	PA,QL(30 per 30 days)
AUSTEDO XR 24 MG TABLET, ER 24 HR. DL	4	PA,QL(60 per 30 days)
AUSTEDO XR TITRATION KT(WK1-4) 12-18-24-30 MG TABLET, ER 24 HR., DOSE PACK DL	4	PA,QL(28 per 28 days)
AUSTEDO XR TITRATION KT(WK1-4) 6 MG (14)-12 MG (14)-24 MG (14) TABLET, ER 24 HR., DOSE PACK DL	4	PA,QL(42 per 28 days)
AVONEX 30 MCG/0.5 ML PEN INJECTOR KIT DL	4	PA,QL(1 per 28 days)
AVONEX 30 MCG/0.5 ML SYRINGE KIT DL	4	PA,QL(1 per 28 days)
AZSTARYS 26.1 MG- 5.2 MG, 39.2 MG- 7.8 MG, 52.3 MG- 10.4 MG CAPSULE MO	3	QL(30 per 30 days)
BAFIERTAM 95 MG CAPSULE, DR/EC DL	4	PA,QL(120 per 30 days)
BETASERON 0.3 MG KIT DL	4	PA,QL(15 per 30 days)
BRIUMVI 25 MG/ML SOLUTION	4	PA
<i>clonidine hcl 0.1 mg TABLET, ER 12 HR. MO</i>	1	QL(120 per 30 days)
CONCERTA 18 MG, 27 MG, 54 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
CONCERTA 36 MG TABLET, ER 24 HR. MO	3	PA,QL(60 per 30 days)
COPAXONE 20 MG/ML SYRINGE DL	4	PA,QL(30 per 30 days)
COPAXONE 40 MG/ML SYRINGE DL	4	PA,QL(12 per 28 days)
COTEMPLA XR-ODT 17.3 MG, 8.6 MG TABLET, DISINTEGRATING ER BIPH MO	3	QL(30 per 30 days)
COTEMPLA XR-ODT 25.9 MG TABLET, DISINTEGRATING ER BIPH MO	3	QL(60 per 30 days)
CYMBALTA 20 MG CAPSULE, DR/EC MO	3	PA,QL(120 per 30 days)
CYMBALTA 30 MG CAPSULE, DR/EC MO	3	PA,QL(90 per 30 days)
CYMBALTA 60 MG CAPSULE, DR/EC MO	3	PA,QL(60 per 30 days)
<i>dalfampridine 10 mg TABLET, ER 12 HR. MO</i>	1	PA,QL(60 per 30 days)
DAYTRANA 10 MG/9 HR, 15 MG/9 HR, 20 MG/9 HR, 30 MG/9 HR PATCH, 24 HR. MO	3	QL(30 per 30 days)
DESOXYN 5 MG TABLET DL	4	PA,QL(150 per 30 days)
DEXEDRINE SPANSULE 10 MG CAPSULE, ER DL	4	PA,QL(180 per 30 days)
DEXEDRINE SPANSULE 15 MG CAPSULE, ER DL	4	PA,QL(120 per 30 days)
<i>dexmethylphenidate 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg CAPSULE, ER, BIPHASIC MO</i>	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dexamethylphenidate 10 mg, 2.5 mg, 5 mg TABLET MO	1	QL(60 per 30 days)
dextroamphetamine sulfate 10 mg CAPSULE, ER MO	1	QL(180 per 30 days)
dextroamphetamine sulfate 10 mg TABLET MO	1	QL(180 per 30 days)
dextroamphetamine sulfate 15 mg CAPSULE, ER MO	1	QL(120 per 30 days)
dextroamphetamine sulfate 15 mg TABLET MO	1	QL(120 per 30 days)
dextroamphetamine sulfate 2.5 mg, 20 mg, 7.5 mg TABLET MO	1	QL(90 per 30 days)
dextroamphetamine sulfate 30 mg TABLET MO	1	QL(60 per 30 days)
dextroamphetamine sulfate 5 mg CAPSULE, ER MO	1	QL(60 per 30 days)
dextroamphetamine sulfate 5 mg TABLET MO	1	QL(150 per 30 days)
dextroamphetamine sulfate 5 mg/5 ml SOLUTION MO	1	QL(1800 per 30 days)
dextroamphetamine-amphetamine 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg TABLET MO	1	QL(90 per 30 days)
dextroamphetamine-amphetamine 10 mg, 15 mg, 5 mg CAPSULE, ER 24 HR. MO	1	QL(30 per 30 days)
dextroamphetamine-amphetamine 12.5 mg, 25 mg, 37.5 mg, 50 mg CAPSULE ER TRIPHASIC 24 HR. MO	1	QL(30 per 30 days)
dextroamphetamine-amphetamine 20 mg, 25 mg, 30 mg CAPSULE, ER 24 HR. MO	1	QL(60 per 30 days)
dextroamphetamine-amphetamine 30 mg TABLET MO	1	QL(60 per 30 days)
dimethyl fumarate 120 mg (14)- 240 mg (46), 240 mg CAPSULE, DR/EC MO	1	PA,QL(60 per 30 days)
dimethyl fumarate 120 mg CAPSULE, DR/EC MO	1	PA,QL(14 per 30 days)
DRIZALMA SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG CAPSULE, DR SPRINKLE MO	3	PA,QL(60 per 30 days)
duloxetine 20 mg CAPSULE, DR/EC MO	1	QL(120 per 30 days)
duloxetine 30 mg CAPSULE, DR/EC MO	1	QL(90 per 30 days)
duloxetine 40 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
duloxetine 60 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
DYANAVEL XR 10 MG, 15 MG, 20 MG, 5 MG TABLET, IR/ER 24 HR., BIPHASIC MO	3	QL(30 per 30 days)
DYANAVEL XR 2.5 MG/ML SUSPENSION, IR/ER BIPHASIC MO	3	QL(240 per 30 days)
edaravone 30 mg/100 ml, 60 mg/100 ml SOLUTION DL	4	PA
EVEKEO 10 MG, 5 MG TABLET MO	1	QL(90 per 30 days)
EVEKEO ODT 10 MG, 5 MG TABLET, DISINTEGRATING MO	3	QL(90 per 30 days)
EVEKEO ODT 15 MG, 20 MG TABLET, DISINTEGRATING MO	3	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EXSERVAN 50 MG FILM DL	4	PA,QL(60 per 30 days)
EXTAVIA 0.3 MG KIT DL	4	PA,QL(15 per 30 days)
EXTAVIA 0.3 MG RECON SOLUTION DL	4	PA,QL(15 per 30 days)
<i>fingolimod</i> 0.5 mg CAPSULE MO	1	PA,QL(30 per 30 days)
FIRDAPSE 10 MG TABLET DL	4	PA,QL(240 per 30 days)
FOCALIN 10 MG, 2.5 MG, 5 MG TABLET MO	3	PA,QL(60 per 30 days)
FOCALIN XR 10 MG, 15 MG, 20 MG, 25 MG, 30 MG, 35 MG, 40 MG, 5 MG CAPSULE, ER, BIPHASIC MO	3	QL(30 per 30 days)
<i>gabapentin</i> 300 mg TABLET, ER 24 HR. MO	1	ST,QL(30 per 30 days)
<i>gabapentin</i> 600 mg TABLET, ER 24 HR. MO	1	ST,QL(90 per 30 days)
GILENYA 0.25 MG, 0.5 MG CAPSULE DL	4	PA,QL(30 per 30 days)
<i>glatiramer</i> 20 mg/ml SYRINGE DL	4	PA,QL(30 per 30 days)
<i>glatiramer</i> 40 mg/ml SYRINGE DL	4	PA,QL(12 per 28 days)
<i>glatopa</i> 20 mg/ml SYRINGE DL	4	PA,QL(30 per 30 days)
<i>glatopa</i> 40 mg/ml SYRINGE DL	4	PA,QL(12 per 28 days)
GRALISE 300 MG TABLET, ER 24 HR. MO	3	ST,QL(30 per 30 days)
GRALISE 450 MG, 600 MG TABLET, ER 24 HR. MO	3	ST,QL(90 per 30 days)
GRALISE 750 MG, 900 MG TABLET, ER 24 HR. MO	3	ST,QL(60 per 30 days)
<i>guanfacine</i> 1 mg, 2 mg, 3 mg, 4 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
HORIZANT 300 MG, 600 MG TABLET ER MO	3	PA,QL(60 per 30 days)
INGREZZA 40 MG, 60 MG, 80 MG CAPSULE DL	4	PA,QL(30 per 30 days)
INGREZZA INITIATION PK(TARDIV) 40 MG (7)- 80 MG (21) CAPSULE, DOSE PACK DL	4	PA,QL(28 per 28 days)
INGREZZA SPRINKLE 40 MG, 60 MG, 80 MG CAPSULE, SPRINKLE DL	4	PA,QL(30 per 30 days)
INTUNIV ER 1 MG, 2 MG, 3 MG, 4 MG TABLET, ER 24 HR. MO	3	QL(30 per 30 days)
JORNAY PM 100 MG, 20 MG, 40 MG, 60 MG, 80 MG CAPSULE, DR, ER SPRINKLE MO	3	QL(30 per 30 days)
KAPVAY 0.1 MG TABLET, ER 12 HR. MO	3	QL(120 per 30 days)
KESIMPTA PEN 20 MG/0.4 ML PEN INJECTOR DL	4	PA,QL(1.2 per 28 days)
LEMTRADA 12 MG/1.2 ML SOLUTION DL	4	PA,QL(6 per 365 days)
<i>lisdexamfetamine</i> 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg CHEWABLE TABLET MO	1	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>lisdexamfetamine</i> 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg CAPSULE MO	1	PA,QL(30 per 30 days)
LYRICA 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG CAPSULE MO	3	PA,QL(90 per 30 days)
LYRICA 20 MG/ML SOLUTION MO	3	PA,QL(900 per 30 days)
LYRICA 225 MG, 300 MG CAPSULE MO	3	PA,QL(60 per 30 days)
LYRICA CR 165 MG, 82.5 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
LYRICA CR 330 MG TABLET, ER 24 HR. MO	3	PA,QL(60 per 30 days)
MAVENCLAD (10 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (4 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (5 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (6 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (7 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (8 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (9 TABLET PACK) 10 MG TABLET DL	4	PA
MAYZENT 0.25 MG TABLET DL	4	PA,QL(120 per 30 days)
MAYZENT 1 MG, 2 MG TABLET DL	4	PA,QL(30 per 30 days)
MAYZENT STARTER(FOR 1MG MAINT) 0.25 MG (7 TABS) TABLET, DOSE PACK DL	4	PA,QL(7 per 30 days)
MAYZENT STARTER(FOR 2MG MAINT) 0.25 MG (12 TABS) TABLET, DOSE PACK DL	4	PA,QL(12 per 30 days)
METADATE CD 10 MG, 40 MG, 50 MG, 60 MG CAPSULE, ER, BIPHASIC MO	3	QL(30 per 30 days)
METADATE CD 20 MG, 30 MG CAPSULE, ER, BIPHASIC MO	3	QL(60 per 30 days)
<i>metadate er</i> 20 mg TABLET ER MO	1	QL(90 per 30 days)
<i>methamphetamine</i> 5 mg TABLET DL	4	QL(150 per 30 days)
METHYLIN 10 MG/5 ML SOLUTION MO	3	PA,QL(900 per 30 days)
METHYLIN 5 MG/5 ML SOLUTION MO	3	PA,QL(1800 per 30 days)
<i>methylphenidate</i> 10 mg/9 hr, 15 mg/9 hr, 20 mg/9 hr, 30 mg/9 hr PATCH, 24 HR. MO	1	QL(30 per 30 days)
<i>methylphenidate hcl</i> 10 mg CHEWABLE TABLET MO	1	QL(180 per 30 days)
<i>methylphenidate hcl</i> 10 mg TABLET ER MO	1	QL(180 per 30 days)
<i>methylphenidate hcl</i> 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg CAPSULE, ER SPRINKLE, BIPHASIC MO	3	QL(30 per 30 days)
<i>methylphenidate hcl</i> 10 mg, 20 mg, 40 mg, 50 mg, 60 mg CAPSULE, ER, BIPHASIC MO	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>methylphenidate hcl 10 mg, 20 mg, 5 mg TABLET</i> MO	1	QL(90 per 30 days)
<i>methylphenidate hcl 10 mg/5 ml SOLUTION</i> MO	1	QL(900 per 30 days)
<i>methylphenidate hcl 18 mg, 27 mg, 54 mg, 72 mg TABLET, ER 24 HR.</i> MO	1	QL(30 per 30 days)
<i>methylphenidate hcl 2.5 mg, 5 mg CHEWABLE TABLET</i> MO	1	QL(150 per 30 days)
<i>methylphenidate hcl 20 mg TABLET ER</i> MO	1	QL(90 per 30 days)
<i>methylphenidate hcl 20 mg, 30 mg CAPSULE, ER, BIPHASIC</i> MO	1	QL(60 per 30 days)
<i>methylphenidate hcl 36 mg TABLET, ER 24 HR.</i> MO	1	QL(60 per 30 days)
<i>methylphenidate hcl 45 mg, 63 mg TABLET, ER 24 HR.</i> MO	3	QL(30 per 30 days)
<i>methylphenidate hcl 5 mg/5 ml SOLUTION</i> MO	1	QL(1800 per 30 days)
MYDAYIS 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE ER TRIPHASIC 24 HR. MO	3	QL(30 per 30 days)
NUEDEXTA 20-10 MG CAPSULE	4	PA,QL(60 per 30 days)
OCREVUS 30 MG/ML SOLUTION	4	PA,QL(40 per 365 days)
OCREVUS ZUNOVO 920 MG-23,000 UNIT/23 ML SOLUTION	4	PA,QL(46 per 365 days)
ONYDA XR 0.1 MG/ML SUSPENSION, ER 24 HR. DL	4	QL(120 per 30 days)
PLEGRIDY 125 MCG/0.5 ML, 63 MCG/0.5 ML - 94 MCG/0.5 ML PEN INJECTOR DL	4	PA,QL(1 per 28 days)
PLEGRIDY 125 MCG/0.5 ML, 63 MCG/0.5 ML - 94 MCG/0.5 ML SYRINGE DL	4	PA,QL(1 per 28 days)
PONVORY 20 MG TABLET DL	4	PA,QL(30 per 30 days)
PONVORY 14-DAY STARTER PACK 2 MG (2) - 10 MG (3) TABLET, DOSE PACK DL	4	PA,QL(14 per 30 days)
<i>pregabalin 100 mg, 150 mg, 50 mg, 75 mg CAPSULE</i> MO	1	QL(90 per 30 days)
<i>pregabalin 165 mg, 82.5 mg TABLET, ER 24 HR.</i> MO	1	PA,QL(30 per 30 days)
<i>pregabalin 20 mg/ml SOLUTION</i> MO	1	QL(900 per 30 days)
<i>pregabalin 200 mg, 25 mg CAPSULE</i> MO	1	QL(90 per 30 days)
<i>pregabalin 225 mg, 300 mg CAPSULE</i> MO	1	QL(60 per 30 days)
<i>pregabalin 330 mg TABLET, ER 24 HR.</i> MO	1	PA,QL(60 per 30 days)
<i>procentra 5 mg/5 ml SOLUTION</i> DL	4	QL(1800 per 30 days)
QALSODY 100 MG/15 ML (6.7 MG/ML) SOLUTION DL	4	PA
QELBREE 100 MG CAPSULE, ER 24 HR. MO	3	PA,QL(30 per 30 days)
QELBREE 150 MG, 200 MG CAPSULE, ER 24 HR. MO	3	PA,QL(60 per 30 days)
QUILLICHEW ER 20 MG, 40 MG CHEWABLE TABLET, IR/ER BIPHASE MO	3	QL(30 per 30 days)
QUILLICHEW ER 30 MG CHEWABLE TABLET, IR/ER BIPHASE MO	3	QL(60 per 30 days)
QUILLIVANT XR 5 MG/ML (25 MG/5 ML) SUSPENSION, ER, RECON MO	3	QL(360 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RADICAVA 30 MG/100 ML SOLUTION DL	4	PA
RADICAVA ORS 105 MG/5 ML SUSPENSION DL	4	PA,QL(70 per 28 days)
RADICAVA ORS STARTER KIT SUSP 105 MG/5 ML SUSPENSION DL	4	PA,QL(70 per 28 days)
REBIF (WITH ALBUMIN) 22 MCG/0.5 ML, 44 MCG/0.5 ML SYRINGE DL	4	PA,QL(6 per 28 days)
REBIF REBIDOSE 22 MCG/0.5 ML, 44 MCG/0.5 ML PEN INJECTOR DL	4	PA,QL(6 per 28 days)
REBIF REBIDOSE 8.8MCG/0.2ML-22 MCG/0.5ML (6) PEN INJECTOR DL	4	PA,QL(4.2 per 28 days)
REBIF TITRATION PACK 8.8MCG/0.2ML-22 MCG/0.5ML (6) SYRINGE DL	4	PA,QL(4.2 per 28 days)
RELEXXII 18 MG, 27 MG, 45 MG, 54 MG, 63 MG, 72 MG TABLET, ER 24 HR. MO	3	QL(30 per 30 days)
RELEXXII 36 MG TABLET, ER 24 HR. MO	3	QL(60 per 30 days)
RILUTEK 50 MG TABLET DL	4	
<i>riluzole 50 mg TABLET</i> MO	1	
RITALIN 10 MG, 20 MG, 5 MG TABLET MO	3	PA,QL(90 per 30 days)
RITALIN LA 10 MG, 20 MG, 40 MG CAPSULE, ER, BIPHASIC MO	3	PA,QL(30 per 30 days)
RITALIN LA 30 MG CAPSULE, ER, BIPHASIC MO	3	PA,QL(60 per 30 days)
SAVELLA 100 MG, 12.5 MG, 25 MG, 50 MG TABLET MO	3	PA,QL(60 per 30 days)
SAVELLA 12.5 MG (5)-25 MG(8)-50 MG(42) TABLET, DOSE PACK MO	3	PA,QL(55 per 28 days)
SKYCLARYS 50 MG CAPSULE DL	4	PA,QL(90 per 30 days)
STRATTERA 10 MG, 18 MG, 25 MG, 40 MG CAPSULE MO	3	PA,QL(60 per 30 days)
STRATTERA 100 MG, 60 MG, 80 MG CAPSULE MO	3	PA,QL(30 per 30 days)
TASCENSO ODT 0.25 MG, 0.5 MG TABLET, DISINTEGRATING DL	4	PA,QL(30 per 30 days)
TECFIDERA 120 MG (14)- 240 MG (46), 240 MG CAPSULE, DR/EC DL	4	PA,QL(60 per 30 days)
TECFIDERA 120 MG CAPSULE, DR/EC DL	4	PA,QL(14 per 30 days)
TEGLUTIK 50 MG/10 ML SUSPENSION DL	4	PA,QL(600 per 30 days)
<i>teriflunomide 14 mg, 7 mg TABLET</i> MO	1	PA,QL(30 per 30 days)
<i>tetrabenazine 12.5 mg TABLET</i> MO	1	PA,QL(240 per 30 days)
<i>tetrabenazine 25 mg TABLET</i> MO	1	PA,QL(120 per 30 days)
TIGLUTIK 50 MG/10 ML SUSPENSION DL	4	PA,QL(600 per 30 days)
TYSABRI 300 MG/15 ML SOLUTION DL	4	PA,QL(15 per 28 days)
VEOZAH 45 MG TABLET MO	3	PA,QL(30 per 30 days)
VUMERITY 231 MG CAPSULE, DR/EC DL	4	PA,QL(120 per 30 days)
VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG CHEWABLE TABLET MO	3	PA,QL(30 per 30 days)
VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG, 70 MG CAPSULE MO	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
XELSTRYM 13.5 MG/9 HOUR, 18 MG/9 HOUR, 4.5 MG/9 HOUR, 9 MG/9 HOUR PATCH, 24 HR. MO	3	QL(30 per 30 days)
XENAZINE 12.5 MG TABLET DL	4	PA,QL(240 per 30 days)
XENAZINE 25 MG TABLET DL	4	PA,QL(120 per 30 days)
zenzedi 10 mg TABLET MO	1	QL(180 per 30 days)
ZENZEDI 15 MG TABLET MO	1	QL(120 per 30 days)
ZENZEDI 2.5 MG, 20 MG, 7.5 MG TABLET MO	1	QL(90 per 30 days)
ZENZEDI 30 MG TABLET MO	1	QL(60 per 30 days)
zenzedi 5 mg TABLET MO	1	QL(150 per 30 days)
ZEPOSIA 0.92 MG CAPSULE DL	4	PA,QL(30 per 30 days)
ZEPOSIA STARTER KIT (28-DAY) 0.23 MG-0.46 MG -0.92 MG (21) CAPSULE, DOSE PACK DL	4	PA,QL(28 per 28 days)
ZEPOSIA STARTER PACK (7-DAY) 0.23 MG (4)- 0.46 MG (3) CAPSULE, DOSE PACK DL	4	PA,QL(7 per 7 days)
DENTAL & ORAL AGENTS		
cevimeline 30 mg CAPSULE MO	1	
chlorhexidine gluconate 0.12 % MOUTHWASH MO	1	
EVOXAC 30 MG CAPSULE MO	3	PA
KEPIVANCE 5.16 MG, 6.25 MG RECON SOLUTION DL	4	
kourzeq 0.1 % PASTE MO	1	
oralone 0.1 % PASTE MO	1	
periogard 0.12 % MOUTHWASH MO	1	
pilocarpine hcl 5 mg, 7.5 mg TABLET MO	1	
SALAGEN (PILOCARPINE) 5 MG, 7.5 MG TABLET MO	3	
triamcinolone acetonide 0.1 % PASTE MO	1	
DERMATOLOGICAL AGENTS		
ABSORICA 10 MG, 20 MG, 25 MG, 30 MG, 35 MG, 40 MG CAPSULE DL	4	ST
ABSORICA LD 16 MG, 24 MG, 32 MG, 8 MG CAPSULE DL	4	ST
ACANYA 1.2-2.5 % GEL WITH PUMP MO	3	QL(50 per 30 days)
accutane 10 mg, 20 mg, 30 mg, 40 mg CAPSULE MO	1	
acitretin 10 mg, 17.5 mg, 25 mg CAPSULE MO	1	PA
ACZONE 5 % GEL MO	3	QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ACZONE 7.5 % GEL WITH PUMP MO	3	QL(90 per 30 days)
adapalene 0.1 % CREAM MO	1	QL(45 per 30 days)
adapalene 0.1 % SOLUTION DL	4	QL(60 per 30 days)
adapalene 0.1 % SWAB MO	1	QL(30 per 30 days)
adapalene 0.3 % GEL MO	1	QL(45 per 30 days)
adapalene 0.3 % GEL WITH PUMP MO	1	QL(45 per 30 days)
adapalene-benzoyl peroxide 0.1-2.5 % GEL WITH PUMP MO	1	QL(45 per 30 days)
adapalene-benzoyl peroxide 0.3-2.5 % GEL WITH PUMP MO	1	QL(60 per 30 days)
ADBRY 150 MG/ML SYRINGE DL	4	PA,QL(6 per 28 days)
ADBRY 300 MG/2 ML AUTO-INJECTOR DL	4	PA,QL(6 per 28 days)
AKLIEF 0.005 % CREAM MO	3	PA,QL(90 per 30 days)
ALA-CORT 1 % CREAM MO	1	QL(240 per 30 days)
ALA-SCALP 2 % LOTION MO	1	QL(236.8 per 30 days)
alclometasone 0.05 % CREAM MO	1	QL(240 per 30 days)
alclometasone 0.05 % OINTMENT MO	1	QL(240 per 30 days)
ALTABAX 1 % OINTMENT MO	3	
ALTRENO 0.05 % LOTION MO	3	PA,QL(90 per 30 days)
amcinonide 0.1 % CREAM MO	1	QL(120 per 30 days)
amcinonide 0.1 % OINTMENT DL	4	ST,QL(120 per 30 days)
ammonium lactate 12 % CREAM MO	1	
ammonium lactate 12 % LOTION MO	1	
amnesteem 10 mg, 20 mg, 30 mg, 40 mg CAPSULE MO	1	
AMZEEQ 4 % FOAM MO	3	PA,QL(30 per 30 days)
anusol-hc 2.5 % CREAM W/PERINEAL APPLICATOR MO	1	QL(60 per 30 days)
apexicon e 0.05 % CREAM MO	1	QL(60 per 30 days)
ARAZLO 0.045 % LOTION MO	3	PA
ATRALIN 0.05 % GEL MO	3	PA,QL(45 per 30 days)
AVITA 0.025 % CREAM MO	3	PA,QL(45 per 30 days)
AVITA 0.025 % GEL MO	3	PA,QL(45 per 30 days)
azelaic acid 15 % GEL MO	1	ST,QL(50 per 30 days)
AZELEX 20 % CREAM MO	3	QL(50 per 30 days)
BENZAMYCIN 3-5 % GEL MO	3	QL(46.6 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
beseer 0.05 % LOTION MO	1	QL(240 per 30 days)
betamethasone dipropionate 0.05 % CREAM MO	1	QL(90 per 30 days)
betamethasone dipropionate 0.05 % LOTION MO	1	QL(120 per 30 days)
betamethasone dipropionate 0.05 % OINTMENT MO	1	QL(90 per 30 days)
betamethasone valerate 0.1 % CREAM MO	1	QL(180 per 30 days)
betamethasone valerate 0.1 % LOTION MO	1	QL(120 per 30 days)
betamethasone valerate 0.1 % OINTMENT MO	1	QL(180 per 30 days)
betamethasone valerate 0.12 % FOAM MO	1	QL(200 per 30 days)
betamethasone, augmented 0.05 % CREAM MO	1	QL(100 per 30 days)
betamethasone, augmented 0.05 % GEL MO	1	QL(100 per 30 days)
betamethasone, augmented 0.05 % LOTION MO	1	QL(120 per 30 days)
betamethasone, augmented 0.05 % OINTMENT MO	1	QL(100 per 30 days)
brimonidine 0.33 % GEL WITH PUMP MO	1	ST,QL(30 per 30 days)
BRYHALI 0.01 % LOTION MO	3	ST,QL(200 per 30 days)
CABTREO 0.15-3.1-1.2 % GEL MO	3	QL(50 per 30 days)
calcipotriene 0.005 % CREAM MO	1	PA,QL(120 per 30 days)
calcipotriene 0.005 % FOAM MO	1	ST,QL(120 per 28 days)
calcipotriene 0.005 % OINTMENT MO	1	QL(240 per 30 days)
calcipotriene 0.005 % SOLUTION MO	1	QL(60 per 30 days)
calcipotriene-betamethasone 0.005-0.064 % OINTMENT MO	1	PA,QL(60 per 30 days)
calcipotriene-betamethasone 0.005-0.064 % SUSPENSION MO	1	PA,QL(420 per 30 days)
calcitriol 3 mcg/gram OINTMENT MO	1	ST,QL(800 per 28 days)
CAPEX 0.01 % SHAMPOO MO	3	QL(840 per 30 days)
CARAC 0.5 % CREAM DL	4	PA,QL(60 per 30 days)
CENTANY 2 % OINTMENT MO	3	
claravis 10 mg, 20 mg, 30 mg, 40 mg CAPSULE MO	1	
CLEOCIN T 1 % LOTION MO	3	QL(60 per 30 days)
clindacin 1 % FOAM MO	1	QL(100 per 30 days)
clindacin etz 1 % SWAB MO	1	
clindacin p 1 % SWAB MO	1	
CLINDAGEL 1 % GEL, ONCE DAILY DL	4	PA,QL(75 per 30 days)
clindamycin phosphate 1 % FOAM MO	1	QL(100 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
clindamycin phosphate 1 % GEL MO	1	QL(60 per 30 days)
clindamycin phosphate 1 % GEL, ONCE DAILY MO	1	PA,QL(75 per 30 days)
clindamycin phosphate 1 % LOTION MO	1	QL(60 per 30 days)
clindamycin phosphate 1 % SOLUTION MO	1	QL(60 per 30 days)
clindamycin phosphate 1 % SWAB MO	1	
clindamycin-benzoyl peroxide 1-5 % GEL MO	1	QL(50 per 30 days)
clindamycin-benzoyl peroxide 1-5 %, 1.2 %(1 % base) -3.75 %, 1.2-2.5 % GEL WITH PUMP MO	1	QL(50 per 30 days)
clindamycin-benzoyl peroxide 1.2 %(1 % base) -5 % GEL MO	1	QL(45 per 30 days)
clindamycin-tretinoin 1.2-0.025 % GEL MO	1	QL(60 per 30 days)
clobetasol 0.05 % CREAM MO	1	QL(120 per 30 days)
clobetasol 0.05 % FOAM MO	1	QL(100 per 28 days)
clobetasol 0.05 % GEL MO	1	QL(120 per 28 days)
clobetasol 0.05 % LOTION MO	1	QL(240 per 28 days)
clobetasol 0.05 % OINTMENT MO	1	QL(120 per 28 days)
clobetasol 0.05 % SHAMPOO MO	1	QL(240 per 30 days)
clobetasol 0.05 % SOLUTION MO	1	QL(100 per 30 days)
clobetasol 0.05 % SPRAY, NON-AEROSOL MO	1	QL(240 per 30 days)
clobetasol-emollient 0.05 % CREAM MO	1	QL(120 per 30 days)
clobetasol-emollient 0.05 % FOAM MO	1	QL(100 per 30 days)
CLOBEX 0.05 % LOTION MO	3	ST,QL(240 per 28 days)
CLOBEX 0.05 % SHAMPOO MO	3	ST,QL(240 per 30 days)
CLOBEX 0.05 % SPRAY, NON-AEROSOL MO	3	ST,QL(240 per 30 days)
clocortolone pivalate 0.1 % CREAM MO	1	QL(180 per 30 days)
clodan 0.05 % SHAMPOO MO	1	QL(240 per 30 days)
CONDYLOX 0.5 % GEL MO	3	
CORDRAN 0.025 % CREAM MO	3	ST,QL(240 per 30 days)
CORDRAN 0.05 % CREAM DL	4	ST,QL(240 per 30 days)
CORDRAN 0.05 % LOTION DL	4	ST,QL(240 per 30 days)
CORDRAN 0.05 % OINTMENT MO	3	ST,QL(240 per 30 days)
CORDRAN TAPE LARGE ROLL 4 MCG/CM2 TAPE MO	3	QL(2 per 30 days)
CORTEF 10 MG, 20 MG, 5 MG TABLET MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>crotan</i> 10 % LOTION DL	4	PA,QL(454 per 30 days)
<i>dapsone</i> 5 %, 7.5 % GEL MO	1	QL(90 per 30 days)
<i>dapsone</i> 7.5 % GEL WITH PUMP MO	1	QL(90 per 30 days)
DERMA-SMOOTHIE/FS BODY OIL 0.01 % OIL MO	3	QL(118.28 per 30 days)
DERMA-SMOOTHIE/FS SCALP OIL 0.01 % OIL MO	3	QL(118.28 per 30 days)
<i>desonide</i> 0.05 % CREAM MO	1	QL(240 per 30 days)
<i>desonide</i> 0.05 % GEL MO	1	QL(240 per 30 days)
<i>desonide</i> 0.05 % LOTION MO	1	QL(240 per 30 days)
<i>desonide</i> 0.05 % OINTMENT MO	1	QL(240 per 30 days)
DESOWEN 0.05 % CREAM MO	3	QL(240 per 30 days)
<i>desoximetasone</i> 0.05 % CREAM MO	1	QL(240 per 30 days)
<i>desoximetasone</i> 0.05 % GEL MO	1	QL(240 per 30 days)
<i>desoximetasone</i> 0.05 % OINTMENT MO	1	QL(240 per 30 days)
<i>desoximetasone</i> 0.25 % CREAM MO	1	QL(120 per 30 days)
<i>desoximetasone</i> 0.25 % OINTMENT MO	1	QL(120 per 30 days)
<i>desoximetasone</i> 0.25 % SPRAY, NON-AEROSOL MO	1	QL(100 per 30 days)
<i>desrx</i> 0.05 % GEL MO	1	QL(240 per 30 days)
<i>diclofenac sodium</i> 3 % GEL MO	1	PA
DIFFERIN 0.1 % CREAM MO	3	PA,QL(45 per 30 days)
DIFFERIN 0.1 % LOTION MO	3	QL(59 per 30 days)
DIFFERIN 0.3 % GEL WITH PUMP MO	3	QL(45 per 30 days)
<i>diflorasone</i> 0.05 % CREAM DL	4	QL(120 per 30 days)
<i>diflorasone</i> 0.05 % OINTMENT MO	3	QL(120 per 30 days)
DIPROLENE (AUGMENTED) 0.05 % OINTMENT MO	3	QL(100 per 30 days)
<i>doxepin</i> 5 % CREAM DL	4	PA,QL(45 per 30 days)
DUOBRII 0.01-0.045 % LOTION MO	3	PA,QL(200 per 28 days)
EBGLYSS PEN 250 MG/2 ML PEN INJECTOR DL	4	PA,QL(8 per 28 days)
EBGLYSS SYRINGE 250 MG/2 ML SYRINGE DL	4	PA,QL(8 per 28 days)
EFUDEX 5 % CREAM MO	3	PA
ELIDEL 1 % CREAM MO	3	PA,QL(100 per 30 days)
ELIMITE 5 % CREAM MO	3	
ENSTILAR 0.005-0.064 % FOAM MO	3	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EPIDUO 0.1-2.5 % GEL WITH PUMP MO	3	QL(45 per 30 days)
EPIDUO FORTE 0.3-2.5 % GEL WITH PUMP MO	3	QL(60 per 30 days)
EPIFOAM 1-1 % FOAM MO	1	
EPSOLAY 5 % CREAM MO	3	ST,QL(30 per 30 days)
<i>ery pads</i> 2 % SWAB MO	1	QL(60 per 30 days)
ERYGEL 2 % GEL MO	1	QL(60 per 30 days)
<i>erythromycin with ethanol</i> 2 % GEL MO	1	QL(60 per 30 days)
<i>erythromycin with ethanol</i> 2 % SOLUTION MO	1	QL(120 per 30 days)
<i>erythromycin-benzoyl peroxide</i> 3-5 % GEL MO	1	QL(46.6 per 30 days)
EUCRISA 2 % OINTMENT MO	3	PA,QL(100 per 30 days)
EURAX 10 % CREAM MO	3	PA
EURAX 10 % LOTION MO	3	PA,QL(454 per 30 days)
EVOCLIN 1 % FOAM MO	3	PA,QL(100 per 30 days)
FABIOR 0.1 % FOAM MO	3	PA,QL(100 per 30 days)
FINACEA 15 % FOAM MO	3	ST,QL(50 per 30 days)
FINACEA 15 % GEL MO	3	ST,QL(50 per 30 days)
<i>fluocinolone</i> 0.01 % OIL MO	1	QL(118.28 per 30 days)
<i>fluocinolone</i> 0.01 % SOLUTION MO	1	QL(180 per 30 days)
<i>fluocinolone</i> 0.01 %, 0.025 % CREAM MO	1	QL(120 per 30 days)
<i>fluocinolone</i> 0.025 % OINTMENT MO	1	QL(120 per 30 days)
<i>fluocinolone and shower cap</i> 0.01 % OIL MO	1	QL(118.28 per 30 days)
<i>fluocinonide</i> 0.05 % CREAM MO	1	QL(120 per 30 days)
<i>fluocinonide</i> 0.05 % GEL MO	1	QL(120 per 30 days)
<i>fluocinonide</i> 0.05 % OINTMENT MO	1	QL(120 per 30 days)
<i>fluocinonide</i> 0.05 % SOLUTION MO	1	QL(120 per 30 days)
<i>fluocinonide</i> 0.1 % CREAM MO	1	QL(120 per 28 days)
<i>fluocinonide-e</i> 0.05 % CREAM MO	1	QL(120 per 30 days)
<i>fluocinonide-emollient</i> 0.05 % CREAM MO	1	QL(120 per 30 days)
FLUOROPLEX 1 % CREAM DL	4	
<i>fluorouracil</i> 0.5 % CREAM DL	4	QL(60 per 30 days)
<i>fluorouracil</i> 2 % SOLUTION MO	1	QL(30 per 30 days)
<i>fluorouracil</i> 5 % CREAM MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
fluorouracil 5 % SOLUTION MO	1	QL(60 per 30 days)
flurandrenolide 0.05 % CREAM MO	1	QL(240 per 30 days)
flurandrenolide 0.05 % LOTION MO	3	QL(240 per 30 days)
flurandrenolide 0.05 % OINTMENT MO	1	QL(240 per 30 days)
fluticasone propionate 0.005 % OINTMENT MO	1	QL(240 per 30 days)
fluticasone propionate 0.05 % CREAM MO	1	QL(240 per 30 days)
fluticasone propionate 0.05 % LOTION MO	1	QL(240 per 30 days)
halcinonide 0.1 % CREAM DL	4	QL(120 per 30 days)
halcinonide 0.1 % SOLUTION MO	1	QL(120 per 30 days)
halobetasol propionate 0.05 % CREAM MO	1	QL(100 per 30 days)
halobetasol propionate 0.05 % FOAM MO	3	PA,QL(100 per 30 days)
halobetasol propionate 0.05 % OINTMENT MO	1	QL(100 per 30 days)
HALOG 0.1 % CREAM DL	4	QL(120 per 30 days)
HALOG 0.1 % OINTMENT MO	3	QL(120 per 30 days)
HALOG 0.1 % SOLUTION MO	3	QL(120 per 30 days)
hydrocortisone 1 % CREAM W/PERINEAL APPLICATOR MO	1	QL(28.4 per 30 days)
hydrocortisone 1 %, 2.5 % CREAM MO	1	QL(240 per 30 days)
hydrocortisone 1 %, 2.5 % OINTMENT MO	1	QL(240 per 30 days)
hydrocortisone 10 mg, 20 mg, 5 mg TABLET MO	1	
hydrocortisone 2 % LOTION DL	4	QL(236.8 per 30 days)
hydrocortisone 2.5 % CREAM W/PERINEAL APPLICATOR MO	1	QL(60 per 30 days)
hydrocortisone 2.5 % LOTION MO	1	QL(236 per 30 days)
hydrocortisone 2.5 % SOLUTION DL	4	QL(240 per 30 days)
hydrocortisone butyr-emollient 0.1 % CREAM MO	1	QL(240 per 30 days)
hydrocortisone butyrate 0.1 % CREAM MO	1	QL(240 per 30 days)
hydrocortisone butyrate 0.1 % LOTION MO	1	QL(236 per 30 days)
hydrocortisone butyrate 0.1 % OINTMENT MO	1	QL(180 per 30 days)
hydrocortisone butyrate 0.1 % SOLUTION MO	1	QL(240 per 30 days)
hydrocortisone valerate 0.2 % CREAM MO	1	QL(240 per 30 days)
hydrocortisone valerate 0.2 % OINTMENT MO	1	QL(240 per 30 days)
HYFTOR 0.2 % GEL DL	4	PA
imiquimod 3.75 % CREAM IN PACKET MO	3	ST,QL(28 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>imiquimod</i> 3.75 % CREAM, METERED DOSE PUMP DL	4	ST,QL(15 per 30 days)
<i>imiquimod</i> 5 % CREAM IN PACKET MO	1	QL(12 per 30 days)
IMPEKLO 0.05 % LOTION IN METERED DOSE PUMP DL	4	ST,QL(136 per 28 days)
<i>isotretinoin</i> 10 mg, 20 mg, 30 mg, 40 mg CAPSULE MO	1	
<i>isotretinoin</i> 25 mg, 35 mg CAPSULE DL	4	
<i>ivermectin</i> 1 % CREAM MO	1	ST,QL(45 per 30 days)
KLISYRI (250 MG) 1 % OINTMENT IN PACKET DL	4	PA,QL(5 per 30 days)
KLISYRI (350 MG) 1 % OINTMENT IN PACKET DL	4	PA,QL(5 per 30 days)
LEXETTE 0.05 % FOAM MO	3	PA,QL(100 per 30 days)
<i>lindane</i> 1 % SHAMPOO MO	1	QL(60 per 30 days)
LOCOID 0.1 % LOTION MO	3	QL(236 per 30 days)
LOCOID LIPOCREAM 0.1 % CREAM MO	3	QL(240 per 30 days)
LUXIQ 0.12 % FOAM MO	3	ST,QL(200 per 30 days)
<i>mafenide acetate</i> 50 gram PACKET MO	1	
<i>malathion</i> 0.5 % LOTION MO	1	
<i>methoxsalen</i> 10 mg CAPSULE, LIQ FILLED, RAPID REL MO	1	
MIRVASO 0.33 % GEL WITH PUMP MO	3	ST,QL(30 per 30 days)
<i>mometasone</i> 0.1 % CREAM MO	1	QL(180 per 30 days)
<i>mometasone</i> 0.1 % OINTMENT MO	1	QL(180 per 30 days)
<i>mometasone</i> 0.1 % SOLUTION MO	1	QL(180 per 30 days)
<i>mupirocin</i> 2 % OINTMENT MO	1	
<i>mupirocin calcium</i> 2 % CREAM MO	1	ST
NATROBA 0.9 % SUSPENSION MO	3	QL(240 per 30 days)
NEO-SYNALAR 0.5 % (0.35 % BASE)-0.025 % CREAM MO	3	
<i>neuac</i> 1.2 %(1 % base) -5 % GEL MO	1	QL(45 per 30 days)
OLUX 0.05 % FOAM MO	3	PA,QL(100 per 28 days)
OLUX-E 0.05 % FOAM MO	3	PA,QL(100 per 30 days)
ONEXTON 1.2 %(1 % BASE) -3.75 % GEL MO	3	
ONEXTON 1.2 %(1 % BASE) -3.75 % GEL WITH PUMP MO	3	QL(50 per 30 days)
OPZELURA 1.5 % CREAM DL	4	PA,QL(240 per 28 days)
OTEZLA 20 MG, 30 MG TABLET DL	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OTEZLA STARTER 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47) TABLET, DOSE PACK DL	4	PA,QL(55 per 28 days)
OTEZLA STARTER 10 MG (4)-20 MG (4)-30 MG(19) TABLET, DOSE PACK DL	4	PA,QL(27 per 30 days)
OVIDE 0.5 % LOTION MO	3	PA
PANDEL 0.1 % CREAM DL	4	QL(160 per 30 days)
<i>permethrin</i> 5 % CREAM MO	1	
<i>pimecrolimus</i> 1 % CREAM MO	1	PA,QL(100 per 30 days)
<i>podofilox</i> 0.5 % GEL MO	1	
<i>podofilox</i> 0.5 % SOLUTION MO	1	QL(7 per 30 days)
<i>prednicarbate</i> 0.1 % CREAM MO	1	QL(240 per 30 days)
<i>prednicarbate</i> 0.1 % OINTMENT MO	1	QL(240 per 30 days)
<i>procto-med hc</i> 2.5 % CREAM W/PERINEAL APPLICATOR MO	1	QL(60 per 30 days)
<i>proctosol hc</i> 2.5 % CREAM W/PERINEAL APPLICATOR MO	1	QL(60 per 30 days)
<i>proctozone-hc</i> 2.5 % CREAM W/PERINEAL APPLICATOR MO	1	QL(60 per 30 days)
PRUDOXIN 5 % CREAM DL	4	PA,QL(45 per 30 days)
<i>pruradik</i> 10 % LOTION DL	4	PA,QL(454 per 30 days)
QBREXZA 2.4 % TOWELETTE MO	3	PA,QL(30 per 30 days)
REGRANEX 0.01 % GEL	4	PA
RETIN-A 0.01 %, 0.025 % GEL MO	3	PA,QL(45 per 30 days)
RETIN-A 0.025 %, 0.05 %, 0.1 % CREAM MO	3	PA,QL(45 per 30 days)
RETIN-A MICRO 0.04 % GEL DL	4	PA,QL(45 per 30 days)
RETIN-A MICRO 0.1 % GEL MO	3	PA,QL(45 per 30 days)
RETIN-A MICRO PUMP 0.04 %, 0.1 % GEL WITH PUMP DL	4	PA,QL(50 per 30 days)
RETIN-A MICRO PUMP 0.06 %, 0.08 % GEL WITH PUMP MO	3	PA,QL(50 per 30 days)
RHOFADE 1 % CREAM MO	3	ST,QL(30 per 30 days)
SANTYL 250 UNIT/GRAM OINTMENT MO	3	PA,QL(180 per 30 days)
<i>selenium sulfide</i> 2.5 % LOTION MO	1	QL(120 per 30 days)
SILVADENE 1 % CREAM MO	2	
<i>silver sulfadiazine</i> 1 % CREAM MO	1	
SOOLANTRA 1 % CREAM MO	3	ST,QL(45 per 30 days)
SORILUX 0.005 % FOAM DL	4	ST,QL(120 per 28 days)
<i>spinosad</i> 0.9 % SUSPENSION MO	3	QL(240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SSD 1 % CREAM MO	1	
SULFAMYLON 50 GRAM PACKET MO	3	
SULFAMYLON 85 MG/G CREAM MO	3	
SYNALAR 0.01 % SOLUTION MO	3	QL(180 per 30 days)
TACLONEX 0.005-0.064 % OINTMENT DL	4	PA,QL(60 per 30 days)
TACLONEX 0.005-0.064 % SUSPENSION DL	4	PA,QL(420 per 30 days)
<i>tacrolimus</i> 0.03 %, 0.1 % OINTMENT MO	1	QL(200 per 30 days)
<i>tazarotene</i> 0.05 % CREAM MO	1	PA,QL(120 per 30 days)
<i>tazarotene</i> 0.05 %, 0.1 % GEL MO	1	PA,QL(200 per 30 days)
<i>tazarotene</i> 0.1 % CREAM MO	1	QL(120 per 30 days)
<i>tazarotene</i> 0.1 % FOAM DL	4	PA,QL(100 per 30 days)
TAZORAC 0.05 %, 0.1 % CREAM MO	3	PA,QL(120 per 30 days)
TAZORAC 0.05 %, 0.1 % GEL MO	3	PA,QL(200 per 30 days)
TEMOVATE 0.05 % OINTMENT MO	3	PA,QL(120 per 28 days)
TEXACORT 2.5 % SOLUTION MO	1	QL(240 per 30 days)
TOPICORT 0.05 % CREAM MO	1	QL(240 per 30 days)
TOPICORT 0.05 % GEL MO	1	QL(240 per 30 days)
TOPICORT 0.05 % OINTMENT MO	3	QL(240 per 30 days)
TOPICORT 0.25 % CREAM MO	1	QL(120 per 30 days)
TOPICORT 0.25 % OINTMENT MO	1	QL(120 per 30 days)
TOPICORT 0.25 % SPRAY, NON-AEROSOL MO	3	QL(100 per 30 days)
<i>tovet emollient</i> 0.05 % FOAM MO	1	QL(100 per 30 days)
<i>tretinoin</i> 0.01 %, 0.025 %, 0.05 % GEL MO	1	PA,QL(45 per 30 days)
<i>tretinoin</i> 0.025 %, 0.05 %, 0.1 % CREAM MO	1	PA,QL(45 per 30 days)
<i>tretinoin microspheres</i> 0.04 %, 0.08 %, 0.1 % GEL WITH PUMP MO	1	PA,QL(50 per 30 days)
<i>tretinoin microspheres</i> 0.04 %, 0.1 % GEL MO	1	PA,QL(45 per 30 days)
TWYNEO 0.1-3 % CREAM MO	3	QL(30 per 30 days)
ULTRAVATE 0.05 % LOTION MO	3	QL(120 per 30 days)
VANOS 0.1 % CREAM MO	3	QL(120 per 28 days)
VECTICAL 3 MCG/GRAM OINTMENT DL	4	ST,QL(800 per 28 days)
VELTIN 1.2-0.025 % GEL MO	3	PA,QL(60 per 30 days)
VERDESO 0.05 % FOAM DL	4	QL(200 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VEREGEN 15 % OINTMENT DL	4	QL(30 per 30 days)
VTAMA 1 % CREAM DL	4	PA,QL(60 per 30 days)
WINLEVI 1 % CREAM MO	3	PA
ZELSUVMI 10.3 % GEL DL	4	PA
zenatane 10 mg, 20 mg, 30 mg, 40 mg CAPSULE MO	1	
ZIANA 1.2-0.025 % GEL MO	3	PA,QL(60 per 30 days)
ZILXI 1.5 % FOAM MO	3	PA,QL(30 per 30 days)
ZONALON 5 % CREAM MO	3	PA,QL(45 per 30 days)
ZORYVE 0.15 %, 0.3 % CREAM DL	4	PA,QL(120 per 30 days)
ZORYVE 0.3 % FOAM DL	4	PA,QL(120 per 30 days)
ZYCLARA 2.5 %, 3.75 % CREAM, METERED DOSE PUMP DL	4	ST,QL(15 per 30 days)
ZYCLARA 3.75 % CREAM IN PACKET MO	3	ST,QL(28 per 28 days)
ELECTROLYTES/MINERALS/METALS/VITAMINS		
AMINOSYN II 10 % 10 % PARENTERAL SOLUTION MO	3	BvsD
bal-care dha 27-1-430 mg COMBO PACK, DR TAB/DR CAP MO	1	
c-nate dha 28 mg iron-1 mg -200 mg CAPSULE MO	1	
calcium chloride 100 mg/ml (10 %) SOLUTION MO	1	
calcium chloride 100 mg/ml (10 %) SYRINGE MO	1	
calcium gluconate 100 mg/ml (10%) SOLUTION MO	1	
CARBAGLU 200 MG TABLET, DISPERSIBLE DL	4	PA
carglumic acid 200 mg TABLET, DISPERSIBLE DL	4	PA
CARNITOR 100 MG/ML, 200 MG/ML SOLUTION MO	3	
CARNITOR 330 MG TABLET MO	3	
CARNITOR (SUGAR-FREE) 100 MG/ML SOLUTION MO	3	
CHEMET 100 MG CAPSULE DL	4	
CITRANATAL B-CALM (FE GLUC) 20 MG IRON-1 MG -25 MG/25 MG TABLET, SEQUENTIAL MO	3	
CLINIMIX 5%/D15W SULFITE FREE 5 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 4.25%/D10W SULF FREE 4.25 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 4.25%/D5W SULFIT FREE 4.25 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 5%-D20W(SULFITE-FREE) 5 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 6%-D5W (SULFITE-FREE) 6-5 % PARENTERAL SOLUTION MO	3	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CLINIMIX 8%-D10W(SULFITE-FREE) 8-10 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 8%-D14W(SULFITE-FREE) 8-14 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 2.75%/D5W SULF FREE 2.75 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 4.25%/D10W SUL FREE 4.25 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 4.25%/D5W SULF FREE 4.25 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 5%/D15W SULFIT FREE 5 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 5%/D20W SULFIT FREE 5 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 8%-D10W SULFITEFREE 8-10 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 8%-D14W SULFITEFREE 8-14 % PARENTERAL SOLUTION MO	3	BvsD
CLINISOL SF 15 % 15 % PARENTERAL SOLUTION MO	1	BvsD
CLINOLIPID 20 % EMULSION MO	3	BvsD
complete natal dha 29 mg iron- 1 mg-200 mg COMBO PACK MO	1	
CUPRIMINE 250 MG CAPSULE DL	4	PA,QL(600 per 30 days)
CUVRIOR 300 MG TABLET DL	4	PA,QL(300 per 30 days)
d10 %-0.45 % sodium chloride PARENTERAL SOLUTION MO	1	
d2.5 %-0.45 % sodium chloride PARENTERAL SOLUTION MO	1	
d5 % (d-glucose)-0.9 % sodchlr PARENTERAL SOLUTION MO	1	
d5 % and 0.9 % sodium chloride PARENTERAL SOLUTION MO	1	
d5 %-0.45 % sodium chloride PARENTERAL SOLUTION MO	1	
deferasirox 125 mg, 250 mg, 500 mg TABLET, DISPERSIBLE DL	4	PA
deferasirox 180 mg, 360 mg, 90 mg GRANULES IN PACKET DL	4	PA
deferasirox 180 mg, 360 mg, 90 mg TABLET MO	1	PA
deferiprone 1,000 mg TABLET DL	4	PA,QL(300 per 30 days)
deferiprone 500 mg TABLET DL	4	PA,QL(720 per 30 days)
deferoxamine 2 gram, 500 mg RECON SOLUTION MO	1	BvsD
DEPEN TITRATABS 250 MG TABLET DL	4	PA
DESFERAL 500 MG RECON SOLUTION MO	3	BvsD
dextrose 10 % and 0.2 % nacl PARENTERAL SOLUTION MO	1	
dextrose 10 % in water (d10w) 10 % PARENTERAL SOLUTION MO	1	
dextrose 25 % in water (d25w) SYRINGE MO	1	
dextrose 5 % in water (d5w) PARENTERAL SOLUTION MO	1	
dextrose 5 % in water (d5w) 5 % PIGGYBACK MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dextrose 5 %-lactated ringers PARENTERAL SOLUTION MO	1	
dextrose 5%-0.2 % sod chloride PARENTERAL SOLUTION MO	1	
dextrose 5%-0.3 % sod.chloride PARENTERAL SOLUTION MO	1	
dextrose 50 % in water (d50w) PARENTERAL SOLUTION MO	1	
dextrose 50 % in water (d50w) SYRINGE MO	1	
dextrose 70 % in water (d70w) PARENTERAL SOLUTION MO	1	
DUET DHA WITH OMEGA-3 25 MG IRON-1 MG -400 MG COMBO PACK MO	3	
electrolyte-148 PARENTERAL SOLUTION MO	1	
electrolyte-48 in d5w PARENTERAL SOLUTION MO	1	
electrolyte-a PARENTERAL SOLUTION MO	1	
EXJADE 125 MG, 250 MG, 500 MG TABLET, DISPERSIBLE DL	4	PA
FERRIPROX 1,000 MG TABLET DL	4	PA,QL(300 per 30 days)
FERRIPROX 100 MG/ML SOLUTION DL	4	PA,QL(3600 per 30 days)
FERRIPROX 500 MG TABLET DL	4	PA,QL(720 per 30 days)
FERRIPROX (2 TIMES A DAY) 1,000 MG TABLET, MODIFIED RELEASE DL	4	PA,QL(300 per 30 days)
GLYCOPHOS 1 MMOL/ML SOLUTION MO	1	
INTRALIPID 20 %, 30 % EMULSION MO	3	BvsD
IONOSOL-MB IN D5W 5 % PARENTERAL SOLUTION MO	3	
ISOLYTE S PH 7.4 PARENTERAL SOLUTION MO	3	
ISOLYTE-P IN 5 % DEXTROSE 5 % PARENTERAL SOLUTION MO	3	
ISOLYTE-S PARENTERAL SOLUTION MO	3	
JADENU 180 MG, 360 MG, 90 MG TABLET DL	4	PA
JADENU SPRINKLE 180 MG, 360 MG, 90 MG GRANULES IN PACKET DL	4	PA
JYNARQUE 15 MG (AM)/ 15 MG (PM), 30 MG (AM)/ 15 MG (PM), 45 MG (AM)/ 15 MG (PM), 60 MG (AM)/ 30 MG (PM), 90 MG (AM)/ 30 MG (PM) TABLET, SEQUENTIAL DL	4	PA,QL(56 per 28 days)
JYNARQUE 15 MG, 30 MG TABLET DL	4	PA,QL(60 per 30 days)
KABIVEN 3.31-10.8-3.9 % EMULSION MO	3	BvsD
kionex (with sorbitol) 15-20 gram/60 ml SUSPENSION MO	1	
klor-con 20 meq PACKET MO	1	QL(240 per 30 days)
KLOR-CON 10 10 MEQ TABLET ER MO	1	
KLOR-CON 8 8 MEQ TABLET ER MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>klor-con m10 10 meq TABLET, ER PARTICLES/CRYSTALS</i> MO	1	
KLOR-CON M15 15 MEQ TABLET, ER PARTICLES/CRYSTALS MO	1	
<i>klor-con m20 20 meq TABLET, ER PARTICLES/CRYSTALS</i> MO	1	
KOSHER PRENATAL PLUS IRON 30 MG IRON- 1 MG TABLET MO	3	
<i>lactated ringers PARENTERAL SOLUTION</i> MO	1	
<i>levocarnitine 100 mg/ml, 200 mg/ml SOLUTION</i> MO	1	
<i>levocarnitine 330 mg TABLET</i> MO	1	
<i>levocarnitine (with sugar) 100 mg/ml SOLUTION</i> MO	1	
LOKELMA 10 GRAM, 5 GRAM POWDER IN PACKET MO	2	QL(30 per 30 days)
<i>m-natal plus 27 mg iron- 1 mg TABLET</i> MO	1	
<i>magnesium sulfate 500 mg/ml (50 %) SOLUTION</i> MO	1	
<i>magnesium sulfate 500 mg/ml (50 %) SYRINGE</i> MO	1	
<i>magnesium sulfate in d5w 1 gram/100 ml PIGGYBACK</i> MO	1	
<i>magnesium sulfate in water 2 gram/50 ml (4 %), 4 gram/100 ml (4 %), 4 gram/50 ml (8 %) PIGGYBACK</i> MO	1	
<i>magnesium sulfate in water 20 gram/500 ml (4 %), 40 gram/1,000 ml (4 %) PARENTERAL SOLUTION</i> MO	1	
NATACHEW (FE BIS-GLYCINATE) 28 MG IRON -1 MG CHEWABLE TABLET MO	3	
<i>neo-vital rx 27 mg iron- 1 mg TABLET</i> MO	1	
NEONATAL COMPLETE 29-1 MG TABLET MO	1	
NEONATAL PLUS VITAMIN 27 MG IRON- 1 MG TABLET MO	1	
NEONATAL-DHA 29-1-200-500 MG COMBO PACK MO	1	
NORMOSOL-M IN 5 % DEXTROSE PARENTERAL SOLUTION MO	3	
NUTRILIPID 20 % EMULSION MO	3	BvsD
OB COMPLETE ONE 40-10-1-300 MG CAPSULE MO	3	
OB COMPLETE PETITE 35 MG IRON-5 MG IRON-1 MG CAPSULE MO	3	
OB COMPLETE PREMIER 30-20-1 MG TABLET MO	3	
OMEGAVEN 10 % EMULSION DL	4	BvsD
<i>penicillamine 250 mg CAPSULE</i> DL	4	PA,QL(600 per 30 days)
<i>penicillamine 250 mg TABLET</i> DL	4	
PERIKABIVEN 2.36-7.5-3.5 % EMULSION MO	3	BvsD
PLASMA-LYTE 148 PARENTERAL SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PLASMA-LYTE A PARENTERAL SOLUTION MO	3	
PLENAMINE 15 % PARENTERAL SOLUTION MO	1	BvsD
<i>prn</i> -dha 27 mg iron-1 mg -300 mg CAPSULE MO	1	
<i>prn</i> -omega 28-1-300 mg CAPSULE MO	1	
POKONZA 10 MEQ PACKET DL	4	
potassium acetate 2 meq/ml SOLUTION MO	1	
potassium chlorid-d5-0.45%nacl 10 meq/l, 20 meq/l, 30 meq/l, 40 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride 10 meq CAPSULE, ER MO	1	
potassium chloride 10 meq, 20 meq TABLET ER MO	1	
potassium chloride 10 meq, 20 meq TABLET, ER PARTICLES/CRYSTALS MO	1	
potassium chloride 15 meq TABLET, ER PARTICLES/CRYSTALS MO	1	
potassium chloride 15 meq, 8 meq TABLET ER MO	1	
potassium chloride 2 meq/ml SOLUTION MO	1	
potassium chloride 20 meq PACKET MO	1	QL(240 per 30 days)
potassium chloride 20 meq/15 ml, 40 meq/15 ml LIQUID MO	1	
potassium chloride 8 meq CAPSULE, ER MO	1	
potassium chloride in 0.9%nacl 20 meq/l, 40 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride in 5 % dex 10 meq/l, 20 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride in lr-d5 20 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride in water 10 meq/100 ml, 10 meq/50 ml, 20 meq/100 ml, 20 meq/50 ml, 40 meq/100 ml PIGGYBACK MO	1	
potassium chloride-0.45 % nacl 20 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride-d5-0.2%nacl 20 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride-d5-0.9%nacl 20 meq/l, 40 meq/l PARENTERAL SOLUTION MO	1	
potassium citrate 10 meq (1,080 mg), 15 meq, 5 meq (540 mg) TABLET ER MO	1	
<i>pr natal</i> 400 29-1-400 mg COMBO PACK MO	1	
<i>pr natal</i> 400 ec 29-1-400 mg COMBO PACK, DR TAB/DR CAP MO	1	
<i>pr natal</i> 430 29 mg iron-1 mg -430 mg COMBO PACK MO	1	
<i>pr natal</i> 430 ec 29-1-430 mg COMBO PACK, DR TAB/DR CAP MO	1	
PREMASOL 10 % 10 % PARENTERAL SOLUTION MO	1	BvsD
PRENATA 29 MG IRON- 1 MG CHEWABLE TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PRENATABS FA 29-1 MG TABLET MO	1	
<i>prenatal plus (calcium carb) 27 mg iron- 1 mg TABLET MO</i>	1	
<i>prenatal plus dha 27 mg iron-1 mg -312 mg-250 mg COMBO PACK MO</i>	3	
<i>prenatal plus vitamin-mineral 27 mg iron- 1 mg TABLET MO</i>	1	
<i>prenatal vitamin plus low iron 27 mg iron- 1 mg TABLET MO</i>	1	
<i>prenatal-u 106.5-1 mg CAPSULE MO</i>	1	
PRENATE ELITE 26 MG IRON- 1 MG TABLET MO	1	
PROSOL 20 % PARENTERAL SOLUTION MO	3	BvsD
<i>ringer's PARENTERAL SOLUTION MO</i>	1	
SAMSCA 15 MG, 30 MG TABLET DL	4	PA,QL(60 per 30 days)
<i>se-natal 19 chewable 29 mg iron- 1 mg CHEWABLE TABLET MO</i>	1	
SELECT-OB 29 MG IRON- 1 MG CHEWABLE TABLET MO	3	
SELECT-OB (FOLIC ACID) 29 MG IRON- 1 MG CHEWABLE TABLET MO	3	
SELECT-OB + DHA 29 MG IRON-1 MG -250 MG COMBO PACK MO	3	
SMOFLIPID 20 % EMULSION MO	3	BvsD
<i>sodium bicarbonate 8.4 % (1 meq/ml) SYRINGE MO</i>	1	
<i>sodium chloride 2.5 meq/ml SOLUTION MO</i>	1	
<i>sodium chloride 0.45 % 0.45 % PARENTERAL SOLUTION MO</i>	1	
<i>sodium chloride 0.9 % PARENTERAL SOLUTION MO</i>	1	
<i>sodium chloride 0.9 % PIGGYBACK MO</i>	1	
<i>sodium chloride 0.9 % SOLUTION MO</i>	1	
<i>sodium chloride 3 % hypertonic 3 % PARENTERAL SOLUTION MO</i>	1	
<i>sodium chloride 5 % hypertonic 5 % PARENTERAL SOLUTION MO</i>	1	
<i>sodium phosphate 3 mmol/ml SOLUTION MO</i>	1	
<i>sodium polystyrene sulfonate 15 gram POWDER MO</i>	1	
SPS (WITH SORBITOL) 15-20 GRAM/60 ML SUSPENSION MO	1	
SPS (WITH SORBITOL) 30-40 GRAM/120 ML ENEMA MO	1	
SYPRINE 250 MG CAPSULE DL	4	PA,QL(240 per 30 days)
THAM 36 MG/ML (0.3 M) SOLUTION MO	3	
<i>tolvaptan 15 mg, 30 mg TABLET DL</i>	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>tolvaptan (polycys kidney dis) 15 mg (am)/ 15 mg (pm), 30 mg (am)/ 15 mg (pm), 45 mg (am)/ 15 mg (pm), 60 mg (am)/ 30 mg (pm), 90 mg (am)/ 30 mg (pm) TABLET, SEQUENTIAL</i> DL	4	PA,QL(56 per 28 days)
<i>tolvaptan (polycys kidney dis) 15 mg, 30 mg</i> TABLET DL	4	PA,QL(60 per 30 days)
TPN ELECTROLYTES 35-20-5 MEQ/20 ML SOLUTION MO	3	
TRAVASOL 10 % 10 % PARENTERAL SOLUTION MO	3	BvsD
TRICARE 27 MG IRON- 1 MG TABLET MO	1	
<i>trientine 250 mg</i> CAPSULE DL	4	QL(240 per 30 days)
<i>trientine 500 mg</i> CAPSULE DL	4	QL(120 per 30 days)
<i>trinatal rx 1 60 mg iron-1 mg</i> TABLET MO	1	
TRISTART DHA 31 MG IRON- 1 MG-200 MG CAPSULE MO	3	
<i>tromethamine 36 mg/ml (0.3 m)</i> SOLUTION MO	1	
TROPHAMINE 10 % 10 % PARENTERAL SOLUTION MO	3	BvsD
UROCIT-K 10 10 MEQ (1,080 MG) TABLET ER MO	3	
UROCIT-K 15 15 MEQ TABLET ER MO	3	
UROCIT-K 5 5 MEQ (540 MG) TABLET ER MO	3	
VAPRISOL IN 5 % DEXTROSE 20 MG/100 ML SOLUTION MO	3	
VELTASSA 1 GRAM POWDER IN PACKET MO	3	PA,QL(240 per 30 days)
VELTASSA 16.8 GRAM, 25.2 GRAM, 8.4 GRAM POWDER IN PACKET MO	3	PA,QL(30 per 30 days)
<i>virt-pn dha 27 mg iron-1 mg -300 mg</i> CAPSULE MO	1	
VITAFOL FE PLUS 90 MG IRON- 1 MG-200 MG CAPSULE MO	3	
VITAFOL GUMMIES 3.33 MG IRON- 0.33 MG CHEWABLE TABLET MO	3	
VITAFOL ULTRA 29 MG IRON- 1 MG-200 MG CAPSULE MO	3	
VITAFOL-OB 65-1 MG TABLET MO	3	
VITAFOL-OB+DHA 65-1-250 MG COMBO PACK MO	3	
VITAFOL-ONE 29 MG IRON- 1 MG-200 MG CAPSULE MO	3	
VITAMEDMD ONE RX 30 MG IRON-1MG -200 MG CAPSULE MO	3	
<i>wescap-pn dha 27 mg iron-1 mg -300 mg</i> CAPSULE MO	1	
<i>wesnatal dha complete 29 mg iron- 1 mg-200 mg</i> COMBO PACK MO	1	
<i>wesnate dha 28 mg iron-1 mg -200 mg</i> CAPSULE MO	1	
<i>westab plus 27 mg iron- 1 mg</i> TABLET MO	1	
<i>westgel dha 31 mg iron- 1 mg-200 mg</i> CAPSULE MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>zatean-pn dha 27 mg iron-1 mg -300 mg CAPSULE</i> MO	1	
<i>zatean-pn plus 28-1-300 mg CAPSULE</i> MO	1	
GASTROINTESTINAL AGENTS		
ACIPHEX 20 MG TABLET, DR/EC MO	3	PA,QL(60 per 30 days)
AEMCOLO 194 MG TABLET, DR/EC MO	3	PA,QL(12 per 30 days)
<i>alosetron 0.5 mg, 1 mg TABLET</i> MO	1	PA,QL(60 per 30 days)
AMITIZA 24 MCG, 8 MCG CAPSULE MO	3	PA,QL(60 per 30 days)
<i>amoxicil-clarithromy-lansopraz 500-500-30 mg COMBO PACK</i> MO	1	ST
<i>atropine 0.1 mg/ml, 0.25 mg/5 ml (0.05 mg/ml) SYRINGE</i> MO	1	
BENTYL 10 MG/ML SOLUTION MO	3	
<i>bismuth subcit k-metronidz-tcn 140-125-125 mg CAPSULE</i> MO	1	ST,QL(120 per 30 days)
CARAFATE 1 GRAM TABLET MO	3	
CARAFATE 100 MG/ML SUSPENSION MO	3	
<i>chenodal 250 mg TABLET</i> DL	4	PA
<i>cimetidine 200 mg, 300 mg, 400 mg, 800 mg TABLET</i> MO	1	
<i>cimetidine hcl 300 mg/5 ml SOLUTION</i> MO	1	
CLENPIQ 10 MG-3.5 GRAM- 12 GRAM/160 ML, 10 MG-3.5 GRAM- 12 GRAM/175 ML SOLUTION MO	3	ST
<i>constulose 10 gram/15 ml SOLUTION</i> MO	1	
CTEXLI 250 MG TABLET DL	4	PA
CUVPOSA 1 MG/5 ML (0.2 MG/ML) SOLUTION MO	3	
CYTOTEC 100 MCG, 200 MCG TABLET DL	4	
DARTISLA 1.7 MG TABLET, DISINTEGRATING MO	3	ST,QL(120 per 30 days)
DEXILANT 30 MG, 60 MG CAPSULE, DR, BIPHASIC MO	3	PA,QL(30 per 30 days)
<i>dexlansoprazole 30 mg, 60 mg CAPSULE, DR, BIPHASIC</i> MO	3	QL(30 per 30 days)
<i>dicyclomine 10 mg CAPSULE</i> MO	1	
<i>dicyclomine 10 mg/5 ml, 10 mg/ml SOLUTION</i> MO	1	
<i>dicyclomine 20 mg TABLET</i> MO	1	
<i>diphenoxylate-atropine 2.5-0.025 mg TABLET</i> MO	1	
<i>diphenoxylate-atropine 2.5-0.025 mg/5 ml LIQUID</i> MO	1	
ENDARI 5 GRAM POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
<i>enulose 10 gram/15 ml SOLUTION</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
esomeprazole magnesium 10 mg, 2.5 mg, 20 mg, 40 mg, 5 mg DR GRANULES IN PACKET MO	1	QL(30 per 30 days)
esomeprazole magnesium 20 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
esomeprazole magnesium 40 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
esomeprazole sodium 20 mg, 40 mg RECON SOLUTION MO	1	
famotidine 10 mg/ml SOLUTION MO	1	
famotidine 20 mg, 40 mg TABLET MO	1	
famotidine 40 mg/5 ml (8 mg/ml) SUSPENSION FOR RECONSTITUTION MO	1	
famotidine (pf) 20 mg/2 ml SOLUTION MO	1	
famotidine (pf)-nacl (iso-os) 20 mg/50 ml PIGGYBACK MO	1	
GATTEX 30-VIAL 5 MG KIT DL	4	PA
GATTEX ONE-VIAL 5 MG KIT DL	4	PA
gavilyte-c 240-22.72-6.72 -5.84 gram RECON SOLUTION MO	1	
gavilyte-g 236-22.74-6.74 -5.86 gram RECON SOLUTION MO	1	
gavilyte-n 420 gram RECON SOLUTION MO	1	
generlac 10 gram/15 ml SOLUTION MO	1	
glutamine (sickle cell) 5 gram POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
GLYCATE 1.5 MG TABLET MO	1	
glycopyrrolate 0.2 mg/ml, 1 mg/5 ml (0.2 mg/ml) SOLUTION MO	1	
glycopyrrolate 1 mg, 1.5 mg, 2 mg TABLET MO	1	
glycopyrrolate (pf) 0.4 mg/2 ml (0.2 mg/ml) SYRINGE MO	1	
glycopyrrolate (pf) 0.6 mg/3 ml (0.2 mg/ml) SYRINGE MO	3	
glycopyrrolate (pf) in water 0.2 mg/ml SYRINGE MO	1	
GOLYTELY 236-22.74-6.74 -5.86 GRAM RECON SOLUTION MO	3	ST
IBSRELA 50 MG TABLET DL	4	PA,QL(60 per 30 days)
IQIRVO 80 MG TABLET DL	4	PA,QL(30 per 30 days)
KONVOMEPE 2-84 MG/ML SUSPENSION FOR RECONSTITUTION DL	4	ST,QL(600 per 30 days)
KRISTALOSE 10 GRAM, 20 GRAM PACKET MO	1	
lactulose 10 gram, 20 gram PACKET DL	4	
lactulose 10 gram/15 ml SOLUTION MO	1	
lansoprazole 15 mg, 30 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
lansoprazole 15 mg, 30 mg TABLET, DISINTEGRATING DR MO	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LINZESS 145 MCG, 290 MCG, 72 MCG CAPSULE MO	2	QL(30 per 30 days)
LIVDELZI 10 MG CAPSULE DL	4	PA,QL(30 per 30 days)
LIVMARLI 10 MG, 15 MG, 20 MG TABLET DL	4	PA,QL(60 per 30 days)
LIVMARLI 19 MG/ML SOLUTION DL	4	PA,QL(60 per 30 days)
LIVMARLI 30 MG TABLET DL	4	PA,QL(30 per 30 days)
LIVMARLI 9.5 MG/ML SOLUTION DL	4	PA,QL(90 per 30 days)
LOMOTIL 2.5-0.025 MG TABLET MO	3	
<i>loperamide</i> 2 mg CAPSULE MO	1	
LOTRONEX 0.5 MG, 1 MG TABLET	4	PA,QL(60 per 30 days)
<i>lubiprostone</i> 24 mcg, 8 mcg CAPSULE MO	1	QL(60 per 30 days)
<i>methscopolamine</i> 2.5 mg, 5 mg TABLET MO	1	
<i>misoprostol</i> 100 mcg, 200 mcg TABLET MO	1	
MOTEGRITY 1 MG, 2 MG TABLET MO	3	PA,QL(30 per 30 days)
MOTOFEN 1-0.025 MG TABLET MO	3	
MOVANTIK 12.5 MG, 25 MG TABLET MO	2	QL(30 per 30 days)
MOVIPREP 100-7.5-2.691 GRAM POWDER IN PACKET MO	3	ST
MYALEPT 5 MG/ML (FINAL CONC.) RECON SOLUTION DL	4	PA,QL(30 per 30 days)
MYTESI 125 MG TABLET, DR/EC DL	4	PA,QL(60 per 30 days)
NEXIUM 20 MG, 40 MG CAPSULE, DR/EC MO	3	PA,QL(60 per 30 days)
NEXIUM IV 40 MG RECON SOLUTION MO	3	PA
NEXIUM PACKET 10 MG, 2.5 MG, 20 MG, 40 MG, 5 MG DR GRANULES IN PACKET MO	3	QL(30 per 30 days)
<i>nizatidine</i> 150 mg, 300 mg CAPSULE MO	1	
OCALIVA 10 MG, 5 MG TABLET DL	4	PA,QL(30 per 30 days)
OMECLAMOX-PAK 20 MG-500 MG- 500 MG (40) COMBO PACK MO	3	ST
<i>omeprazole</i> 10 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
<i>omeprazole</i> 20 mg, 40 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
<i>omeprazole-sodium bicarbonate</i> 20-1,680 mg, 40-1,680 mg PACKET DL	4	ST,QL(30 per 30 days)
<i>omeprazole-sodium bicarbonate</i> 20-1.1 mg-gram, 40-1.1 mg-gram CAPSULE MO	1	QL(30 per 30 days)
<i>opium tincture</i> 10 mg/ml (morphine) TINCTURE MO	3	QL(180 per 30 days)
<i>pantoprazole</i> 20 mg, 40 mg TABLET, DR/EC MO	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>pantoprazole 40 mg DR GRANULES IN PACKET</i> MO	1	QL(30 per 30 days)
<i>pantoprazole 40 mg RECON SOLUTION</i> MO	1	
<i>pantoprazole in 0.9% sod chlor 40 mg/100 ml (0.4 mg/ml), 40 mg/50 ml (0.8 mg/ml), 80 mg/100 ml (0.8 mg/ml) PIGGYBACK</i> MO	3	
PANTOPRAZOLE IN 0.9% SOD CHLOR 40 MG/50 ML (0.8 MG/ML) PIGGYBACK MO	3	
<i>peg 3350-electrolytes 236-22.74-6.74 -5.86 gram RECON SOLUTION</i> MO	1	
<i>peg-electrolyte soln 420 gram RECON SOLUTION</i> MO	1	
<i>peg3350-sod sul-nacl-kcl-asb-c 100-7.5-2.691 gram POWDER IN PACKET</i> MO	1	ST
<i>pepcid 20 mg, 40 mg TABLET</i> MO	3	PA
PLENVU 140-9-5.2 GRAM POWDER IN PACKET, SEQUENTIAL MO	3	ST
PREVACID 30 MG CAPSULE, DR/EC MO	3	PA,QL(60 per 30 days)
PREVACID SOLUTAB 15 MG, 30 MG TABLET, DISINTEGRATING DR MO	3	QL(30 per 30 days)
PRILOSEC 10 MG, 2.5 MG SUSPENSION, DR FOR RECON MO	3	
PROTONIX 20 MG, 40 MG TABLET, DR/EC MO	3	PA,QL(60 per 30 days)
PROTONIX 40 MG DR GRANULES IN PACKET MO	3	QL(30 per 30 days)
PROTONIX 40 MG RECON SOLUTION MO	3	PA
<i>prucalopride 1 mg, 2 mg TABLET</i> MO	1	PA,QL(30 per 30 days)
PYLERA 140-125-125 MG CAPSULE MO	3	ST,QL(120 per 30 days)
<i>rabeprazole 20 mg TABLET, DR/EC</i> MO	1	QL(60 per 30 days)
REBYOTA 150 ML ENEMA DL	4	PA
RELISTOR 12 MG/0.6 ML SOLUTION DL	4	PA,QL(36 per 30 days)
RELISTOR 12 MG/0.6 ML SYRINGE DL	4	PA,QL(36 per 28 days)
RELISTOR 150 MG TABLET DL	4	PA,QL(90 per 30 days)
RELISTOR 8 MG/0.4 ML SYRINGE DL	4	PA,QL(12 per 30 days)
RELTONE 200 MG CAPSULE DL	4	PA,QL(150 per 30 days)
RELTONE 400 MG CAPSULE DL	4	PA,QL(60 per 30 days)
ROBINUL 1 MG TABLET MO	3	PA
ROBINUL FORTE 2 MG TABLET MO	3	PA
<i>sodium,potassium,mag sulfates 17.5-3.13-1.6 gram RECON SOLUTION</i> MO	1	
<i>sucralfate 1 gram TABLET</i> MO	1	
<i>sucralfate 100 mg/ml SUSPENSION</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SUFLAVE 178.7-7.3-0.5 GRAM RECON SOLUTION MO	3	
SUPREP BOWEL PREP KIT 17.5-3.13-1.6 GRAM RECON SOLUTION MO	3	ST
SUTAB 1.479-0.188- 0.225 GRAM TABLET MO	2	
SYMPROIC 0.2 MG TABLET MO	3	PA,QL(30 per 30 days)
TALICIA 10-250-12.5 MG CAPSULE, IR/DR, BIPHASIC MO	3	
TRULANCE 3 MG TABLET MO	3	PA,QL(30 per 30 days)
URSO 250 250 MG TABLET MO	3	PA
URSO FORTE 500 MG TABLET MO	3	PA
ursodiol 200 mg CAPSULE DL	4	PA,QL(150 per 30 days)
ursodiol 250 mg, 500 mg TABLET MO	1	
ursodiol 300 mg CAPSULE MO	1	
ursodiol 400 mg CAPSULE DL	4	PA,QL(60 per 30 days)
VIBERZI 100 MG, 75 MG TABLET	4	PA,QL(60 per 30 days)
VOQUEZNA 10 MG TABLET MO	3	PA,QL(30 per 30 days)
VOQUEZNA 20 MG TABLET MO	3	PA,QL(60 per 30 days)
VOQUEZNA DUAL PAK 20 MG (28)- 500 MG (84) COMBO PACK MO	3	ST,QL(112 per 30 days)
VOQUEZNA TRIPLE PAK 20-500-500 MG COMBO PACK MO	3	ST,QL(112 per 30 days)
VOWST CAPSULE DL	4	PA
XERMELO 250 MG TABLET DL	4	PA,QL(84 per 28 days)
XIFAXAN 200 MG TABLET MO	3	PA,QL(9 per 30 days)
XIFAXAN 550 MG TABLET	4	PA,QL(84 per 28 days)
ZEGERID 20-1,680 MG, 40-1,680 MG PACKET DL	4	ST,QL(30 per 30 days)
ZEGERID 20-1.1 MG-GRAM, 40-1.1 MG-GRAM CAPSULE DL	4	PA,QL(30 per 30 days)
ZINPLAVA 25 MG/ML SOLUTION DL	4	
GENETIC/ENZYME/PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT		
ALDURAZYME 2.9 MG/5 ML SOLUTION DL	4	PA
AMVUTTRA 25 MG/0.5 ML SYRINGE DL	4	PA,QL(0.5 per 90 days)
ARALAST NP 1,000 MG, 500 MG RECON SOLUTION DL	4	PA
ATTRUBY 356 MG TABLET DL	4	PA,QL(120 per 30 days)
betaine 1 gram/scoop POWDER DL	4	
BUPHENYL 0.94 GRAM/GRAM POWDER DL	4	PA
BUPHENYL 500 MG TABLET DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CERDELGA 84 MG CAPSULE DL	4	PA
CEREZYME 400 UNIT RECON SOLUTION DL	4	PA
CHOLBAM 250 MG, 50 MG CAPSULE DL	4	PA,QL(120 per 30 days)
CREON 12,000-38,000 -60,000 UNIT, 24,000-76,000 -120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT CAPSULE, DR/EC MO	2	
CRYSVITA 10 MG/ML, 20 MG/ML SOLUTION DL	4	PA,QL(2 per 28 days)
CRYSVITA 30 MG/ML SOLUTION DL	4	PA,QL(6 per 28 days)
CYSTADANE 1 GRAM/SCOOP POWDER DL	4	PA
CYSTAGON 150 MG, 50 MG CAPSULE MO	3	
DAYBUE 200 MG/ML SOLUTION DL	4	PA,QL(3600 per 30 days)
<i>dichlorphenamide 50 mg TABLET DL</i>	4	PA,QL(120 per 30 days)
DOJOLVI 8.3 KCAL/ML LIQUID DL	4	PA
DUVYZAT 8.86 MG/ML SUSPENSION DL	4	PA,QL(360 per 30 days)
ELAPRASE 6 MG/3 ML SOLUTION DL	4	PA
ELELYSO 200 UNIT RECON SOLUTION DL	4	PA
ELEVIDYS 1.33 X 10EXP13 VG/ML SUSPENSION DL	4	PA
ELFABRIO 2 MG/ML SOLUTION DL	4	PA
EVRYSDI 0.75 MG/ML RECON SOLUTION DL	4	PA,QL(240 per 30 days)
EVRYSDI 5 MG TABLET DL	4	PA,QL(30 per 30 days)
FABRAZYME 35 MG, 5 MG RECON SOLUTION DL	4	PA
GALAFOLD 123 MG CAPSULE DL	4	PA,QL(14 per 28 days)
GLASSIA 20 MG/ML (2 %) SOLUTION DL	4	PA
HARLIKU 2 MG TABLET DL	4	PA
<i>javygtor 100 mg TABLET, SOLUBLE DL</i>	4	PA
<i>javygtor 100 mg, 500 mg POWDER IN PACKET DL</i>	4	PA
JOENJA 70 MG TABLET DL	4	PA,QL(60 per 30 days)
KANUMA 2 MG/ML SOLUTION DL	4	PA
KEVEYIS 50 MG TABLET DL	4	PA,QL(120 per 30 days)
KUVAN 100 MG TABLET, SOLUBLE DL	4	PA
KUVAN 100 MG, 500 MG POWDER IN PACKET DL	4	PA
LAMZEDE 10 MG RECON SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LUMIZYME 50 MG RECON SOLUTION DL	4	PA
MEPSEVII 2 MG/ML SOLUTION DL	4	PA
<i>miglustat 100 mg CAPSULE</i> DL	4	PA,QL(90 per 30 days)
MIPLYFFA 124 MG, 47 MG, 62 MG, 93 MG CAPSULE DL	4	PA,QL(90 per 30 days)
NAGLAZYME 5 MG/5 ML SOLUTION DL	4	PA
NEXVIAZYME 100 MG RECON SOLUTION DL	4	PA
<i>nitisinone 10 mg, 2 mg, 20 mg, 5 mg CAPSULE</i> DL	4	
NITYR 10 MG, 2 MG, 5 MG TABLET DL	4	
NULIBRY 9.5 MG RECON SOLUTION DL	4	PA
OLPRUVA 2 GRAM, 3 GRAM, 4 GRAM, 5 GRAM, 6 GRAM, 6.67 GRAM PELLETS IN PACKET DL	4	PA
ONPATTRO 2 MG/ML SOLUTION DL	4	PA
OPFOLDA 65 MG CAPSULE MO	3	PA
ORFADIN 10 MG, 2 MG, 20 MG, 5 MG CAPSULE DL	4	
ORFADIN 4 MG/ML SUSPENSION DL	4	
<i>ormalvi 50 mg TABLET</i> DL	4	PA,QL(120 per 30 days)
PALYNZIQ 10 MG/0.5 ML SYRINGE DL	4	PA,QL(15 per 30 days)
PALYNZIQ 2.5 MG/0.5 ML SYRINGE DL	4	PA,QL(4 per 28 days)
PALYNZIQ 20 MG/ML SYRINGE DL	4	PA,QL(90 per 30 days)
PANCREAZE 10,500-35,500- 61,500 UNIT, 4,200-14,200- 24,600 UNIT CAPSULE, DR/EC MO	3	ST
PANCREAZE 16,800-56,800- 98,400 UNIT, 2,600-8,800- 15,200 UNIT, 21,000-54,700- 83,900 UNIT CAPSULE, DR/EC	4	ST
PANCREAZE 37,000-97,300- 149,900 UNIT CAPSULE, DR/EC DL	4	ST
PERTZYE 16,000-57,500- 60,500 UNIT, 24,000-86,250- 90,750 UNIT, 4,000-14,375- 15,125 UNIT, 8,000-28,750- 30,250 UNIT CAPSULE, DR/EC DL	4	ST
PHEBURANE 483 MG/GRAM GRANULES DL	4	PA
POMBILITI 105 MG RECON SOLUTION DL	4	PA
PROCYSBI 25 MG CAPSULE, DR SPRINKLE DL	4	PA,QL(120 per 30 days)
PROCYSBI 300 MG DR GRANULES IN PACKET DL	4	PA,QL(210 per 30 days)
PROCYSBI 75 MG CAPSULE, DR SPRINKLE DL	4	PA,QL(780 per 30 days)
PROCYSBI 75 MG DR GRANULES IN PACKET DL	4	PA,QL(780 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROLASTIN-C 1,000 MG (+-)/20 ML SOLUTION DL	4	PA
PYRUKYND 20 MG (7)- 5 MG (7), 50 MG (7)- 20 MG (7) TABLET, DOSE PACK DL	4	PA,QL(14 per 14 days)
PYRUKYND 20 MG, 5 MG, 50 MG TABLET DL	4	PA,QL(60 per 30 days)
RAVICTI 1.1 GRAM/ML LIQUID DL	4	PA,QL(525 per 30 days)
REVCOVI 2.4 MG/1.5 ML (1.6 MG/ML) SOLUTION DL	4	
sapropterin 100 mg TABLET, SOLUBLE DL	4	PA
sapropterin 100 mg, 500 mg POWDER IN PACKET DL	4	PA
sodium phenylbutyrate 0.94 gram/gram POWDER DL	4	
sodium phenylbutyrate 500 mg TABLET DL	4	
STRENSIQ 18 MG/0.45 ML, 28 MG/0.7 ML, 80 MG/0.8 ML SOLUTION DL	4	PA
STRENSIQ 40 MG/ML SOLUTION DL	4	PA
SUCRAID 8,500 UNIT/ML SOLUTION DL	4	PA
TEGSEDI 284 MG/1.5 ML SYRINGE DL	4	PA,QL(6 per 28 days)
VIJOICE 125 MG, 50 MG TABLET DL	4	PA,QL(28 per 28 days)
VIJOICE 250 MG/DAY (200 MG X1-50 MG X1) TABLET DL	4	PA,QL(56 per 28 days)
VIJOICE 50 MG GRANULES IN PACKET DL	4	PA,QL(28 per 28 days)
VIOKACE 10,440-39,150- 39,150 UNIT, 20,880-78,300- 78,300 UNIT TABLET DL	4	ST
VOXZOGO 0.4 MG, 0.56 MG, 1.2 MG RECON SOLUTION DL	4	PA,QL(30 per 30 days)
VPRIV 400 UNIT RECON SOLUTION DL	4	PA
VYNDAMAX 61 MG CAPSULE DL	4	PA,QL(30 per 30 days)
VYENDAQEL 20 MG CAPSULE DL	4	PA,QL(120 per 30 days)
WAINUA 45 MG/0.8 ML AUTO-INJECTOR DL	4	PA,QL(0.8 per 28 days)
WELIREG 40 MG TABLET DL	4	PA,QL(90 per 30 days)
XENPOZYME 20 MG, 4 MG RECON SOLUTION DL	4	PA
yargesa 100 mg CAPSULE DL	4	PA,QL(90 per 30 days)
ZAVESCA 100 MG CAPSULE DL	4	PA,QL(90 per 30 days)
ZEMAIRA 1,000 MG RECON SOLUTION DL	4	PA
ZEMAIRA 4,000 MG, 5,000 MG RECON SOLUTION DL	4	PA
ZENPEP 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT CAPSULE, DR/EC MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GENITOURINARY AGENTS		
<i>alfuzosin 10 mg TABLET, ER 24 HR. MO</i>	1	
AVODART 0.5 MG CAPSULE MO	3	PA,QL(30 per 30 days)
<i>bethanechol chloride 10 mg, 25 mg, 5 mg, 50 mg TABLET MO</i>	1	
CIALIS 2.5 MG, 5 MG TABLET MO	3	PA
<i>darifenacin 15 mg, 7.5 mg TABLET, ER 24 HR. MO</i>	1	QL(30 per 30 days)
DETROL 1 MG, 2 MG TABLET MO	3	PA,QL(60 per 30 days)
DETROL LA 2 MG, 4 MG CAPSULE, ER 24 HR. MO	3	PA,QL(30 per 30 days)
DITROPAN XL 5 MG TABLET, ER 24 HR. MO	3	PA,QL(60 per 30 days)
<i>dutasteride 0.5 mg CAPSULE MO</i>	1	QL(30 per 30 days)
<i>dutasteride-tamsulosin 0.5-0.4 mg CAPSULE ER MULTIPHASE 24 HR. MO</i>	1	QL(30 per 30 days)
ELMIRON 100 MG CAPSULE MO	3	QL(90 per 30 days)
<i>fesoterodine 4 mg, 8 mg TABLET, ER 24 HR. MO</i>	1	QL(30 per 30 days)
<i>finasteride 5 mg TABLET MO</i>	1	QL(30 per 30 days)
<i>flavoxate 100 mg TABLET MO</i>	1	
FLOMAX 0.4 MG CAPSULE MO	3	
GELNIQUE 10 % (100 MG/GRAM) GEL IN PACKET MO	3	ST,QL(30 per 30 days)
GEMTESA 75 MG TABLET MO	3	QL(30 per 30 days)
JALYN 0.5-0.4 MG CAPSULE ER MULTIPHASE 24 HR. MO	3	PA,QL(30 per 30 days)
MYRBETRIQ 25 MG, 50 MG TABLET, ER 24 HR. MO	2	QL(30 per 30 days)
MYRBETRIQ 8 MG/ML SUSPENSION, ER, RECON MO	2	QL(300 per 30 days)
<i>oxybutynin chloride 10 mg TABLET, ER 24 HR. MO</i>	1	QL(60 per 30 days)
<i>oxybutynin chloride 15 mg, 5 mg TABLET, ER 24 HR. MO</i>	1	QL(60 per 30 days)
<i>oxybutynin chloride 2.5 mg TABLET MO</i>	1	QL(90 per 30 days)
<i>oxybutynin chloride 5 mg TABLET MO</i>	1	
<i>oxybutynin chloride 5 mg/5 ml SYRUP MO</i>	1	
OXYTROL 3.9 MG/24 HR PATCH, SEMIWEEKLY MO	3	ST,QL(8 per 28 days)
PROSCAR 5 MG TABLET MO	3	PA,QL(30 per 30 days)
RAPAFLO 4 MG, 8 MG CAPSULE MO	3	PA,QL(30 per 30 days)
<i>silodosin 4 mg, 8 mg CAPSULE MO</i>	1	QL(30 per 30 days)
<i>solifenacin 10 mg, 5 mg TABLET MO</i>	1	QL(30 per 30 days)
<i>tadalafil 2.5 mg, 5 mg TABLET MO</i>	1	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>tamsulosin 0.4 mg CAPSULE</i> MO	1	
THIOLA 100 MG TABLET DL	4	
THIOLA EC 100 MG, 300 MG TABLET, DR/EC DL	4	
<i>tiopronin 100 mg TABLET</i> DL	4	
<i>tiopronin 100 mg, 300 mg TABLET, DR/EC</i> DL	4	
<i>tolterodine 1 mg, 2 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>tolterodine 2 mg, 4 mg CAPSULE, ER 24 HR.</i> MO	1	QL(30 per 30 days)
TOVIAZ 4 MG, 8 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
<i>tropium 20 mg TABLET</i> MO	1	
<i>tropium 60 mg CAPSULE, ER 24 HR.</i> MO	1	QL(30 per 30 days)
UROXATRAL 10 MG TABLET, ER 24 HR. MO	3	
<i>venxiva 100 mg, 300 mg TABLET, DR/EC</i> DL	4	
VESICARE 10 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
VESICARE LS 1 MG/ML SUSPENSION MO	3	PA,QL(300 per 30 days)
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (ADRENAL)		
ACTHAR 80 UNIT/ML GEL DL	4	PA,QL(30 per 30 days)
ACTHAR SELFJECT 40 UNIT/0.5 ML, 80 UNIT/ML PEN INJECTOR DL	4	PA,QL(45 per 30 days)
AGAMREE 40 MG/ML SUSPENSION DL	4	PA,QL(225 per 30 days)
ALKINDI SPRINKLE 0.5 MG, 1 MG, 2 MG, 5 MG CAPSULE, SPRINKLE DL	4	PA
<i>betamethasone acet,sod phos 6 mg/ml SUSPENSION</i> MO	1	
CELESTONE SOLUSPAN 6 MG/ML SUSPENSION MO	3	
CORTROPHIN GEL 40 UNIT/0.5 ML SYRINGE DL	4	PA,QL(45 per 30 days)
CORTROPHIN GEL 80 UNIT/ML GEL DL	4	PA,QL(30 per 30 days)
CORTROPHIN GEL 80 UNIT/ML SYRINGE DL	4	PA,QL(30 per 30 days)
<i>deflazacort 18 mg, 30 mg, 36 mg, 6 mg TABLET</i> DL	4	PA
<i>deflazacort 22.75 mg/ml SUSPENSION</i> DL	4	PA
DEPO-MEDROL 20 MG/ML, 40 MG/ML, 80 MG/ML SUSPENSION MO	3	
<i>dexabliss 1.5 mg (39 tabs) TABLET, DOSE PACK</i> MO	1	
<i>dexamethasone 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg TABLET</i> MO	1	
<i>dexamethasone 0.5 mg/5 ml ELIXIR</i> MO	1	
<i>dexamethasone 0.5 mg/5 ml SOLUTION</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dexamethasone 1.5 mg (21 tabs), 1.5 mg (35 tabs), 1.5 mg (51 tabs) TABLET, DOSE PACK MO	1	
dexamethasone intensol 1 mg/ml DROPS MO	1	
dexamethasone sodium phos (pf) 10 mg/ml SOLUTION MO	1	
dexamethasone sodium phos (pf) 10 mg/ml SYRINGE MO	1	
dexamethasone sodium phosphate 10 mg/ml, 4 mg/ml SOLUTION MO	1	
dexamethasone sodium phosphate 4 mg/ml SYRINGE MO	1	
EMFLAZA 18 MG, 30 MG, 36 MG, 6 MG TABLET DL	4	PA
EMFLAZA 22.75 MG/ML SUSPENSION DL	4	PA
fludrocortisone 0.1 mg TABLET MO	1	
HEMADY 20 MG TABLET MO	3	PA,QL(24 per 28 days)
hydrocortisone sod succinate 100 mg RECON SOLUTION MO	1	
KENALOG 0.147 MG/GRAM AEROSOL MO	3	QL(200 per 30 days)
KENALOG 10 MG/ML, 40 MG/ML SUSPENSION MO	3	
KENALOG-80 80 MG/ML SUSPENSION MO	3	
KHINDIVI 1 MG/ML SOLUTION DL	4	PA
MEDROL 16 MG, 2 MG, 4 MG, 8 MG TABLET MO	3	BvsD
MEDROL (PAK) 4 MG TABLET, DOSE PACK MO	3	
methylprednisolone 16 mg, 32 mg, 4 mg, 8 mg TABLET MO	1	BvsD
methylprednisolone 4 mg TABLET, DOSE PACK MO	1	
methylprednisolone acetate 40 mg/ml, 80 mg/ml SUSPENSION MO	1	
methylprednisolone sodium succ 1,000 mg, 125 mg, 40 mg, 500 mg RECON SOLUTION MO	1	
millipred 5 mg TABLET MO	1	BvsD
millipred dp 5 mg (21 tabs), 5 mg (48 tabs) TABLET, DOSE PACK MO	1	
ORAPRED ODT 10 MG, 15 MG, 30 MG TABLET, DISINTEGRATING MO	3	
PEDIAPRED 5 MG BASE/5 ML (6.7 MG/5 ML) SOLUTION MO	3	
prednisolone 15 mg/5 ml SOLUTION MO	1	
prednisolone 5 mg TABLET MO	1	BvsD
prednisolone sodium phosphate 10 mg, 15 mg, 30 mg TABLET, DISINTEGRATING MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
prednisolone sodium phosphate 10 mg/5 ml, 15 mg/5 ml (3 mg/ml), 20 mg/5 ml (4 mg/ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml) SOLUTION MO	1	
prednisone 1 mg, 2.5 mg, 50 mg TABLET MO	1	BvsD
prednisone 10 mg, 20 mg, 5 mg TABLET MO	1	BvsD
prednisone 10 mg, 5 mg TABLET, DOSE PACK MO	1	
prednisone 5 mg/5 ml SOLUTION MO	1	BvsD
prednisone intensol 5 mg/ml CONCENTRATE MO	1	BvsD
RAYOS 1 MG, 2 MG, 5 MG TABLET, DR/EC DL	4	PA
SOLU-CORTEF 100 MG RECON SOLUTION MO	3	
SOLU-CORTEF ACT-O-VIAL (PF) 1,000 MG/8 ML, 100 MG/2 ML, 250 MG/2 ML, 500 MG/4 ML RECON SOLUTION MO	3	
SOLU-MEDROL 1,000 MG, 2 GRAM, 500 MG RECON SOLUTION MO	3	
SOLU-MEDROL (PF) 1,000 MG/8 ML, 125 MG/2 ML, 40 MG/ML, 500 MG/4 ML RECON SOLUTION MO	3	
taperdex 1.5 mg (21 tabs), 1.5 mg (27 tabs), 1.5 mg (49 tabs) TABLET, DOSE PACK MO	1	
triamcinolone acetonide 0.025 %, 0.05 %, 0.1 %, 0.5 % OINTMENT MO	1	
triamcinolone acetonide 0.025 %, 0.1 % LOTION MO	1	
triamcinolone acetonide 0.025 %, 0.5 % CREAM MO	1	
triamcinolone acetonide 0.1 % CREAM MO	1	
triamcinolone acetonide 0.147 mg/gram AEROSOL MO	1	QL(200 per 30 days)
triamcinolone acetonide 40 mg/ml SUSPENSION MO	1	
trianex 0.05 % OINTMENT MO	1	
triderm 0.1 %, 0.5 % CREAM MO	1	
VERIPRED 20 20 MG/5 ML (4 MG/ML) SOLUTION MO	1	
ZCORT 1.5 MG (25 TABS) TABLET, DOSE PACK MO	1	
ZILRETTA 32 MG SUSPENSION, ER, RECON MO	3	PA
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PITUITARY)		
CHORIONIC GONADOTROPIN, HUMAN 10,000 UNIT RECON SOLUTION MO	3	PA
DDAVP 0.1 MG TABLET MO	3	PA
DDAVP 0.2 MG TABLET DL	4	PA
DDAVP 4 MCG/ML SOLUTION MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
desmopressin 0.1 mg, 0.2 mg TABLET MO	1	
desmopressin 10 mcg/spray (0.1 ml) SPRAY WITH PUMP MO	1	PA,QL(25 per 30 days)
desmopressin 10 mcg/spray (0.1 ml) SPRAY, NON-AEROSOL MO	1	PA,QL(25 per 30 days)
desmopressin 4 mcg/ml SOLUTION DL	4	
EGRIFTA SV 2 MG RECON SOLUTION DL	4	PA,QL(30 per 30 days)
GENOTROPIN 12 MG/ML (36 UNIT/ML), 5 MG/ML (15 UNIT/ML) CARTRIDGE DL	4	PA
GENOTROPIN MINIQUICK 0.2 MG/0.25 ML, 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML SYRINGE DL	4	PA
HUMATROPE 12 MG (36 UNIT), 24 MG (72 UNIT), 6 MG (18 UNIT) CARTRIDGE DL	4	PA
HUMATROPE 5 (15 UNIT) MG RECON SOLUTION DL	4	PA
INCRELEX 10 MG/ML SOLUTION DL	4	PA
ISTURISA 1 MG TABLET DL	4	PA,QL(240 per 30 days)
ISTURISA 5 MG TABLET DL	4	PA,QL(360 per 30 days)
NGENLA 24 MG/1.2 ML (20 MG/ML), 60 MG/1.2 ML (50 MG/ML) PEN INJECTOR DL	4	PA
NOCDURNA (MEN) 55.3 MCG TABLET, DISINTEGRATING MO	3	PA,QL(30 per 30 days)
NOCDURNA (WOMEN) 27.7 MCG TABLET, DISINTEGRATING MO	3	PA,QL(30 per 30 days)
NORDITROPIN FLEXPRO 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) PEN INJECTOR DL	4	PA
NOVAREL 5,000 UNIT RECON SOLUTION MO	3	PA
NUTROPIN AQ NUSPIN 10 MG/2 ML (5 MG/ML), 20 MG/2 ML (10 MG/ML), 5 MG/2 ML (2.5 MG/ML) PEN INJECTOR DL	4	PA
OMNITROPE 10 MG/1.5 ML (6.7 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) CARTRIDGE DL	4	PA
OMNITROPE 5.8 MG RECON SOLUTION DL	4	PA
PREGNYL 10,000 UNIT RECON SOLUTION MO	3	PA
SAIZEN SAIZENPREP 8.8 MG/1.51 ML (FINAL CONC.) CARTRIDGE DL	4	PA
SEROSTIM 4 MG, 5 MG, 6 MG RECON SOLUTION DL	4	PA,QL(28 per 28 days)
SKYTROFA 11 MG, 7.6 MG, 9.1 MG CARTRIDGE DL	4	PA,QL(8 per 28 days)
SKYTROFA 13.3 MG, 3 MG, 3.6 MG, 4.3 MG, 5.2 MG, 6.3 MG CARTRIDGE DL	4	PA,QL(4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SOGROYA 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) PEN INJECTOR DL	4	PA,QL(6 per 28 days)
ZOMACTON 10 MG RECON SOLUTION DL	4	PA
ZOMACTON 5 MG RECON SOLUTION DL	4	PA,QL(28 per 28 days)
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PROSTAGLANDINS)		
carboprost tromethamine 250 mcg/ml SOLUTION MO	1	
carboprost tromethamine 250 mcg/ml SYRINGE MO	1	
HEMABATE 250 MCG/ML SOLUTION MO	3	
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS)		
abigale 1-0.5 mg TABLET MO	1	
abigale lo 0.5-0.1 mg TABLET MO	1	
ACTIVELLA 1-0.5 MG TABLET MO	3	
afirmelle 0.1-20 mg-mcg TABLET MO	1	
altavera (28) 0.15-0.03 mg TABLET MO	1	
alyacen 1/35 (28) 1-35 mg-mcg TABLET MO	1	
alyacen 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET MO	1	
amabelz 0.5-0.1 mg, 1-0.5 mg TABLET MO	1	
amethia 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	3	QL(91 per 90 days)
amethyst (28) 90-20 mcg (28) TABLET MO	1	
ANDROGEL 1 % (25 MG/2.5GRAM), 1 % (50 MG/5 GRAM) GEL IN PACKET MO	3	PA,QL(300 per 30 days)
ANDROGEL 1.62 % (20.25 MG/1.25 GRAM) GEL IN PACKET DL	4	PA,QL(37.5 per 30 days)
ANDROGEL 1.62 % (40.5 MG/2.5 GRAM) GEL IN PACKET DL	4	PA,QL(150 per 30 days)
ANDROGEL 20.25 MG/1.25 GRAM (1.62 %) GEL IN METERED DOSE PUMP DL	4	PA,QL(150 per 30 days)
ANGELIQ 0.25-0.5 MG, 0.5-1 MG TABLET MO	3	
ANNOVERA 0.15-0.013 MG/24 HOUR RING MO	3	QL(1 per 365 days)
apri 0.15-0.03 mg TABLET MO	1	
aranelle (28) 0.5/1/0.5-35 mg-mcg TABLET MO	1	
ashlyna 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
abra 0.1-20 mg-mcg TABLET MO	1	
abra eq 0.1-20 mg-mcg TABLET MO	1	
aurovela 1.5/30 (21) 1.5-30 mg-mcg TABLET MO	1	
aurovela 1/20 (21) 1-20 mg-mcg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>aurovela 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET</i> MO	1	
<i>aurovela fe 1-20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET</i> MO	1	
<i>aurovela fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET</i> MO	1	
AVEED 750 MG/3 ML (250 MG/ML) SOLUTION	4	PA
AVERI 0.15 MG-0.03 MG (21)/36.5 MG(7) TABLET MO	1	
<i>aviane 0.1-20 mg-mcg TABLET</i> MO	1	
AYGESTIN 5 MG TABLET MO	1	
<i>ayuna 0.15-0.03 mg TABLET</i> MO	1	
AZMIRO 200 MG/ML SYRINGE MO	3	PA
<i>azurette (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET</i> MO	1	
BALCOLTRA 0.1 MG-0.02 MG (21)/IRON (7) TABLET MO	3	
<i>balziva (28) 0.4-35 mg-mcg TABLET</i> MO	1	
BEYAZ 3-0.02-0.451 MG (24) (4) TABLET MO	3	
BIJUVA 0.5-100 MG, 1-100 MG CAPSULE MO	3	QL(30 per 30 days)
<i>blisovi 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET</i> MO	1	
<i>blisovi fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET</i> MO	1	
<i>blisovi fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET</i> MO	1	
<i>briellyn 0.4-35 mg-mcg TABLET</i> MO	1	
<i>camila 0.35 mg TABLET</i> MO	1	
<i>camrese 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH</i> MO	3	QL(91 per 90 days)
<i>camrese lo 0.1 mg-20 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH</i> MO	1	QL(91 per 90 days)
<i>charlotte 24 fe 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET</i> MO	1	
<i>chateal eq (28) 0.15-0.03 mg TABLET</i> MO	1	
CLIMARA 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.06 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR PATCH, WEEKLY MO	3	QL(4 per 28 days)
CLIMARA PRO 0.045-0.015 MG/24 HR PATCH, WEEKLY MO	3	QL(4 per 28 days)
COMBIPATCH 0.05-0.14 MG/24 HR, 0.05-0.25 MG/24 HR PATCH, SEMIWEEKLY MO	3	QL(8 per 28 days)
CRENESSITY 100 MG CAPSULE DL	4	PA,QL(120 per 30 days)
CRENESSITY 25 MG, 50 MG CAPSULE DL	4	PA,QL(90 per 30 days)
CRENESSITY 50 MG/ML SOLUTION DL	4	PA,QL(240 per 30 days)
CRINONE 4 %, 8 % GEL MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>cryselle</i> (28) 0.3-30 mg-mcg TABLET MO	1	
<i>cyred</i> 0.15-0.03 mg TABLET MO	1	
<i>cyred eq</i> 0.15-0.03 mg TABLET MO	1	
<i>danazol</i> 100 mg, 200 mg, 50 mg CAPSULE MO	1	
<i>dasetta</i> 1/35 (28) 1-35 mg-mcg TABLET MO	1	
<i>dasetta</i> 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET MO	1	
<i>daysee</i> 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
<i>deblitane</i> 0.35 mg TABLET MO	1	
DELESTROGEN 10 MG/ML, 20 MG/ML, 40 MG/ML OIL MO	3	
DEPO-ESTRADIOL 5 MG/ML OIL MO	1	QL(5 per 30 days)
DEPO-PROVERA 150 MG/ML SUSPENSION MO	3	QL(1 per 90 days)
DEPO-PROVERA 150 MG/ML SYRINGE MO	3	QL(1 per 90 days)
DEPO-SUBQ PROVERA 104 104 MG/0.65 ML SYRINGE MO	2	QL(0.65 per 90 days)
DEPO-TESTOSTERONE 100 MG/ML, 200 MG/ML OIL MO	1	PA
<i>desog-e.estradiol/e.estradiol</i> 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
DIVIGEL 0.25 MG/0.25 GRAM (0.1 %), 0.5 MG/0.5 GRAM (0.1 %), 0.75 MG/0.75 GRAM (0.1%), 1 MG/GRAM (0.1 %), 1.25 MG/1.25 GRAM (0.1 %) GEL IN PACKET MO	3	
<i>dolishale</i> 90-20 mcg (28) TABLET MO	1	
<i>dotti</i> 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, SEMIWEEKLY MO	1	QL(8 per 28 days)
<i>drospirenone-e.estradiol-lm.fa</i> 3-0.02-0.451 mg (24) (4), 3-0.03-0.451 mg (21) (7) TABLET MO	1	
<i>drospirenone-ethinyl estradiol</i> 3-0.02 mg, 3-0.03 mg TABLET MO	1	
DUAVEE 0.45-20 MG TABLET MO	3	PA,QL(30 per 30 days)
ELESTRIN 0.87 GRAM/ACTUATION GEL IN METERED DOSE PUMP MO	3	QL(52 per 30 days)
<i>elinest</i> 0.3-30 mg-mcg TABLET MO	1	
<i>eluryng</i> 0.12-0.015 mg/24 hr RING MO	1	QL(1 per 28 days)
<i>emzahn</i> 0.35 mg TABLET MO	1	
ENDOMETRIN 100 MG INSERT MO	3	
<i>enilloring</i> 0.12-0.015 mg/24 hr RING MO	1	QL(1 per 28 days)
<i>enpresse</i> 50-30 (6)/75-40 (5)/125-30(10) TABLET MO	1	
<i>enskyce</i> 0.15-0.03 mg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>errin</i> 0.35 mg TABLET MO	1	
<i>estarylla</i> 0.25-0.035 mg TABLET MO	1	
ESTRACE 0.01 % (0.1 MG/GRAM) CREAM MO	3	PA
ESTRACE 0.5 MG, 1 MG, 2 MG TABLET MO	1	
<i>estradiol</i> 0.01 % (0.1 mg/gram) CREAM MO	1	
<i>estradiol</i> 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, WEEKLY MO	1	QL(4 per 28 days)
<i>estradiol</i> 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, SEMIWEEKLY MO	1	QL(8 per 28 days)
<i>estradiol</i> 0.25 mg/0.25 gram (0.1 %), 0.5 mg/0.5 gram (0.1 %), 0.75 mg/0.75 gram (0.1%), 1 mg/gram (0.1 %), 1.25 mg/1.25 gram (0.1 %) GEL IN PACKET MO	1	
<i>estradiol</i> 0.5 mg, 1 mg, 10 mcg, 2 mg TABLET MO	1	
<i>estradiol</i> 1.25 gram/actuation GEL IN METERED DOSE PUMP MO	1	
<i>estradiol valerate</i> 10 mg/ml, 20 mg/ml, 40 mg/ml OIL MO	1	
<i>estradiol-norethindrone acet</i> 0.5-0.1 mg, 1-0.5 mg TABLET MO	1	
ESTRING 2 MG (7.5 MCG/24 HOUR) RING MO	3	QL(1 per 90 days)
<i>ethynodiol diac-eth estradiol</i> 1-35 mg-mcg, 1-50 mg-mcg TABLET MO	1	
<i>etonogestrel-ethinyl estradiol</i> 0.12-0.015 mg/24 hr RING MO	1	QL(1 per 28 days)
EVAMIST 1.53 MG/SPRAY (1.7%) SPRAY, NON-AEROSOL MO	3	
EVISTA 60 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>falmina</i> (28) 0.1-20 mg-mcg TABLET MO	1	
<i>feirza</i> 1 mg-20 mcg (21)/75 mg (7), 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
FEMLYV 1 MG- 20 MCG TABLET, DISINTEGRATING MO	3	
FEMRING 0.05 MG/24 HR, 0.1 MG/24 HR RING MO	3	QL(1 per 90 days)
<i>finzala</i> 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET MO	1	
FORTESTA 10 MG/0.5 GRAM /ACTUATION GEL IN METERED DOSE PUMP MO	3	PA,QL(120 per 30 days)
<i>fyavolv</i> 0.5-2.5 mg-mcg, 1-5 mg-mcg TABLET MO	1	
<i>galbriela</i> 0.8mg-25mcg(24) and 75 mg (4) CHEWABLE TABLET MO	1	
<i>gallifrey</i> 5 mg TABLET MO	1	
<i>gemmily</i> 1 mg-20 mcg (24)/75 mg (4) CAPSULE MO	1	
<i>hailey</i> 1.5-30 mg-mcg TABLET MO	1	
<i>hailey</i> 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
hailey fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
hailey fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
haloette 0.12-0.015 mg/24 hr RING MO	1	QL(1 per 28 days)
heather 0.35 mg TABLET MO	1	
iclevia 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
IMVEXXY MAINTENANCE PACK 10 MCG, 4 MCG INSERT MO	3	PA,QL(8 per 28 days)
IMVEXXY STARTER PACK 10 MCG, 4 MCG INSERT, DOSE PACK MO	3	PA,QL(18 per 28 days)
incassia 0.35 mg TABLET MO	1	
INTRAROSA 6.5 MG INSERT MO	3	PA
introvale 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
isibloom 0.15-0.03 mg TABLET MO	1	
jaimiess 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
jasmiel (28) 3-0.02 mg TABLET MO	1	
JATENZO 158 MG, 198 MG CAPSULE MO	3	PA,QL(120 per 30 days)
JATENZO 237 MG CAPSULE MO	3	PA,QL(60 per 30 days)
jencycla 0.35 mg TABLET MO	1	
jinteli 1-5 mg-mcg TABLET MO	1	
jolessa 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
joyeaux 0.1 mg-0.02 mg (21)/iron (7) TABLET MO	1	
juleber 0.15-0.03 mg TABLET MO	1	
junel 1.5/30 (21) 1.5-30 mg-mcg TABLET MO	1	
junel 1/20 (21) 1-20 mg-mcg TABLET MO	1	
junel fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
junel fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
junel fe 24 1 mg-20 mcg (24)/75 mg (4) TABLET MO	1	
kaitlib fe 0.8mg-25mcg(24) and 75 mg (4) CHEWABLE TABLET MO	1	
kalliga 0.15-0.03 mg TABLET MO	1	
kariva (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
kelnor 1/35 (28) 1-35 mg-mcg TABLET MO	1	
kelnor 1/50 (28) 1-50 mg-mcg TABLET MO	1	
kurvelo (28) 0.15-0.03 mg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>l norgest/e.estradiol-e.estrad 0.1 mg-20 mcg (84)/10 mcg (7), 0.15 mg-20 mcg/ 0.15 mg-25 mcg, 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH</i> MO	1	QL(91 per 90 days)
<i>larin 1.5/30 (21) 1.5-30 mg-mcg TABLET</i> MO	1	
<i>larin 1/20 (21) 1-20 mg-mcg TABLET</i> MO	1	
<i>larin 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET</i> MO	1	
<i>larin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET</i> MO	1	
<i>larin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET</i> MO	1	
<i>LAYOLIS FE 0.8MG-25MCG(24) AND 75 MG (4) CHEWABLE TABLET</i> MO	3	
<i>leena 28 0.5/1/0.5-35 mg-mcg TABLET</i> MO	1	
<i>lessina 0.1-20 mg-mcg TABLET</i> MO	1	
<i>levonest (28) 50-30 (6)/75-40 (5)/125-30(10) TABLET</i> MO	1	
<i>levonorg-eth estrad triphasic 50-30 (6)/75-40 (5)/125-30(10) TABLET</i> MO	1	
<i>levonorgest-eth.estradiol-iron 0.1 mg-0.02 mg (21)/iron (7) TABLET</i> MO	3	
<i>levonorgestrel-ethinyl estrad 0.1-20 mg-mcg, 0.15-0.03 mg, 90-20 mcg (28) TABLET</i> MO	1	
<i>levonorgestrel-ethinyl estrad 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH</i> MO	1	QL(91 per 90 days)
<i>levora-28 0.15-0.03 mg TABLET</i> MO	1	
<i>LO LOESTRIN FE 1 MG-10 MCG (24)/10 MCG (2) TABLET</i> MO	3	
<i>lo-zumandimine (28) 3-0.02 mg TABLET</i> MO	1	
<i>LOESTRIN 1.5/30 (21) 1.5-30 MG-MCG TABLET</i> MO	1	
<i>LOESTRIN 1/20 (21) 1-20 MG-MCG TABLET</i> MO	1	
<i>LOESTRIN FE 1.5/30 (28-DAY) 1.5 MG-30 MCG (21)/75 MG (7) TABLET</i> MO	1	
<i>LOESTRIN FE 1/20 (28-DAY) 1 MG-20 MCG (21)/75 MG (7) TABLET</i> MO	1	
<i>lojaimiess 0.1 mg-20 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH</i> MO	1	QL(91 per 90 days)
<i>loryna (28) 3-0.02 mg TABLET</i> MO	1	
<i>low-ogestrel (28) 0.3-30 mg-mcg TABLET</i> MO	1	
<i>lutura (28) 0.1-20 mg-mcg TABLET</i> MO	1	
<i>lyleq 0.35 mg TABLET</i> MO	1	
<i>lyllana 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, SEMIWEEKLY</i> MO	1	QL(8 per 28 days)
<i>lyza 0.35 mg TABLET</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
marlissa (28) 0.15-0.03 mg TABLET MO	1	
medroxyprogesterone 10 mg, 2.5 mg, 5 mg TABLET MO	1	
medroxyprogesterone 150 mg/ml SUSPENSION MO	1	QL(1 per 90 days)
medroxyprogesterone 150 mg/ml SYRINGE MO	1	QL(1 per 90 days)
megestrol 20 mg, 40 mg TABLET MO	1	
megestrol 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml) SUSPENSION MO	1	
meleya 0.35 mg TABLET MO	1	
MENEST 0.3 MG, 0.625 MG, 1.25 MG, 2.5 MG TABLET MO	1	
MENOSTAR 14 MCG/24 HR PATCH, WEEKLY MO	3	QL(8 per 28 days)
merzee 1 mg-20 mcg (24)/75 mg (4) CAPSULE MO	1	
METHITEST 10 MG TABLET DL	4	
methyltestosterone 10 mg CAPSULE DL	4	
mibelas 24 fe 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET MO	1	
microgestin 1.5/30 (21) 1.5-30 mg-mcg TABLET MO	1	
microgestin 1/20 (21) 1-20 mg-mcg TABLET MO	1	
microgestin 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO	1	
microgestin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
microgestin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
mili 0.25-0.035 mg TABLET MO	1	
mimvey 1-0.5 mg TABLET MO	1	
MINASTRIN 24 FE 1 MG-20 MCG(24) /75 MG (4) CHEWABLE TABLET MO	3	
MINIVELLE 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR PATCH, SEMIWEEKLY MO	3	QL(8 per 28 days)
minzoya 0.1 mg-0.02 mg (21)/iron (7) TABLET MO	1	
mono-linyah 0.25-0.035 mg TABLET MO	1	
NATAZIA 3 MG/2 MG-2 MG/ 2 MG-3 MG/1 MG TABLET MO	3	
necon 0.5/35 (28) 0.5-35 mg-mcg TABLET MO	1	
NEXPLANON 68 MG IMPLANT DL	2	
NEXTSTELLIS 3 MG- 14.2 MG (28) TABLET MO	3	
nikki (28) 3-0.02 mg TABLET MO	1	
NORA-BE 0.35 MG TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
nora-be 0.35 mg TABLET MO	1	
norelgestromin-ethin.estradiol 150-35 mcg/24 hr PATCH, WEEKLY MO	1	QL(3 per 28 days)
noreth-ethinyl estradiol-iron 0.4mg-35mcg(21) and 75 mg (7), 0.8mg-25mcg(24) and 75 mg (4) CHEWABLE TABLET MO	1	
norethindrone (contraceptive) 0.35 mg TABLET MO	1	
norethindrone ac-eth estradiol 0.5-2.5 mg-mcg, 1-20 mg-mcg, 1-5 mg-mcg, 1.5-30 mg-mcg TABLET MO	1	
norethindrone acetate 5 mg TABLET MO	1	
norethindrone-e.estradiol-iron 1 mg-20 mcg (21)/75 mg (7), 1-20(5)/1-30(7) /1mg-35mcg (9), 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
norethindrone-e.estradiol-iron 1 mg-20 mcg (24)/75 mg (4) CAPSULE MO	1	
norethindrone-e.estradiol-iron 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET MO	1	
norgestimate-ethinyl estradiol 0.18/0.215/0.25 mg-0.025 mg, 0.18/0.215/0.25 mg-0.035mg (28), 0.25-0.035 mg TABLET MO	1	
nortrel 0.5/35 (28) 0.5-35 mg-mcg TABLET MO	1	
nortrel 1/35 (21) 1-35 mg-mcg (21) TABLET MO	1	
nortrel 1/35 (28) 1-35 mg-mcg TABLET MO	1	
nortrel 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET MO	1	
NUVARING 0.12-0.015 MG/24 HR RING MO	3	QL(1 per 28 days)
nylia 1/35 (28) 1-35 mg-mcg TABLET MO	1	
nylia 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET MO	1	
nymyo 0.25-35 mg-mcg TABLET MO	1	
ocella 3-0.03 mg TABLET MO	1	
orquidea 0.35 mg TABLET MO	1	
OSPHENA 60 MG TABLET MO	2	PA
philith 0.4-35 mg-mcg TABLET MO	1	
pimtrea (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
portia 28 0.15-0.03 mg TABLET MO	1	
PREFEST 1 MG (15)/1 MG- 0.09 MG (15) TABLET MO	1	
PREMARIN 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG TABLET MO	3	
PREMARIN 0.625 MG/GRAM CREAM MO	2	
PREMARIN 25 MG RECON SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PREMPHASE 0.625 MG (14)/ 0.625MG-5MG(14) TABLET MO	3	
PREMPRO 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG TABLET MO	3	
progesterone 50 mg/ml OIL MO	1	
progesterone micronized 100 mg, 200 mg CAPSULE MO	1	
PROMETRIUM 100 MG, 200 MG CAPSULE MO	3	
PROVERA 10 MG, 2.5 MG, 5 MG TABLET MO	3	
QUARTETTE 0.15 MG-20 MCG/ 0.15 MG-25 MCG TABLET, DOSE PACK, 3 MONTH MO	3	QL(91 per 90 days)
raloxifene 60 mg TABLET MO	1	QL(30 per 30 days)
reclipsen (28) 0.15-0.03 mg TABLET MO	1	
rivelsa 0.15 mg-20 mcg/ 0.15 mg-25 mcg TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
rosyrah 0.15 mg-20 mcg/ 0.15 mg-25 mcg TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
SAFYRAL 3-0.03-0.451 MG (21) (7) TABLET MO	3	
SEASONIQUE 0.15 MG-30 MCG (84)/10 MCG (7) TABLET, DOSE PACK, 3 MONTH MO	3	QL(91 per 90 days)
setlakin 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
sharobel 0.35 mg TABLET MO	1	
simliya (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
simpesse 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
sprintec (28) 0.25-0.035 mg TABLET MO	1	
sronyx 0.1-20 mg-mcg TABLET MO	1	
syeda 3-0.03 mg TABLET MO	1	
tarina 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO	1	
tarina fe 1-20 eq (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
tarina fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
taysofy 1 mg-20 mcg (24)/75 mg (4) CAPSULE MO	1	
TAYTULLA 1 MG-20 MCG (24)/75 MG (4) CAPSULE MO	3	
TESTIM 50 MG/5 GRAM (1 %) GEL MO	3	PA,QL(300 per 30 days)
testosterone 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram) GEL IN PACKET MO	1	PA,QL(300 per 30 days)
testosterone 1.62 % (20.25 mg/1.25 gram) GEL IN PACKET MO	1	PA,QL(37.5 per 30 days)
testosterone 1.62 % (40.5 mg/2.5 gram) GEL IN PACKET MO	1	PA,QL(150 per 30 days)
testosterone 10 mg/0.5 gram /actuation GEL IN METERED DOSE PUMP MO	1	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
testosterone 12.5 mg/ 1.25 gram (1 %) GEL IN METERED DOSE PUMP MO	1	PA,QL(300 per 30 days)
testosterone 20.25 mg/1.25 gram (1.62 %) GEL IN METERED DOSE PUMP MO	1	PA,QL(150 per 30 days)
testosterone 30 mg/actuation (1.5 ml) SOLUTION IN METERED DOSE PUMP MO	3	PA,QL(180 per 30 days)
testosterone 50 mg/5 gram (1 %) GEL MO	3	PA,QL(300 per 30 days)
testosterone cypionate 100 mg/ml, 200 mg/ml OIL MO	1	PA
testosterone enanthate 200 mg/ml OIL MO	1	PA,QL(25 per 90 days)
tilia fe 1-20(5)/1-30(7) /1mg-35mcg (9) TABLET MO	1	
TLANDO 112.5 MG CAPSULE MO	3	PA,QL(120 per 30 days)
tri-estarylla 0.18/0.215/0.25 mg-0.035mg (28) TABLET MO	1	
tri-legest fe 1-20(5)/1-30(7) /1mg-35mcg (9) TABLET MO	1	
tri-linyah 0.18/0.215/0.25 mg-0.035mg (28) TABLET MO	1	
tri-lo-estarylla 0.18/0.215/0.25 mg-0.025 mg TABLET MO	1	
tri-lo-marzia 0.18/0.215/0.25 mg-0.025 mg TABLET MO	1	
tri-lo-mili 0.18/0.215/0.25 mg-0.025 mg TABLET MO	1	
tri-lo-sprintec 0.18/0.215/0.25 mg-0.025 mg TABLET MO	1	
tri-mili 0.18/0.215/0.25 mg-0.035mg (28) TABLET MO	1	
tri-nymyo 0.18/0.215/0.25 mg-35 mcg (28) TABLET MO	1	
tri-sprintec (28) 0.18/0.215/0.25 mg-0.035mg (28) TABLET MO	1	
tri-vylibra 0.18/0.215/0.25 mg-0.035mg (28) TABLET MO	1	
tri-vylibra lo 0.18/0.215/0.25 mg-0.025 mg TABLET MO	1	
trivora (28) 50-30 (6)/75-40 (5)/125-30(10) TABLET MO	1	
tulana 0.35 mg TABLET MO	1	
turqoz (28) 0.3-30 mg-mcg TABLET MO	1	
tydemy 3-0.03-0.451 mg (21) (7) TABLET MO	1	
UNDECATREX 200 MG CAPSULE DL	4	PA,QL(120 per 30 days)
VAGIFEM 10 MCG TABLET MO	3	PA
valtya 1-50 mg-mcg TABLET MO	1	
velivet triphasic regimen (28) 0.1/.125/.15-25 mg-mcg TABLET MO	1	
vestura (28) 3-0.02 mg TABLET MO	1	
vienva 0.1-20 mg-mcg TABLET MO	1	
violele (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VIVELLE-DOT 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR PATCH, SEMIWEEKLY MO	3	QL(8 per 28 days)
VOGELXO 1 % (50 MG/5 GRAM) GEL IN PACKET MO	3	PA,QL(300 per 30 days)
VOGELXO 12.5 MG/ 1.25 GRAM (1 %) GEL IN METERED DOSE PUMP MO	3	PA,QL(300 per 30 days)
VOGELXO 50 MG/5 GRAM (1 %) GEL MO	3	PA,QL(300 per 30 days)
volnea (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
vyfemla (28) 0.4-35 mg-mcg TABLET MO	1	
vylibra 0.25-0.035 mg TABLET MO	1	
wera (28) 0.5-35 mg-mcg TABLET MO	1	
wymzya fe 0.4mg-35mcg(21) and 75 mg (7) CHEWABLE TABLET MO	1	
xarah fe 1-20(5)/1-30(7) /1mg-35mcg (9) TABLET MO	1	
xelria fe 0.4mg-35mcg(21) and 75 mg (7) CHEWABLE TABLET MO	1	
xulane 150-35 mcg/24 hr PATCH, WEEKLY MO	1	QL(3 per 28 days)
XYOSTED 100 MG/0.5 ML, 50 MG/0.5 ML, 75 MG/0.5 ML AUTO-INJECTOR MO	3	PA,QL(2 per 28 days)
YASMIN (28) 3-0.03 MG TABLET MO	3	
YAZ (28) 3-0.02 MG TABLET MO	3	
yuvafem 10 mcg TABLET MO	1	
zafemy 150-35 mcg/24 hr PATCH, WEEKLY MO	1	QL(3 per 28 days)
zarah 3-0.03 mg TABLET MO	1	
zovia 1-35 (28) 1-35 mg-mcg TABLET MO	1	
zumandimine (28) 3-0.03 mg TABLET MO	1	
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID)		
ARMOUR THYROID 120 MG, 15 MG, 180 MG, 240 MG, 30 MG, 300 MG, 60 MG, 90 MG TABLET MO	2	
CYTOMEL 25 MCG, 5 MCG, 50 MCG TABLET MO	3	
ERMEZA 30 MCG/ML SOLUTION MO	3	PA
EUTHYROX 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	1	
LEVO-T 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	2	
levothyroxine 100 mcg RECON SOLUTION MO	1	
levothyroxine 100 mcg, 112 mcg, 125 mcg, 13 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg CAPSULE MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
levothyroxine 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg TABLET MO	1	
levothyroxine 100 mcg/ml, 20 mcg/ml, 40 mcg/ml SOLUTION MO	1	
levothyroxine 175 mcg, 200 mcg, 300 mcg TABLET MO	1	
levothyroxine 200 mcg, 500 mcg RECON SOLUTION DL	4	
LEVOXYL 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	1	
liothyronine 10 mcg/ml SOLUTION MO	1	
liothyronine 25 mcg, 5 mcg, 50 mcg TABLET MO	1	
np thyroid 120 mg, 15 mg, 30 mg, 60 mg, 90 mg TABLET MO	2	
SYNTHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	2	
THYQUIDITY 20 MCG/ML SOLUTION MO	3	PA
TIROSINT 100 MCG, 112 MCG, 125 MCG, 13 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 37.5 MCG, 44 MCG, 50 MCG, 62.5 MCG, 75 MCG, 88 MCG CAPSULE MO	3	
TIROSINT-SOL 100 MCG/ML, 112 MCG/ML, 125 MCG/ML, 13 MCG/ML, 137 MCG/ML, 150 MCG/ML, 175 MCG/ML, 200 MCG/ML, 25 MCG/ML, 37.5 MCG/ML, 44 MCG/ML, 50 MCG/ML, 62.5 MCG/ML, 75 MCG/ML, 88 MCG/ML SOLUTION MO	3	
UNITHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	2	
HORMONAL AGENTS, SUPPRESSANT (ADRENAL OR PITUITARY)		
cabergoline 0.5 mg TABLET MO	1	
ELIGARD 7.5 MG (1 MONTH) SYRINGE MO	3	PA
ELIGARD (3 MONTH) 22.5 MG SYRINGE MO	3	PA
ELIGARD (4 MONTH) 30 MG SYRINGE MO	3	PA
ELIGARD (6 MONTH) 45 MG SYRINGE MO	3	PA
FENSOLVI 45 MG SYRINGE	4	PA,QL(1 per 180 days)
FIRMAGON 120 MG RECON SOLUTION DL	4	PA
FIRMAGON KIT W DILUENT SYRINGE 120 MG RECON SOLUTION DL	4	PA
FIRMAGON KIT W DILUENT SYRINGE 80 MG RECON SOLUTION MO	3	PA
lanreotide 120 mg/0.5 ml SYRINGE DL	4	PA,QL(0.5 per 28 days)
lanreotide 60 mg/0.2 ml SYRINGE DL	4	PA,QL(0.2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
lanreotide 90 mg/0.3 ml SYRINGE DL	4	PA,QL(0.3 per 28 days)
leuprolide 1 mg/0.2 ml KIT MO	1	
leuprolide (3 month) 22.5 mg SUSPENSION FOR RECONSTITUTION MO	3	PA,QL(1 per 90 days)
LUPRON DEPOT 3.75 MG SYRINGE KIT MO	3	PA,QL(1 per 30 days)
LUPRON DEPOT 7.5 MG SYRINGE KIT DL	4	PA,QL(1 per 30 days)
LUPRON DEPOT (3 MONTH) 11.25 MG, 22.5 MG SYRINGE KIT MO	3	PA,QL(1 per 90 days)
LUPRON DEPOT (4 MONTH) 30 MG SYRINGE KIT MO	3	PA,QL(1 per 112 days)
LUPRON DEPOT (6 MONTH) 45 MG SYRINGE KIT	4	PA,QL(1 per 168 days)
LUPRON DEPOT-PED 11.25 MG, 15 MG, 7.5 MG (PED) KIT DL	4	PA,QL(1 per 28 days)
LUPRON DEPOT-PED 45 MG SYRINGE KIT	4	PA,QL(1 per 168 days)
LUPRON DEPOT-PED (3 MONTH) 11.25 MG, 30 MG SYRINGE KIT	4	PA,QL(1 per 90 days)
LUTRATE DEPOT (3 MONTH) 22.5 MG SUSPENSION FOR RECONSTITUTION MO	3	PA,QL(1 per 90 days)
MYCAPSSA 20 MG CAPSULE, DR/EC DL	4	PA,QL(112 per 28 days)
MYFEMBREE 40-1-0.5 MG TABLET DL	4	PA,QL(28 per 28 days)
octreotide acetate 1,000 mcg/ml, 100 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml SOLUTION MO	1	PA
octreotide acetate 100 mcg/ml (1 ml), 50 mcg/ml (1 ml), 500 mcg/ml (1 ml) SYRINGE MO	1	PA
octreotide,microspheres 10 mg, 20 mg, 30 mg SUSPENSION, ER, RECON DL	4	PA
ORIAHNN 300-1-0.5MG(AM) /300 MG(PM) CAPSULE, SEQUENTIAL DL	4	PA,QL(56 per 28 days)
ORILISSA 150 MG TABLET DL	4	PA,QL(28 per 28 days)
ORILISSA 200 MG TABLET DL	4	PA,QL(56 per 28 days)
RECORLEV 150 MG TABLET DL	4	PA,QL(240 per 30 days)
SANDOSTATIN 100 MCG/ML, 50 MCG/ML, 500 MCG/ML SOLUTION DL	4	PA
SANDOSTATIN LAR DEPOT 10 MG, 20 MG, 30 MG SUSPENSION, ER, RECON DL	4	PA
SIGNIFOR 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) SOLUTION DL	4	PA,QL(60 per 30 days)
SIGNIFOR LAR 10 MG, 20 MG, 30 MG, 40 MG, 60 MG SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(1 per 28 days)
SOMATULINE DEPOT 120 MG/0.5 ML SYRINGE DL	4	PA,QL(0.5 per 28 days)
SOMATULINE DEPOT 60 MG/0.2 ML SYRINGE DL	4	PA,QL(0.2 per 28 days)
SOMATULINE DEPOT 90 MG/0.3 ML SYRINGE DL	4	PA,QL(0.3 per 28 days)
SOMAVERT 10 MG, 15 MG, 20 MG RECON SOLUTION DL	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SOMAVERT 25 MG, 30 MG RECON SOLUTION DL	4	PA,QL(30 per 30 days)
SYNAREL 2 MG/ML SPRAY, NON-AEROSOL DL	4	
TRELSTAR 11.25 MG, 22.5 MG, 3.75 MG SUSPENSION FOR RECONSTITUTION MO	3	PA
TRIPTODUR 22.5 MG SUSPENSION FOR RECONSTITUTION	4	PA,QL(1 per 168 days)
ZOLADEX 10.8 MG IMPLANT MO	3	PA,QL(1 per 84 days)
ZOLADEX 3.6 MG IMPLANT MO	3	PA,QL(1 per 28 days)
HORMONAL AGENTS, SUPPRESSANT (THYROID)		
<i>methimazole 10 mg, 5 mg TABLET</i> MO	1	
<i>propylthiouracil 50 mg TABLET</i> MO	1	
IMMUNOLOGICAL AGENTS		
ABRILADA(CF) 20 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
ABRILADA(CF) 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ABRILADA(CF) PEN 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ABRYSCO (PF) 120 MCG/0.5 ML RECON SOLUTION \$0,DL	1	
ACTEMRA 162 MG/0.9 ML SYRINGE DL	4	PA,QL(3.6 per 28 days)
ACTEMRA ACTPEN 162 MG/0.9 ML PEN INJECTOR DL	4	PA,QL(3.6 per 28 days)
ACTHIB (PF) 10 MCG/0.5 ML RECON SOLUTION DL	1	
ACTIMMUNE 100 MCG/0.5 ML SOLUTION DL	4	PA
ADACEL(TDAP ADOLESN/ADULT)(PF) 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML SUSPENSION \$0,DL	1	
ADACEL(TDAP ADOLESN/ADULT)(PF) 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML SYRINGE \$0,DL	1	
ADALIMUMAB-AACF 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-AACF 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-AACF(CF) PEN CROHNS 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-AACF(CF) PEN PS-UV 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-AATY 20 MG/0.2 ML, 40 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-AATY 40 MG/0.4 ML, 80 MG/0.8 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-AATY(CF) AI CROHNS 80 MG/0.8 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADAZ 10 MG/0.1 ML SYRINGE DL	4	PA,QL(0.2 per 28 days)
ADALIMUMAB-ADAZ 20 MG/0.2 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ADALIMUMAB-ADAZ 40 MG/0.4 ML PEN INJECTOR DL	4	PA,QL(2.4 per 28 days)
ADALIMUMAB-ADAZ 40 MG/0.4 ML SYRINGE DL	4	PA,QL(2.4 per 28 days)
ADALIMUMAB-ADAZ 80 MG/0.8 ML PEN INJECTOR DL	4	PA,QL(4.8 per 28 days)
ADALIMUMAB-ADB 10 MG/0.2 ML, 20 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
ADALIMUMAB-ADB 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADB 40 MG/0.4 ML, 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADB(CF) PEN CROHNS 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADB(CF) PEN PS-UV 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-FKJP 20 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
ADALIMUMAB-FKJP 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-FKJP 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-RYVK 40 MG/0.4 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-RYVK 40 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ALYGLO 10 % SOLUTION DL	4	PA
AMJEVITA(CF) 10 MG/0.2 ML, 20 MG/0.2 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
AMJEVITA(CF) 20 MG/0.4 ML, 40 MG/0.4 ML SYRINGE DL	4	PA,QL(2.4 per 28 days)
AMJEVITA(CF) 40 MG/0.8 ML SYRINGE DL	4	PA,QL(4.8 per 28 days)
AMJEVITA(CF) AUTOINJECTOR 40 MG/0.4 ML AUTO-INJECTOR DL	4	PA,QL(2.4 per 28 days)
AMJEVITA(CF) AUTOINJECTOR 40 MG/0.8 ML, 80 MG/0.8 ML AUTO-INJECTOR DL	4	PA,QL(4.8 per 28 days)
ANDEMBRY AUTOINJECTOR 200 MG/1.2 ML AUTO-INJECTOR DL	4	PA
ARA 10 MG, 20 MG TABLET DL	4	PA,QL(30 per 30 days)
ARCALYST 220 MG RECON SOLUTION DL	4	PA
AREXVY (PF) 120 MCG/0.5 ML SUSPENSION FOR RECONSTITUTION \$0,DL	1	
ASCENIV 10 % SOLUTION DL	4	PA
ASTAGRAF XL 0.5 MG, 1 MG, 5 MG CAPSULE, ER 24 HR. MO	3	BvsD
ATGAM 50 MG/ML SOLUTION DL	4	PA
<i>auranofin</i> 3 mg CAPSULE DL	4	PA
AVSOLA 100 MG RECON SOLUTION DL	4	PA
AZASAN 100 MG, 75 MG TABLET MO	1	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
azathioprine 100 mg, 50 mg, 75 mg TABLET MO	1	BvsD
azathioprine sodium 100 mg RECON SOLUTION MO	1	BvsD
BCG VACCINE, LIVE (PF) 50 MG SUSPENSION FOR RECONSTITUTION \$0,DL	1	
BENLYSTA 120 MG RECON SOLUTION DL	4	PA,QL(20 per 28 days)
BENLYSTA 200 MG/ML AUTO-INJECTOR DL	4	PA,QL(8 per 28 days)
BENLYSTA 200 MG/ML SYRINGE DL	4	PA,QL(8 per 28 days)
BENLYSTA 400 MG RECON SOLUTION DL	4	PA,QL(6 per 28 days)
BERINERT 500 UNIT (10 ML) KIT DL	4	PA,QL(15 per 30 days)
BERINERT 500 UNIT (10 ML) RECON SOLUTION DL	4	PA,QL(15 per 30 days)
BESREMI 500 MCG/ML SYRINGE DL	4	PA,QL(2 per 28 days)
BEXSERO 50-50-50-25 MCG/0.5 ML SYRINGE \$0,DL	1	
BIMZELX 160 MG/ML, 320 MG/2 ML SYRINGE DL	4	PA,QL(4 per 28 days)
BIMZELX AUTOINJECTOR 160 MG/ML, 320 MG/2 ML AUTO-INJECTOR DL	4	PA,QL(4 per 28 days)
BIVIGAM 10 % SOLUTION DL	4	PA
BKEMV 300 MG/30 ML SOLUTION DL	4	PA
BOOSTRIX TDAP 2.5-8-5 LF-MCG-LF/0.5ML SUSPENSION \$0,DL	1	
BOOSTRIX TDAP 2.5-8-5 LF-MCG-LF/0.5ML SYRINGE \$0,DL	1	
CELLCEPT 200 MG/ML SUSPENSION FOR RECONSTITUTION	4	BvsD
CELLCEPT 250 MG CAPSULE	4	BvsD
CELLCEPT 500 MG TABLET	4	BvsD
CELLCEPT INTRAVENOUS 500 MG RECON SOLUTION MO	3	BvsD
CIBINQO 100 MG, 200 MG, 50 MG TABLET DL	4	PA,QL(30 per 30 days)
CIMZIA 200 MG/ML SYRINGE KIT DL	4	PA,QL(6 per 30 days)
CIMZIA 400 MG/2 ML (200 MG/ML X 2) SYRINGE KIT DL	4	PA,QL(3 per 30 days)
CIMZIA POWDER FOR RECONST 400 MG (200 MG X 2 VIALS) KIT DL	4	PA,QL(3 per 30 days)
CIMZIA STARTER KIT 400 MG/2 ML (200 MG/ML X 2) SYRINGE KIT DL	4	PA,QL(3 per 30 days)
CINRYZE 500 UNIT (5 ML) RECON SOLUTION DL	4	PA,QL(20 per 30 days)
COSENTYX 150 MG/ML SYRINGE DL	4	PA,QL(8 per 28 days)
COSENTYX 25 MG/ML SOLUTION DL	4	PA
COSENTYX 75 MG/0.5 ML SYRINGE DL	4	PA,QL(2 per 28 days)
COSENTYX (2 SYRINGES) 150 MG/ML SYRINGE DL	4	PA,QL(8 per 28 days)
COSENTYX PEN 150 MG/ML PEN INJECTOR DL	4	PA,QL(8 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
COSENTYX PEN (2 PENS) 150 MG/ML PEN INJECTOR DL	4	PA,QL(8 per 28 days)
COSENTYX UNOREADY PEN 300 MG/2 ML PEN INJECTOR DL	4	PA,QL(8 per 28 days)
CUTAQUIG 16.5 % SOLUTION DL	4	PA
<i>cyclosporine 100 mg, 25 mg CAPSULE</i> MO	1	BvsD
<i>cyclosporine modified 100 mg, 25 mg, 50 mg CAPSULE</i> MO	1	BvsD
<i>cyclosporine modified 100 mg/ml SOLUTION</i> MO	1	BvsD
CYLTEZO(CF) 10 MG/0.2 ML, 20 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
CYLTEZO(CF) 40 MG/0.4 ML, 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
CYLTEZO(CF) PEN 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
CYLTEZO(CF) PEN CROHN'S-UC-HS 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
CYLTEZO(CF) PEN PSORIASIS-UV 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
CYTOGAM 50 MG/ML SOLUTION DL	4	PA
DAPTACEL (DTAP PEDIATRIC) (PF) 15-10-5 LF-MCG-LF/0.5ML SUSPENSION DL	1	
DENGAXIA (PF) 10EXP4.5-6 CCID50/0.5 ML SUSPENSION FOR RECONSTITUTION DL	1	
DUPIXENT PEN 200 MG/1.14 ML PEN INJECTOR DL	4	PA,QL(3.42 per 28 days)
DUPIXENT PEN 300 MG/2 ML PEN INJECTOR DL	4	PA,QL(8 per 28 days)
DUPIXENT SYRINGE 100 MG/0.67 ML SYRINGE DL	4	PA,QL(1.34 per 28 days)
DUPIXENT SYRINGE 200 MG/1.14 ML SYRINGE DL	4	PA,QL(3.42 per 28 days)
DUPIXENT SYRINGE 300 MG/2 ML SYRINGE DL	4	PA,QL(8 per 28 days)
EKTERLY 300 MG TABLET DL	4	PA,QL(12 per 30 days)
ENBREL 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) SYRINGE DL	4	PA,QL(8 per 28 days)
ENBREL 25 MG/0.5 ML SOLUTION DL	4	PA,QL(8 per 28 days)
ENBREL MINI 50 MG/ML (1 ML) CARTRIDGE DL	4	PA,QL(8 per 28 days)
ENBREL SURECLICK 50 MG/ML (1 ML) PEN INJECTOR DL	4	PA,QL(8 per 28 days)
ENGERIX-B (PF) 20 MCG/ML SUSPENSION \$0,DL	1	BvsD
ENGERIX-B (PF) 20 MCG/ML SYRINGE \$0,DL	1	BvsD
ENGERIX-B PEDIATRIC (PF) 10 MCG/0.5 ML SYRINGE \$0,DL	1	BvsD
ENJAYMO 50 MG/ML SOLUTION DL	4	PA
ENTYVIO 300 MG RECON SOLUTION	4	PA,QL(8 per 365 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ENTYVIO PEN 108 MG/0.68 ML PEN INJECTOR DL	4	PA,QL(1.36 per 28 days)
ENVARUSUS XR 0.75 MG, 1 MG TABLET, ER 24 HR. MO	3	PA
ENVARUSUS XR 4 MG TABLET, ER 24 HR. DL	3	PA
EPYSQLI 300 MG/30 ML SOLUTION DL	4	PA
<i>everolimus (immunosuppressive) 0.25 mg TABLET</i> MO	1	BvsD,QL(60 per 30 days)
<i>everolimus (immunosuppressive) 0.5 mg TABLET</i>	4	BvsD,QL(120 per 30 days)
<i>everolimus (immunosuppressive) 0.75 mg TABLET</i>	4	BvsD,QL(60 per 30 days)
<i>everolimus (immunosuppressive) 1 mg TABLET</i> DL	4	BvsD,QL(60 per 30 days)
FABHALTA 200 MG CAPSULE DL	4	PA,QL(60 per 30 days)
FIRAZYR 30 MG/3 ML SYRINGE DL	4	PA,QL(18 per 30 days)
FLEBOGAMMA DIF 10 %, 5 % SOLUTION DL	4	PA
GAMASTAN 15-18 % RANGE SOLUTION MO	3	PA
GAMIFANT 5 MG/ML SOLUTION DL	4	PA
GAMMAGARD LIQUID 10 % SOLUTION DL	4	PA
GAMMAGARD S-D (IGA < 1 MCG/ML) 10 GRAM, 5 GRAM RECON SOLUTION DL	4	PA
GAMMAKED 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 20 GRAM/200 ML (10 %), 5 GRAM/50 ML (10 %) SOLUTION DL	4	PA
GAMMAPLEX 10 % SOLUTION DL	4	PA
GAMMAPLEX (WITH SORBITOL) 5 % SOLUTION DL	4	PA
GAMUNEX-C 1 GRAM/10 ML (10 %) SOLUTION DL	4	PA
GAMUNEX-C 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %) SOLUTION DL	4	PA
GARDASIL 9 (PF) 0.5 ML SUSPENSION \$0,DL	1	
GARDASIL 9 (PF) 0.5 ML SYRINGE \$0,DL	1	
<i>gengraf 100 mg, 25 mg CAPSULE</i> MO	1	BvsD
<i>gengraf 100 mg/ml SOLUTION</i> MO	1	BvsD
HADLIMA 40 MG/0.8 ML SYRINGE DL	4	PA,QL(4.8 per 28 days)
HADLIMA PUSH TOUCH 40 MG/0.8 ML AUTO-INJECTOR DL	4	PA,QL(4.8 per 28 days)
HADLIMA(CF) 40 MG/0.4 ML SYRINGE DL	4	PA,QL(2.4 per 28 days)
HADLIMA(CF) PUSH TOUCH 40 MG/0.4 ML AUTO-INJECTOR DL	4	PA,QL(2.4 per 28 days)
HAEGARDA 2,000 UNIT, 3,000 UNIT RECON SOLUTION DL	4	PA,QL(24 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HAVRIX (PF) 1,440 ELISA UNIT/ML SYRINGE \$0,DL	1	
HAVRIX (PF) 720 ELISA UNIT/0.5 ML SYRINGE DL	1	
HEPLISAV-B (PF) 20 MCG/0.5 ML SYRINGE \$0,DL	1	BvsD
HIBERIX (PF) 10 MCG/0.5 ML RECON SOLUTION DL	1	
HIZENTRA 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SOLUTION DL	4	PA
HIZENTRA 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SYRINGE DL	4	PA
HULIO(CF) 20 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
HULIO(CF) 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
HULIO(CF) PEN 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
HUMIRA PEN 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA PEN CROHNS-UC-HS START 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) 10 MG/0.1 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
HUMIRA(CF) 20 MG/0.2 ML, 40 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEDI CROHNS STARTER 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEN 40 MG/0.4 ML, 80 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEN CROHNS-UC-HS 80 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEN PEDIATRIC UC 80 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEN PSOR-UV-ADOL HS 80 MG/0.8 ML-40 MG/0.4 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HYPERRAB (PF) 300 UNIT/ML SOLUTION DL	4	BvsD
HYPERTET (PF) 250 UNIT/ML SYRINGE DL	3	BvsD
HYRIMOZ 40 MG/0.8 ML SYRINGE DL	4	PA,QL(4.8 per 28 days)
HYRIMOZ PEN 40 MG/0.8 ML PEN INJECTOR DL	4	PA,QL(4.8 per 28 days)
HYRIMOZ PEN CROHN'S-UC STARTER 80 MG/0.8 ML PEN INJECTOR DL	4	PA,QL(4.8 per 28 days)
HYRIMOZ PEN PSORIASIS STARTER 80MG/0.8ML(X1)- 40 MG/0.4ML(X2) PEN INJECTOR DL	4	PA,QL(3.2 per 28 days)
HYRIMOZ(CF) 10 MG/0.1 ML SYRINGE DL	4	PA,QL(0.2 per 28 days)
HYRIMOZ(CF) 20 MG/0.2 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
HYRIMOZ(CF) 40 MG/0.4 ML SYRINGE DL	4	PA,QL(2.4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HYRIMOZ(CF) PEDI CROHN STARTER 80 MG/0.8 ML SYRINGE DL	4	PA,QL(4.8 per 28 days)
HYRIMOZ(CF) PEDI CROHN STARTER 80 MG/0.8 ML - 40 MG/0.4 ML SYRINGE DL	4	PA,QL(3.6 per 28 days)
HYRIMOZ(CF) PEN 40 MG/0.4 ML PEN INJECTOR DL	4	PA,QL(2.4 per 28 days)
HYRIMOZ(CF) PEN 80 MG/0.8 ML PEN INJECTOR DL	4	PA,QL(4.8 per 28 days)
<i>icatibant 30 mg/3 ml SYRINGE</i> DL	4	PA,QL(18 per 30 days)
IDACIO(CF) 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
IDACIO(CF) PEN 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
IDACIO(CF) PEN CROHN-UC STARTR 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
IDACIO(CF) PEN PSORIASIS START 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ILUMYA 100 MG/ML SYRINGE	4	PA,QL(6 per 365 days)
IMAAVY 185 MG/ML SOLUTION DL	4	PA
IMOGAM RABIES-HT (PF) 150 UNIT/ML SOLUTION DL	3	BvsD
IMOVAX RABIES VACCINE (PF) 2.5 UNIT RECON SOLUTION \$0,DL	1	BvsD
IMURAN 50 MG TABLET MO	3	BvsD
INFANRIX (DTAP) (PF) 25-58-10 LF-MCG-LF/0.5ML SYRINGE DL	1	
INFLECTRA 100 MG RECON SOLUTION DL	4	PA
INFLIXIMAB 100 MG RECON SOLUTION DL	4	PA
IPOL 40-8-32 UNIT/0.5 ML SUSPENSION \$0,DL	1	
IXCHIQ (PF) 1,000 TCID50/0.5 ML RECON SOLUTION \$0,DL	1	
IXIARO (PF) 6 MCG/0.5 ML SYRINGE \$0,DL	1	
JYLAMVO 2 MG/ML SOLUTION DL	3	PA
JYNNEOS (PF) 0.5X TO 3.95X 10EXP8 UNIT/0.5 SUSPENSION \$0,DL	1	
KEDRAB (PF) 150 UNIT/ML SOLUTION DL	4	BvsD
KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML PEN INJECTOR DL	4	PA,QL(2.28 per 28 days)
KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML SYRINGE DL	4	PA,QL(2.28 per 28 days)
KINERET 100 MG/0.67 ML SYRINGE DL	4	PA,QL(20.1 per 30 days)
KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML SYRINGE DL	1	
<i>leflunomide 10 mg, 20 mg TABLET</i> MO	1	QL(30 per 30 days)
LEQSELVI 8 MG TABLET DL	4	PA,QL(60 per 30 days)
LITFULO 50 MG CAPSULE DL	4	PA,QL(28 per 28 days)
LUPKYNIS 7.9 MG CAPSULE DL	4	PA,QL(180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
M-M-R II (PF) 1,000-12,500 TCID50/0.5 ML RECON SOLUTION \$0,DL	1	
MENACTRA (PF) 4 MCG/0.5 ML SOLUTION \$0,DL	1	
MENQUADFI (PF) 10 MCG/0.5 ML SOLUTION \$0,DL	1	
MENVEO A-C-Y-W-135-DIP (PF) 10-5 MCG/0.5 ML KIT \$0,DL	1	
MENVEO A-C-Y-W-135-DIP (PF) 10-5 MCG/0.5 ML SOLUTION \$0,DL	1	
methotrexate sodium 2.5 mg TABLET MO	1	BvsD
methotrexate sodium 25 mg/ml SOLUTION MO	1	
methotrexate sodium (pf) 1 gram RECON SOLUTION MO	1	
methotrexate sodium (pf) 25 mg/ml SOLUTION MO	1	
MONJUVI 200 MG RECON SOLUTION DL	4	PA
MRESVIA (PF) 50 MCG/0.5 ML SYRINGE \$0,DL	1	
mycophenolate mofetil 200 mg/ml SUSPENSION FOR RECONSTITUTION MO	1	BvsD
mycophenolate mofetil 250 mg CAPSULE MO	1	BvsD
mycophenolate mofetil 500 mg TABLET MO	1	BvsD
mycophenolate mofetil (hcl) 500 mg RECON SOLUTION MO	1	BvsD
mycophenolate sodium 180 mg, 360 mg TABLET, DR/EC MO	1	BvsD
MYFORTIC 180 MG TABLET, DR/EC MO	3	BvsD
MYFORTIC 360 MG TABLET, DR/EC	4	BvsD
MYHIBBIN 200 MG/ML SUSPENSION DL	4	BvsD
NEMLUVIO 30 MG PEN INJECTOR DL	4	PA,QL(2 per 28 days)
NEORAL 100 MG, 25 MG CAPSULE MO	3	BvsD
NEORAL 100 MG/ML SOLUTION MO	3	BvsD
NIKTIMVO 50 MG/ML SOLUTION DL	4	PA
OCTAGAM 10 %, 5 % SOLUTION DL	4	PA
OLUMIANT 1 MG, 2 MG, 4 MG TABLET DL	4	PA,QL(30 per 30 days)
OMVOH 100 MG/ML, 300MG/3ML(100MG /ML-200 MG/2ML) SYRINGE DL	4	PA,QL(3 per 28 days)
OMVOH 300 MG/15 ML (20 MG/ML) SOLUTION DL	4	PA
OMVOH PEN 100 MG/ML, 300MG/3ML(100MG /ML-200 MG/2ML) PEN INJECTOR DL	4	PA,QL(3 per 28 days)
ORENCIA 125 MG/ML SYRINGE DL	4	PA,QL(4 per 28 days)
ORENCIA 50 MG/0.4 ML SYRINGE DL	4	PA,QL(1.6 per 28 days)
ORENCIA 87.5 MG/0.7 ML SYRINGE DL	4	PA,QL(2.8 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ORENCIA CLICKJECT 125 MG/ML AUTO-INJECTOR DL	4	PA,QL(4 per 28 days)
ORLADEYO 110 MG, 150 MG CAPSULE DL	4	PA,QL(28 per 28 days)
OTREXUP (PF) 10 MG/0.4 ML, 12.5 MG/0.4 ML, 15 MG/0.4 ML, 17.5 MG/0.4 ML, 20 MG/0.4 ML, 22.5 MG/0.4 ML, 25 MG/0.4 ML AUTO-INJECTOR MO	3	PA,QL(1.6 per 28 days)
OTULFI 130 MG/26 ML SOLUTION DL	4	PA,QL(104 per 30 days)
OTULFI 45 MG/0.5 ML SYRINGE MO	3	PA,QL(1.5 per 84 days)
OTULFI 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)
PANZYGA 10 % SOLUTION DL	4	PA
PEDIARIX (PF) 10 MCG-25LF-25 MCG-10LF/0.5 ML SYRINGE DL	1	
PEDVAX HIB (PF) 7.5 MCG/0.5 ML SOLUTION DL	1	
PEGASYS 180 MCG/0.5 ML SYRINGE DL	4	PA,QL(2 per 28 days)
PEGASYS 180 MCG/ML SOLUTION DL	4	PA,QL(4 per 28 days)
PENBRAYA (PF) 5-120 MCG/0.5 ML KIT \$0,DL	1	
PENMENVY MEN A-B-C-W-Y (PF) 0.5 ML KIT \$0,DL	1	
PENTACEL (PF) 15LF-20MCG-5LF- 62 DU/0.5 ML KIT DL	1	
PIASKY 340 MG/2 ML SOLUTION DL	4	PA
PRIORIX (PF) 10EXP3.4-4.2- 3.3CCID50/0.5ML SUSPENSION FOR RECONSTITUTION \$0,DL	1	
PRIVIGEN 10 % SOLUTION DL	4	PA
PROGRAF 0.2 MG, 1 MG GRANULES IN PACKET MO	3	BvsD
PROGRAF 0.5 MG, 1 MG, 5 MG CAPSULE MO	3	BvsD
PROQUAD (PF) 10EXP3-4.3-3- 3.99 TCID50/0.5 SUSPENSION FOR RECONSTITUTION DL	1	
PYZCHIVA 130 MG/26 ML SOLUTION DL	4	PA,QL(104 per 30 days)
PYZCHIVA 45 MG/0.5 ML SOLUTION DL	4	PA,QL(1.5 per 84 days)
PYZCHIVA 45 MG/0.5 ML SYRINGE DL	4	PA,QL(1.5 per 84 days)
PYZCHIVA 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)
QUADRACEL (PF) 15 LF-48 MCG- 5 LF UNIT/0.5ML SUSPENSION DL	1	
QUADRACEL (PF) 15 LF-48 MCG- 5 LF UNIT/0.5ML SYRINGE DL	1	
RABAVERT (PF) 2.5 UNIT SUSPENSION FOR RECONSTITUTION \$0,DL	1	BvsD
RAPAMUNE 0.5 MG, 1 MG, 2 MG TABLET	4	BvsD
RAPAMUNE 1 MG/ML SOLUTION	4	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RASUVO (PF) 10 MG/0.2 ML AUTO-INJECTOR MO	3	PA,QL(0.8 per 28 days)
RASUVO (PF) 12.5 MG/0.25 ML AUTO-INJECTOR MO	3	PA,QL(1 per 28 days)
RASUVO (PF) 15 MG/0.3 ML AUTO-INJECTOR MO	3	PA,QL(1.2 per 28 days)
RASUVO (PF) 17.5 MG/0.35 ML AUTO-INJECTOR MO	3	PA,QL(1.4 per 28 days)
RASUVO (PF) 20 MG/0.4 ML AUTO-INJECTOR MO	3	PA,QL(1.6 per 28 days)
RASUVO (PF) 22.5 MG/0.45 ML AUTO-INJECTOR MO	3	PA,QL(1.8 per 28 days)
RASUVO (PF) 25 MG/0.5 ML AUTO-INJECTOR MO	3	PA,QL(2 per 28 days)
RASUVO (PF) 30 MG/0.6 ML AUTO-INJECTOR MO	3	PA,QL(2.4 per 28 days)
RASUVO (PF) 7.5 MG/0.15 ML AUTO-INJECTOR MO	3	PA,QL(0.6 per 28 days)
RECOMBIVAX HB (PF) 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML SUSPENSION \$0,DL	1	BvsD
RECOMBIVAX HB (PF) 10 MCG/ML, 5 MCG/0.5 ML SYRINGE \$0,DL	1	BvsD
REDITREX (PF) 10 MG/0.4 ML SYRINGE MO	3	PA,QL(1.6 per 28 days)
REDITREX (PF) 12.5 MG/0.5 ML SYRINGE MO	3	PA,QL(2 per 28 days)
REDITREX (PF) 15 MG/0.6 ML SYRINGE MO	3	PA,QL(2.4 per 28 days)
REDITREX (PF) 17.5 MG/0.7 ML SYRINGE MO	3	PA,QL(2.8 per 28 days)
REDITREX (PF) 20 MG/0.8 ML SYRINGE MO	3	PA,QL(3.2 per 28 days)
REDITREX (PF) 22.5 MG/0.9 ML SYRINGE MO	3	PA,QL(3.6 per 28 days)
REDITREX (PF) 25 MG/ML SYRINGE MO	3	PA,QL(4 per 28 days)
REDITREX (PF) 7.5 MG/0.3 ML SYRINGE MO	3	PA,QL(1.2 per 28 days)
REMICADE 100 MG RECON SOLUTION DL	4	PA
RENFLEXIS 100 MG RECON SOLUTION DL	4	PA
REZUROCK 200 MG TABLET DL	4	PA,QL(30 per 30 days)
RHOPHYLAC 1,500 UNIT (300 MCG)/2 ML SYRINGE MO	3	
RIDAURA 3 MG CAPSULE DL	4	PA
RINVOQ 15 MG, 30 MG TABLET, ER 24 HR. DL	4	PA,QL(30 per 30 days)
RINVOQ 45 MG TABLET, ER 24 HR. DL	4	PA,QL(168 per 365 days)
RINVOQ LQ 1 MG/ML SOLUTION DL	4	PA,QL(360 per 30 days)
ROTARIX 10EXP6 CCID50 /1.5 ML SUSPENSION DL	1	
ROTARIX 10EXP6 CCID50/ML SUSPENSION FOR RECONSTITUTION DL	1	
ROTATEQ VACCINE 2 ML SOLUTION DL	1	
RUCONEST 2,100 UNIT RECON SOLUTION DL	4	PA,QL(8 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RYSTIGGO 140 MG/ML SOLUTION DL	4	PA
<i>sajazir</i> 30 mg/3 ml SYRINGE DL	4	PA,QL(18 per 30 days)
SANDIMMUNE 100 MG, 25 MG CAPSULE MO	3	BvsD
SANDIMMUNE 100 MG/ML SOLUTION MO	3	BvsD
SAPHNELO 300 MG/2 ML (150 MG/ML) SOLUTION DL	4	PA,QL(2 per 28 days)
SELARSDI 130 MG/26 ML SOLUTION DL	4	PA,QL(104 per 30 days)
SELARSDI 45 MG/0.5 ML SYRINGE DL	4	PA,QL(1.5 per 84 days)
SELARSDI 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)
SHINGRIX (PF) 50 MCG/0.5 ML SUSPENSION FOR RECONSTITUTION \$0,DL	1	
SILIQ 210 MG/1.5 ML SYRINGE DL	4	PA,QL(6 per 28 days)
SIMLANDI(CF) 20 MG/0.2 ML, 40 MG/0.4 ML, 80 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
SIMLANDI(CF) AUTOINJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)
SIMPONI 100 MG/ML PEN INJECTOR DL	4	PA,QL(3 per 28 days)
SIMPONI 100 MG/ML SYRINGE DL	4	PA,QL(3 per 28 days)
SIMPONI 50 MG/0.5 ML PEN INJECTOR DL	4	PA,QL(0.5 per 30 days)
SIMPONI 50 MG/0.5 ML SYRINGE DL	4	PA,QL(0.5 per 30 days)
SIMPONI ARIA 12.5 MG/ML SOLUTION DL	4	PA,QL(20 per 28 days)
SIMULECT 10 MG, 20 MG RECON SOLUTION DL	4	BvsD
<i>sirolimus</i> 0.5 mg, 1 mg, 2 mg TABLET MO	1	BvsD
<i>sirolimus</i> 1 mg/ml SOLUTION MO	1	BvsD
SKYRIZI 150 MG/ML PEN INJECTOR	4	PA,QL(2 per 84 days)
SKYRIZI 150 MG/ML SYRINGE	4	PA,QL(2 per 84 days)
SKYRIZI 180 MG/1.2 ML (150 MG/ML) WEARABLE INJECTOR DL	4	PA,QL(8.4 per 365 days)
SKYRIZI 360 MG/2.4 ML (150 MG/ML) WEARABLE INJECTOR DL	4	PA,QL(16.8 per 365 days)
SKYRIZI 60 MG/ML SOLUTION DL	4	PA,QL(30 per 365 days)
SOLIRIS 300 MG/30 ML SOLUTION DL	4	PA
SOTYKTU 6 MG TABLET DL	4	PA,QL(30 per 30 days)
SPEVIGO 150 MG/ML SYRINGE DL	4	PA,QL(4 per 28 days)
SPEVIGO 60 MG/ML SOLUTION DL	4	PA,QL(30 per 84 days)
STELARA 130 MG/26 ML SOLUTION DL	4	PA,QL(104 per 30 days)
STELARA 45 MG/0.5 ML SOLUTION DL	4	PA,QL(1.5 per 84 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
STELARA 45 MG/0.5 ML SYRINGE DL	4	PA,QL(1.5 per 84 days)
STELARA 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)
STEQEYMA 45 MG/0.5 ML SYRINGE DL	4	PA,QL(1.5 per 84 days)
STEQEYMA 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)
STEQEYMA I.V. 130 MG/26 ML SOLUTION DL	4	PA,QL(104 per 30 days)
SYLVANT 100 MG, 400 MG RECON SOLUTION DL	4	PA
<i>tacrolimus</i> 0.5 mg, 1 mg, 5 mg CAPSULE MO	1	BvsD
<i>tacrolimus</i> 0.5 mg, 1 mg, 5 mg CAPSULE, ER 24 HR. MO	1	BvsD
TAKHZYRO 150 MG/ML SYRINGE DL	4	PA,QL(2 per 28 days)
TAKHZYRO 300 MG/2 ML (150 MG/ML) SOLUTION DL	4	PA,QL(4 per 28 days)
TAKHZYRO 300 MG/2 ML (150 MG/ML) SYRINGE DL	4	PA,QL(4 per 28 days)
TALTZ AUTOINJECTOR 80 MG/ML AUTO-INJECTOR DL	4	PA,QL(4 per 28 days)
TALTZ AUTOINJECTOR (2 PACK) 80 MG/ML AUTO-INJECTOR DL	4	PA,QL(4 per 28 days)
TALTZ AUTOINJECTOR (3 PACK) 80 MG/ML AUTO-INJECTOR DL	4	PA,QL(4 per 28 days)
TALTZ SYRINGE 20 MG/0.25 ML SYRINGE DL	4	PA,QL(0.25 per 28 days)
TALTZ SYRINGE 40 MG/0.5 ML SYRINGE DL	4	PA,QL(0.5 per 28 days)
TALTZ SYRINGE 80 MG/ML SYRINGE DL	4	PA,QL(4 per 28 days)
TAVNEOS 10 MG CAPSULE DL	4	PA,QL(180 per 30 days)
TDVAX 2-2 LF UNIT/0.5 ML SUSPENSION \$0,DL	1	
TENIVAC (PF) 5 LF UNIT- 2 LF UNIT/0.5ML SUSPENSION \$0,DL	1	
TENIVAC (PF) 5-2 LF UNIT/0.5 ML SYRINGE \$0,DL	1	
TEZSPIRE 210 MG/1.91 ML (110 MG/ML) PEN INJECTOR DL	4	PA,QL(1.91 per 28 days)
TEZSPIRE 210 MG/1.91 ML (110 MG/ML) SYRINGE DL	4	PA,QL(1.91 per 28 days)
THYMOGLOBULIN 25 MG RECON SOLUTION MO	3	PA
TICOVAC 1.2 MCG/0.25 ML, 2.4 MCG/0.5 ML SYRINGE \$0,DL	1	
TREMFYA 100 MG/ML AUTO-INJECTOR	4	PA,QL(3 per 84 days)
TREMFYA 100 MG/ML SYRINGE	4	PA,QL(3 per 84 days)
TREMFYA 200 MG/2 ML SYRINGE DL	4	PA,QL(4 per 28 days)
TREMFYA 200 MG/20 ML (10 MG/ML) SOLUTION DL	4	PA,QL(120 per 365 days)
TREMFYA PEN 100 MG/ML PEN INJECTOR	4	PA,QL(3 per 84 days)
TREMFYA PEN 200 MG/2 ML PEN INJECTOR DL	4	PA,QL(4 per 28 days)
TREMFYA PEN INDUCTION PK-CROHN 200 MG/2 ML PEN INJECTOR DL	4	PA,QL(4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TREXALL 10 MG, 15 MG, 5 MG, 7.5 MG TABLET MO	1	BvsD
TRUMENBA 120 MCG/0.5 ML SYRINGE \$0,DL	1	
TWINRIX (PF) 720 ELISA UNIT- 20 MCG/ML SYRINGE \$0,DL	1	
TYENNE 162 MG/0.9 ML SYRINGE DL	4	PA,QL(3.6 per 28 days)
TYENNE AUTOINJECTOR 162 MG/0.9 ML PEN INJECTOR DL	4	PA,QL(3.6 per 28 days)
TYPHIM VI 25 MCG/0.5 ML SOLUTION \$0,DL	1	
TYPHIM VI 25 MCG/0.5 ML SYRINGE \$0,DL	1	
ULTOMIRIS 100 MG/ML SOLUTION	4	PA
UPLIZNA 10 MG/ML SOLUTION DL	4	PA,QL(120 per 365 days)
USTEKINUMAB 130 MG/26 ML SOLUTION DL	4	PA,QL(104 per 30 days)
USTEKINUMAB 45 MG/0.5 ML SOLUTION DL	4	PA,QL(1.5 per 84 days)
USTEKINUMAB 45 MG/0.5 ML SYRINGE DL	4	PA,QL(1.5 per 84 days)
USTEKINUMAB 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)
USTEKINUMAB-AEKN 45 MG/0.5 ML SYRINGE DL	4	PA,QL(1.5 per 84 days)
USTEKINUMAB-AEKN 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)
USTEKINUMAB-TTWE 130 MG/26 ML SOLUTION DL	4	PA,QL(104 per 30 days)
USTEKINUMAB-TTWE 45 MG/0.5 ML SYRINGE DL	4	PA,QL(1.5 per 84 days)
USTEKINUMAB-TTWE 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)
VAQTA (PF) 25 UNIT/0.5 ML SUSPENSION DL	1	
VAQTA (PF) 25 UNIT/0.5 ML SYRINGE DL	1	
VAQTA (PF) 50 UNIT/ML SUSPENSION \$0,DL	1	
VAQTA (PF) 50 UNIT/ML SYRINGE \$0,DL	1	
VARIVAX (PF) 1,350 UNIT/0.5 ML SUSPENSION FOR RECONSTITUTION \$0,DL	1	
VARIZIG 125 UNIT/1.2 ML SOLUTION DL	4	PA,QL(12 per 30 days)
VAXCHORA VACCINE 4X10EXP8 TO 2X 10EXP9 CF UNIT SUSPENSION FOR RECONSTITUTION \$0,MO	1	
VELSIPITY 2 MG TABLET DL	4	PA,QL(30 per 30 days)
VEOPOZ 200 MG/ML SOLUTION DL	4	PA
VIMKUNYA 40 MCG/0.8 ML SYRINGE \$0,DL	1	
VIVOTIF 2 BILLION UNIT CAPSULE, DR/EC \$0,MO	1	
VOYDEYA 100 MG, 150 MG (50 MG X 1-100 MG X 1) TABLET DL	4	PA,QL(180 per 30 days)
WEZLANA 45 MG/0.5 ML SOLUTION DL	4	PA,QL(1.5 per 84 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
WEZLANA 45 MG/0.5 ML SYRINGE DL	4	PA,QL(1.5 per 84 days)
WEZLANA 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)
WEZLANA I.V. 130 MG/26 ML SOLUTION DL	4	PA,QL(104 per 30 days)
XATMEP 2.5 MG/ML SOLUTION MO	3	PA
XELJANZ 1 MG/ML SOLUTION DL	4	PA,QL(300 per 30 days)
XELJANZ 10 MG, 5 MG TABLET DL	4	PA,QL(60 per 30 days)
XELJANZ XR 11 MG, 22 MG TABLET, ER 24 HR. DL	4	PA,QL(30 per 30 days)
XEMBIFY 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SOLUTION DL	4	PA
XOLAIR 150 MG RECON SOLUTION DL	4	PA,QL(8 per 28 days)
XOLAIR 150 MG/ML, 300 MG/2 ML AUTO-INJECTOR DL,LA	4	PA,QL(8 per 28 days)
XOLAIR 150 MG/ML, 300 MG/2 ML SYRINGE DL,LA	4	PA,QL(8 per 28 days)
XOLAIR 75 MG/0.5 ML AUTO-INJECTOR DL,LA	4	PA,QL(4 per 28 days)
XOLAIR 75 MG/0.5 ML SYRINGE DL,LA	4	PA,QL(4 per 28 days)
YESINTEK 130 MG/26 ML SOLUTION DL	4	PA,QL(104 per 30 days)
YESINTEK 45 MG/0.5 ML SOLUTION MO	3	PA,QL(1.5 per 84 days)
YESINTEK 45 MG/0.5 ML SYRINGE MO	3	PA,QL(1.5 per 84 days)
YESINTEK 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)
YF-VAX (PF) 10 EXP4.74 UNIT/0.5 ML SUSPENSION FOR RECONSTITUTION \$0,DL	1	
YUFLYMA(CF) 20 MG/0.2 ML, 40 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
YUFLYMA(CF) AI CROHN'S-UC-HS 80 MG/0.8 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)
YUFLYMA(CF) AUTOINJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)
YUSIMRY(CF) PEN 40 MG/0.8 ML PEN INJECTOR DL	4	PA,QL(4.8 per 28 days)
ZILBRYSQ 16.6 MG/0.416 ML, 23 MG/0.574 ML, 32.4 MG/0.81 ML SYRINGE DL	4	PA
ZORTRESS 0.25 MG, 0.75 MG, 1 MG TABLET	4	BvsD,QL(60 per 30 days)
ZORTRESS 0.5 MG TABLET	4	BvsD,QL(120 per 30 days)
ZYMFENTRA 120 MG/ML PEN INJECTOR KIT DL	4	PA,QL(2 per 28 days)
ZYMFENTRA 120 MG/ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
INFLAMMATORY BOWEL DISEASE AGENTS		
APRISO 0.375 GRAM CAPSULE, ER 24 HR. MO	3	ST,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AZULFIDINE 500 MG TABLET MO	3	
AZULFIDINE EN-TABS 500 MG TABLET, DR/EC MO	3	
balsalazide 750 mg CAPSULE MO	1	
budesonide 2 mg/actuation FOAM MO	1	PA
budesonide 3 mg CAPSULE, DR/EC MO	1	
budesonide 9 mg TABLET, DR/ER	4	PA,QL(30 per 30 days)
CANASA 1,000 MG SUPPOSITORY	4	ST,QL(30 per 30 days)
COLAZAL 750 MG CAPSULE	4	PA
CORTENEMA 100 MG/60 ML ENEMA MO	3	
CORTIFOAM 10 % (80 MG) FOAM MO	3	
DELZICOL 400 MG CAPSULE (WITH DR TABLETS) MO	3	ST,QL(180 per 30 days)
DIPENTUM 250 MG CAPSULE	4	ST,QL(120 per 30 days)
hydrocortisone 100 mg/60 ml ENEMA MO	1	
LIALDA 1.2 GRAM TABLET, DR/EC MO	3	ST,QL(120 per 30 days)
mesalamine 0.375 gram CAPSULE, ER 24 HR. MO	1	QL(120 per 30 days)
mesalamine 1,000 mg SUPPOSITORY MO	1	QL(30 per 30 days)
mesalamine 1.2 gram TABLET, DR/EC MO	1	ST,QL(120 per 30 days)
mesalamine 4 gram/60 ml ENEMA MO	1	QL(1800 per 30 days)
mesalamine 400 mg CAPSULE (WITH DR TABLETS) MO	1	ST,QL(180 per 30 days)
mesalamine 500 mg CAPSULE, ER MO	1	ST,QL(300 per 30 days)
mesalamine 800 mg TABLET, DR/EC MO	1	ST,QL(180 per 30 days)
ORTIKOS 6 MG, 9 MG CAPSULE, ER DL	4	PA,QL(30 per 30 days)
PENTASA 250 MG CAPSULE, ER MO	3	ST,QL(150 per 30 days)
PENTASA 500 MG CAPSULE, ER	4	ST,QL(300 per 30 days)
PROCTOFOAM HC 1-1 % FOAM MO	1	
ROWASA 4 GRAM/60 ML ENEMA MO	3	QL(1800 per 30 days)
SFROWASA 4 GRAM/60 ML ENEMA MO	3	QL(1800 per 30 days)
sulfasalazine 500 mg TABLET MO	1	
sulfasalazine 500 mg TABLET, DR/EC MO	1	
TARPEYO 4 MG CAPSULE, DR/EC DL	4	PA,QL(120 per 30 days)
UCERIS 2 MG/ACTUATION FOAM MO	3	PA
UCERIS 9 MG TABLET, DR/ER MO	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
METABOLIC BONE DISEASE AGENTS		
ACTONEL 150 MG TABLET MO	3	PA,QL(1 per 30 days)
ACTONEL 35 MG TABLET MO	3	PA,QL(4 per 28 days)
<i>alendronate 10 mg, 5 mg TABLET MO</i>	1	QL(30 per 30 days)
<i>alendronate 35 mg TABLET MO</i>	1	QL(4 per 28 days)
<i>alendronate 70 mg TABLET MO</i>	1	QL(4 per 28 days)
<i>alendronate 70 mg/75 ml SOLUTION MO</i>	1	QL(300 per 28 days)
ATELVIA 35 MG TABLET, DR/EC MO	3	PA,QL(4 per 28 days)
BINOSTO 70 MG TABLET, EFFERVESCENT MO	3	ST,QL(4 per 28 days)
BONIVA 150 MG TABLET MO	3	PA,QL(1 per 28 days)
<i>calcitonin (salmon) 200 unit/actuation SPRAY, NON-AEROSOL MO</i>	1	QL(3.7 per 28 days)
<i>calcitonin (salmon) 200 unit/ml SOLUTION DL</i>	4	
<i>calcitriol 0.25 mcg, 0.5 mcg CAPSULE MO</i>	1	
<i>calcitriol 1 mcg/ml SOLUTION MO</i>	1	
<i>cinacalcet 30 mg, 60 mg TABLET MO</i>	1	QL(60 per 30 days)
<i>cinacalcet 90 mg TABLET MO</i>	1	QL(120 per 30 days)
<i>doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg CAPSULE MO</i>	1	
<i>doxercalciferol 4 mcg/2 ml SOLUTION MO</i>	1	
EVENITY 105 MG/1.17 ML, 210MG/2.34ML (105MG/1.17MLX2) SYRINGE DL	4	PA,QL(2.34 per 30 days)
FORTEO 20 MCG/DOSE (560MCG/2.24ML) PEN INJECTOR DL	4	PA,QL(2.4 per 28 days)
FOSAMAX 70 MG TABLET MO	3	PA,QL(4 per 28 days)
FOSAMAX PLUS D 70 MG- 2,800 UNIT, 70 MG- 5,600 UNIT TABLET MO	3	ST,QL(4 per 28 days)
HECTOROL 4 MCG/2 ML SOLUTION MO	3	
<i>ibandronate 150 mg TABLET MO</i>	1	QL(1 per 28 days)
<i>ibandronate 3 mg/3 ml SOLUTION MO</i>	1	PA,QL(3 per 90 days)
<i>ibandronate 3 mg/3 ml SYRINGE MO</i>	1	PA,QL(3 per 90 days)
MIACALCIN 200 UNIT/ML SOLUTION DL	4	
<i>pamidronate 30 mg/10 ml (3 mg/ml) SOLUTION MO</i>	1	QL(30 per 21 days)
<i>pamidronate 60 mg/10 ml (6 mg/ml), 90 mg/10 ml (9 mg/ml) SOLUTION MO</i>	1	QL(10 per 21 days)
<i>paricalcitol 1 mcg, 2 mcg, 4 mcg CAPSULE MO</i>	1	
<i>paricalcitol 2 mcg/ml SOLUTION MO</i>	1	QL(24 per 30 days)
<i>paricalcitol 5 mcg/ml SOLUTION MO</i>	1	QL(48 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROLIA 60 MG/ML SYRINGE MO	3	QL(1 per 180 days)
RAYALDEE 30 MCG CAPSULE, ER 24 HR. DL	4	QL(60 per 30 days)
RECLAST 5 MG/100 ML PIGGYBACK MO	3	PA,QL(100 per 365 days)
<i>risedronate 150 mg TABLET MO</i>	1	QL(1 per 30 days)
<i>risedronate 30 mg, 5 mg TABLET MO</i>	1	QL(30 per 30 days)
<i>risedronate 35 mg TABLET MO</i>	1	QL(4 per 28 days)
<i>risedronate 35 mg TABLET, DR/EC MO</i>	1	QL(4 per 28 days)
ROCALTROL 0.25 MCG, 0.5 MCG CAPSULE MO	3	
ROCALTROL 1 MCG/ML SOLUTION MO	3	
SENSIPAR 30 MG TABLET MO	3	QL(60 per 30 days)
SENSIPAR 60 MG TABLET	4	QL(60 per 30 days)
SENSIPAR 90 MG TABLET	4	QL(120 per 30 days)
TYMLOS 80 MCG (3,120 MCG/1.56 ML) PEN INJECTOR DL	4	PA,QL(1.56 per 30 days)
XGEVA 120 MG/1.7 ML (70 MG/ML) SOLUTION DL	4	PA,QL(1.7 per 28 days)
YORVIPATH 168 MCG/0.56 ML PEN INJECTOR DL	4	PA,QL(1.12 per 28 days)
YORVIPATH 294 MCG/0.98 ML PEN INJECTOR DL	4	PA,QL(1.96 per 28 days)
YORVIPATH 420 MCG/1.4 ML PEN INJECTOR DL	4	PA,QL(2.8 per 28 days)
ZEMPLAR 1 MCG, 2 MCG CAPSULE MO	3	
ZEMPLAR 2 MCG/ML SOLUTION DL	4	QL(24 per 30 days)
ZEMPLAR 5 MCG/ML SOLUTION DL	4	QL(48 per 28 days)
<i>zoledronic ac-mannitol-0.9nacl 4 mg/100 ml PIGGYBACK MO</i>	1	QL(300 per 21 days)
<i>zoledronic acid 4 mg RECON SOLUTION MO</i>	1	
<i>zoledronic acid 4 mg/5 ml SOLUTION MO</i>	1	QL(15 per 21 days)
<i>zoledronic acid-mannitol-water 4 mg/100 ml PIGGYBACK MO</i>	1	QL(300 per 21 days)
<i>zoledronic acid-mannitol-water 5 mg/100 ml PIGGYBACK MO</i>	1	PA,QL(100 per 365 days)
MISCELLANEOUS THERAPEUTIC AGENTS		
ACETADOTE 200 MG/ML (20 %) SOLUTION MO	3	
acetaminophen 1,000 mg/100 ml (10 mg/ml), 500 mg/50 ml (10 mg/ml) SOLUTION MO	1	
acetic acid 0.25 % SOLUTION MO	1	
acetylcysteine 200 mg/ml (20 %) SOLUTION MO	1	
ADAKVEO 10 MG/ML SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ADSTILADRIN 3X10EXP11 VP/ML SUSPENSION	4	PA
ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
ALCOHOL SWABS PADS, MEDICATED \$0,MO	1	
ALCOHOL WIPES PADS, MEDICATED \$0,MO	1	
AMMONUL 10-10 % SOLUTION DL	4	
AQNEURSA 1 GRAM GRANULES IN PACKET DL	4	PA,QL(112 per 28 days)
AUTOJECT 2 INJECTION DEVICE INSULIN PEN \$0,MO	1	
AUTOPEN 1 TO 21 UNITS INSULIN PEN \$0,MO	1	
AUTOPEN 2 TO 42 UNITS INSULIN PEN \$0,MO	1	
AUTOSHIELD DUO PEN NEEDLE 30 GAUGE X 3/16" NEEDLE \$0,PDS,MO	1	
BAND-AID GAUZE PADS 2 X 2 " BANDAGE \$0,MO	1	
BD ALCOHOL SWABS PADS, MEDICATED \$0,MO	1	
BD AUTOSHIELD DUO PEN NEEDLE 30 GAUGE X 3/16" NEEDLE \$0,PDS,MO	1	
BD ECLIPSE LUER-LOK 1 ML 30 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.5 ML 29 GAUGE X 1/2", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE (HALF UNIT) 0.3 ML 31 GAUGE X 5/16" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE MICRO-FINE 1 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE U-500 1/2 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16 SYRINGE \$0,PDS,MO	1	
BD LO-DOSE MICRO-FINE IV 1/2 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD NANO 2ND GEN PEN NEEDLE 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
BD SAFETYGLIDE INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 1 ML 29 GAUGE X 1/2", 1 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BD SAFETYGLIDE SYRINGE 1 ML 27 GAUGE X 5/8" SYRINGE \$0,PDS,MO	1	
BD ULTRA-FINE MICRO PEN NEEDLE 32 GAUGE X 1/4" NEEDLE \$0,PDS,MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BD ULTRA-FINE MINI PEN NEEDLE 31 GAUGE X 3/16" NEEDLE \$0,PDS,MO	1	
BD ULTRA-FINE NANO PEN NEEDLE 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
BD ULTRA-FINE ORIG PEN NEEDLE 29 GAUGE X 1/2" NEEDLE \$0,PDS,MO	1	
BD ULTRA-FINE SHORT PEN NEEDLE 31 GAUGE X 5/16" NEEDLE \$0,PDS,MO	1	
BD VEO INSULIN SYR (HALF UNIT) 0.3 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BD VEO INSULIN SYRINGE UF 0.3 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 15/64", 1/2 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BEYFORTUS 100 MG/ML, 50 MG/0.5 ML SYRINGE DL	4	
BORDERED GAUZE 2 X 2 " BANDAGE \$0,MO	1	
bupap 50-300 mg TABLET MO	1	QL(180 per 30 days)
butalbital-acetaminop-caf-cod 50-300-40-30 mg CAPSULE DL	1	QL(180 per 30 days)
butalbital-acetaminop-caf-cod 50-325-40-30 mg CAPSULE DL	1	QL(360 per 30 days)
butalbital-acetaminophen 50-300 mg CAPSULE MO	1	QL(180 per 30 days)
butalbital-acetaminophen 50-300 mg, 50-325 mg TABLET MO	1	QL(180 per 30 days)
butalbital-acetaminophen-caff 50-300-40 mg, 50-325-40 mg CAPSULE MO	1	QL(180 per 30 days)
butalbital-acetaminophen-caff 50-325-40 mg TABLET MO	1	QL(180 per 30 days)
butalbital-aspirin-caffeine 50-325-40 mg CAPSULE MO	1	QL(180 per 30 days)
butalbital-aspirin-caffeine 50-325-40 mg TABLET MO	1	QL(180 per 30 days)
BYLVAY 1,200 MCG CAPSULE DL	4	PA,QL(150 per 30 days)
BYLVAY 200 MCG PELLETT DL	4	PA,QL(360 per 30 days)
BYLVAY 400 MCG CAPSULE DL	4	PA,QL(420 per 30 days)
BYLVAY 600 MCG PELLETT DL	4	PA,QL(120 per 30 days)
CAFCIT 60 MG/3 ML (20 MG/ML) SOLUTION MO	3	
caffeine citrate 60 mg/3 ml (20 mg/ml) SOLUTION MO	1	
CARETOUCH ALCOHOL PREP PAD PADS, MEDICATED \$0,MO	1	
CEQUR SIMPLICITY 2 UNIT DEVICE \$0,MO	2	
CEQUR SIMPLICITY INSERTER MISCELLANEOUS MO	2	
CERVIDIL 10 MG INSERT, ER MO	3	
CLARINEX-D 12 HOUR 2.5-120 MG TABLET, ER 12 HR., MULTIPHASE MO	3	ST,QL(60 per 30 days)
COBENFY 100-20 MG, 125-30 MG, 50-20 MG CAPSULE DL	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
COBENFY STARTER PACK 50 MG-20 MG /100 MG-20 MG CAPSULE, DOSE PACK DL	4	PA,QL(56 per 28 days)
COMBOGESIC IV 300-1,000 MG/100 ML SOLUTION MO	3	
CURITY ALCOHOL SWABS PADS, MEDICATED \$0,MO	1	
CURITY GAUZE 2 X 2 " BANDAGE \$0,MO	1	
DEFITELIO 80 MG/ML SOLUTION DL	4	PA
DERMACEA 2 X 2 " BANDAGE \$0,MO	1	
DROPLET INSULIN SYR(HALF UNIT) 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 1/4", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 0.5 ML 31 GAUGE X 5/16", 0.5ML 30 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
DROPLET INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 15/64", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 15/64", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16 SYRINGE \$0,PDS,MO	1	
DROPLET INSULIN SYRINGE 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 31 GAUGE X 1/4", 1/2 ML 31 GAUGE X 1/4" SYRINGE \$0,PDS,MO	1	
DROPLET MICRON PEN NEEDLE 34 GAUGE X 9/64" NEEDLE \$0,PDS,MO	1	
DROPLET PEN NEEDLE 29 GAUGE X 1/2", 29 GAUGE X 3/8", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
DROPSAFE ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
DROPSAFE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16" NEEDLE \$0,PDS,MO	1	
DROXIA 200 MG, 300 MG, 400 MG CAPSULE MO	3	
EASY COMFORT ALCOHOL PAD PADS, MEDICATED \$0,MO	1	
EASY TOUCH ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
edetate calcium disodium 200 mg/ml SOLUTION DL	4	
ELYXYB 120 MG/4.8 ML (25 MG/ML) SOLUTION DL	4	ST,QL(43.2 per 30 days)
EMPAVELI 1,080 MG/20 ML SOLUTION DL	4	PA,QL(160 per 28 days)
ENFLONIA 105 MG/0.7 ML SYRINGE MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EOHILIA 2 MG/10 ML SUSPENSION IN PACKET DL	4	PA
ESGIC 50-325-40 MG CAPSULE MO	1	QL(180 per 30 days)
ESGIC 50-325-40 MG TABLET MO	1	QL(180 per 30 days)
FILSPARI 200 MG, 400 MG TABLET DL	4	PA,QL(30 per 30 days)
FILSUVEZ 10 % GEL DL	4	PA
<i>fioricet</i> 50-300-40 mg CAPSULE MO	1	QL(180 per 30 days)
FIORICET WITH CODEINE 50-300-40-30 MG CAPSULE DL	3	QL(180 per 30 days)
<i>flumazenil</i> 0.1 mg/ml SOLUTION MO	1	
<i>fomepizole</i> 1 gram/ml SOLUTION MO	1	
GAUZE BANDAGE 2 X 2 " BANDAGE \$0,MO	1	
GAUZE PAD 2 X 2 " BANDAGE \$0,MO	1	
GIVLAARI 189 MG/ML SOLUTION DL	4	PA
IGALMI 120 MCG, 180 MCG FILM MO	3	PA
INCONTROL ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
INSULIN SYRINGE 0.5 ML 29 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
INSULIN SYRINGE MICROFINE 1 ML 27 GAUGE X 5/8", 1/2 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
INSULIN SYRINGE-NEEDLE U-100 1 ML 27 GAUGE X 5/8", 1 ML 28 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
INSULIN U-500 SYRINGE-NEEDLE 1/2 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
IV PREP WIPES PADS, MEDICATED \$0,MO	1	
JOURNAVX 50 MG TABLET MO	3	PA,QL(30 per 180 days)
KORLYM 300 MG TABLET DL	4	PA,QL(120 per 30 days)
<i>lactated ringers</i> SOLUTION MO	1	
LITHOSTAT 250 MG TABLET MO	3	
<i>methylergonovine</i> 0.2 mg TABLET DL	4	
<i>methylergonovine</i> 0.2 mg/ml (1 ml) SOLUTION MO	1	
<i>mifepristone</i> 300 mg TABLET DL	4	PA,QL(120 per 30 days)
MIRENA 21 MCG/24HR (UP TO 8 YRS) 52 MG IUD MO	2	
NANO 2ND GEN PEN NEEDLE 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
NANO PEN NEEDLE 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
neomycin-polymyxin b gu 40 mg-200,000 unit/ml SOLUTION MO	1	
nitroglycerin 0.4 % (w/w) OINTMENT MO	1	QL(30 per 30 days)
NOVOPEN ECHO INSULIN PEN \$0,MO	1	
OMNIPOD 5 (G6/LIBRE 2 PLUS) CARTRIDGE \$0,MO	2	
OMNIPOD 5 G6-G7 INTRO KT(GEN5) CARTRIDGE \$0,MO	2	
OMNIPOD 5 G6-G7 PODS (GEN 5) CARTRIDGE \$0,MO	2	
OMNIPOD 5 INTRO(G6/LIBRE2PLUS) CARTRIDGE \$0,MO	2	
OMNIPOD CLASSIC PODS (GEN 3) CARTRIDGE \$0,MO	2	
OMNIPOD DASH INTRO KIT (GEN 4) CARTRIDGE \$0,MO	2	
OMNIPOD DASH PODS (GEN 4) CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 10 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 15 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 20 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 25 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 30 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 40 UNITS/DAY CARTRIDGE \$0,MO	2	
OXLUMO 94.5 MG/0.5 ML SOLUTION	4	PA
oxytocin 10 unit/ml SOLUTION MO	1	
PALFORZIA (LEVEL 1) 3 MG (1 MG X 3) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 2) 6 MG (1 MG X 6) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 3) 12 MG (1 MG X 2, 10 MG X 1) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 4) 20 MG CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 5) 40 MG (20 MG X 2) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 6) 80 MG (20 MG X 4) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 7) 120 MG (20 MG X 1, 100 MG X 1) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 8) 160 MG (20 MG X 3, 100 MG X1) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 9) 200 MG (100 MG X 2) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 10) 240 MG (20 MG X 2, 100 MG X 2) CAPSULE, SPRINKLE MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PALFORZIA (LEVEL 11 UP-DOSE) 300 MG POWDER IN PACKET MO	3	PA
PALFORZIA INITIAL (4-17 YRS) 0.5/1/1.5/3/6 MG CAPSULE, SPRINKLE MO	3	PA
PALFORZIA LEVEL 11 MAINTENANCE 300 MG POWDER IN PACKET MO	3	PA
PEN NEEDLE, DIABETIC 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
<i>phenazopyridine 100 mg, 200 mg TABLET</i> MO	1	
PHEXXI 1.8-1-0.4 % GEL MO	3	QL(60 per 30 days)
PHYSIOLYTE 140-5-3-98 MEQ/L SOLUTION MO	1	
PHYSIOSOL IRRIGATION 140-5-3-98 MEQ/L SOLUTION MO	1	
PITOCIN 10 UNIT/ML SOLUTION MO	3	
PREVDUO 0.6 MG-3 MG/3ML (0.2 MG-1MG/ML) SYRINGE MO	3	
PRIALT 100 MCG/ML, 25 MCG/ML SOLUTION DL	4	PA
PRO COMFORT ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
<i>promethazine vc 6.25-5 mg/5 ml SYRUP</i> MO	1	
<i>promethazine-phenylephrine 6.25-5 mg/5 ml SYRUP</i> MO	1	
<i>protamine 10 mg/ml SOLUTION</i> MO	1	
PURE COMFORT ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
PYRIDIUM 100 MG, 200 MG TABLET MO	3	
QUTENZA 8 % KIT DL	4	PA
RECTIV 0.4 % (W/W) OINTMENT MO	3	QL(30 per 30 days)
RENACIDIN 1980.6 MG-59.4 MG-980.4MG/30ML SOLUTION MO	3	
REZDIFFRA 100 MG, 60 MG, 80 MG TABLET DL	4	PA,QL(30 per 30 days)
<i>ribavirin 6 gram RECON SOLUTION</i> DL	4	BvsD
RIMSO-50 50 % SOLUTION DL	4	
<i>ringer's SOLUTION</i> MO	1	
RIVFLOZA 128 MG/0.8 ML, 160 MG/ML SYRINGE DL	4	PA
RIVFLOZA 80 MG/0.5 ML (160 MG/ML) SOLUTION DL	4	PA
SIKLOS 1,000 MG, 100 MG TABLET MO	3	PA
<i>sodium benzoate-sod phenylacet 10-10 % SOLUTION</i> DL	4	
<i>sodium chloride 0.9 % SOLUTION</i> MO	1	
SOHONOS 1 MG, 1.5 MG, 10 MG, 2.5 MG, 5 MG CAPSULE DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SURE COMFORT ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
SURE-PREP ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
SYNAGIS 100 MG/ML, 50 MG/0.5 ML SOLUTION DL	4	PA
tencon 50-325 mg TABLET MO	1	QL(180 per 30 days)
TEPEZZA 500 MG RECON SOLUTION DL	4	PA
TRUE COMFORT ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
TRUE COMFORT PRO ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
ULTILET ALCOHOL SWAB PADS, MEDICATED \$0,MO	1	
ULTRA-FINE INS SYR (HALF UNIT) 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16" SYRINGE \$0,PDS,MO	1	
ULTRA-FINE INSULIN SYRINGE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16, 1/2 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
ULTRA-FINE PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4" NEEDLE \$0,PDS,MO	1	
V-GO 20 DEVICE \$0,MO	3	PA
V-GO 30 DEVICE \$0,MO	3	PA
V-GO 40 DEVICE \$0,MO	3	PA
VANRAFIA 0.75 MG TABLET DL	4	PA,QL(30 per 30 days)
VIRAZOLE 6 GRAM RECON SOLUTION DL	4	BvsD
VYJUVEK 5 X 10EXP9 PFU/2.5 ML GEL DL	4	PA,QL(10 per 28 days)
VYKAT XR 150 MG, 25 MG, 75 MG TABLET, ER 24 HR. DL	4	PA
water for irrigation, sterile SOLUTION MO	1	
WEBCOL PADS, MEDICATED \$0,MO	1	
WEGOVY 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML, 1.7 MG/0.75 ML, 2.4 MG/0.75 ML PEN INJECTOR DL	4	PA
XDEMVI 0.25 % DROPS MO	3	PA,QL(10 per 42 days)
XROMI 100 MG/ML SOLUTION DL	4	PA
YCANTH 0.7 % SOLUTION W/APPLICATOR DL	4	PA
ZEBUTAL 50-325-40 MG CAPSULE MO	1	QL(180 per 30 days)
ZEPBOUND 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML PEN INJECTOR MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZEPBOUND 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML SOLUTION MO	3	PA
ZEVALIN (Y-90) 3.2 MG/2 ML KIT DL	4	PA
zingiber 1.2 mg-40 mg- 124.1 mg-100 mg TABLET MO	1	
ZYNRELEF 200 MG-6 MG /7 ML, 400 MG-12 MG /14 ML ER SOLUTION MO	3	
OPHTHALMIC AGENTS		
ACULAR 0.5 % DROPS MO	3	ST,QL(10 per 30 days)
ACULAR LS 0.4 % DROPS MO	3	ST,QL(10 per 30 days)
ACUVAIL (PF) 0.45 % DROPPERETTE MO	3	ST
ALCAINE 0.5 % DROPS MO	1	
ALOMIDE 0.1 % DROPS MO	3	
ALPHAGAN P 0.1 %, 0.15 % DROPS MO	3	ST
ALREX 0.2 % DROPS, SUSPENSION MO	3	ST
apraclonidine 0.5 % DROPS MO	1	
atropine 1 % DROPS MO	1	
ATROPINE SULFATE (PF) 1 % DROPPERETTE MO	1	
AZASITE 1 % DROPS MO	3	ST,QL(2.5 per 25 days)
azelastine 0.05 % DROPS MO	1	
AZOPT 1 % DROPS, SUSPENSION MO	3	ST,QL(10 per 28 days)
bacitracin 500 unit/gram OINTMENT MO	1	
bacitracin-polymyxin b 500-10,000 unit/gram OINTMENT MO	1	
balanced salt SOLUTION MO	1	
bepotastine besilate 1.5 % DROPS MO	1	ST,QL(5 per 25 days)
BEPREVE 1.5 % DROPS MO	3	ST,QL(5 per 25 days)
BESIVANCE 0.6 % DROPS, SUSPENSION MO	3	ST
BETADINE OPHTHALMIC PREP 5 % SOLUTION MO	3	
betaxolol 0.5 % DROPS MO	1	
BETIMOL 0.25 %, 0.5 % DROPS MO	3	ST
BETOPTIC S 0.25 % DROPS, SUSPENSION MO	3	ST
bimatoprost 0.03 % DROPS MO	1	QL(2.5 per 25 days)
brimonidine 0.1 %, 0.15 % DROPS MO	1	ST
brimonidine 0.2 % DROPS MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
brinzolamide 1 % DROPS, SUSPENSION MO	1	ST,QL(10 per 28 days)
bromfenac 0.07 % DROPS MO	1	ST,QL(3 per 30 days)
bromfenac 0.075 % DROPS MO	1	ST,QL(5 per 30 days)
bromfenac 0.09 % DROPS MO	1	QL(1.7 per 30 days)
BROMSITE 0.075 % DROPS MO	3	ST,QL(5 per 30 days)
BSS SOLUTION MO	3	
BSS PLUS SOLUTION MO	3	
carteolol 1 % DROPS MO	1	
CEQUA 0.09 % DROPPERETTE MO	3	PA,QL(60 per 30 days)
CILOXAN 0.3 % OINTMENT MO	3	
ciprofloxacin hcl 0.3 % DROPS MO	1	
COMBIGAN 0.2-0.5 % DROPS MO	2	QL(5 per 25 days)
COSOPT 22.3-6.8 MG/ML DROPS MO	3	ST
COSOPT (PF) 2-0.5 % DROPPERETTE MO	3	ST,QL(60 per 30 days)
cromolyn 4 % DROPS MO	1	
cyclosporine 0.05 % DROPPERETTE MO	1	QL(60 per 30 days)
CYSTADROPS 0.37 % DROPS DL	4	PA,QL(20 per 28 days)
CYSTARAN 0.44 % DROPS DL	4	PA,QL(60 per 28 days)
dexamethasone sodium phosphate 0.1 % DROPS MO	1	
DEXTENZA 0.4 MG INSERT MO	3	QL(1 per 30 days)
diclofenac sodium 0.1 % DROPS MO	1	
difluprednate 0.05 % DROPS MO	1	ST
dorzolamide 2 % DROPS MO	1	
dorzolamide-timolol 22.3-6.8 mg/ml DROPS MO	1	
dorzolamide-timolol (pf) 2-0.5 % DROPPERETTE MO	1	QL(60 per 30 days)
DUREZOL 0.05 % DROPS MO	3	ST
DURYSTA 10 MCG IMPLANT DL	4	PA
ENSPRYNG 120 MG/ML SYRINGE DL	4	PA,QL(2 per 28 days)
epinastine 0.05 % DROPS MO	1	ST,QL(5 per 25 days)
erythromycin 5 mg/gram (0.5 %) OINTMENT MO	1	QL(3.5 per 28 days)
EYSUVIS 0.25 % DROPS, SUSPENSION MO	2	QL(16.6 per 30 days)
FLAREX 0.1 % DROPS, SUSPENSION MO	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
fluorometholone 0.1 % DROPS, SUSPENSION MO	1	
flurbiprofen sodium 0.03 % DROPS MO	1	
FML FORTE 0.25 % DROPS, SUSPENSION MO	3	ST
FML LIQUIFILM 0.1 % DROPS, SUSPENSION MO	3	ST
gatifloxacin 0.5 % DROPS MO	1	QL(2.5 per 25 days)
gentamicin 0.3 % DROPS MO	1	
ILEVRO 0.3 % DROPS, SUSPENSION MO	2	QL(3 per 30 days)
INVELTYS 1 % DROPS, SUSPENSION MO	3	ST
IOPIDINE 1 % DROPPERETTE MO	3	
ISTALOL 0.5 % DROPS, ONCE DAILY MO	3	
IYUZEH (PF) 0.005 % DROPPERETTE MO	3	ST,QL(30 per 30 days)
ketorolac 0.4 %, 0.5 % DROPS MO	1	QL(10 per 30 days)
LACRISERT 5 MG INSERT MO	3	
latanoprost 0.005 % DROPS MO	1	QL(5 per 25 days)
levobunolol 0.5 % DROPS MO	1	
levofloxacin 0.5 %, 1.5 % DROPS MO	1	
LOTEMAX 0.5 % DROPS, GEL MO	3	ST
LOTEMAX 0.5 % DROPS, SUSPENSION MO	3	ST
LOTEMAX 0.5 % OINTMENT MO	3	ST
LOTEMAX SM 0.38 % DROPS, GEL MO	3	
loteprednol etabonate 0.2 %, 0.5 % DROPS, SUSPENSION MO	1	ST
loteprednol etabonate 0.5 % DROPS, GEL MO	1	ST
LUMIGAN 0.01 % DROPS MO	2	QL(2.5 per 25 days)
MAXIDEX 0.1 % DROPS, SUSPENSION MO	3	ST
MAXITROL 3.5 MG/G-10,000 UNIT/G-0.1 % OINTMENT MO	3	
MAXITROL 3.5MG/ML-10,000 UNIT/ML-0.1 % DROPS, SUSPENSION MO	1	
methazolamide 25 mg, 50 mg TABLET MO	1	
MIEBO (PF) 100 % DROPS MO	3	PA,QL(3 per 30 days)
MIOSTAT 0.01 % SOLUTION MO	3	
moxifloxacin 0.5 % DROPS MO	1	
moxifloxacin 0.5 % DROPS, VISCOUS MO	1	ST
NATACYN 5 % DROPS, SUSPENSION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
neo-polycin 3.5-400-10,000 mg-unit-unit/g OINTMENT MO	1	
neo-polycin hc 3.5-400-10,000 mg-unit/g-1% OINTMENT MO	1	
neomycin-bacitracin-poly-hc 3.5-400-10,000 mg-unit/g-1% OINTMENT MO	1	
neomycin-bacitracin-polymyxin 3.5-400-10,000 mg-unit-unit/g OINTMENT MO	1	
neomycin-polymyxin b-dexameth 3.5 mg/g-10,000 unit/g-0.1 % OINTMENT MO	1	
neomycin-polymyxin b-dexameth 3.5mg/ml-10,000 unit/ml-0.1 % DROPS, SUSPENSION MO	1	
neomycin-polymyxin-gramicidin 1.75 mg-10,000 unit-0.025mg/ml DROPS MO	1	
neomycin-polymyxin-hc 3.5-10,000-10 mg-unit-mg/ml DROPS, SUSPENSION MO	1	
NEVANAC 0.1 % DROPS, SUSPENSION MO	3	ST
OCUFLOX 0.3 % DROPS MO	3	
ofloxacin 0.3 % DROPS MO	1	
olopatadine 0.1 %, 0.2 % DROPS MO	1	
OXERVATE 0.002 % DROPS DL	4	PA,QL(112 per 365 days)
PHOSPHOLINE IODIDE 0.125 % DROPS MO	3	
pilocarpine hcl 1 %, 1.25 %, 2 %, 4 % DROPS MO	1	
polycin 500-10,000 unit/gram OINTMENT MO	1	
polymyxin b sulf-trimethoprim 10,000 unit- 1 mg/ml DROPS MO	1	
PRED FORTE 1 % DROPS, SUSPENSION MO	3	ST
PRED MILD 0.12 % DROPS, SUSPENSION MO	3	ST
prednisolone acetate 1 % DROPS, SUSPENSION MO	1	
prednisolone sodium phosphate 1 % DROPS MO	1	
PROLENSA 0.07 % DROPS MO	3	ST,QL(3 per 30 days)
proparacaine 0.5 % DROPS MO	1	
RESTASIS 0.05 % DROPPERETTE MO	3	PA,QL(60 per 30 days)
RESTASIS MULTIDOSE 0.05 % DROPS MO	3	PA,QL(5.5 per 25 days)
RHOPRESSA 0.02 % DROPS MO	2	ST,QL(2.5 per 25 days)
ROCKLATAN 0.02-0.005 % DROPS MO	2	ST,QL(2.5 per 25 days)
SIMBRINZA 1-0.2 % DROPS, SUSPENSION MO	3	QL(16 per 30 days)
sulfacetamide sodium 10 % DROPS MO	1	
sulfacetamide-prednisolone 10 %-0.23 % (0.25 %) DROPS MO	1	
tafluprost (pf) 0.0015 % DROPPERETTE MO	3	ST,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
timolol 0.5 % DROPS MO	1	ST
timolol maleate 0.25 % DROPS MO	1	
timolol maleate 0.25 %, 0.5 % GEL FORMING SOLUTION MO	1	
timolol maleate 0.5 % DROPS MO	1	
timolol maleate 0.5 % DROPS, ONCE DAILY MO	1	
timolol maleate (pf) 0.25 %, 0.5 % DROPPERETTE MO	1	
TIMOPTIC OCUDOSE (PF) 0.25 %, 0.5 % DROPPERETTE MO	3	ST
TOBRADEX 0.3-0.1 % DROPS, SUSPENSION MO	3	
TOBRADEX 0.3-0.1 % OINTMENT MO	3	
TOBRADEX ST 0.3-0.05 % DROPS, SUSPENSION MO	3	
tobramycin 0.3 % DROPS MO	1	
tobramycin-dexamethasone 0.3-0.1 % DROPS, SUSPENSION MO	1	
TOBREX 0.3 % OINTMENT MO	3	
TRAVATAN Z 0.004 % DROPS MO	3	ST,QL(2.5 per 25 days)
travoprost 0.004 % DROPS MO	1	QL(2.5 per 25 days)
trifluridine 1 % DROPS MO	1	
TRYPTYR 0.003 % DROPPERETTE MO	3	PA,QL(60 per 30 days)
TYRVAYA 0.03 MG/SPRAY SPRAY, METERED, NON-AEROSOL MO	3	PA,QL(8.4 per 30 days)
VERKAZIA 0.1 % DROPPERETTE DL	4	PA,QL(120 per 30 days)
VEVYE 0.1 % DROPS MO	3	PA,QL(2 per 30 days)
VIGAMOX 0.5 % DROPS MO	3	PA
VUITY 1.25 % DROPS MO	3	
VYZULTA 0.024 % DROPS MO	3	QL(2.5 per 25 days)
XALATAN 0.005 % DROPS MO	3	PA,QL(5 per 25 days)
XELPROS 0.005 % DROPS, EMULSION MO	3	ST,QL(2.5 per 25 days)
XIIDRA 5 % DROPPERETTE MO	3	PA,QL(60 per 30 days)
ZERVIAE 0.24 % DROPPERETTE MO	3	QL(60 per 30 days)
ZIOPTAN (PF) 0.0015 % DROPPERETTE MO	3	ST,QL(30 per 30 days)
ZYLET 0.3-0.5 % DROPS, SUSPENSION MO	3	
OTIC AGENTS		
CIPRO HC 0.2-1 % DROPS, SUSPENSION MO	3	
CIPRODEX 0.3-0.1 % DROPS, SUSPENSION MO	3	QL(7.5 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ciprofloxacin hcl 0.2 % DROPPERETTE</i> MO	1	
<i>ciprofloxacin-dexamethasone 0.3-0.1 % DROPS, SUSPENSION</i> MO	3	QL(7.5 per 30 days)
CORTISPORIN-TC 3.3-3-10-0.5 MG/ML DROPS, SUSPENSION MO	3	
DERMOTIC OIL 0.01 % DROPS MO	3	
<i>flac otic oil 0.01 % DROPS</i> MO	1	
<i>fluocinolone acetonide oil 0.01 % DROPS</i> MO	1	
<i>hydrocortisone-acetic acid 1-2 % DROPS</i> MO	1	
<i>neomycin-polymyxin-hc 3.5-10,000-1 mg/ml-unit/ml-% DROPS, SUSPENSION</i> MO	1	
<i>neomycin-polymyxin-hc 3.5-10,000-1 mg/ml-unit/ml-% SOLUTION</i> MO	1	
<i>ofloxacin 0.3 % DROPS</i> MO	1	
RESPIRATORY TRACT/PULMONARY AGENTS		
ACCOLATE 10 MG, 20 MG TABLET MO	3	PA,QL(60 per 30 days)
<i>acetylcysteine 100 mg/ml (10 %), 200 mg/ml (20 %) SOLUTION</i> MO	1	BvsD
ADCIRCA 20 MG TABLET DL	4	PA,QL(60 per 30 days)
ADEMPAS 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG TABLET DL,LA	4	PA,QL(90 per 30 days)
ADRENALIN 1 MG/ML, 1 MG/ML (1 ML) SOLUTION MO	3	
ADVAIR DISKUS 100-50 MCG/DOSE, 250-50 MCG/DOSE, 500-50 MCG/DOSE BLISTER WITH DEVICE MO	3	PA,QL(60 per 30 days)
ADVAIR HFA 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL(12 per 30 days)
AIRDUO DIGIHALER 113 MCG-14 MCG/ACTUATION, 232-14 MCG/ACTUATION, 55-14 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(1 per 30 days)
AIRDUO RESPICLICK 113-14 MCG/ACTUATION, 232-14 MCG/ACTUATION, 55-14 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(1 per 30 days)
AIRSUPRA 90-80 MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL(32.1 per 30 days)
<i>albuterol sulfate 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg/0.5 ml, 5 mg/ml SOLUTION FOR NEBULIZATION</i> MO	1	BvsD
<i>albuterol sulfate 2 mg, 4 mg TABLET</i> MO	1	
<i>albuterol sulfate 2 mg/5 ml SYRUP</i> MO	1	
<i>albuterol sulfate 2.5 mg /3 ml (0.083 %) SOLUTION FOR NEBULIZATION</i> MO	1	BvsD
<i>albuterol sulfate 4 mg, 8 mg TABLET, ER 12 HR.</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>albuterol sulfate 90 mcg/actuation HFA AEROSOL INHALER</i> MO	1	QL(36 per 30 days)
ALVESCO 160 MCG/ACTUATION, 80 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(18.3 per 28 days)
ALYFTREK 10-50-125 MG TABLET DL	4	PA,QL(56 per 28 days)
ALYFTREK 4-20-50 MG TABLET DL	4	PA,QL(84 per 28 days)
<i>alyq 20 mg TABLET</i> MO	1	PA,QL(60 per 30 days)
<i>ambrisentan 10 mg, 5 mg TABLET</i> DL	4	PA,QL(30 per 30 days)
<i>aminophylline 250 mg/10 ml, 500 mg/20 ml SOLUTION</i> MO	1	
ANORO ELLIPTA 62.5-25 MCG/ACTUATION BLISTER WITH DEVICE MO	3	PA,QL(60 per 30 days)
<i>arformoterol 15 mcg/2 ml SOLUTION FOR NEBULIZATION</i> MO	1	BvsD,QL(120 per 30 days)
ARMONAIR DIGIHALER 113 MCG/ACTUATION, 232 MCG/ACTUATION, 55 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(1 per 30 days)
ARNUITY ELLIPTA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION BLISTER WITH DEVICE MO	2	QL(30 per 30 days)
ASMANEX HFA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(13 per 30 days)
ASMANEX TWISTHALER 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (14), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60) AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(1 per 28 days)
ATROVENT HFA 17 MCG/ACTUATION HFA AEROSOL INHALER MO	3	PA,QL(25.8 per 30 days)
AUVI-Q 0.1 MG/0.1 ML, 0.15 MG/0.15 ML, 0.3 MG/0.3 ML AUTO-INJECTOR MO	2	QL(4 per 30 days)
<i>azelastine 137 mcg (0.1 %) SPRAY, NON-AEROSOL</i> MO	1	QL(30 per 25 days)
<i>azelastine 205.5 mcg (0.15 %) SPRAY, NON-AEROSOL</i> MO	1	QL(30 per 25 days)
<i>azelastine-fluticasone 137-50 mcg/spray SPRAY, NON-AEROSOL</i> MO	1	ST,QL(23 per 28 days)
BECONASE AQ 42 MCG (0.042 %) SPRAY, NON-AEROSOL MO	3	ST,QL(50 per 30 days)
BEVESPI AEROSPHERE 9-4.8 MCG HFA AEROSOL INHALER MO	3	PA,QL(10.7 per 30 days)
<i>bosentan 125 mg, 62.5 mg TABLET</i> DL	4	PA,QL(60 per 30 days)
<i>bosentan 32 mg TABLET FOR SUSPENSION</i> DL	4	PA,QL(120 per 30 days)
BREO ELLIPTA 100-25 MCG/DOSE, 200-25 MCG/DOSE, 50-25 MCG/DOSE BLISTER WITH DEVICE MO	2	QL(60 per 30 days)
BREZTRI AEROSPHERE 160-9-4.8 MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL(10.7 per 30 days)
BRONCHITOL 40 MG CAPSULE, W/INHALATION DEVICE DL	4	PA,QL(560 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BROVANA 15 MCG/2 ML SOLUTION FOR NEBULIZATION	4	BvsD,QL(120 per 30 days)
budesonide 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml SUSPENSION FOR NEBULIZATION MO	1	BvsD
carbinoxamine maleate 4 mg TABLET MO	1	
carbinoxamine maleate 4 mg/5 ml LIQUID MO	1	
carbinoxamine maleate 6 mg TABLET DL	4	QL(120 per 30 days)
carbzah 4 mg/5 ml LIQUID DL	4	
CAYSTON 75 MG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL(84 per 28 days)
cetirizine 1 mg/ml SOLUTION MO	1	QL(300 per 30 days)
CINQAIR 10 MG/ML SOLUTION DL	4	PA
CLARINEX 5 MG TABLET MO	3	PA,QL(30 per 30 days)
clemastine 0.5 mg/5 ml SYRUP DL	4	PA,QL(1800 per 30 days)
clemastine 2.68 mg TABLET MO	1	
clemasz 2.68 mg TABLET MO	1	
COMBIVENT RESPIMAT 20-100 MCG/ACTUATION MIST MO	3	QL(4 per 20 days)
cromolyn 100 mg/5 ml CONCENTRATE MO	1	
cromolyn 20 mg/2 ml SOLUTION FOR NEBULIZATION MO	1	BvsD
cyproheptadine 2 mg/5 ml SYRUP MO	1	
cyproheptadine 4 mg TABLET MO	1	
DALIRESP 250 MCG TABLET MO	3	PA,QL(28 per 365 days)
DALIRESP 500 MCG TABLET MO	3	PA,QL(30 per 30 days)
desloratadine 2.5 mg, 5 mg TABLET, DISINTEGRATING MO	1	ST,QL(30 per 30 days)
desloratadine 5 mg TABLET MO	1	QL(30 per 30 days)
dexchlorpheniramine maleate 2 mg/5 ml SOLUTION MO	1	PA
DIPHEN 12.5 MG/5 ML ELIXIR MO	1	
diphen 12.5 mg/5 ml ELIXIR MO	1	
diphenhydramine hcl 12.5 mg/5 ml ELIXIR MO	1	
diphenhydramine hcl 50 mg/ml SOLUTION MO	1	
diphenhydramine hcl 50 mg/ml SYRINGE MO	1	
DOPRAM 20 MG/ML SOLUTION MO	3	
DUAKLIR PRESSAIR 400-12 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	PA,QL(1 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DULERA 100-5 MCG/ACTUATION, 200-5 MCG/ACTUATION, 50-5 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(13 per 30 days)
DYMISTA 137-50 MCG/SPRAY SPRAY, NON-AEROSOL MO	3	ST,QL(23 per 28 days)
ELIXOPHYLLIN 80 MG/15 ML ELIXIR MO	1	
<i>epinephrine</i> 0.15 mg/0.15 ml, 0.15 mg/0.3 ml, 0.3 mg/0.3 ml AUTO-INJECTOR MO	1	QL(4 per 30 days)
EPIPEN 0.3 MG/0.3 ML AUTO-INJECTOR MO	3	PA,QL(4 per 30 days)
EPIPEN 2-PAK 0.3 MG/0.3 ML AUTO-INJECTOR MO	3	PA,QL(4 per 30 days)
EPIPEN JR 0.15 MG/0.3 ML AUTO-INJECTOR MO	3	PA,QL(4 per 30 days)
EPIPEN JR 2-PAK 0.15 MG/0.3 ML AUTO-INJECTOR MO	3	PA,QL(4 per 30 days)
<i>epoprostenol</i> 0.5 mg, 1.5 mg RECON SOLUTION DL	4	PA
ESBRIET 267 MG CAPSULE DL	4	PA,QL(270 per 30 days)
ESBRIET 267 MG TABLET DL	4	PA,QL(270 per 30 days)
ESBRIET 801 MG TABLET DL	4	PA,QL(90 per 30 days)
FASENRA 10 MG/0.5 ML SYRINGE DL	4	PA,QL(0.5 per 28 days)
FASENRA 30 MG/ML SYRINGE DL	4	PA,QL(1 per 28 days)
FASENRA PEN 30 MG/ML AUTO-INJECTOR DL	4	PA,QL(1 per 28 days)
<i>flunisolide</i> 25 mcg (0.025 %) SPRAY, NON-AEROSOL MO	1	QL(50 per 30 days)
<i>fluticasone propion-salmeterol</i> 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose BLISTER WITH DEVICE MO	1	QL(60 per 30 days)
<i>fluticasone propion-salmeterol</i> 113-14 mcg/actuation, 232-14 mcg/actuation, 55-14 mcg/actuation AEROSOL POWDER BREATH ACTIV. MO	2	QL(1 per 30 days)
<i>fluticasone propionate</i> 100 mcg/actuation, 250 mcg/actuation, 50 mcg/actuation BLISTER WITH DEVICE MO	3	ST,QL(60 per 30 days)
<i>fluticasone propionate</i> 110 mcg/actuation, 220 mcg/actuation HFA AEROSOL INHALER MO	3	ST,QL(24 per 30 days)
<i>fluticasone propionate</i> 44 mcg/actuation HFA AEROSOL INHALER MO	3	ST,QL(10.6 per 30 days)
<i>fluticasone propionate</i> 50 mcg/actuation SPRAY, SUSPENSION MO	1	QL(16 per 30 days)
<i>formoterol fumarate</i> 20 mcg/2 ml SOLUTION FOR NEBULIZATION MO	1	BvsD,QL(120 per 30 days)
GASTROCROM 100 MG/5 ML CONCENTRATE MO	3	
GRASTEK 2,800 BAU SUBLINGUAL TABLET MO	3	PA,QL(30 per 30 days)
<i>hydroxyzine pamoate</i> 100 mg, 25 mg, 50 mg CAPSULE MO	1	
INCRUSE ELLIPTA 62.5 MCG/ACTUATION BLISTER WITH DEVICE MO	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ipratropium bromide 0.02 % SOLUTION</i> MO	1	BvsD
<i>ipratropium bromide 21 mcg (0.03 %) SPRAY, NON-AEROSOL</i> MO	1	QL(30 per 30 days)
<i>ipratropium bromide 42 mcg (0.06 %) SPRAY, NON-AEROSOL</i> MO	1	QL(45 per 30 days)
<i>ipratropium-albuterol 0.5 mg-3 mg(2.5 mg base)/3 ml SOLUTION FOR NEBULIZATION</i> MO	1	BvsD
KALYDECO 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG GRANULES IN PACKET DL	4	PA,QL(56 per 28 days)
KALYDECO 150 MG TABLET DL	4	PA,QL(60 per 30 days)
LETAIRIS 10 MG, 5 MG TABLET DL	4	PA,QL(30 per 30 days)
<i>levalbuterol hcl 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml SOLUTION FOR NEBULIZATION</i> MO	1	BvsD
<i>levalbuterol tartrate 45 mcg/actuation HFA AEROSOL INHALER</i> MO	1	ST,QL(30 per 30 days)
<i>levocetirizine 2.5 mg/5 ml SOLUTION</i> MO	1	QL(300 per 30 days)
<i>levocetirizine 5 mg TABLET</i> MO	1	QL(30 per 30 days)
LIQREV 10 MG/ML SUSPENSION DL	4	PA,QL(180 per 30 days)
<i>mometasone 50 mcg/actuation SPRAY, NON-AEROSOL</i> MO	1	QL(34 per 30 days)
<i>montelukast 10 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>montelukast 4 mg GRANULES IN PACKET</i> MO	1	QL(30 per 30 days)
<i>montelukast 4 mg, 5 mg CHEWABLE TABLET</i> MO	1	QL(30 per 30 days)
NEFFY 1 MG/SPRAY (0.1 ML), 2 MG/SPRAY (0.1 ML) SPRAY, NON-AEROSOL DL	4	PA,QL(4 per 30 days)
NUCALA 100 MG RECON SOLUTION DL	4	PA,QL(3 per 28 days)
NUCALA 100 MG/ML AUTO-INJECTOR DL	4	PA,QL(3 per 28 days)
NUCALA 100 MG/ML SYRINGE DL	4	PA,QL(3 per 28 days)
NUCALA 40 MG/0.4 ML SYRINGE DL	4	PA,QL(0.4 per 28 days)
ODACTRA 12 SQ-HDM SUBLINGUAL TABLET MO	3	PA,QL(30 per 30 days)
OFEV 100 MG, 150 MG CAPSULE DL,LA	4	PA,QL(60 per 30 days)
OHTUVAYRE 3 MG/2.5 ML SUSPENSION FOR NEBULIZATION DL	4	PA,QL(150 per 30 days)
<i>olopatadine 0.6 % SPRAY, NON-AEROSOL</i> MO	1	ST,QL(30.5 per 30 days)
OMNARIS 50 MCG SPRAY, NON-AEROSOL MO	3	ST,QL(12.5 per 30 days)
OPSUMIT 10 MG TABLET DL	4	PA,QL(30 per 30 days)
OPSYNVI 10-20 MG, 10-40 MG TABLET DL	4	PA,QL(30 per 30 days)
ORENITRAM 0.125 MG TABLET ER DL	4	PA,QL(1000 per 30 days)
ORENITRAM 0.25 MG TABLET ER DL	4	PA,QL(500 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ORENITRAM 1 MG TABLET ER DL	4	PA,QL(720 per 30 days)
ORENITRAM 2.5 MG TABLET ER DL	4	PA,QL(300 per 30 days)
ORENITRAM 5 MG TABLET ER DL	4	PA,QL(150 per 30 days)
ORENITRAM MONTH 1 TITRATION KT 0.125 MG (126)- 0.25 MG (42) TABLET, ER, DOSE PACK DL	4	PA,QL(168 per 28 days)
ORENITRAM MONTH 2 TITRATION KT 0.125 MG (126)- 0.25 MG (210) TABLET, ER, DOSE PACK DL	4	PA,QL(336 per 28 days)
ORENITRAM MONTH 3 TITRATION KT 0.125 MG (126)- 0.25 MG(42)-1MG TABLET, ER, DOSE PACK DL	4	PA,QL(252 per 28 days)
ORKAMBI 100-125 MG, 150-188 MG, 75-94 MG GRANULES IN PACKET DL	4	PA,QL(56 per 28 days)
ORKAMBI 100-125 MG, 200-125 MG TABLET DL	4	PA,QL(112 per 28 days)
PATANASE 0.6 % SPRAY, NON-AEROSOL MO	3	ST,QL(30.5 per 30 days)
PERFORMIST 20 MCG/2 ML SOLUTION FOR NEBULIZATION DL	4	BvsD,QL(120 per 30 days)
<i>pirfenidone</i> 267 mg CAPSULE DL	4	PA,QL(270 per 30 days)
<i>pirfenidone</i> 267 mg TABLET DL	4	PA,QL(270 per 30 days)
<i>pirfenidone</i> 534 mg, 801 mg TABLET DL	4	PA,QL(90 per 30 days)
PROAIR DIGIHALER 90 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(2 per 30 days)
PROAIR RESPICLICK 90 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(2 per 30 days)
PULMICORT 0.25 MG/2 ML, 0.5 MG/2 ML, 1 MG/2 ML SUSPENSION FOR NEBULIZATION MO	3	BvsD
PULMICORT FLEXHALER 180 MCG/ACTUATION, 90 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(2 per 30 days)
PULMOZYME 1 MG/ML SOLUTION DL	4	BvsD
QNASL 40 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(6.8 per 30 days)
QNASL 80 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(10.6 per 30 days)
QUZYTIR 10 MG/ML SOLUTION MO	3	
QVAR REDHALER 40 MCG/ACTUATION HFA AEROSOL BREATH ACTIVATED MO	3	ST,QL(10.6 per 30 days)
QVAR REDHALER 80 MCG/ACTUATION HFA AEROSOL BREATH ACTIVATED MO	3	ST,QL(21.2 per 30 days)
RAGWITEK 12 AMB A 1 UNIT SUBLINGUAL TABLET MO	3	PA,QL(30 per 30 days)
REMODULIN 1 MG/ML, 10 MG/ML, 2.5 MG/ML, 5 MG/ML SOLUTION DL	4	PA
REVATIO 10 MG/ML SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
REVATIO 20 MG TABLET DL	4	PA,QL(90 per 30 days)
roflumilast 250 mcg TABLET MO	1	QL(28 per 365 days)
roflumilast 500 mcg TABLET MO	1	QL(30 per 30 days)
RYALTRIS 665-25 MCG/SPRAY SPRAY, NON-AEROSOL MO	3	ST,QL(29 per 30 days)
RYCLORA 2 MG/5 ML SOLUTION MO	1	
RYVENT 6 MG TABLET MO	1	QL(120 per 30 days)
SEREVENT DISKUS 50 MCG/DOSE BLISTER WITH DEVICE MO	3	PA,QL(60 per 30 days)
sildenafil (pulm.hypertension) 10 mg/ml SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(180 per 30 days)
sildenafil (pulm.hypertension) 20 mg TABLET MO	1	PA,QL(90 per 30 days)
SINGULAIR 10 MG TABLET MO	3	PA,QL(30 per 30 days)
SINGULAIR 4 MG GRANULES IN PACKET MO	3	PA,QL(30 per 30 days)
SINGULAIR 4 MG, 5 MG CHEWABLE TABLET MO	3	PA,QL(30 per 30 days)
SPIRIVA RESPIMAT 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION MIST MO	2	QL(4 per 28 days)
SPIRIVA WITH HANDIHALER 18 MCG CAPSULE, W/INHALATION DEVICE MO	2	QL(30 per 30 days)
STIOLTO RESPIMAT 2.5-2.5 MCG/ACTUATION MIST MO	2	QL(4 per 28 days)
STRIVERDI RESPIMAT 2.5 MCG/ACTUATION MIST MO	2	QL(4 per 30 days)
SYMBICORT 160-4.5 MCG/ACTUATION, 80-4.5 MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL(30.6 per 30 days)
SYMDEKO 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) TABLET, SEQUENTIAL DL	4	PA,QL(56 per 28 days)
tadalafil (pulm. hypertension) 20 mg TABLET MO	1	PA,QL(60 per 30 days)
TADLIQ 20 MG/5 ML (4 MG/ML) SUSPENSION DL	4	PA,QL(300 per 30 days)
terbutaline 1 mg/ml SOLUTION MO	1	
terbutaline 2.5 mg, 5 mg TABLET MO	1	
THEO-24 100 MG, 200 MG, 300 MG, 400 MG CAPSULE, ER 24 HR. MO	1	
theophylline 100 mg, 200 mg, 300 mg, 450 mg TABLET, ER 12 HR. MO	1	
theophylline 400 mg, 600 mg TABLET, ER 24 HR. MO	1	
theophylline 80 mg/15 ml ELIXIR MO	1	
theophylline 80 mg/15 ml SOLUTION MO	1	
TOBI PODHALER 28 MG CAPSULE, W/INHALATION DEVICE DL	4	PA,QL(224 per 28 days)
TRACLEER 125 MG, 62.5 MG TABLET DL	4	PA,QL(60 per 30 days)
TRACLEER 32 MG TABLET FOR SUSPENSION DL	4	PA,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TRELEGY ELLIPTA 100-62.5-25 MCG, 200-62.5-25 MCG BLISTER WITH DEVICE MO	2	QL(60 per 30 days)
<i>treprostinil sodium 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml SOLUTION</i> DL	4	PA
TRIKAFTA 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) TABLET, SEQUENTIAL DL	4	PA,QL(84 per 28 days)
TRIKAFTA 100-50-75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) GRANULES IN PACKET, SEQUENTIAL DL	4	PA,QL(56 per 28 days)
TUDORZA PRESSAIR 400 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	PA,QL(1 per 30 days)
TYVASO 1.74 MG/2.9 ML (0.6 MG/ML) SOLUTION FOR NEBULIZATION DL	4	PA
TYVASO DPI 16 MCG (112)- 32 MCG (84) CARTRIDGE WITH INHALER DL	4	PA,QL(196 per 28 days)
TYVASO DPI 16 MCG, 32 MCG, 48 MCG, 64 MCG CARTRIDGE WITH INHALER DL	4	PA,QL(112 per 28 days)
TYVASO DPI 16(112)-32(112) -48(28) MCG CARTRIDGE WITH INHALER DL	4	PA,QL(252 per 28 days)
TYVASO INSTITUTIONAL START KIT 1.74 MG/2.9 ML SOLUTION FOR NEBULIZATION DL	4	PA
TYVASO REFILL KIT 1.74 MG/2.9 ML (0.6 MG/ML) SOLUTION FOR NEBULIZATION DL	4	PA
TYVASO STARTER KIT 1.74 MG/2.9 ML SOLUTION FOR NEBULIZATION DL	4	PA
<i>umeclidinium-vilanterol 62.5-25 mcg/actuation BLISTER WITH DEVICE</i> MO	3	PA,QL(60 per 30 days)
UPTRAVI 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG TABLET DL	4	PA,QL(60 per 30 days)
UPTRAVI 1,800 MCG RECON SOLUTION DL	4	PA
UPTRAVI 200 MCG (140)- 800 MCG (60) TABLET, DOSE PACK DL	4	PA,QL(200 per 30 days)
VELETRI 0.5 MG, 1.5 MG RECON SOLUTION DL	4	PA
VENTAVIS 10 MCG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL(150 per 30 days)
VENTAVIS 20 MCG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL(90 per 30 days)
VENTOLIN HFA 90 MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL(36 per 30 days)
VISTARIL 25 MG, 50 MG CAPSULE MO	3	
WINREVAIR 120 MG (60 MG X 2), 45 MG, 60 MG, 90 MG (45 MG X 2) KIT DL	4	PA
<i>wixela inhub 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose BLISTER WITH DEVICE</i> MO	1	QL(60 per 30 days)
XHANCE 93 MCG/ACTUATION AEROSOL BREATH ACTIVATED MO	3	PA,QL(32 per 30 days)
XOPENEX HFA 45 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
YUPELRI 175 MCG/3 ML SOLUTION FOR NEBULIZATION	4	PA,QL(90 per 30 days)
YUTREPIA 106 MCG, 26.5 MCG, 53 MCG, 79.5 MCG CAPSULE, W/INHALATION DEVICE DL	4	PA
<i>zafirlukast</i> 10 mg, 20 mg TABLET MO	1	QL(60 per 30 days)
ZETONNA 37 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(6.1 per 28 days)
<i>zileuton</i> 600 mg TABLET, ER 12 HR., MULTIPHASE	4	ST,QL(120 per 30 days)
ZYFLO 600 MG TABLET DL	4	ST,QL(120 per 30 days)
SKELETAL MUSCLE RELAXANTS		
AMRIX 15 MG, 30 MG CAPSULE, ER 24 HR. DL	4	ST,QL(21 per 30 days)
<i>carisoprodol</i> 250 mg TABLET MO	1	ST,QL(120 per 30 days)
<i>carisoprodol</i> 350 mg TABLET MO	1	QL(120 per 30 days)
<i>chlorzoxazone</i> 250 mg TABLET DL	4	ST,QL(360 per 30 days)
<i>chlorzoxazone</i> 375 mg, 750 mg TABLET MO	1	ST,QL(120 per 30 days)
<i>chlorzoxazone</i> 500 mg TABLET MO	1	ST
<i>cyclobenzaprine</i> 10 mg, 5 mg TABLET MO	1	
<i>cyclobenzaprine</i> 15 mg, 30 mg CAPSULE, ER 24 HR. MO	1	ST,QL(21 per 30 days)
<i>cyclobenzaprine</i> 7.5 mg TABLET MO	1	QL(90 per 30 days)
FEXMID 7.5 MG TABLET MO	1	ST,QL(90 per 30 days)
LORZONE 375 MG TABLET MO	1	ST,QL(120 per 30 days)
LORZONE 750 MG TABLET DL	4	ST,QL(120 per 30 days)
<i>metaxalone</i> 400 mg, 800 mg TABLET MO	1	ST,QL(120 per 30 days)
<i>methocarbamol</i> 1,000 mg TABLET DL	4	PA
<i>methocarbamol</i> 100 mg/ml SOLUTION MO	1	
<i>methocarbamol</i> 500 mg, 750 mg TABLET MO	1	
<i>norgesic</i> 25-385-30 mg TABLET DL	4	PA,QL(240 per 30 days)
NORGESIC FORTE 50-770-60 MG TABLET DL	4	PA,QL(120 per 30 days)
<i>orphenadrine citrate</i> 100 mg TABLET ER MO	1	
<i>orphenadrine citrate</i> 30 mg/ml SOLUTION MO	1	ST
<i>orphenadrine-asa-caffeine</i> 25-385-30 mg TABLET DL	4	PA,QL(240 per 30 days)
<i>orphenadrine-asa-caffeine</i> 50-770-60 mg TABLET DL	4	PA,QL(120 per 30 days)
<i>orphengestic forte</i> 50-770-60 mg TABLET DL	4	PA,QL(120 per 30 days)
ROBAXIN 100 MG/ML SOLUTION DL	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SOMA 250 MG, 350 MG TABLET DL	4	ST,QL(120 per 30 days)
tanlor 1,000 mg TABLET DL	4	PA
SLEEP DISORDER AGENTS		
AMBIEN 10 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
AMBIEN CR 12.5 MG, 6.25 MG TABLET, ER MULTIPHASE MO	3	PA,QL(30 per 30 days)
armodafinil 150 mg, 200 mg, 250 mg TABLET MO	1	PA,QL(30 per 30 days)
armodafinil 50 mg TABLET MO	1	PA,QL(60 per 30 days)
BELSOMRA 10 MG TABLET MO	2	QL(60 per 30 days)
BELSOMRA 15 MG, 20 MG TABLET MO	2	QL(30 per 30 days)
BELSOMRA 5 MG TABLET MO	2	QL(120 per 30 days)
DAYVIGO 10 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
doxepin 3 mg, 6 mg TABLET MO	1	QL(30 per 30 days)
EDLUAR 10 MG SUBLINGUAL TABLET MO	3	
EDLUAR 5 MG SUBLINGUAL TABLET MO	3	QL(30 per 30 days)
estazolam 1 mg, 2 mg TABLET DL	1	QL(30 per 30 days)
eszopiclone 1 mg, 2 mg, 3 mg TABLET MO	1	QL(30 per 30 days)
flurazepam 15 mg CAPSULE DL	1	QL(60 per 30 days)
flurazepam 30 mg CAPSULE DL	1	QL(30 per 30 days)
HALCION 0.25 MG TABLET DL	3	PA,QL(30 per 30 days)
HETLIOZ 20 MG CAPSULE DL	4	PA,QL(30 per 30 days)
HETLIOZ LQ 4 MG/ML SUSPENSION DL	4	PA,QL(158 per 30 days)
LUMRYZ 4.5 GRAM, 6 GRAM, 7.5 GRAM, 9 GRAM ER GRANULES, PACKET DL	4	PA,QL(30 per 30 days)
LUMRYZ STARTER PACK 4.5-6-7.5 GRAM GRANULES ER PACKET, DOSE PACK DL	4	PA,QL(28 per 28 days)
LUNESTA 1 MG, 2 MG, 3 MG TABLET MO	3	PA,QL(30 per 30 days)
modafinil 100 mg, 200 mg TABLET MO	1	PA,QL(60 per 30 days)
NUVIGIL 150 MG, 200 MG, 250 MG TABLET	4	PA,QL(30 per 30 days)
NUVIGIL 50 MG TABLET	4	PA,QL(60 per 30 days)
PROVIGIL 100 MG, 200 MG TABLET	4	PA,QL(60 per 30 days)
QUVIVIQ 25 MG, 50 MG TABLET MO	3	ST,QL(30 per 30 days)
ramelteon 8 mg TABLET MO	1	ST,QL(30 per 30 days)
RESTORIL 15 MG, 22.5 MG, 30 MG, 7.5 MG CAPSULE DL	4	PA,QL(30 per 30 days)
ROZEREM 8 MG TABLET MO	3	ST,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SILENOR 3 MG, 6 MG TABLET MO	3	QL(30 per 30 days)
sodium oxybate 500 mg/ml SOLUTION DL	4	PA,QL(540 per 30 days)
SUNOSI 150 MG, 75 MG TABLET MO	3	PA,QL(30 per 30 days)
tasimelteon 20 mg CAPSULE DL	4	PA,QL(30 per 30 days)
temazepam 15 mg, 30 mg CAPSULE DL	1	QL(30 per 30 days)
temazepam 22.5 mg, 7.5 mg CAPSULE DL	1	QL(30 per 30 days)
triazolam 0.125 mg, 0.25 mg TABLET DL	1	QL(30 per 30 days)
WAKIX 17.8 MG, 4.45 MG TABLET DL	4	PA,QL(60 per 30 days)
XYREM 500 MG/ML SOLUTION DL	4	PA,QL(540 per 30 days)
XYWAV 0.5 GRAM/ML SOLUTION DL	4	PA,QL(540 per 30 days)
zaleplon 10 mg, 5 mg CAPSULE MO	1	QL(30 per 30 days)
zolpidem 1.75 mg, 3.5 mg SUBLINGUAL TABLET MO	1	QL(30 per 30 days)
zolpidem 10 mg, 5 mg TABLET MO	1	QL(30 per 30 days)
zolpidem 12.5 mg, 6.25 mg TABLET, ER MULTIPHASE MO	1	QL(30 per 30 days)
ZOLPIDEM 7.5 MG CAPSULE MO	3	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

Humana Group Medicare Plan Coverage of Additional Prescription Drugs

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
Cough/Cold - Mail Order Available		
<i>benzonatate 100 mg, 150 mg, 200 mg CAPSULE</i>	1	
<i>bromfed dm 2-30-10 mg/5 ml SYRUP</i>	1	
<i>brompheniramine-pseudoeph-dm 2-30-10 mg/5 ml SYRUP</i>	1	
HYCODAN 5-1.5 MG/5 ML (5 ML) SOLUTION	1	
HYCODAN (WITH HOMATROPINE) 5-1.5 MG TABLET	1	
HYCODAN (WITH HOMATROPINE) 5-1.5 MG/5 ML SOLUTION	1	
<i>hydrocodone-chlorpheniramine 10-8 mg/5 ml SUSPENSION, ER 12 HR.</i>	1	
<i>hydrocodone-homatropine 5-1.5 mg TABLET</i>	1	
<i>hydrocodone-homatropine 5-1.5 mg/5 ml, 5-1.5 mg/5 ml (5 ml) SOLUTION</i>	1	
<i>hydromet 5-1.5 mg/5 ml SOLUTION</i>	1	
<i>promethazine vc-codeine 6.25-5-10 mg/5 ml SYRUP</i>	1	
<i>promethazine-codeine 6.25-10 mg/5 ml SYRUP</i>	1	
<i>promethazine-dm 6.25-15 mg/5 ml SYRUP</i>	1	
RESPA-AR 8-90-0.24 MG TABLET, ER 12 HR.	3	
TUXARIN ER 8-54.3 MG TABLET, ER 12 HR.	3	
TUZISTRA XR 14.7-2.8 MG/5 ML SUSPENSION, ER 12 HR.	3	
Fertility - Mail Order Available		
<i>cetorelix 0.25 mg KIT</i>	1	
CETROTIDE 0.25 MG KIT	3	
<i>clomid 50 mg TABLET</i>	1	

Your Humana Group Medicare Plan has additional coverage for some drugs that are not normally covered under Medicare Part D. Guidelines that apply to these drugs include: they are not subject to the Medicare appeals process and your member cost share does not apply to your annual maximum out-of-pocket (MOOP) spend.

BvsD - Part B vs Part D • CI - Covered Insulin Products • DL - Dispensing Limit • LA - Limited Access • MO - Mail Order • PA - Prior Authorization • PDS - BD/HTL- Droplet are the Preferred Diabetic Supplies • QL - Quantity Limit • \$0 - Vaccine/Diabetic • ST - Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
Fertility - Mail Order Available		
<i>clomiphene citrate 50 mg TABLET</i>	1	
FOLLISTIM AQ 300 UNIT/0.36 ML, 600 UNIT/0.72 ML, 900 UNIT/1.08 ML CARTRIDGE	3	
<i>fyremadel 250 mcg/0.5 ml SYRINGE</i>	1	
GANIRELIX 250 MCG/0.5 ML SYRINGE	3	
<i>ganirelix 250 mcg/0.5 ml SYRINGE</i>	3	
GONAL-F 1,050 UNIT, 450 UNIT RECON SOLUTION	3	
GONAL-F RFF 75 UNIT RECON SOLUTION	3	
GONAL-F RFF REDI-JECT 300/0.5 UNIT/ML, 450/0.75 UNIT/ML PEN INJECTOR	3	
MENOPUR 75 UNIT RECON SOLUTION	3	
OVIDREL 250 MCG/0.5 ML SYRINGE	3	
Vitamins/Minerals - Mail Order Available		
<i>ascorbic acid (vitamin c) 500 mg/ml SOLUTION</i>	1	
<i>b complex 100 100-2-100-2-2 mg/ml SOLUTION</i>	1	
<i>b-complex injection 100-2-100-2-2 mg/ml SOLUTION</i>	1	
<i>cyanocobalamin (vitamin b-12) 1,000 mcg/ml SOLUTION</i>	1	
<i>cyanocobalamin (vitamin b-12) 500 mcg/spray SPRAY, NON-AEROSOL</i>	1	
<i>dodex 1,000 mcg/ml SOLUTION</i>	1	
DRISDOL 1,250 MCG (50,000 UNIT) CAPSULE	3	

Your Humana Group Medicare Plan has additional coverage for some drugs that are not normally covered under Medicare Part D. Guidelines that apply to these drugs include: they are not subject to the Medicare appeals process and your member cost share does not apply to your annual maximum out-of-pocket (MOOP) spend.

BvsD - Part B vs Part D • CI - Covered Insulin Products • DL - Dispensing Limit • LA - Limited Access • MO - Mail Order • PA - Prior Authorization • PDS - BD/HTL- Droplet are the Preferred Diabetic Supplies • QL - Quantity Limit • \$0 - Vaccine/Diabetic • ST - Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
Vitamins/Minerals - Mail Order Available		
<i>ergocalciferol (vitamin d2) 1,250 mcg (50,000 unit) CAPSULE</i>	1	
<i>folic acid 1 mg TABLET</i>	1	
<i>folic acid 5 mg/ml SOLUTION</i>	1	
<i>hydroxocobalamin 1,000 mcg/ml SOLUTION</i>	1	
INFUVITE ADULT 3,300 UNIT- 150 MCG/10 ML SOLUTION	3	
INFUVITE PEDIATRIC 80 MG-400 UNIT- 200 MCG/5 ML SOLUTION	3	
MEPHYTON 5 MG TABLET	3	
NASCOBAL 500 MCG/SPRAY SPRAY, NON-AEROSOL	3	
<i>phytonadione (vitamin k1) 1 mg/0.5 ml SYRINGE</i>	1	
<i>phytonadione (vitamin k1) 1 mg/0.5 ml, 10 mg/ml SOLUTION</i>	1	
<i>phytonadione (vitamin k1) 5 mg TABLET</i>	1	
<i>pyridoxine (vitamin b6) 100 mg/ml SOLUTION</i>	1	
<i>thiamine hcl (vitamin b1) 100 mg/ml SOLUTION</i>	1	
<i>vitamin d2 1,250 mcg (50,000 unit) CAPSULE</i>	1	
<i>vitamin k 1 mg/0.5 ml SOLUTION</i>	1	
<i>vitamin k1 10 mg/ml SOLUTION</i>	1	

Your Humana Group Medicare Plan has additional coverage for some drugs that are not normally covered under Medicare Part D. Guidelines that apply to these drugs include: they are not subject to the Medicare appeals process and your member cost share does not apply to your annual maximum out-of-pocket (MOOP) spend.

BvsD - Part B vs Part D • CI - Covered Insulin Products • DL - Dispensing Limit • LA - Limited Access • MO - Mail Order • PA - Prior Authorization • PDS - BD/HTL- Droplet are the Preferred Diabetic Supplies • QL - Quantity Limit • \$0 - Vaccine/Diabetic • ST - Step Therapy

Index

A

- abacavir-lamivudine... 75
abacavir... 75
ABELCET... 45
abigale lo... 146
abigale... 146
ABILIFY ASIMTUFIG... 70
ABILIFY MAINTENA... 70
ABILIFY MYCITE MAINTENANCE
KIT... 70
ABILIFY MYCITE STARTER KIT... 70
ABILIFY... 70
abiraterone... 51
abirtega... 51
ABRAXANE... 51
ABRILADA(CF) PEN... 159
ABRILADA(CF)... 159
ABRYSVO (PF)... 159
ABSORICA LD... 116
ABSORICA... 116
acamprosate... 21
ACANYA... 116
acarbose... 83
ACCOLATE... 188
ACCUPRIL... 94
ACCURETIC... 94
accutane... 116
acebutolol... 94
ACETADOTE... 175
acetaminophen-caff-dihydrocod...
11
acetaminophen-codeine... 11
acetaminophen... 175
acetazolamide sodium... 94
acetazolamide... 94
acetic acid... 22, 175
acetylcysteine... 175, 188
ACIPHEX... 133
acitretin... 116
ACTEMRA ACTPEN... 159
ACTEMRA... 159
ACTHAR SELFJECT... 142
ACTHAR... 142
ACTHIB (PF)... 159
ACTICLATE... 22
ACTIMMUNE... 159
ACTIVELLA... 146
ACTONEL... 174
ACTOPLUS MET... 83
ACTOS... 83
ACULAR LS... 183
ACULAR... 183
ACUVAIL (PF)... 183
acyclovir sodium... 76
acyclovir... 75, 76
ACZONE... 116, 117
ADACEL(TDAP
ADOLESN/ADULT)(PF)... 159
ADAKVEO... 175
ADALIMUMAB-AACF(CF) PEN
CROHNS... 159
ADALIMUMAB-AACF(CF) PEN
PS-UV... 159
ADALIMUMAB-AACF... 159
ADALIMUMAB-AATY(CF) AI
CROHNS... 159
ADALIMUMAB-AATY... 159
ADALIMUMAB-ADAZ... 159, 160
ADALIMUMAB-ADBM(CF) PEN
CROHNS... 160
ADALIMUMAB-ADBM(CF) PEN
PS-UV... 160
ADALIMUMAB-ADBM... 160
ADALIMUMAB-FKJP... 160
ADALIMUMAB-RYVK... 160
adapalene-benzoyl peroxide... 117
adapalene... 117
ADBRY... 117
ADCETRIS... 51
ADCIRCA... 188
ADDERALL XR... 109
ADDERALL... 109
adefovir... 76
ADEMPAS... 188
adenosine... 94
ADLARITY... 38
ADMELOG SOLOSTAR U-100
INSULIN... 83
ADMELOG U-100 INSULIN LISPRO...
83
ADRENALIN IN 0.9 % SOD CHLOR...
94
ADRENALIN... 188
ADRIAMYCIN... 52
adrucil... 52
ADSTILADRIN... 176
ADVAIR DISKUS... 188
ADVAIR HFA... 188
ADZENYS XR-ODT... 109

ADZYNMA... 89
 AEMCOLO... 133
 AFINITOR DISPERZ... 52
 AFINITOR... 52
 afirmelle... 146
 AFREZZA... 83
 AGAMREE... 142
 AGGRASTAT CONCENTRATE... 89
 AGGRASTAT IN SODIUM CHLORIDE... 89
 AGRYLIN... 89
 AIMOVIG AUTOINJECTOR... 49
 AIRDUO DIGIHALER... 188
 AIRDUO RESPICLICK... 188
 AIRSUPRA... 188
 AJOVY AUTOINJECTOR... 49
 AJOVY SYRINGE... 49
 AKEEGA... 52
 AKLIEF... 117
 AKYNZEO (FOSNETUPITANT)... 43
 AKYNZEO (NETUPITANT)... 43
 ALA-CORT... 117
 ALA-SCALP... 117
 albendazole... 67
 albuterol sulfate... 188, 189
 ALCaine... 183
 alclometasone... 117
 ALCOHOL PADS... 176
 ALCOHOL PREP PADS... 176
 ALCOHOL SWABS... 176
 ALCOHOL WIPES... 176
 ALDACTONE... 94
 ALDURAZYME... 137
 ALECENSA... 52
 alendronate... 174
 alfuzosin... 141
 ALIMTA... 52
 ALIQOPA... 52
 aliskiren... 94
 ALKINDI SPRINKLE... 142
 allopurinol sodium... 48
 allopurinol... 48
 almotriptan malate... 49
 ALOMIDE... 183
 ALOPRIM... 48
 alosetron... 133
 ALPHAGAN P... 183
 alprazolam intensol... 81
 alprazolam... 81
 ALREX... 183
 ALTABAX... 117
 ALTACE... 94
 altavera (28)... 146
 ALTOPREV... 94
 ALTRENO... 117
 ALUNBRIG... 52
 ALVAIZ... 89
 ALVESCO... 189
 alyacen 1/35 (28)... 146
 alyacen 7/7/7 (28)... 146
 ALYFTREK... 189
 ALYGLO... 160
 ALYMSYS... 52
 alyq... 189
 amabelz... 146
 amantadine hcl... 68
 AMBIEN CR... 197
 AMBIEN... 197
 AMBISOME... 45
 ambisentan... 189
 amcinonide... 117
 amethia... 146
 amethyst (28)... 146
 amikacin... 22
 amiloride-hydrochlorothiazide... 94
 amiloride... 94
 aminocaproic acid... 89, 90
 aminophylline... 189
 AMINOSYN II 10 %... 126
 amiodarone... 94, 95
 AMITIZA... 133
 amitriptyline-chlordiazepoxide... 39
 amitriptyline... 39
 AMJEVITA(CF) AUTOINJECTOR... 160
 AMJEVITA(CF)... 160
 amlodipine-atorvastatin... 95
 amlodipine-benazepril... 95
 amlodipine-olmesartan... 95
 amlodipine-valsartan-hcthiazyd... 95
 amlodipine-valsartan... 95
 amlodipine... 95
 ammonium lactate... 117
 AMMONUL... 176
 amnesteem... 117
 amoxapine... 40
 amoxicil-clarithromy-lansopraz... 133
 amoxicillin-pot clavulanate... 22, 23
 amoxicillin... 22
 amphetamine sulfate... 109
 amphotericin b liposome... 45
 amphotericin b... 45
 ampicillin sodium... 23

ampicillin-sulbactam... 23	AQNEURSA... 176	aspirin-dipyridamole... 90
ampicillin... 23	ARALAST NP... 137	ASPRUZYO SPRINKLE... 95
AMPYRA... 109	aranelle (28)... 146	ASTAGRAF XL... 160
AMRIX... 196	ARANESP (IN POLYSORBATE)... 90	ATACAND HCT... 95
AMVUTTRA... 137	ARAVA... 160	ATACAND... 95
AMZEEQ... 117	ARAZLO... 117	atazanavir... 76
ANAFRANIL... 40	ARBLI... 95	ATELVIA... 174
anagrelide... 90	ARCALYST... 160	atenolol-chlorthalidone... 95
anastrozole... 52	AREXVY (PF)... 160	atenolol... 95
ANCOBON... 45	arformoterol... 189	ATGAM... 160
ANDEMBRY AUTOINJECTOR... 160	ARICEPT... 39	ATIVAN... 81
ANDROGEL... 146	ARIKAYCE... 23	atomoxetine... 109
ANGELIQ... 146	ARIMIDEX... 52	ATORVALIQ... 95
ANKTIVA... 52	aripiprazole... 70	atorvastatin... 95
ANNOVERA... 146	ARISTADA INITIO... 70	atovaquone-proguanil... 67
ANORO ELLIPTA... 189	ARISTADA... 70	atovaquone... 67
ANTIVERT... 43	ARIXTRA... 90	ATRALIN... 117
anusol-hc... 117	armodafinil... 197	ATRIPLA... 76
ANZEMET... 43	ARMONAIR DIGIHALER... 189	ATROPINE SULFATE (PF)... 183
APADAZ... 11	ARMOUR THYROID... 156	atropine... 133, 183
apexicon e... 117	ARNUITY ELLIPTA... 189	ATROVENT HFA... 189
APIDRA SOLOSTAR U-100 INSULIN... 83	AROMASIN... 52	ATTRUBY... 137
APIDRA U-100 INSULIN... 83	ARRANON... 52	AUBAGIO... 109
APLENZIN... 40	arsenic trioxide... 52	aubra eq... 146
APOKYN... 68	ARTHROTEC 50... 11	aubra... 146
apomorphine... 68	ARTHROTEC 75... 11	AUGMENTIN ES-600... 23
APONVIE... 43	ASCENIV... 160	AUGMENTIN XR... 23
apraclonidine... 183	ascomp with codeine... 11	AUGMENTIN... 23
aprepitant... 43	ascorbic acid (vitamin c)... 200	AUGTYRO... 52
apri... 146	asenapine maleate... 70	auranofin... 160
APRISO... 172	ashlyna... 146	aurovela 1.5/30 (21)... 146
APTENSIO XR... 109	ASMANEX HFA... 189	aurovela 1/20 (21)... 146
APTIOM... 32	ASMANEX TWISTHALER... 189	aurovela 24 fe... 147
APTIVUS... 76	ASPARLAS... 52	aurovela fe 1-20 (28)... 147

aurovela fe 1.5/30 (28)... 147	AZASITE... 183	BARACLUDE... 76
AUSTEDO XR TITRATION KT(WK1-4)... 110	azathioprine sodium... 161	BASAGLAR KWIKPEN U-100 INSULIN... 83
AUSTEDO XR... 110	azathioprine... 161	BASAGLAR TEMPO PEN(U-100)INSLN... 83
AUSTEDO... 110	azelaic acid... 117	BAVENCIO... 52
AUTOJECT 2 INJECTION DEVICE... 176	azelastine-fluticasone... 189	BAXDELA... 23
AUTOPEN 1 TO 21 UNITS... 176	azelastine... 183, 189	BCG VACCINE, LIVE (PF)... 161
AUTOPEN 2 TO 42 UNITS... 176	AZELEX... 117	BD ALCOHOL SWABS... 176
AUTOSHIELD DUO PEN NEEDLE... 176	AZILECT... 68	BD AUTOSHIELD DUO PEN NEEDLE... 176
AUVELITY... 40	azithromycin... 23	BD ECLIPSE LUER-LOK... 176
AUVI-Q... 189	AZMIRO... 147	BD INSULIN SYRINGE (HALF UNIT)... 176
AVALIDE... 95	AZOPT... 183	BD INSULIN SYRINGE MICRO-FINE... 176
AVAPRO... 95	AZOR... 95	BD INSULIN SYRINGE U-500... 176
AVASTIN... 52	AZSTARYS... 110	BD INSULIN SYRINGE ULTRA-FINE... 176
AVEED... 147	aztreonam... 23	BD INSULIN SYRINGE... 176
AVELOX IN NACL (ISO-OSMOTIC)... 23	AZULFIDINE EN-TABS... 173	BD LO-DOSE MICRO-FINE IV... 176
AVERI... 147	AZULFIDINE... 173	BD NANO 2ND GEN PEN NEEDLE... 176
aviane... 147	azurette (28)... 147	BD SAFETYGLIDE INSULIN SYRINGE... 176
avidoxy... 23	B	BD SAFETYGLIDE SYRINGE... 176
AVITA... 117	b complex 100... 200	BD ULTRA-FINE MICRO PEN NEEDLE... 176
AVMAPKI-FAKZYNJA... 52	b-complex injection... 200	BD ULTRA-FINE MINI PEN NEEDLE... 177
AVODART... 141	bacitracin-polymyxin b... 183	BD ULTRA-FINE NANO PEN NEEDLE... 177
AVONEX... 110	bacitracin... 23, 183	BD ULTRA-FINE ORIG PEN NEEDLE... 177
AVSOLA... 160	baclofen... 75	BD ULTRA-FINE SHORT PEN NEEDLE... 177
AVYCAZ... 23	BACTRIM DS... 23	
AXTLE... 52	BACTRIM... 23	
AYGESTIN... 147	BAFIERTAM... 110	
ayuna... 147	bal-care dha... 126	
AYVAKIT... 52	balanced salt... 183	
azacitidine... 52	BALCOLTRA... 147	
AZACTAM... 23	balsalazide... 173	
AZASAN... 160	BALVERSA... 52	
	balziva (28)... 147	
	BAND-AID GAUZE PADS... 176	
	BANZEL... 32	
	BAQSIMI... 83	

BD VEO INSULIN SYR (HALF UNIT)... 177	BETAPACE... 95	blisovi fe 1/20 (28)... 147
BD VEO INSULIN SYRINGE UF... 177	BETASERON... 110	BONIVA... 174
BECONASE AQ... 189	betaxolol... 96, 183	BONJESTA... 43
BELBUCA... 11	bethanechol chloride... 141	BOOSTRIX TDAP... 161
BELEODAQ... 52	BETHKIS... 23	BORDERED GAUZE... 177
BELSOMRA... 197	BETIMOL... 183	BORTEZOMIB... 53
benazepril-hydrochlorothiazide... 95	BETOPTIC S... 183	BORUZU... 53
benazepril... 95	BEVESPI AEROSPHERE... 189	bosentan... 189
bendamustine... 52, 53	bexarotene... 53	BOSULIF... 53
BENDEKA... 53	BEXSERO... 161	BRAFTOVI... 53
BENICAR HCT... 95	BEYAZ... 147	BREO ELLIPTA... 189
BENICAR... 95	BEYFORTUS... 177	BREVIBLOC IN NACL (ISO-OSM)... 96
BENLYSTA... 161	bicalutamide... 53	BREVIBLOC... 96
BENTYL... 133	BICILLIN C-R... 23	BREZTRI AEROSPHERE... 189
BENZAMYCIN... 117	BICILLIN L-A... 23	briellyn... 147
benzhydrocodone-acetaminophen... 11	BICNU... 53	BRILINTA... 90
benzonatate... 199	BIDIL... 96	brimonidine... 118, 183
benztropine... 68	BIJUVA... 147	brinzolamide... 184
bepotastine besilate... 183	BIKTARVY... 76	BRIUMVI... 110
BEPREVE... 183	BILTRICIDE... 67	BRIVIACT... 32
BERINERT... 161	bimatoprost... 183	bromfed dm... 199
besser... 118	BIMZELX AUTOINJECTOR... 161	bromfenac... 184
BESIVANCE... 183	BIMZELX... 161	bromocriptine... 68
BESPONSA... 53	BINOSTO... 174	brompheniramine-pseudoeph-dm... 199
BESREMI... 161	BIORPHEN... 96	BROMSITE... 184
BETADINE OPHTHALMIC PREP... 183	bismuth subcit k-metronidz-tcn... 133	BRONCHITOL... 189
betaine... 137	bisoprolol fumarate... 96	BROVANA... 190
betamethasone acet,sod phos... 142	bisoprolol-hydrochlorothiazide... 96	BRUKINSA... 53
betamethasone dipropionate... 118	BIVIGAM... 161	BRYHALI... 118
betamethasone valerate... 118	BIZENGRI... 53	BRYNOVIN... 83
betamethasone, augmented... 118	BKEMV... 161	BSS PLUS... 184
BETAPACE AF... 95	bleomycin... 53	BSS... 184
	blisovi 24 fe... 147	BUCAPSOL... 81
	blisovi fe 1.5/30 (28)... 147	budesonide... 173, 190

bumetanide... 96	CABLIVI... 90	carbamazepine... 32
bupap... 177	CABOMETYX... 53	CARBATROL... 32
BUPHENYL... 137	CABTREO... 118	carbidopa-levodopa-entacapone... 68
bupivacaine (pf)... 19	CADUET... 96	carbidopa-levodopa... 68
bupivacaine hcl... 19	CAFCIT... 177	carbidopa... 68
bupivacaine liposome (pf)... 19	caffeine citrate... 177	carbinoxamine maleate... 190
bupivacaine-dextrose-water(pf)... 19	CALAN SR... 96	CARBOCAINE WITH NEO-COBEFRIN... 19
bupivacaine-epinephrine (pf)... 19	calcipotriene-betamethasone... 118	carboplatin... 53
bupivacaine-epinephrine... 19	calcipotriene... 118	carboprost tromethamine... 146
BUPRENEX... 11	calcitonin (salmon)... 174	carbzah... 190
buprenorphine hcl... 11, 21	calcitriol... 118, 174	CARDIZEM CD... 96
buprenorphine-naloxone... 21	calcium chloride... 126	CARDIZEM LA... 96
buprenorphine... 11	calcium gluconate... 126	CARDIZEM... 96
bupropion hcl (smoking deter)... 21	CALDOLOR... 11	CARDURA XL... 96
bupropion hcl... 40	CALQUENCE (ACALABRUTINIB MAL)... 53	CARDURA... 96
bupirone... 81	CAMBIA... 11	CARETOUCH ALCOHOL PREP PAD... 177
busulfan... 53	camila... 147	carglumic acid... 126
BUSULFEX... 53	CAMPTOSAR... 53	carisoprodol... 196
butalbital-acetaminop-caf-cod... 177	camrese lo... 147	carmustine... 53
butalbital-acetaminophen-caff... 177	camrese... 147	CARNITOR (SUGAR-FREE)... 126
butalbital-acetaminophen... 177	CAMZYOS... 96	CARNITOR... 126
butalbital-aspirin-caffeine... 177	CANASA... 173	CAROSPIR... 96
butorphanol... 11	CANCIDAS... 45	carteolol... 184
BUTRANS... 11	candesartan-hydrochlorothiazid... 96	cartia xt... 97
BYDUREON BCISE... 83	candesartan... 96	carvedilol phosphate... 97
BYETTA... 83	CAPEX... 118	carvedilol... 97
BYLVAY... 177	CAPLYTA... 71	CASODEX... 53
BYSTOLIC... 96	CAPRELSA... 53	casprofungin... 45
C	captopril-hydrochlorothiazide... 96	CAYSTON... 190
c-nate dha... 126	captopril... 96	cefaclor... 24
CABENUVA... 76	CARAC... 118	cefadroxil... 24
cabergoline... 157	CARAFATE... 133	cefazolin in dextrose (iso-os)... 24
	CARBAGLU... 126	

cefazolin... 24	cevimeline... 116	CIMZIA POWDER FOR RECONST... 161
cefdinir... 24	CHANTIX CONTINUING MONTH BOX... 21	CIMZIA STARTER KIT... 161
cefepime in dextrose 5 %... 24	CHANTIX STARTING MONTH BOX... 21	CIMZIA... 161
cefepime in dextrose,iso-osm... 24	CHANTIX... 21	cinacalcet... 174
cefepime... 24	charlotte 24 fe... 147	CINQAIR... 190
cefixime... 24	chateal eq (28)... 147	CINRYZE... 161
cefotetan... 24	CHEMET... 126	CINVANTI... 43
cefoxitin in dextrose, iso-osm... 24	chenodal... 133	CIPRO HC... 187
cefoxitin... 24	chloramphenicol sod succinate... 25	CIPRO... 25
cefpodoxime... 24	chlordiazepoxide hcl... 81	CIPRODEX... 187
cefprozil... 24	chlorhexidine gluconate... 116	ciprofloxacin hcl... 25, 184, 188
ceftazidime... 24	chlorprocaine (pf)... 19	ciprofloxacin in 5 % dextrose... 25
ceftriaxone in dextrose,iso-os... 24	chloroquine phosphate... 67	ciprofloxacin-dexamethasone... 188
ceftriaxone... 24	chlorothiazide sodium... 97	ciprofloxacin... 25
cefuroxime axetil... 24	chlorpromazine... 71	cisplatin... 53
cefuroxime sodium... 24	chlorthalidone... 97	cialopram... 40
CELEBREX... 11	chlorzoxazone... 196	CITRANATAL B-CALM (FE GLUC)... 126
celecoxib... 11	CHOLBAM... 138	cladribine... 53
CELESTONE SOLUSPAN... 142	cholestyramine (with sugar)... 97	CLAFORAN... 25
CELEXA... 40	cholestyramine light... 97	claravis... 118
CELLCEPT INTRAVENOUS... 161	CHORIONIC GONADOTROPIN, HUMAN... 144	CLARINEX-D 12 HOUR... 177
CELLCEPT... 161	CIALIS... 141	CLARINEX... 190
CELONTIN... 32	CIBINQO... 161	clarithromycin... 25
CENTANY... 118	ciclodan... 45	clemastine... 190
cephalexin... 25	ciclopirox... 45	clemasz... 190
CEQUA... 184	cidofovir... 76	CLENPIQ... 133
CEQR SIMPLICITY INSERTER... 177	cilostazol... 90	CLEOCIN HCL... 25
CEQR SIMPLICITY... 177	CILOXAN... 184	CLEOCIN PEDIATRIC... 25
CERDELGA... 138	CIMDUO... 76	CLEOCIN T... 118
CEREBYX... 33	cimetidine hcl... 133	CLEOCIN... 25
CEREZYME... 138	cimetidine... 133	CLEVIPREX... 97
CERVIDIL... 177		CLIMARA PRO... 147
cetirizine... 190		
cetorelix... 199		
CETROTIDE... 199		

CLIMARA... 147
 clindacin etz... 118
 clindacin p... 118
 clindacin... 118
 CLINDAGEL... 118
 clindamycin hcl... 25
 clindamycin in 0.9 % sod chlor... 25
 clindamycin in 5 % dextrose... 25
 clindamycin palmitate hcl... 25
 clindamycin pediatric... 25
 clindamycin phosphate... 25, 118,
 119
 clindamycin-benzoyl peroxide... 119
 clindamycin-tretinoin... 119
 CLINDESSE... 25
 CLINIMIX 4.25%/D10W SULF FREE...
 126
 CLINIMIX 4.25%/D5W SULFIT
 FREE... 126
 CLINIMIX
 5%-D20W(SULFITE-FREE)... 126
 CLINIMIX 5%/D15W SULFITE
 FREE... 126
 CLINIMIX 6%-D5W
 (SULFITE-FREE)... 126
 CLINIMIX
 8%-D10W(SULFITE-FREE)... 127
 CLINIMIX
 8%-D14W(SULFITE-FREE)... 127
 CLINIMIX E 2.75%/D5W SULF
 FREE... 127
 CLINIMIX E 4.25%/D10W SUL
 FREE... 127
 CLINIMIX E 4.25%/D5W SULF
 FREE... 127
 CLINIMIX E 5%/D15W SULFIT
 FREE... 127
 CLINIMIX E 5%/D20W SULFIT
 FREE... 127
 CLINIMIX E 8%-D10W
 SULFITEFREE... 127
 CLINIMIX E 8%-D14W
 SULFITEFREE... 127
 CLINISOL SF 15 %... 127
 CLINOLIPID... 127
 clobazam... 33
 clobetasol-emollient... 119
 clobetasol... 119
 CLOBEX... 119
 clocortolone pivalate... 119
 clodan... 119
 clofarabine... 53
 CLOLAR... 53
 clomid... 199
 clomiphene citrate... 200
 clomipramine... 40
 clonazepam... 82
 clonidine hcl... 97, 110
 clonidine... 97
 clopidogrel... 90
 clorazepate dipotassium... 82
 CLOROTEKAL (PF)... 19
 clotrimazole-betamethasone... 45
 clotrimazole... 45
 clozapine... 71
 CLOZARIL... 71
 COARTEM... 67
 COBENFY STARTER PACK... 178
 COBENFY... 177
 codeine sulfate... 11
 codeine-butalbital-asa-caff... 11
 COLAZAL... 173
 colchicine... 48
 COLCRYS... 48
 colesevelam... 97
 COLESTID FLAVORED... 97
 COLESTID... 97
 colestipol... 97
 colistin (colistimethate na)... 25
 COLUMVI... 54
 COLY-MYCIN M PARENTERAL... 26
 COMBIGAN... 184
 COMBIPATCH... 147
 COMBIVENT RESPIMAT... 190
 COMBIVIR... 76
 COMBOGESIC IV... 178
 COMETRIQ... 54
 COMPAZINE... 43
 COMPLERA... 76
 complete natal dha... 127
 compro... 43
 COMTAN... 68
 CONCERTA... 110
 CONDYLOX... 119
 constulose... 133
 CONZIP... 11
 COPAXONE... 110
 COPIKTRA... 54
 CORDRAN TAPE LARGE ROLL... 119
 CORDRAN... 119
 COREG CR... 97
 COREG... 97
 CORGARD... 97
 CORLANOR... 97

CORLOPAM... 97
CORTEF... 119
CORTENEMA... 173
CORTIFOAM... 173
CORTISPORIN-TC... 188
CORTROPHIN GEL... 142
CORVERT... 98
COSENTYX (2 SYRINGES)... 161
COSENTYX PEN (2 PENS)... 162
COSENTYX PEN... 161
COSENTYX UNOREADY PEN... 162
COSENTYX... 161
COSMEGEN... 54
COSOPT (PF)... 184
COSOPT... 184
COTELLIC... 54
COTEMPLA XR-ODT... 110
COZAAR... 98
CRENESSITY... 147
CREON... 138
CRESEMBA... 46
CRESTOR... 98
CREXONT... 68
CRINONE... 147
cromolyn... 184, 190
crotan... 120
cryselle (28)... 148
CRYSVITA... 138
CTEXLI... 133
CUBICIN RF... 26
CUPRIMINE... 127
CURITY ALCOHOL SWABS... 178
CURITY GAUZE... 178
CUTAQUIG... 162
CUVPOSA... 133
CUVRIOR... 127
cyanocobalamin (vitamin b-12)...
200
cyclobenzaprine... 196
cyclophosphamide... 54
cycloserine... 51
CYCLOSET... 83
cyclosporine modified... 162
cyclosporine... 162, 184
CYKLOKAPRON... 90
CYLTEZO(CF) PEN CROHN'S-UC-HS...
162
CYLTEZO(CF) PEN PSORIASIS-UV...
162
CYLTEZO(CF) PEN... 162
CYLTEZO(CF)... 162
CYMBALTA... 110
cyproheptadine... 190
CYRAMZA... 54
cyred eq... 148
cyred... 148
CYSTADANE... 138
CYSTADROPS... 184
CYSTAGON... 138
CYSTARAN... 184
cytarabine (pf)... 54
cytarabine... 54
CYTOGAM... 162
CYTOMEL... 156
CYTOTEC... 133

D

d10 %-0.45 % sodium chloride...
127
d2.5 %-0.45 % sodium chloride...
127
d5 % (d-glucose)-0.9 % sodchlr...
127
d5 % and 0.9 % sodium chloride...
127
d5 %-0.45 % sodium chloride... 127
dabigatran etexilate... 90
dacarbazine... 54
dactinomycin... 54
dalfampridine... 110
DALIRESP... 190
DALVANCE... 26
danazol... 148
DANTRIUM... 75
dantrolene... 75
DANYELZA... 54
DANZITEN... 54
dapson... 51, 120
DAPTACEL (DTAP PEDIATRIC) (PF)...
162
daptomycin in 0.9 % sod chlor... 26
daptomycin... 26
DARAPRIM... 67
darifenacin... 141
DARTISLA... 133
darunavir... 76
DARZALEX FASPRO... 54
DARZALEX... 54
dasatinib... 54
dasetta 1/35 (28)... 148
dasetta 7/7/7 (28)... 148
DATROWAY... 54
daunorubicin... 54
DAURISMO... 54
DAYBUE... 138
DAYPRO... 11

daysee... 148	DERMOTIC OIL... 188	dextrose 10 % in water (d10w)... 127
DAYTRANA... 110	DESCOVY... 76	dextrose 25 % in water (d25w)... 127
DAYVIGO... 197	DESFERAL... 127	dextrose 5 % in water (d5w)... 127
DDAVP... 144	desipramine... 40	dextrose 5 %-lactated ringers... 128
deblitane... 148	desloratadine... 190	dextrose 5%-0.2 % sod chloride... 128
decitabine... 54	desmopressin... 145	dextrose 5%-0.3 % sod.chloride... 128
deferasirox... 127	desog-e.estradiol/e.estradiol... 148	dextrose 50 % in water (d50w)... 128
deferiprone... 127	desonide... 120	dextrose 70 % in water (d70w)... 128
deferoxamine... 127	DESOWEN... 120	DHIVY... 68
DEFITELIO... 178	desoximetasone... 120	DIACOMIT... 33
deflazacort... 142	DESOXYN... 110	DIASTAT ACUDIAL... 33
DELESTROGEN... 148	desrx... 120	DIASTAT... 33
DELSTRIGO... 76	desvenlafaxine succinate... 40	diazepam intensol... 82
DELZICOL... 173	desvenlafaxine... 40	diazepam... 33, 82
demeclocycline... 26	DETROL LA... 141	diazoxide... 83
DEMEROL (PF)... 12	DETROL... 141	DIBENZYLINE... 98
DEMEROL... 12	dexabliss... 142	dichlorphenamide... 138
DEMSER... 98	dexamethasone intensol... 143	DICLEGIS... 43
DENAVIR... 76	dexamethasone sodium phos (pf)... 143	diclofenac epolamine... 12
DENGVAXIA (PF)... 162	dexamethasone sodium phosphate... 143, 184	diclofenac potassium... 12
DEPAKOTE ER... 33	dexamethasone... 142, 143	diclofenac sodium... 12, 120, 184
DEPAKOTE SPRINKLES... 33	dexchlorpheniramine maleate... 190	diclofenac-misoprostol... 12
DEPAKOTE... 33	DEXEDRINE SPANSULE... 110	dicloxacillin... 26
DEPEN TITRATABS... 127	DEXILANT... 133	dicyclomine... 133
DEPO-ESTRADIOL... 148	dexlansoprazole... 133	didanosine... 76
DEPO-MEDROL... 142	dexmethylphenidate... 110, 111	DIFFERIN... 120
DEPO-PROVERA... 148	dexrazoxane hcl... 54	DIFICID... 26
DEPO-SUBQ PROVERA 104... 148	DEXTENZA... 184	diflorasone... 120
DEPO-TESTOSTERONE... 148	dextroamphetamine sulfate... 111	DIFLUCAN... 46
DERMA-SMOOTH/FS BODY OIL... 120	dextroamphetamine-amphetamine... 111	
DERMA-SMOOTH/FS SCALP OIL... 120	dextrose 10 % and 0.2 % nacl... 127	
DERMACEA... 178		
dermacinrx lidocan... 19		

diflunisal... 12
 difluprednate... 184
 digitek... 98
 digoxin... 98
 dihydroergotamine... 49
 DILANTIN EXTENDED... 33
 DILANTIN INFATABS... 33
 DILANTIN-125... 33
 DILANTIN... 33
 DILAUDID... 12
 dilt-xr... 98
 diltiazem hcl... 98
 dimenhydrinate... 43
 dimethyl fumarate... 111
 DIOVAN HCT... 98
 DIOVAN... 98
 DIPENTUM... 173
 DIPHEN... 190
 diphenhydramine hcl... 190
 diphenoxylate-atropine... 133
 DIPROLENE (AUGMENTED)... 120
 dipyridamole... 90
 disopyramide phosphate... 98
 disulfiram... 21
 DITROPAN XL... 141
 DIURIL... 98
 divalproex... 33
 DIVIGEL... 148
 dobutamine in d5w... 98
 dobutamine... 98
 docetaxel... 55
 DOCIVYX... 55
 dodex... 200
 dofetilide... 98
 DOJOLVI... 138
 dolishale... 148
 dolobid... 12
 donepezil... 39
 dopamine in 5 % dextrose... 98
 dopamine... 98
 DOPRAM... 190
 DOPTelet (10 TAB PACK)... 90
 DOPTelet (15 TAB PACK)... 90
 DOPTelet (30 TAB PACK)... 90
 DORYX MPC... 26
 DORYX... 26
 dorzolamide-timolol (pf)... 184
 dorzolamide-timolol... 184
 dorzolamide... 184
 dotti... 148
 DOVATO... 76
 doxazosin... 98
 doxepin... 82, 120, 197
 doxercalciferol... 174
 DOXIL... 55
 doxorubicin, peg-liposomal... 55
 doxorubicin... 55
 doxy-100... 26
 doxycycline hyclate... 26
 doxycycline monohydrate... 26, 27
 doxylamine-pyridoxine (vit b6)... 43
 DRISDOL... 200
 DRIZALMA SPRINKLE... 111
 dronabinol... 44
 droperidol... 71
 DROPLET INSULIN SYR(HALF UNIT)... 178
 DROPLET INSULIN SYRINGE... 178
 DROPLET MICRON PEN NEEDLE... 178
 DROPLET PEN NEEDLE... 178
 DROPSAFE ALCOHOL PREP PADS... 178
 DROPSAFE PEN NEEDLE... 178
 drospirenone-e.estradiol-lm.fa... 148
 drospirenone-ethinyl estradiol... 148
 DROXIA... 178
 droxidopa... 99
 DUAKLIR PRESSAIR... 190
 DUAVEE... 148
 DUET DHA WITH OMEGA-3... 128
 DUETACT... 83
 DUEXIS... 12
 DULERA... 191
 duloxetine... 111
 DUOBRII... 120
 DUOPA... 68
 DUPIXENT PEN... 162
 DUPIXENT SYRINGE... 162
 DURAMORPH (PF)... 12
 DUREZOL... 184
 DURYSTA... 184
 dutasteride-tamsulosin... 141
 dutasteride... 141
 DUVYZAT... 138
 DUZALLO... 48
 DYANAVEL XR... 111
 DYMISTA... 191
 DYRENIUM... 99

E

E.E.S. 400... 27
 E.E.S. GRANULES... 27
 EASY COMFORT ALCOHOL PAD... 178

EASY TOUCH ALCOHOL PREP PADS... 178	ELIDEL... 120	emzahn... 148
EBGLYSS PEN... 120	ELIGARD (3 MONTH)... 157	enalapril maleate... 99
EBGLYSS SYRINGE... 120	ELIGARD (4 MONTH)... 157	enalapril-hydrochlorothiazide... 99
ec-naproxen... 12	ELIGARD (6 MONTH)... 157	enalaprilat... 99
econazole nitrate... 46	ELIGARD... 157	ENBREL MINI... 162
edaravone... 111	ELIMITE... 120	ENBREL SURECLICK... 162
EDARBI... 99	elinest... 148	ENBREL... 162
EDARBYCLOR... 99	ELIQUIS DVT-PE TREAT 30D START... 91	ENDARI... 133
EDECIN... 99	ELIQUIS... 90, 91	endocet... 12
edetate calcium disodium... 178	ELITEK... 55	ENDOMETRIN... 148
EDLUAR... 197	ELIXOPHYLLIN... 191	ENFLONSIA... 178
EDURANT PED... 76	ELLECE... 55	ENGERIX-B (PF)... 162
EDURANT... 76	ELMIRON... 141	ENGERIX-B PEDIATRIC (PF)... 162
efavirenz-emtricitabin-tenofov... 76	ELREXFIO... 55	ENHERTU... 55
efavirenz-lamivu-tenofov disop... 76	eluryng... 148	enilloring... 148
efavirenz... 76	ELYXYB... 178	ENJAYMO... 162
EFFEXOR XR... 40	ELZONRIS... 55	enoxaparin... 91
EFFIENT... 90	EMBLAVEO... 27	enpresse... 148
EFUDEX... 120	EMCYT... 55	enskyce... 148
EGATEN... 67	EMEND (FOSAPREPITANT)... 44	ENSPRYNG... 184
EGRIFTA SV... 145	EMEND... 44	ENSTILAR... 120
EKTERLY... 162	EMFLAZA... 143	entacapone... 69
ELAHERE... 55	EMGALITY PEN... 49	entecavir... 77
ELAPRASE... 138	EMGALITY SYRINGE... 49	ENTRESTO SPRINKLE... 99
electrolyte-148... 128	EMPAVELI... 178	ENTRESTO... 99
electrolyte-48 in d5w... 128	EMPLICITI... 55	ENTYVIO PEN... 163
electrolyte-a... 128	EMRELIS... 55	ENTYVIO... 162
ELELYSO... 138	EMROSI... 27	enulose... 133
ELEPSIA XR... 33	EMSAM... 40	ENVARUSUS XR... 163
ELESTRIN... 148	emtricitabine-tenofov df... 76	EOHILIA... 179
eletriptan... 49	emtricitabine-tenofov (tdf)... 77	EPANED... 99
ELEVIDYS... 138	emtricitabine... 76	EPCLUSA... 77
ELFABRIO... 138	EMTRIVA... 77	EPIDIOLEX... 33
	emverm... 67	EPIDUO FORTE... 121

EPIDUO... 121	ERTACZO... 46	ethynodiol diac-eth estradiol... 149
EPIFOAM... 121	ertapenem... 27	etodolac... 12, 13
epinastine... 184	ery pads... 121	etonogestrel-ethinyl estradiol... 149
epineph bitart in 0.9% sod chl... 99	ERY-TAB... 27	ETOPOPHOS... 55
epinephrine... 191	ERYGEL... 121	etoposide... 55
EPIPEN 2-PAK... 191	ERYPED 200... 27	etravirine... 77
EPIPEN JR 2-PAK... 191	ERYPED 400... 27	EUCRISA... 121
EPIPEN JR... 191	ERYTHROCIN (AS STEARATE)... 27	EULEXIN... 55
EPIPEN... 191	ERYTHROCIN... 27	EURAX... 121
epirubicin... 55	erythromycin ethylsuccinate... 27	EUTHYROX... 156
epitol... 33	erythromycin lactobionate... 27	EVAMIST... 149
EPIVIR... 77	erythromycin with ethanol... 121	EVEKEO ODT... 111
EPKINLY... 55	erythromycin-benzoyl peroxide... 121	EVEKEO... 111
eplerenone... 99	erythromycin... 27, 184	EVENITY... 174
EPOGEN... 91	ESBRIET... 191	everolimus (antineoplastic)... 55
epoprostenol... 191	escitalopram oxalate... 40	everolimus (immunosuppressive)... 163
EPRONTIA... 33	ESGIC... 179	EVISTA... 149
eprosartan... 99	eslicarbazepine... 33	EVKEEZA... 99
EPSOLAY... 121	esmolol in nacl (iso-osm)... 99	EVOCLIN... 121
eptifibatide... 91	esmolol... 99	EVOMELA... 56
EPYSQLI... 163	esomeprazole magnesium... 134	EVOTAZ... 77
EPZICOM... 77	esomeprazole sodium... 134	EVOXAC... 116
EQUETRO... 33	estarylla... 149	EVRYSDI... 138
ERAXIS(WATER DILUENT)... 46	estazolam... 197	EXELDERM... 46
ERBITUX... 55	ESTRACE... 149	EXELON PATCH... 39
ergocalciferol (vitamin d2)... 201	estradiol valerate... 149	exemestane... 56
ergoloid... 39	estradiol-norethindrone acet... 149	exenatide... 84
ERGOMAR... 49	estradiol... 149	EXFORGE HCT... 99
ergotamine-caffeine... 49	ESTRING... 149	EXFORGE... 99
eribulin... 55	eszopiclone... 197	EXJADE... 128
ERIVEDGE... 55	ethacrynate sodium... 99	EXKIVITY... 56
ERLEADA... 55	ethacrynic acid... 99	EXPAREL (PF)... 19
erlotinib... 55	ethambutol... 51	EXSERVAN... 112
ERMEZA... 156	ethosuximide... 33	EXTAVIA... 112
errin... 149		

EXTINA... 46
 EYSUVIS... 184
 EZALLOR SPRINKLE... 99
 ezetimibe-rosuvastatin... 99
 ezetimibe-simvastatin... 99
 ezetimibe... 99
F
 FABHALTA... 163
 FABIOR... 121
 FABRAZYME... 138
 falmina (28)... 149
 famciclovir... 77
 famotidine (pf)-nacl (iso-os)... 134
 famotidine (pf)... 134
 famotidine... 134
 FANAPT TITRATION PACK A... 71
 FANAPT TITRATION PACK B... 71
 FANAPT TITRATION PACK C... 71
 FANAPT... 71
 FARESTON... 56
 FARXIGA... 84
 FASENRA PEN... 191
 FASENRA... 191
 FASLODEX... 56
 febuxostat... 48
 feirza... 149
 felbamate... 33
 FELBATOL... 33
 FELDENE... 13
 felodipine... 99
 FEMARA... 56
 FEMLYV... 149
 FEMRING... 149
 fenofibrate micronized... 100
 fenofibrate nanocrystallized... 100
 fenofibrate... 99, 100
 fenofibric acid (choline)... 100
 fenofibric acid... 100
 FENOGLIDE... 100
 fenoprofen... 13
 fenopron... 13
 FENSOLVI... 157
 fentanyl citrate (pf)... 13
 fentanyl citrate... 13
 fentanyl... 13
 FENTORA... 13
 FERRIPROX (2 TIMES A DAY)... 128
 FERRIPROX... 128
 fesoterodine... 141
 FETROJA... 27
 FETZIMA... 40
 FEXMID... 196
 FIASP FLEXTOUCH U-100 INSULIN... 84
 FIASP PENFILL U-100 INSULIN... 84
 FIASP U-100 INSULIN... 84
 FIBRICOR... 100
 fidaxomicin... 27
 FILSPARI... 179
 FILSUEVZ... 179
 FINACEA... 121
 finasteride... 141
 fingolimod... 112
 FINTEPLA... 33
 finzala... 149
 FIORICET WITH CODEINE... 179
 fioricet... 179
 FIRAZYR... 163
 FIRDAPSE... 112
 FIRMAGON KIT W DILUENT SYRINGE... 157
 FIRMAGON... 157
 FIRVANQ... 27
 flac otic oil... 188
 FLAGYL... 27
 FLAREX... 184
 flavoxate... 141
 FLEBOGAMMA DIF... 163
 flecainide... 100
 FLECTOR... 13
 FLEQSUVY... 75
 FLOLIPID... 100
 FLOMAX... 141
 floxuridine... 56
 fluconazole in nacl (iso-osm)... 46
 fluconazole... 46
 flucytosine... 46
 fludarabine... 56
 fludrocortisone... 143
 FLUMADINE... 77
 flumazenil... 179
 flunisolide... 191
 fluocinolone acetonide oil... 188
 fluocinolone and shower cap... 121
 fluocinolone... 121
 fluocinonide-e... 121
 fluocinonide-emollient... 121
 fluocinonide... 121
 fluorometholone... 185
 FLUOROPLEX... 121
 fluorouracil... 56, 121, 122
 fluoxetine... 40, 41
 fluphenazine decanoate... 71
 fluphenazine hcl... 71

flurandrenolide... 122	FRINDOVYX... 56	GANIRELIX... 200
flurazepam... 197	FROVA... 49	GARDASIL 9 (PF)... 163
flurbiprofen sodium... 185	frovatriptan... 49	GASTROCROM... 191
flurbiprofen... 13	FRUZAQLA... 56	gatifloxacin... 185
fluticasone propion-salmeterol... 191	FULPHILA... 91	GATTEX 30-VIAL... 134
fluticasone propionate... 122, 191	fulvestrant... 56	GATTEX ONE-VIAL... 134
fluvastatin... 100	FULVICIN P/G... 46	GAUZE BANDAGE... 179
fluvoxamine... 41	FURADANTIN... 27	GAUZE PAD... 179
FML FORTE... 185	FUROSCIX... 100	gavilyte-c... 134
FML LIQUIFILM... 185	furosemide... 100	gavilyte-g... 134
FOCALIN XR... 112	FUSILEV... 56	gavilyte-n... 134
FOCALIN... 112	FUZEON... 77	GAVRETO... 56
FOCINVEZ... 44	FYARRO... 56	GAZYVA... 56
folic acid... 201	fyavolv... 149	gefitinib... 56
FOLLISTIM AQ... 200	FYCOMPA... 34	GELNIQUE... 141
FOLOTYN... 56	FYLNETRA... 91	gemcitabine... 56
fomepizole... 179	fyremadel... 200	gemfibrozil... 100
fondaparinux... 91	G	gemmily... 149
FORFIVO XL... 41	gabapentin... 34, 112	GEMTESA... 141
formoterol fumarate... 191	GABARONE... 34	generlac... 134
FORTEO... 174	GALAFOLD... 138	gengraf... 163
FORTESTA... 149	galantamine... 39	GENOTROPIN MINIQUICK... 145
FOSAMAX PLUS D... 174	galbriela... 149	GENOTROPIN... 145
FOSAMAX... 174	gallifrey... 149	gentamicin in nacl (iso-osm)... 27
fosamprenavir... 77	GAMASTAN... 163	gentamicin sulfate (ped) (pf)... 28
fosaprepitant... 44	GAMIFANT... 163	gentamicin... 27, 185
foscarnet... 77	GAMMAGARD LIQUID... 163	GENVOYA... 77
fosfomycin tromethamine... 27	GAMMAGARD S-D (IGA < 1 MCG/ML)... 163	GEODON... 71, 72
fosinopril-hydrochlorothiazide... 100	GAMMAKED... 163	GILENYA... 112
fosinopril... 100	GAMMAPLEX (WITH SORBITOL)... 163	GILOTRIF... 56
fosphenytoin... 34	GAMMAPLEX... 163	GIMOTI... 44
FOTIVDA... 56	GAMUNEX-C... 163	GIVLAARI... 179
FRAGMIN... 91	ganciclovir sodium... 77	GLASSIA... 138
		glatiramer... 112

glatopa... 112	granisetron (pf)... 44	HAVRIX (PF)... 164
GLEEVEC... 56	granisetron hcl... 44	heather... 150
GLEOSTINE... 56	GRANIX... 91	HECTOROL... 174
glimepiride... 84	GRASTEK... 191	HEMABATE... 146
glipizide-metformin... 84	griseofulvin microsize... 46	HEMADY... 143
glipizide... 84	griseofulvin ultramicrosize... 46	HEMANGEOL... 100
GLOPERBA... 48	guanfacine... 100, 112	HEMICLOR... 100
GLUCAGEN HYPOKIT... 84	GVOKE HYPOPEN 1-PACK... 84	heparin (porcine)... 91
GLUCAGON (HCL) EMERGENCY KIT... 84	GVOKE HYPOPEN 2-PACK... 84	heparin, porcine (pf)... 91, 92
glucagon emergency kit (human)... 84	GVOKE PFS 1-PACK SYRINGE... 84	HEPLISAV-B (PF)... 164
GLUCOTROL XL... 84	GVOKE PFS 2-PACK SYRINGE... 84	HEPSERA... 77
GLUMETZA... 84	GVOKE... 84	HERCEPTIN HYLECTA... 57
glutamine (sickle cell)... 134	gynazole-1... 46	HERCEPTIN... 57
glyburide micronized... 84	H	HERZUMA... 57
glyburide-metformin... 84	HADLIMA PUSHTOUCH... 163	HETLIOZ LQ... 197
glyburide... 84	HADLIMA(CF) PUSHTOUCH... 163	HETLIOZ... 197
GLYCATE... 134	HADLIMA(CF)... 163	HIBERIX (PF)... 164
GLYCOPHOS... 128	HADLIMA... 163	HIPREX... 28
glycopyrrolate (pf) in water... 134	HAEGARDA... 163	HIZENTRA... 164
glycopyrrolate (pf)... 134	hailey 24 fe... 149	HORIZANT... 112
glycopyrrolate... 134	hailey fe 1.5/30 (28)... 150	HULIO(CF) PEN... 164
glydo... 19	hailey fe 1/20 (28)... 150	HULIO(CF)... 164
GLYNASE... 84	hailey... 149	HUMALOG JUNIOR KWIKPEN U-100... 84
GLYXAMBI... 84	HALAVEN... 57	HUMALOG KWIKPEN INSULIN... 85
GOCOVRI... 69	halcinonide... 122	HUMALOG MIX 50-50 INSULN U-100... 85
GOLYTELY... 134	HALCION... 197	HUMALOG MIX 50-50 KWIKPEN... 85
GOMEKLI... 56, 57	HALDOL DECANOATE... 72	HUMALOG MIX 75-25 KWIKPEN... 85
GONAL-F RFF REDI-JECT... 200	halobetasol propionate... 122	HUMALOG MIX 75-25 KWIKPEN... 85
GONAL-F RFF... 200	haloette... 150	HUMALOG MIX 75-25(U-100)INSULN... 85
GONAL-F... 200	HALOG... 122	HUMALOG TEMPO PEN(U-100)INSULN... 85
GONITRO... 100	haloperidol decanoate... 72	HUMALOG U-100 INSULIN... 85
GRAFAPEX... 57	haloperidol lactate... 72	HUMATIN... 28
GRALISE... 112	haloperidol... 72	
	HARLIKU... 138	
	HARVONI... 77	

HUMATROPE... 145	hydrocodone bitartrate... 13	HYZAAR... 101
HUMIRA PEN CROHNS-UC-HS START... 164	hydrocodone-acetaminophen... 13	I
HUMIRA PEN... 164	hydrocodone-chlorpheniramine... 199	ibandronate... 174
HUMIRA(CF) PEDI CROHNS STARTER... 164	hydrocodone-homatropine... 199	IBRANCE... 57
HUMIRA(CF) PEN CROHNS-UC-HS... 164	hydrocodone-ibuprofen... 13	IBSRELA... 134
HUMIRA(CF) PEN PEDIATRIC UC... 164	hydrocortisone butyr-emollient... 122	IBTROZI... 57
HUMIRA(CF) PEN PSOR-UV-ADOL HS... 164	hydrocortisone butyrate... 122	ibu... 14
HUMIRA(CF) PEN... 164	hydrocortisone sod succinate... 143	ibuprofen-famotidine... 14
HUMIRA(CF)... 164	hydrocortisone valerate... 122	ibuprofen... 14
HUMIRA... 164	hydrocortisone-acetic acid... 188	ibutilide fumarate... 101
HUMULIN 70/30 U-100 INSULIN... 85	hydrocortisone... 122, 173	icatibant... 165
HUMULIN 70/30 U-100 KWIKPEN... 85	hydromet... 199	iclevia... 150
HUMULIN N NPH INSULIN KWIKPEN... 85	hydromorphone (pf)... 14	ICLUSIG... 57
HUMULIN N NPH U-100 INSULIN... 85	HYDROMORPHONE... 13, 14	IDACIO(CF) PEN CROHN-UC STARTR... 165
HUMULIN R REGULAR U-100 INSULN... 85	hydroxocobalamin... 201	IDACIO(CF) PEN PSORIASIS START... 165
HUMULIN R U-500 (CONC) INSULIN... 85	hydroxychloroquine... 67	IDACIO(CF) PEN... 165
HUMULIN R U-500 (CONC) KWIKPEN... 85	hydroxyurea... 57	IDACIO(CF)... 165
HYCAMTIN... 57	hydroxyzine hcl... 82	IDAMYCIN PFS... 57
HYCODAN (WITH HOMATROPINE)... 199	hydroxyzine pamoate... 191	idarubicin... 57
HYCODAN... 199	HYFTOR... 122	IDHIFA... 57
hydralazine... 100	HYPERRAB (PF)... 164	IFEX... 57
HYDREA... 57	HYPERTET (PF)... 164	ifosfamide... 57
hydrochlorothiazide... 101	HYRIMOZ PEN CROHN'S-UC STARTER... 164	IGALMI... 179
	HYRIMOZ PEN PSORIASIS STARTER... 164	ILEVRO... 185
	HYRIMOZ PEN... 164	ILUMYA... 165
	HYRIMOZ(CF) PEDI CROHN STARTER... 165	IMAAVY... 165
	HYRIMOZ(CF) PEN... 165	imatinib... 57
	HYRIMOZ(CF)... 164	IMBRUVICA... 57
	HYRIMOZ... 164	IMDELLTRA... 57
	HYSINGLA ER... 14	IMFINZI... 57
		imipenem-cilastatin... 28
		imipramine hcl... 41
		imipramine pamoate... 41

imiquimod... 122, 123	INGREZZA... 112	INVOKAMET... 86
IMITREX STATDOSE PEN... 49	INLYTA... 58	INVOKANA... 86
IMITREX STATDOSE REFILL... 49	INNOPRAN XL... 101	INZIRQO... 101
IMITREX... 49	INPEFA... 101	IONOSOL-MB IN D5W... 128
IMJUDO... 57	INQOVI... 58	IOPIDINE... 185
IMKELDI... 57	INREBIC... 58	IPOL... 165
IMLYGIC... 57	INSPRA... 101	ipratropium bromide... 192
IMMPHENTIV... 101	INSULIN ASP PRT-INSULIN ASPART... 85	ipratropium-albuterol... 192
IMOGAM RABIES-HT (PF)... 165	INSULIN ASPART U-100... 85	IQIRVO... 134
IMOVAX RABIES VACCINE (PF)... 165	INSULIN DEGLUDEC... 85	irbesartan-hydrochlorothiazide... 101
IMPAVIDO... 67	INSULIN GLARGINE U-300 CONC... 85	irbesartan... 101
IMPEKLO... 123	INSULIN GLARGINE-YFGN... 85	IRESSA... 58
IMURAN... 165	INSULIN GLARGINE... 85	irinotecan... 58
IMVEXXY MAINTENANCE PACK... 150	INSULIN LISPRO PROTAMIN-LISPRO... 86	ISENTRESS HD... 78
IMVEXXY STARTER PACK... 150	INSULIN LISPRO... 86	ISENTRESS... 77, 78
INBRIJA... 69	INSULIN SYRINGE MICROFINE... 179	isibloom... 150
incassia... 150	INSULIN SYRINGE-NEEDLE U-100... 179	ISOLYTE S PH 7.4... 128
INCONTROL ALCOHOL PADS... 179	INSULIN SYRINGE... 179	ISOLYTE-P IN 5 % DEXTROSE... 128
INCRELEX... 145	INSULIN U-500 SYRINGE-NEEDLE... 179	ISOLYTE-S... 128
INCRUSE ELLIPTA... 191	INTELENCE... 77	isoniazid... 51
indapamide... 101	INTRALIPID... 128	ISORDIL TITRADOSE... 101
INDERAL LA... 101	INTRAROSA... 150	ISORDIL... 101
INDOCIN... 14	introvale... 150	isosorbide dinitrate... 101
indomethacin sodium... 14	INTUNIVER... 112	isosorbide mononitrate... 101
indomethacin... 14	INVEGA HAFYERA... 72	isosorbide-hydralazine... 101
INFANRIX (DTAP) (PF)... 165	INVEGA SUSTENNA... 72	isotretinoin... 123
INFLECTRA... 165	INVEGA TRINZA... 72	isradipine... 101
INFLIXIMAB... 165	INVEGA... 72	ISTALOL... 185
INFUGEM... 58	INVELTYS... 185	ISTODAX... 58
INFUMORPH P/F... 14	INVOKAMET XR... 86	ISTURISA... 145
INFUVITE ADULT... 201		ISUPREL... 101
INFUVITE PEDIATRIC... 201		ITOVEBI... 58
INGREZZA INITIATION PK(TARDIV)... 112		itraconazole... 46
INGREZZA SPRINKLE... 112		IV PREP WIPES... 179

ivabradine... 101	juleber... 150	KESIMPTA PEN... 112
ivermectin... 67, 123	JULUCA... 78	ketoconazole... 46
IVRA... 58	junel 1.5/30 (21)... 150	ketodan... 46
IWILFIN... 58	junel 1/20 (21)... 150	ketoprofen... 14, 15
IXCHIQ (PF)... 165	junel fe 1.5/30 (28)... 150	ketorolac... 15, 185
IXEMPRA... 58	junel fe 1/20 (28)... 150	KEVEYIS... 138
IXIARO (PF)... 165	junel fe 24... 150	KEVZARA... 165
IYUZEH (PF)... 185	JUXTAPID... 101	KEYTRUDA... 58
J	JYLAMVO... 165	KHAPZORY... 58
JADENU SPRINKLE... 128	JYNARQUE... 128	KHINDIVI... 143
JADENU... 128	JYNNEOS (PF)... 165	KIMMTRAK... 58
jaimiess... 150	K	KIMYRSA... 28
JAKAFI... 58	KABIVEN... 128	KINERET... 165
JALYN... 141	KADCYLA... 58	KINRIX (PF)... 165
jantoven... 92	kaitlib fe... 150	kionex (with sorbitol)... 128
JANUMET XR... 86	KALETRA... 78	kiprofen... 15
JANUMET... 86	kalliga... 150	KISQALI FEMARA CO-PACK... 58
JANUVIA... 86	KALYDECO... 192	KISQALI... 58
JARDIANCE... 86	KANJINTI... 58	KITABIS PAK... 28
jasmiel (28)... 150	KANUMA... 138	KLARON... 28
JATENZO... 150	KAPSPARGO SPRINKLE... 101	klayesta... 46
javygtor... 138	KAPVAY... 112	KLISYRI (250 MG)... 123
JAYPIRCA... 58	kariva (28)... 150	KLISYRI (350 MG)... 123
JEMPERLI... 58	KATERZIA... 101	KLONOPIN... 82
jencycla... 150	KAZANO... 86	KLOR-CON 10... 128
JENTADUETO XR... 86	KEDRAB (PF)... 165	KLOR-CON 8... 128
JENTADUETO... 86	kelnor 1/35 (28)... 150	klor-con m10... 129
JEVTANA... 58	kelnor 1/50 (28)... 150	KLOR-CON M15... 129
jjinteli... 150	KENALOG-80... 143	klor-con m20... 129
JOENJA... 138	KENALOG... 143	klor-con... 128
jolessa... 150	KENGREAL... 92	KLOXXADO... 21
JORNAY PM... 112	KEPIVANCE... 116	KONVOMEF... 134
JOURNAVX... 179	KEPPRA XR... 34	KORLYM... 179
joyeaux... 150	KEPPRA... 34	KOSELUGO... 59
JUBLIA... 46	KERENDIA... 101, 102	

KOSHER PRENATAL PLUS IRON... 129
 kourzeq... 116
 KRAZATI... 59
 KRINTAFEL... 67
 KRISTALOSE... 134
 kurvelo (28)... 150
 KUVAN... 138
 KYPROLIS... 59

L

l norgest/e.estradiol-e.estradiol... 151
 LABETALOL IN DEXTROSE,ISO-OSM... 102
 LABETALOL IN NAACL (ISO-OSMOT)... 102
 labetalol... 102
 lacosamide... 34
 LACRISERT... 185
 lactated ringers... 129, 179
 lactulose... 134
 LAMICTAL ODT STARTER (BLUE)... 34
 LAMICTAL ODT STARTER (GREEN)... 34
 LAMICTAL ODT STARTER (ORANGE)... 34
 LAMICTAL ODT... 34
 LAMICTAL STARTER (BLUE) KIT... 34
 LAMICTAL STARTER (GREEN) KIT... 34
 LAMICTAL STARTER (ORANGE) KIT... 34
 LAMICTAL XR STARTER (BLUE)... 35
 LAMICTAL XR STARTER (GREEN)... 35
 LAMICTAL XR STARTER (ORANGE)... 35
 LAMICTAL XR... 34

LAMICTAL... 34
 lamivudine-zidovudine... 78
 lamivudine... 78
 lamotrigine... 35
 LAMPIT... 67
 LAMZEDE... 138
 LANOXIN PEDIATRIC... 102
 LANOXIN... 102
 lanreotide... 157, 158
 lansoprazole... 134
 LANTUS SOLOSTAR U-100 INSULIN... 86
 LANTUS U-100 INSULIN... 86
 lapatinib... 59
 larin 1.5/30 (21)... 151
 larin 1/20 (21)... 151
 larin 24 fe... 151
 larin fe 1.5/30 (28)... 151
 larin fe 1/20 (28)... 151
 LASIX... 102
 latanoprost... 185
 LATUDA... 72
 LAYOLIS FE... 151
 LAZCLUZE... 59
 ledipasvir-sofosbuvir... 78
 leena 28... 151
 leflunomide... 165
 LEMTRADA... 112
 lenalidomide... 59
 LENVIMA... 59
 LEQSELVI... 165
 LEQVIO... 102
 LESCOL XL... 102
 lessina... 151
 LETAIRIS... 192

letrozole... 59
 leucovorin calcium... 59
 LEUKERAN... 59
 LEUKINE... 92
 leuprolide (3 month)... 158
 leuprolide... 158
 levalbuterol hcl... 192
 levalbuterol tartrate... 192
 LEVEMIR FLEXPEN... 86
 LEVEMIR U-100 INSULIN... 86
 levetiracetam in nacl (iso-os)... 35
 levetiracetam... 35
 LEVO-T... 156
 levobunolol... 185
 levocarnitine (with sugar)... 129
 levocarnitine... 129
 levocetirizine... 192
 levofloxacin in d5w... 28
 levofloxacin... 28, 185
 levoleucovorin calcium... 59
 levonest (28)... 151
 levonorg-eth estrad triphasic... 151
 levonorgest-eth.estradiol-iron... 151
 levonorgestrel-ethinyl estrad... 151
 LEVOPHED (BITARTRATE)... 102
 levora-28... 151
 levorphanol tartrate... 15
 levothyroxine... 156, 157
 LEVOXYL... 157
 LEVULAN... 59
 LEXAPRO... 41
 LEXETTE... 123
 LEXIVA... 78
 LIALDA... 173

LIBERVANT... 35	LITHOSTAT... 179	LORZONE... 196
LIBTAYO... 59	LIVALO... 102	losartan-hydrochlorothiazide... 102
LICART... 15	LIVDELZI... 135	losartan... 102
lidocaine (pf)... 20, 102	LIVMARLI... 135	LOTEMAX SM... 185
lidocaine hcl... 20	LIVTENCITY... 78	LOTEMAX... 185
lidocaine in 5 % dextrose (pf)... 102	LO LOESTRIN FE... 151	LOTENSIN HCT... 102
lidocaine viscous... 20	lo-zumandimine (28)... 151	LOTENSIN... 102
lidocaine-epinephrine bit... 20	LOCOID LIPOCREAM... 123	loteprednol etabonate... 185
lidocaine-epinephrine... 20	LOCOID... 123	LOTREL... 103
lidocaine-prilocaine... 20	LODINE... 15	LOTRONEX... 135
lidocaine... 19	LODOCO... 102	lovastatin... 103
lidocan iii... 20	LODOSYN... 69	LOVAZA... 103
lidocan iv... 20	LOESTRIN 1.5/30 (21)... 151	LOVENOX... 92
lidocan v... 20	LOESTRIN 1/20 (21)... 151	low-ogestrel (28)... 151
LIDODERM... 20	LOESTRIN FE 1.5/30 (28-DAY)... 151	loxapine succinate... 72
lignospan standard... 20	LOESTRIN FE 1/20 (28-DAY)... 151	lubiprostone... 135
LINCOCIN... 28	lofena... 15	LUCEMYRA... 21
lincomycin... 28	lofexidine... 21	luliconazole... 47
lindane... 123	lojaimiess... 151	LUMAKRAS... 59, 60
linezolid in dextrose 5%... 28	LOKELMA... 129	LUMIGAN... 185
linezolid-0.9% sodium chloride... 28	LOMOTIL... 135	LUMIZYME... 139
linezolid... 28	LONSURF... 59	LUMRYZ STARTER PACK... 197
LINZESS... 135	loperamide... 135	LUMRYZ... 197
liothyronine... 157	LOPID... 102	LUNESTA... 197
LIPITOR... 102	lopinavir-ritonavir... 78	LUNSUMIO... 60
LIPOFEN... 102	LOPRESSOR... 102	LUPKYNIS... 165
LIQREV... 192	LOPROX (AS OLAMINE)... 47	LUPRON DEPOT (3 MONTH)... 158
liraglutide... 86	LOPROX... 46	LUPRON DEPOT (4 MONTH)... 158
lisdexamphetamine... 112, 113	LOQTORZI... 59	LUPRON DEPOT (6 MONTH)... 158
lisinopril-hydrochlorothiazide... 102	lorazepam intensol... 82	LUPRON DEPOT-PED (3 MONTH)... 158
lisinopril... 102	lorazepam... 82	158
LITFULO... 165	LORBRENA... 59	LUPRON DEPOT-PED... 158
lithium carbonate... 83	LOREEV XR... 82	LUPRON DEPOT... 158
lithium citrate... 83	loryna (28)... 151	lurasidone... 72
LITHOBID... 83		lurbipr... 15

lutra (28)... 151	mannitol 25 %... 103	MEDROL (PAK)... 143
LUTRATE DEPOT (3 MONTH)... 158	maraviroc... 78	MEDROL... 143
LUXIQ... 123	MARCAINE (PF)... 20	medroxyprogesterone... 152
LUZU... 47	MARCAINE SPINAL (PF)... 20	mefenamic acid... 15
LYBALVI... 72	MARCAINE-EPINEPHRINE (PF)... 20	mefloquine... 67
lyleq... 151	MARCAINE-EPINEPHRINE... 20	megestrol... 152
lyllana... 151	MARCAINE... 20	MEKINIST... 60
LYNOZYFIC... 60	MARGENZA... 60	MEKTOVI... 60
LYNPARZA... 60	MARINOL... 44	meleya... 152
LYRICA CR... 113	marlissa (28)... 152	meloxicam submicronized... 15
LYRICA... 113	MARPLAN... 41	meloxicam... 15
LYSODREN... 60	MATULANE... 60	melphalan hcl... 60
LYTGOBI... 60	matzim la... 103	melphalan... 60
LYUMJEV KWIKPEN U-100	MAVENCLAD (10 TABLET PACK)...	memantine... 39
INSULIN... 86	113	MENACTRA (PF)... 166
LYUMJEV KWIKPEN U-200	MAVENCLAD (4 TABLET PACK)... 113	MENEST... 152
INSULIN... 86	MAVENCLAD (5 TABLET PACK)... 113	MENOPUR... 200
LYUMJEV TEMPO	MAVENCLAD (6 TABLET PACK)... 113	MENOSTAR... 152
PEN(U-100)INSULN... 86	MAVENCLAD (7 TABLET PACK)... 113	MENQUADFI (PF)... 166
LYUMJEV U-100 INSULIN... 86	MAVENCLAD (8 TABLET PACK)... 113	MENTAX... 47
LYVISPAH... 75	MAVENCLAD (9 TABLET PACK)... 113	MENVEO A-C-Y-W-135-DIP (PF)...
lyza... 151	MAVYRET... 78	166
	MAXALT-MLT... 49	meperidine (pf)... 15
M	MAXALT... 49	meperidine... 15
M-M-R II (PF)... 166	MAXIDEX... 185	MEPHYTON... 201
m-natal plus... 129	MAXITROL... 185	meprobamate... 82
MACROBID... 28	MAXZIDE-25MG... 103	MEPRON... 67
MACRODANTIN... 28	MAXZIDE... 103	MEPSEVII... 139
mafenide acetate... 123	MAYZENT STARTER(FOR 1MG	mercaptopurine... 60
magnesium sulfate in d5w... 129	MAINT)... 113	MERILOG SOLOSTAR... 86
magnesium sulfate in water... 129	MAYZENT STARTER(FOR 2MG	MERILOG... 86
magnesium sulfate... 129	MAINT)... 113	meropenem-0.9% sodium
MALARONE PEDIATRIC... 67	MAYZENT... 113	chloride... 28
MALARONE... 67	meclizine... 44	meropenem... 28
malathion... 123	meclofenamate... 15	merzee... 152
mannitol 20 %... 103		

mesalamine... 173
mesna... 60
MESNEX... 60
MESTINON TIMESPAN... 51
MESTINON... 50, 51
METADATE CD... 113
metadate er... 113
metaxalone... 196
metformin... 86, 87
methadone intensol... 15
methadone... 15
METHADOSE... 15
methamphetamine... 113
methazolamide... 185
methenamine hippurate... 28
methimazole... 159
METHITEST... 152
methocarbamol... 196
methotrexate sodium (pf)... 166
methotrexate sodium... 166
methoxsalen... 123
methscopolamine... 135
methsuximide... 35
methyldopa-hydrochlorothiazide... 103
methyldopa... 103
methyldopate... 103
methylergonovine... 179
METHYLIN... 113
methylphenidate hcl... 113, 114
methylphenidate... 113
methylprednisolone acetate... 143
methylprednisolone sodium succ... 143
methylprednisolone... 143
methyltestosterone... 152
metoclopramide hcl... 44
metolazone... 103
metoprolol succinate... 103
metoprolol ta-hydrochlorothiaz... 103
metoprolol tartrate... 103
METRO I.V.... 28
METROCREAM... 28
METROGEL... 28
METROLOTION... 28
metronidazole in nacl (iso-os)... 29
metronidazole... 28, 29
metyrosine... 103
mexiletine... 103
MIACALCIN... 174
mibelas 24 fe... 152
MICAFLUNGIN IN 0.9 % SODIUM
CHL... 47
micafungin... 47
MICARDIS HCT... 103
MICARDIS... 103
miconazole nitrate-zinc ox-pet... 47
miconazole-3... 47
microgestin 1.5/30 (21)... 152
microgestin 1/20 (21)... 152
microgestin 24 fe... 152
microgestin fe 1.5/30 (28)... 152
microgestin fe 1/20 (28)... 152
midodrine... 103
MIEBO (PF)... 185
mifepristone... 179
migergot... 49
miglitol... 87
miglustat... 139
MIGRANAL... 49
mili... 152
millipred dp... 143
millipred... 143
milrinone in 5 % dextrose... 103
milrinone... 103
mimvey... 152
MINASTRIN 24 FE... 152
MINIPRESS... 103
MINIVELLE... 152
MINOCIN... 29
minocycline... 29
minoxidil... 104
minzoya... 152
MIOSTAT... 185
MIPLYFFA... 139
MIRAPEX ER... 69
MIRCERA... 92
MIRENA... 179
mirtazapine... 41
MIRVASO... 123
misoprostol... 135
MITIGARE... 49
mitigo (pf)... 15
mitomycin... 60
mitoxantrone... 60
modafinil... 197
moexipril... 104
molindone... 72
mometasone... 123, 192
mondoxyne nl... 29
MONJUVI... 166
mono-lynyah... 152
montelukast... 192

morgidox... 29	MYLOTARG... 60	NATACHEW (FE BIS-GLYCINATE)... 129
morphine (pf)... 16	MYRBETRIQ... 141	NATACYN... 185
morphine concentrate... 16	MYSOLINE... 35	NATAZIA... 152
morphine... 16	MYTESI... 135	nateglinide... 87
MOTTEGRITY... 135	N	NATROBA... 123
MOTOFEN... 135	nabumetone... 16	NAYZILAM... 35
MOTPOLY XR... 35	nadolol... 104	neбиволол... 104
MOUNJARO... 87	nafcillin in dextrose iso-osm... 29	NEBUPENT... 67
MOVANTIK... 135	nafcillin... 29	necon 0.5/35 (28)... 152
MOVIPREP... 135	naftifine... 47	nefazodone... 41
moxifloxacin-sod.ace,sul-water... 29	NAFTIN... 47	NEFFY... 192
moxifloxacin-sod.chloride(iso)... 29	NAGLAZYME... 139	nelarabine... 60
moxifloxacin... 29, 185	nalbuphine... 16	NEMLUVIO... 166
MOZOBIL... 92	NALFON... 16	neo-polycin hc... 186
MRESVIA (PF)... 166	nalmeфene... 21	neo-polycin... 186
MS CONTIN... 16	nalocet... 16	NEO-SYNALAR... 123
MULPLETA... 92	naloxone... 21	neo-vital rx... 129
MULTAQ... 104	naltrexone... 22	neomycin-bacitracin-poly-hc... 186
mupirocin calcium... 123	NAMENDA TITRATION PAK... 39	neomycin-bacitracin-polymyxin... 186
mupirocin... 123	NAMENDA XR... 39	neomycin-polymyxin b gu... 180
MUTAMYCIN... 60	NAMENDA... 39	neomycin-polymyxin b-dexameth... 186
MVASI... 60	NAMZARIC... 39	neomycin-polymyxin-gramicidin... 186
MYALEPT... 135	NANO 2ND GEN PEN NEEDLE... 179	neomycin-polymyxin-hc... 186, 188
MYAMBUTOL... 51	NANO PEN NEEDLE... 179	neomycin... 29
MYCAMINE... 47	NAPRELAN CR... 17	NEONATAL COMPLETE... 129
MYCAPSSA... 158	NAPROSYN... 17	NEONATAL PLUS VITAMIN... 129
MYCOBUTIN... 51	naproxen sodium... 17	NEONATAL-DHA... 129
mycophenolate mofetil (hcl)... 166	naproxen-esomeprazole... 17	NEORAL... 166
mycophenolate mofetil... 166	naproxen... 17	NERLYNX... 60
mycophenolate sodium... 166	naratriptan... 49	NESACAINE-MPF... 20
MYDAYIS... 114	NARCAN... 22	NESACAINE... 20
MYFEMBREE... 158	NARDIL... 41	
MYFORTIC... 166	NAROPIN (PF)... 20	
MYHIBBIN... 166	NASCOBAL... 201	

NESINA... 87
 neuac... 123
 NEULASTA ONPRO... 92
 NEULASTA... 92
 NEUPOGEN... 92
 NEUPRO... 69
 NEURONTIN... 35
 NEVANAC... 186
 nevirapine... 78
 NEXAVAR... 60
 NEXICLON XR... 104
 NEXIUM IV... 135
 NEXIUM PACKET... 135
 NEXIUM... 135
 NEXLETOL... 104
 NEXLIZET... 104
 NEXPLANON... 152
 NEXTERONE... 104
 NEXTSTELLIS... 152
 NEXVIAZYME... 139
 NGENLA... 145
 niacin... 104
 niacor... 104
 nicardipine... 104
 NICOTROL NS... 22
 NICOTROL... 22
 nifedipine... 104
 nikki (28)... 152
 NIKTIMVO... 166
 NILANDRON... 60
 nilotinib hcl... 60
 nilotinib tartrate... 60
 nilutamide... 61
 nimodipine... 104
 NINLARO... 61
 NIPENT... 61
 nisoldipine... 104
 nitazoxanide... 67
 nitisinone... 139
 NITRO-BID... 104
 NITRO-DUR... 104
 nitrofurantoin macrocrystal... 29
 nitrofurantoin monohyd/m-cryst... 29
 nitrofurantoin... 29
 nitroglycerin in 5 % dextrose... 105
 nitroglycerin... 104, 105, 180
 NITROLINGUAL... 105
 NITROSTAT... 105
 NITYR... 139
 NIVESTYM... 92
 nizatidine... 135
 NOCDURNA (MEN)... 145
 NOCDURNA (WOMEN)... 145
 NORA-BE... 152, 153
 NORDITROPIN FLEXPEN... 145
 norelgestromin-ethin.estradiol... 153
 norepinephrine bitartrate... 105
 noreth-ethinyl estradiol-iron... 153
 norethindrone (contraceptive)... 153
 norethindrone ac-eth estradiol... 153
 norethindrone acetate... 153
 norethindrone-e.estradiol-iron... 153
 NORGESIC FORTE... 196
 norgesic... 196
 norgestimate-ethinyl estradiol... 153
 NORITATE... 29
 NORLIQVA... 105
 NORMOSOL-M IN 5 % DEXTROSE... 129
 NORPACE CR... 105
 NORPACE... 105
 NORPRAMIN... 41
 NORTHERA... 105
 nortrel 0.5/35 (28)... 153
 nortrel 1/35 (21)... 153
 nortrel 1/35 (28)... 153
 nortrel 7/7/7 (28)... 153
 nortriptyline... 41
 NORVASC... 105
 NORVIR... 78
 NOURIANZ... 69
 NOVAREL... 145
 NOVOLIN 70-30 FLEXPEN U-100... 87
 NOVOLIN 70/30 U-100 INSULIN... 87
 NOVOLIN N FLEXPEN... 87
 NOVOLIN N NPH U-100 INSULIN... 87
 NOVOLIN R FLEXPEN... 87
 NOVOLIN R REGULAR U100 INSULIN... 87
 NOVOLOG FLEXPEN U-100 INSULIN... 87
 NOVOLOG MIX 70-30 U-100 INSULN... 87
 NOVOLOG MIX 70-30FLEXPEN U-100... 87
 NOVOLOG PENFILL U-100 INSULIN... 87

NOVOLOG U-100 INSULIN ASPART... 87	OCTAGAM... 166	OMNIPOD 5 (G6/LIBRE 2 PLUS)... 180
NOVOPEN ECHO... 180	octreotide acetate... 158	OMNIPOD 5 G6-G7 INTRO KT(GEN5)... 180
NOXAFIL... 47	octreotide,microspheres... 158	OMNIPOD 5 G6-G7 PODS (GEN 5)... 180
np thyroid... 157	OCUFLOX... 186	OMNIPOD 5 INTRO(G6/LIBRE2PLUS)... 180
NUBEQA... 61	ODACTRA... 192	OMNIPOD CLASSIC PODS (GEN 3)... 180
NUCALA... 192	ODEFSEY... 78	OMNIPOD DASH INTRO KIT (GEN 4)... 180
NUCYNTA ER... 17	ODOMZO... 61	OMNIPOD DASH PODS (GEN 4)... 180
NUCYNTA... 17	OFEV... 192	OMNIPOD GO PODS 10 UNITS/DAY... 180
NUEDEXTA... 114	ofloxacin... 29, 186, 188	OMNIPOD GO PODS 15 UNITS/DAY... 180
NULIBRY... 139	OGIVRI... 61	OMNIPOD GO PODS 20 UNITS/DAY... 180
NUPLAZID... 72	OGSIVEO... 61	OMNIPOD GO PODS 25 UNITS/DAY... 180
NURTEC ODT... 49	OHTUVAYRE... 192	OMNIPOD GO PODS 30 UNITS/DAY... 180
NUTRILIPID... 129	OJEMDA... 61	OMNIPOD GO PODS 40 UNITS/DAY... 180
NUTROPIN AQ NUSPIN... 145	OJJAARA... 61	OMNITROPE... 145
NUVARING... 153	olanzapine-fluoxetine... 41	OMVOH PEN... 166
NUVIGIL... 197	olanzapine... 72, 73	OMVOH... 166
NUZYRA... 29	OLINVYK... 17	ONAPGO... 69
nyamyc... 47	olmesartan-amlo地平in-hcthiaid... 105	ONCASPAR... 61
nylia 1/35 (28)... 153	olmesartan-hydrochlorothiazide... 105	ondansetron hcl (pf)... 44
nylia 7/7/7 (28)... 153	olmesartan... 105	ondansetron hcl... 44
NYMALIZE... 105	olopatadine... 186, 192	ondansetron... 44
nymyo... 153	OLPRUVA... 139	ONEXTON... 123
nystatin-triamcinolone... 47	OLUMIANT... 166	ONFI... 35, 36
nystatin... 47	OLUX-E... 123	
nystop... 47	OLUX... 123	
NYVEPRIA... 92	OMECLAMOX-PAK... 135	
	omega-3 acid ethyl esters... 105	
O	OMEGAVEN... 129	
OB COMPLETE ONE... 129	omeprazole-sodium bicarbonate... 135	
OB COMPLETE PETITE... 129	omeprazole... 135	
OB COMPLETE PREMIER... 129	OMNARIS... 192	
OICALIVA... 135		
ocella... 153		
OCREVUS ZUNOVO... 114		
OCREVUS... 114		

ONGENTYS... 69	ORLADEYO... 167	oxybutynin chloride... 141
ONIVYDE... 61	ormarvi... 139	oxycodone-acetaminophen... 17, 18
ONPATTRO... 139	orphenadrine citrate... 196	oxycodone... 17
ONTRUZANT... 61	orphenadrine-asa-caffeine... 196	OXYCONTIN... 18
ONUREG... 61	orphengesic forte... 196	oxymorphone... 18
ONYDA XR... 114	orquidea... 153	oxytocin... 180
ONZETRA XSAIL... 50	ORSERDU... 61	OXYTROL... 141
OPDIVO QVANTIG... 61	ORTIKOS... 173	OZEMPIC... 87
OPDIVO... 61	oseltamivir... 78, 79	OZOBAX DS... 75
OPDUALAG... 61	OSENI... 87	OZOBAX... 75
OPFOLDA... 139	OSMITROL 10 %... 105	P
OPIPZA... 73	OSMITROL 15 %... 105	PACERONE... 105
opium tincture... 135	OSMITROL 20 %... 105	paclitaxel protein-bound... 61
OPSUMIT... 192	OSMITROL 5 %... 105	paclitaxel... 61
OPSYNVI... 192	OSMOLEX ER... 69	PADCEV... 61
OPVEE... 22	OSPHENA... 153	PALFORZIA (LEVEL 1)... 180
OPZELURA... 123	OTEZLA STARTER... 124	PALFORZIA (LEVEL 10)... 180
ORACEA... 29	OTEZLA... 123	PALFORZIA (LEVEL 11 UP-DOSE)... 181
oralone... 116	OTREXUP (PF)... 167	PALFORZIA (LEVEL 2)... 180
ORAPRED ODT... 143	OTULFI... 167	PALFORZIA (LEVEL 3)... 180
ORBACTIV... 29	OVIDE... 124	PALFORZIA (LEVEL 4)... 180
ORENCIA CLICKJECT... 167	OVIDREL... 200	PALFORZIA (LEVEL 5)... 180
ORENCIA... 166	oxacillin in dextrose(iso-osm)... 29	PALFORZIA (LEVEL 6)... 180
ORENITRAM MONTH 1 TITRATION KT... 193	oxacillin... 29	PALFORZIA (LEVEL 7)... 180
ORENITRAM MONTH 2 TITRATION KT... 193	oxaliplatin... 61	PALFORZIA (LEVEL 8)... 180
ORENITRAM MONTH 3 TITRATION KT... 193	oxaprozin... 17	PALFORZIA (LEVEL 9)... 180
ORENITRAM... 192, 193	OXAYDO... 17	PALFORZIA INITIAL (4-17 YRS)... 181
ORFADIN... 139	oxazepam... 82	PALFORZIA LEVEL 11 MAINTENANCE... 181
ORGOVYX... 61	oxcarbazepine... 36	paliperidone... 73
ORIAHNN... 158	OXERVATE... 186	PALYNZIQ... 139
ORILISSA... 158	oxiconazole... 47	PAMELOR... 41
ORKAMBI... 193	OXISTAT... 47	
	OXLUMO... 180	
	OXTELLAR XR... 36	

pamidronate... 174
 PANCREAZE... 139
 PANDEL... 124
 PANRETIN... 61
 pantoprazole in 0.9% sod chlor...
 136
 pantoprazole... 135, 136
 PANZYGA... 167
 paraplatin... 62
 paricalcitol... 174
 PARLODEL... 69
 PARNATE... 41
 paroxetine hcl... 41
 paroxetine mesylate(menop.sym)...
 41
 PATANASE... 193
 PAXIL CR... 42
 PAXIL... 41, 42
 PAXLOVID... 79
 pazopanib... 62
 PEDIAPRED... 143
 PEDIARIX (PF)... 167
 PEDMARK... 62
 PEDVAX HIB (PF)... 167
 peg 3350-electrolytes... 136
 peg-electrolyte soln... 136
 peg3350-sod sul-nacl-kcl-asb-c...
 136
 PEGASYS... 167
 PEMAZYRE... 62
 pemetrexed disodium... 62
 pemetrexed... 62
 PEMRYDI RTU... 62
 PEN NEEDLE, DIABETIC... 181
 PENBRAYA (PF)... 167
 penciclovir... 79
 penicillamine... 129
 penicillin g pot in dextrose... 29
 penicillin g potassium... 29
 penicillin g sodium... 30
 penicillin v potassium... 30
 PENMENVY MEN A-B-C-W-Y (PF)...
 167
 PENNSAID... 18
 PENTACEL (PF)... 167
 PENTAM... 67
 pentamidine... 67, 68
 PENTASA... 173
 pentazocine-naloxone... 18
 pentobarbital sodium... 36
 pentoxifylline... 105
 pepcid... 136
 perampanel... 36
 PERCOCET... 18
 PERFOROMIST... 193
 PERIKABIVEN... 129
 perindopril erbumine... 105
 periogard... 116
 PERJETA... 62
 permethrin... 124
 perphenazine-amitriptyline... 42
 perphenazine... 73
 PERSERIS... 73
 PERTZYE... 139
 pfizerpen-g... 30
 PHEBURANE... 139
 phenazopyridine... 181
 phenelzine... 42
 PHENERGAN... 44
 phenobarbital sodium... 36
 phenobarbital... 36
 phenoxybenzamine... 105
 phenylephrine hcl... 105
 PHENYTEK... 36
 phenytoin sodium extended... 36
 phenytoin sodium... 36
 phenytoin... 36
 PHESGO... 62
 PHEXXI... 181
 philith... 153
 PHOSPHOLINE IODIDE... 186
 PHYSIOLYTE... 181
 PHYSIOSOL IRRIGATION... 181
 phytonadione (vitamin k1)... 201
 PIASKY... 167
 PIFELTRO... 79
 pilocarpine hcl... 116, 186
 pimecrolimus... 124
 pimozide... 73
 pimtrex (28)... 153
 pindolol... 106
 pioglitazone-glimepiride... 88
 pioglitazone-metformin... 88
 pioglitazone... 87
 piperacillin-tazobactam... 30
 PIQRAY... 62
 pirfenidone... 193
 piroxicam... 18
 pitavastatin calcium... 106
 PITOCIN... 181
 PLAQUENIL... 68
 PLASMA-LYTE 148... 129
 PLASMA-LYTE A... 130
 PLAVIX... 92

PLEGRIDY... 114	potassium chloride-d5-0.2%nacl... 130	PREMPRO... 154
PLENAMINE... 130	potassium chloride-d5-0.9%nacl... 130	PRENATA... 130
PLENVU... 136	potassium chloride... 130	PRENATABS FA... 131
plerixafor... 92	potassium citrate... 130	prenatal plus (calcium carb)... 131
PLIAGLIS... 20	POTELIGEO... 62	prenatal plus dha... 131
pnv-dha... 130	pr natal 400 ec... 130	prenatal plus vitamin-mineral... 131
pnv-omega... 130	pr natal 400... 130	prenatal vitamin plus low iron... 131
podofilox... 124	pr natal 430 ec... 130	prenatal-u... 131
POKONZA... 130	pr natal 430... 130	PRENATE ELITE... 131
POLIVY... 62	PRADAXA... 92	PRETOMANID... 51
polocaine-mpf... 20	pralatrexate... 62	PREVACID SOLUTAB... 136
polocaine... 20	PRALUENT PEN... 106	PREVACID... 136
polycin... 186	pramipexole... 69	prevalite... 106
polymyxin b sulf-trimethoprim... 186	prasugrel hcl... 92	PREVDUO... 181
polymyxin b sulfate... 30	pravastatin... 106	PREVYMIS... 79
POMALYST... 62	praziquantel... 68	PREZCOBIX... 79
POMBILITI... 139	prazosin... 106	PREZISTA... 79
PONVORY 14-DAY STARTER PACK... 114	PRECOSE... 88	PRIALT... 181
PONVORY... 114	PRED FORTE... 186	PRIFTIN... 51
portia 28... 153	PRED MILD... 186	PRILOSEC... 136
PORTRAZZA... 62	prednicarbate... 124	primaquine... 68
posaconazole... 48	prednisolone acetate... 186	PRIMAXIN IV... 30
potassium acetate... 130	prednisolone sodium phosphate... 143, 144, 186	primidone... 36
potassium chlorid-d5-0.45%nacl... 130	prednisolone... 143	primlev... 18
potassium chloride in 0.9%nacl... 130	prednisone intensol... 144	PRIMSOL... 30
potassium chloride in 5 % dex... 130	prednisone... 144	PRIORIX (PF)... 167
potassium chloride in lr-d5... 130	PREFEST... 153	PRISTIQ... 42
potassium chloride in water... 130	pregabalin... 114	PRIVIGEN... 167
potassium chloride-0.45 % nacl... 130	PREGNYL... 145	PRO COMFORT ALCOHOL PADS... 181
	PREMARIN... 153	PROAIR DIGIHALER... 193
	PREMASOL 10 %... 130	PROAIR RESPICLICK... 193
	PREMPHASE... 154	probenecid-colchicine... 49
		probenecid... 49
		procainamide... 106

PROCARDIA XL... 106
 procentra... 114
 prochlorperazine edisylate... 44
 prochlorperazine maleate... 44
 prochlorperazine... 44
 PROCURIT... 93
 procto-med hc... 124
 PROCTOFOAM HC... 173
 proctosol hc... 124
 proctozone-hc... 124
 PROCYSBI... 139
 progesterone micronized... 154
 progesterone... 154
 PROGLYCEM... 88
 PROGRAF... 167
 PROLASTIN-C... 140
 prolate... 18
 PROLENSA... 186
 PROLIA... 175
 PROMACTA... 93
 promethazine vc-codeine... 199
 promethazine vc... 181
 promethazine-codeine... 199
 promethazine-dm... 199
 promethazine-phenylephrine... 181
 promethazine... 45
 promethegan... 45
 PROMETRIUM... 154
 propafenone... 106
 proparacaine... 186
 propranolol-hydrochlorothiazid... 106
 propranolol... 106
 propylthiouracil... 159
 PROQUAD (PF)... 167
 PROSCAR... 141
 PROSOL 20 %... 131
 protamine... 181
 PROTONIX... 136
 protriptyline... 42
 PROVERA... 154
 PROVIGIL... 197
 PROZAC... 42
 prucalopride... 136
 PRUDOXIN... 124
 pruradik... 124
 PULMICORT FLEXHALER... 193
 PULMICORT... 193
 PULMOZYME... 193
 PURE COMFORT ALCOHOL PADS... 181
 PURIXAN... 62
 PYLERA... 136
 pyrazinamide... 51
 PYRIDIDIUM... 181
 pyridostigmine bromide... 51
 pyridoxine (vitamin b6)... 201
 pyrimethamine... 68
 PYRUKYND... 140
 PYZCHIVA... 167

Q

QALSODY... 114
 QBRELIS... 106
 QBREXZA... 124
 QDOLO... 18
 QELBREE... 114
 QINLOCK... 62
 QNASL... 193
 QTERN... 88
 QUADRACEL (PF)... 167
 QUARTETTE... 154
 QUDEXY XR... 36
 QUESTRAN LIGHT... 106
 QUESTRAN... 106
 quetiapine... 73
 QUILLICHEW ER... 114
 QUILLIVANT XR... 114
 quinapril-hydrochlorothiazide... 106
 quinapril... 106
 quinidine gluconate... 106
 quinidine sulfate... 106
 quinine sulfate... 68
 QULIPTA... 50
 QUTENZA... 181
 QUVIVIQ... 197
 QUZYTIR... 193
 QVAR REDHALER... 193

R

RABAVERT (PF)... 167
 rabeprazole... 136
 RADICAVA ORS STARTER KIT SUSP... 115
 RADICAVA ORS... 115
 RADICAVA... 115
 RAGWITEK... 193
 RALDESY... 42
 raloxifene... 154
 ramelteon... 197
 ramipril... 106
 ranolazine... 106
 RAPAFLO... 141
 RAPAMUNE... 167
 rasagiline... 69
 RASUVO (PF)... 168
 RAVICTI... 140

RAYALDEE... 175	RESTASIS MULTIDOSE... 186	RIMSO-50... 181
RAYOS... 144	RESTASIS... 186	ringer's... 131, 181
REBIF (WITH ALBUMIN)... 115	RESTORIL... 197	RINVOQ LQ... 168
REBIF REBIDOSE... 115	RETACRIT... 93	RINVOQ... 168
REBIF TITRATION PACK... 115	RETEVMO... 62	RIOMET... 88
REBLOZYL... 93	RETIN-A MICRO PUMP... 124	risedronate... 175
REBYOTA... 136	RETIN-A MICRO... 124	RISPERDAL CONSTA... 73
RECARBRIO... 30	RETIN-A... 124	RISPERDAL... 73
RECLAST... 175	RETROVIR... 79	risperidone... 73
reclipsen (28)... 154	REVATIO... 193, 194	RITALIN LA... 115
RECOMBIVAX HB (PF)... 168	REVCOVI... 140	RITALIN... 115
RECORLEV... 158	revonto... 75	ritonavir... 79
RECTIV... 181	REVUFORJ... 62	RITUXAN HYCELA... 63
REDITREX (PF)... 168	REXULTI... 73	RITUXAN... 62
REGLAN... 45	REYATAZ... 79	rivaroxaban... 93
REGONOL... 51	REYVOW... 50	rivastigmine tartrate... 39
REGRANEX... 124	REZDIFFRA... 181	rivastigmine... 39
RELAFEN DS... 18	REZLIDHIA... 62	rivelsa... 154
RELENZA DISKHALER... 79	REZUROCK... 168	RIVFLOZA... 181
RELEUKO... 93	REZVOGLAR KWIKPEN... 88	rizatriptan... 50
RELEXII... 115	REZZAYO... 48	ROBAXIN... 196
RELISTOR... 136	RHOFADE... 124	ROBINUL FORTE... 136
RELPAK... 50	RHOPHYLAC... 168	ROBINUL... 136
RELTONE... 136	RHOPRESSA... 186	ROCALTROL... 175
REMERON SOLTAB... 42	RIABNI... 62	ROCKLATAN... 186
REMERON... 42	RIASTAP... 93	roflumilast... 194
REMICADE... 168	ribavirin... 79, 181	ROLVEDON... 93
REMODULIN... 193	RIDAURA... 168	romidepsin... 63
RENACIDIN... 181	rifabutin... 51	ROMVIMZA... 63
RENFLEXIS... 168	RIFADIN... 51	ropinirole... 69
repaglinide... 88	rifampin... 51	ropivacaine (pf)... 21
REPATHA PUSHTRONEX... 106	RILUTEK... 115	rosadan... 30
REPATHA SURECLICK... 106	riluzole... 115	rosuvastatin... 106
REPATHA SYRINGE... 106	rimantadine... 79	rosyrah... 154
RESPA-AR... 199		

ROTARIX... 168
 ROTATEQ VACCINE... 168
 ROWASA... 173
 roweepra xr... 36
 roweepra... 36
 ROXICODONE... 18
 ROXYBOND... 18
 ROZEREM... 197
 ROZLYTREK... 63
 RUBRACA... 63
 RUCONEST... 168
 rufinamide... 36
 RUKOBIA... 79
 RUXIENCE... 63
 RYALTRIS... 194
 RYBELSUS... 88
 RYBREVANT... 63
 RYCLORA... 194
 RYDAPT... 63
 RYLAZE... 63
 RYSTIGGO... 169
 RYTARY... 69
 RYTELO... 63
 RYTHMOL SR... 106
 RYVENT... 194
 RYZNEUTA... 93

S

SABRIL... 36
 SAFYRAL... 154
 SAIZEN SAIZENPREP... 145
 sajazir... 169
 SALAGEN (PILOCARPINE)... 116
 SAMSCA... 131
 SANCUSO... 45
 SANDIMMUNE... 169

SANDOSTATIN LAR DEPOT... 158
 SANDOSTATIN... 158
 SANTYL... 124
 SAPHNELO... 169
 SAPHRIS... 74
 sapropterin... 140
 SARCLISA... 63
 SAVAYSA... 93
 SAVELLA... 115
 saxagliptin-metformin... 88
 saxagliptin... 88
 SCEMBLIX... 63
 scopolamine base... 45
 se-natal 19 chewable... 131
 SEASONIQUE... 154
 SECUADO... 74
 SEGLENTIS... 18
 SEGLUROMET... 88
 SELARSDI... 169
 SELECT-OB (FOLIC ACID)... 131
 SELECT-OB + DHA... 131
 SELECT-OB... 131
 selegiline hcl... 69
 selenium sulfide... 124
 SELZENTRY... 79, 80
 SEMGLEE(INSULIN
 GLARG-YFGN)PEN... 88
 SEMGLEE(INSULIN
 GLARGINE-YFGN)... 88
 SENSIPAR... 175
 sensorcaine-epinephrine... 21
 sensorcaine-mpf spinal... 21
 SENSORCAINE-MPF... 21
 sensorcaine-mpf/epinephrine... 21
 SENSORCAINE... 21

SEREVENT DISKUS... 194
 SEROQUEL XR... 74
 SEROQUEL... 74
 SEROSTIM... 145
 sertraline... 42
 setlakin... 154
 SEYSARA... 30
 SEZABY... 37
 SFROWASA... 173
 sharobel... 154
 SHINGRIX (PF)... 169
 SIGNIFOR LAR... 158
 SIGNIFOR... 158
 SIKLOS... 181
 sildenafil (pulm.hypertension)... 194
 SILENOR... 198
 SILIQ... 169
 silodosin... 141
 SILVADENE... 124
 silver sulfadiazine... 124
 SIMBRINZA... 186
 SIMLANDI(CF) AUTOINJECTOR...
 169
 SIMLANDI(CF)... 169
 simliya (28)... 154
 simpesse... 154
 SIMPONI ARIA... 169
 SIMPONI... 169
 SIMULECT... 169
 simvastatin... 107
 SINEMET... 69
 SINGULAIR... 194
 sirolimus... 169
 SIRTURO... 51
 sitagliptin-metformin... 88

sitagliptin... 88	SOLU-MEDROL (PF)... 144	STALEVO 75... 70
SIVEXTRO... 30	SOLU-MEDROL... 144	stavudine... 80
SKYCLARYS... 115	SOMA... 197	STEGLATRO... 88
SKYRIZI... 169	SOMATULINE DEPOT... 158	STEGLUJAN... 88
SKYTROFA... 145	SOMAVERT... 158, 159	STELARA... 169, 170
SMOFLIPID... 131	SOOLANTRA... 124	STEQEYMA I.V.... 170
SOAAZ... 107	sorafenib... 63	STEQEYMA... 170
sodium benzoate-sod phenylacet... 181	SORILUX... 124	STIMUFEND... 93
sodium bicarbonate... 131	sorine... 107	STIOLTO RESPIMAT... 194
sodium chloride 0.45 %... 131	sotalol af... 107	STIVARGA... 63
sodium chloride 0.9 %... 131	sotalol... 107	STRATTERA... 115
sodium chloride 3 % hypertonic... 131	SOTYKTU... 169	STRENSIQ... 140
sodium chloride 5 % hypertonic... 131	SOTYLIZE... 107	streptomycin... 30
sodium chloride... 131, 181	SOVALDI... 80	STRIBILD... 80
SODIUM EDECRIN... 107	SOVUNA... 68	STRIVERDI RESPIMAT... 194
sodium oxybate... 198	SPEVIGO... 169	STROMECTOL... 68
sodium phenylbutyrate... 140	spinosad... 124	SUBOXONE... 22
sodium phosphate... 131	SPIRIVA RESPIMAT... 194	subvenite starter (blue) kit... 37
sodium polystyrene sulfonate... 131	SPIRIVA WITH HANDIHALER... 194	subvenite starter (green) kit... 37
sodium,potassium,mag sulfates... 136	spironolacton-hydrochlorothiaz... 107	subvenite starter (orange) kit... 37
SOGROYA... 146	spironolactone... 107	subvenite... 37
SOHONOS... 181	SPORANOX... 48	SUCRAID... 140
solifenacin... 141	sprintec (28)... 154	sucralfate... 136
SOLQUA 100/33... 88	SPRITAM... 37	SUFLAVE... 137
SOLIRIS... 169	SPRIX... 18	SULAR... 107
SOLODYN... 30	SPRYCEL... 63	sulfacetamide sodium (acne)... 30
SOLOSEC... 30	SPS (WITH SORBITOL)... 131	sulfacetamide sodium... 30, 186
SOLTAMOX... 63	sronyx... 154	sulfacetamide-prednisolone... 186
SOLU-CORTEF ACT-O-VIAL (PF)... 144	SSD... 125	sulfadiazine... 30
SOLU-CORTEF... 144	STALEVO 100... 69	sulfamethoxazole-trimethoprim... 30
	STALEVO 125... 69	SULFAMYLON... 125
	STALEVO 150... 69	sulfasalazine... 173
	STALEVO 200... 70	sulindac... 18
	STALEVO 50... 70	sumatriptan succinate... 50

sumatriptan-naproxen... 50	TABRECTA... 63	tavaborole... 48
sumatriptan... 50	TACLONEX... 125	TAVALISSE... 93
sunitinib malate... 63	tacrolimus... 125, 170	TAVNEOS... 170
SUNLENCA... 80	tadalafil (pulm. hypertension)... 194	taysofy... 154
SUNOSI... 198	tadalafil... 141	TAYTULLA... 154
SUPREP BOWEL PREP KIT... 137	TADLIQ... 194	tazarotene... 125
SURE COMFORT ALCOHOL PREP PADS... 182	TAFINLAR... 63	tazicef... 30
SURE-PREP ALCOHOL PREP PADS... 182	tafluprost (pf)... 186	TAZORAC... 125
SUTAB... 137	TAGRISSO... 64	taztia xt... 107
SUTENT... 63	TAKHZYRO... 170	TAZVERIK... 64
syeda... 154	TALICIA... 137	TDVAX... 170
SYLVANT... 170	TALTZ AUTOINJECTOR (2 PACK)... 170	TECENTRIQ HYBREZA... 64
SYMBICORT... 194	TALTZ AUTOINJECTOR (3 PACK)... 170	TECENTRIQ... 64
SYMBRAVO... 50	TALTZ AUTOINJECTOR... 170	TECFIDERA... 115
SYMBYAX... 42	TALTZ SYRINGE... 170	TECVAYLI... 64
SYMDEKO... 194	TALVEY... 64	TEFLARO... 30
SYMFI LO... 80	TALZENNA... 64	TEGLUTIK... 115
SYMFI... 80	TAMIFLU... 80	TEGRETOL XR... 37
SYMLINPEN 120... 88	tamoxifen... 64	TEGRETOL... 37
SYMLINPEN 60... 88	tamsulosin... 142	TEGSEDI... 140
SYMPAZAN... 37	tanlor... 197	TEKTRUNA HCT... 107
SYMPROIC... 137	taperdex... 144	TEKTRUNA... 107
SYMTUZA... 80	TARCEVA... 64	telmisartan-amlodipine... 107
SYNAGIS... 182	TARGADOX... 30	telmisartan-hydrochlorothiazid... 107
SYNALAR... 125	TARGRETIN... 64	telmisartan... 107
SYNAREL... 159	tarina 24 fe... 154	temazepam... 198
SYNJARDY XR... 88	tarina fe 1-20 eq (28)... 154	TEMODAR... 64
SYNJARDY... 88	tarina fe 1/20 (28)... 154	TEMOVATE... 125
SYNRIBO... 63	TARPEYO... 173	temsirolimus... 64
SYNTHROID... 157	TASCENSO ODT... 115	tencon... 182
SYPRINE... 131	TASIGNA... 64	TENIVAC (PF)... 170
	tasimelteon... 198	tenofovir disoproxil fumarate... 80
	TASMAR... 70	TENORETIC 100... 107
		TENORETIC 50... 107

T

TENORMIN... 107
TEPADINA... 64
TEPEZZA... 182
TEPMETKO... 64
TEPYLUTE... 64
terazosin... 107
terbinafine hcl... 48
terbutaline... 194
terconazole... 48
teriflunomide... 115
TESTIM... 154
testosterone cypionate... 155
testosterone enanthate... 155
testosterone... 154, 155
tetrabenazine... 115
tetracycline... 30
TEVIMBRA... 64
TEXACORT... 125
TEZRULY... 107
TEZSPIRE... 170
THALITONE... 107
THALOMID... 64
THAM... 131
THEO-24... 194
theophylline... 194
thiamine hcl (vitamin b1)... 201
THIOLA EC... 142
THIOLA... 142
thioridazine... 74
thiotepa... 64
thiothixene... 74
THYMOGLOBULIN... 170
THYQUIDITY... 157
tiadylt er... 107
tiagabine... 37
TIAZAC... 107, 108
TIBSOVO... 64
ticagrelor... 93
TICOVAC... 170
TIGAN... 45
tigecycline... 30
TIGLUTIK... 115
TIKOSYN... 108
tilia fe... 155
timolol maleate (pf)... 187
timolol maleate... 108, 187
timolol... 187
TIMOPTIC OCUDOSE (PF)... 187
tinidazole... 30
tiopronin... 142
tirofiban-0.9% sodium chloride... 93
TIROSINT-SOL... 157
TIROSINT... 157
TIVDAK... 64
TIVICAY PD... 80
TIVICAY... 80
tizanidine... 75
TLANDO... 155
TOBI PODHALER... 194
TOBI... 31
TOBRADEX ST... 187
TOBRADEX... 187
tobramycin in 0.225 % nacl... 31
tobramycin sulfate... 31
tobramycin-dexamethasone... 187
tobramycin... 31, 187
TOBEX... 187
tolcapone... 70
tolectin 600... 18
tolmetin... 18
TOLSURA... 48
tolterodine... 142
tolvaptan (polycys kidney dis)... 132
tolvaptan... 131
TOPAMAX... 37
TOPICORT... 125
topiramate... 37
topotecan... 64
TOPROL XL... 108
toremifene... 64
TORISEL... 64
torpenz... 64
torseamide... 108
TOSYMRA... 50
TOUJEO MAX U-300 SOLOSTAR... 88
TOUJEO SOLOSTAR U-300
INSULIN... 89
tovet emollient... 125
TOVIAZ... 142
TPN ELECTROLYTES... 132
TRACLEER... 194
TRADJENTA... 89
tramadol-acetaminophen... 19
tramadol... 18, 19
trandolapril-verapamil... 108
trandolapril... 108
tranexamic acid... 93
TRANSDERM-SCOP... 45
tranylcypromine... 42
TRAVASOL 10 %... 132
TRAVATAN Z... 187
travoprost... 187
TRAZIMERA... 65
trazodone... 42

TREANDA... 65	triazolam... 198	TRUE COMFORT PRO ALCOHOL
TRECTOR... 51	TRIBENZOR... 108	PADS... 182
TRELEGY ELLIPTA... 195	TRICARE... 132	TRULANCE... 137
TRELSTAR... 159	TRICOR... 108	TRULICITY... 89
TREMFYA PEN INDUCTION	triderm... 144	TRUMENBA... 171
PK-CROHN... 170	trientine... 132	TRUQAP... 65
TREMFYA PEN... 170	trifluoperazine... 74	TRUVADA... 80
TREMFYA... 170	trifluridine... 187	TRUXIMA... 65
treprostinil sodium... 195	trihexyphenidyl... 70	TRYNGOLZA... 108
TRESIBA FLEXTOUCH U-100... 89	TRIJARDY XR... 89	TRYPTYR... 187
TRESIBA FLEXTOUCH U-200... 89	TRIKAFTA... 195	TRYVIO... 108
TRESIBA U-100 INSULIN... 89	TRILEPTAL... 37	TUDORZA PRESSAIR... 195
tretinoin (antineoplastic)... 65	TRILIPIX... 108	TUKYSA... 65
tretinoin microspheres... 125	trimethobenzamide... 45	tulana... 155
tretinoin... 125	trimethoprim... 31	TURALIO... 65
TREXALL... 171	trimipramine... 42	turqoz (28)... 155
TREXIMET... 50	trinatal rx 1... 132	TUXARIN ER... 199
TREZIX... 19	TRINTELLIX... 42	TUZISTRA XR... 199
tri-estarylla... 155	TRIPTODUR... 159	TWINRIX (PF)... 171
tri-legest fe... 155	TRISENOX... 65	TWYNEO... 125
tri-linyah... 155	TRISTART DHA... 132	TYBOST... 80
tri-lo-estarylla... 155	TRIUMEQ PD... 80	tydemy... 155
tri-lo-marzia... 155	TRIUMEQ... 80	TYENNE AUTOINJECTOR... 171
tri-lo-mili... 155	trivora (28)... 155	TYENNE... 171
tri-lo-sprintec... 155	TRIZIVIR... 80	TYGACIL... 31
tri-mili... 155	TRODELVY... 65	TYKERB... 65
tri-nymyo... 155	TROGARZO... 80	TYMLOS... 175
tri-sprintec (28)... 155	TROKENDI XR... 37, 38	TYPHIM VI... 171
tri-vylibra lo... 155	tromethamine... 132	TYRVAYA... 187
tri-vylibra... 155	TROPHAMINE 10 %... 132	TYSABRI... 115
triamcinolone acetonide... 116, 144	trosipium... 142	TYVASO DPI... 195
triamterene-hydrochlorothiazid...	TRUDHESA... 50	TYVASO INSTITUTIONAL START
108	TRUE COMFORT ALCOHOL PADS...	KIT... 195
triamterene... 108	182	TYVASO REFILL KIT... 195
trianex... 144		TYVASO STARTER KIT... 195

TYVASO... 195

U

UBRELVY... 50

UCERIS... 173

UDENYCA AUTOINJECTOR... 93

UDENYCA ONBODY... 94

UDENYCA... 93

ULORIC... 49

ULTILET ALCOHOL SWAB... 182

ULTOMIRIS... 171

ULTRA-FINE INS SYR (HALF UNIT)...
182

ULTRA-FINE INSULIN SYRINGE...
182

ULTRA-FINE PEN NEEDLE... 182

ULTRAVATE... 125

umeclidinium-vilanterol... 195

UNASYN... 31

UNDECATREX... 155

UNITHROID... 157

UNITUXIN... 65

UPLIZNA... 171

UPTRAVI... 195

UROCIT-K 10... 132

UROCIT-K 15... 132

UROCIT-K 5... 132

UROXATRAL... 142

URSO 250... 137

URSO FORTE... 137

ursodiol... 137

USTEKINUMAB-AEKN... 171

USTEKINUMAB-TTWE... 171

USTEKINUMAB... 171

UZEDY... 74

V

V-GO 20... 182

V-GO 30... 182

V-GO 40... 182

VABOMERE... 31

VAGIFEM... 155

valacyclovir... 80

VALCHLOR... 65

VALCYTE... 80

valganciclovir... 80

VALIUM... 82

valproate sodium... 38

valproic acid (as sodium salt)... 38

valproic acid... 38

valrubicin... 65

valsartan-hydrochlorothiazide...
108

valsartan... 108

VALSTAR... 65

VALTOCO... 38

VALTREX... 80

valtya... 155

VANCOCCIN... 31

vancomycin in 0.9 % sodium chl...
31

vancomycin in dextrose 5 %... 31

vancomycin-diluent combo no.1...
31

vancomycin... 31

VANDAZOLE... 31

VANFLYTA... 65

VANOS... 125

VANRAFIA... 182

VAPRISOL IN 5 % DEXTROSE... 132

VAQTA (PF)... 171

varenicline tartrate... 22

VARIVAX (PF)... 171

VARIZIG... 171

VARUBI... 45

VASCEPA... 108

VASERETIC... 108

VASOTEC... 108

VAXCHORA VACCINE... 171

vecamyl... 108

VECTIBIX... 65

VECTICAL... 125

VEGZELMA... 65

VELCADE... 65

VELETRI... 195

velivet triphasic regimen (28)... 155

VELSIPITY... 171

VELTASSA... 132

VELTIN... 125

VEMLIDY... 81

VENCLEXTA STARTING PACK... 65

VENCLEXTA... 65

VENLAFAXINE BESYLATE... 42

venlafaxine... 42

VENTAVIS... 195

VENTOLIN HFA... 195

venxxiva... 142

VEOPOZ... 171

VEOZAH... 115

verapamil... 108, 109

VERDESO... 125

VEREGEN... 126

VERELAN PM... 109

VERIPRED 20... 144

VERKAZIA... 187

VERQUOVO... 109

VERSACLOZ... 74	virt-pn dha... 132	VOYDEYA... 171
VERZENIO... 65	VISTARIL... 195	VPRIV... 140
VESICARE LS... 142	VITAFOL FE PLUS... 132	VRAYLAR... 74
VESICARE... 142	VITAFOL GUMMIES... 132	VTAMA... 126
vestura (28)... 155	VITAFOL ULTRA... 132	VUITY... 187
VEVYE... 187	VITAFOL-OB+DHA... 132	VUMERITY... 115
VFEND IV... 48	VITAFOL-OB... 132	VUSION... 48
VFEND... 48	VITAFOL-ONE... 132	VYALEV... 70
VIBATIV... 31	VITAMEDMD ONE RX... 132	VYEPTI... 50
VIBERZI... 137	vitamin d2... 201	vyfemla (28)... 156
VIBRAMYCIN... 31	vitamin k... 201	VYJUVEK... 182
VICTOZA 2-PAK... 89	vitamin k1... 201	VYKAT XR... 182
VICTOZA 3-PAK... 89	VITRAKVI... 65, 66	vylibra... 156
VIDAZA... 65	vivacaine... 21	VYLOY... 66
vienva... 155	VIVELLE-DOT... 156	VYNDAMAX... 140
vigabatrin... 38	VIVITROL... 22	VYNDAQEL... 140
vigadrone... 38	VIVJOA... 48	VYTORIN 10-10... 109
VIGAFYDE... 38	VIVLODEX... 19	VYTORIN 10-20... 109
VIGAMOX... 187	VIVOTIF... 171	VYTORIN 10-40... 109
vigpoder... 38	VIZIMPRO... 66	VYTORIN 10-80... 109
VIIBRYD... 43	VOCABRIA... 81	VYVANSE... 115
VIJOICE... 140	VOGELXO... 156	VYVGART HYTRULO... 51
vilazodone... 43	volnea (28)... 156	VYVGART... 51
VIMKUNYA... 171	VONJO... 66	VYXEOS... 66
VIMOVO... 19	VOQUEZNA DUAL PAK... 137	VYZULTA... 187
VIMPAT... 38	VOQUEZNA TRIPLE PAK... 137	W
vinblastine... 65	VOQUEZNA... 137	WAINUA... 140
vincasar pfs... 65	VORANIGO... 66	WAKIX... 198
vincristine... 65	voriconazole-hpbcd... 48	warfarin... 94
vinorelbine... 65	voriconazole... 48	water for irrigation, sterile... 182
VIOKACE... 140	VOSEVI... 81	WEBCOL... 182
viorele (28)... 155	VOTRIENT... 66	WEGOVY... 182
VIRACEPT... 81	VOWST... 137	WELCHOL... 109
VIRAZOLE... 182	VOXZOGO... 140	WELIREG... 140
VIREAD... 81		WELLBUTRIN SR... 43

WELLBUTRIN XL... 43	XEMBIFY... 172	YF-VAX (PF)... 172
wera (28)... 156	XENAZINE... 116	YONDELIS... 66
wescap-pn dha... 132	XENPOZYME... 140	YONSA... 66
wesnata dha complete... 132	XERAVA... 31	YORVIPATH... 175
wesnate dha... 132	XERESE... 81	YUFLYMA(CF) AI CROHN'S-UC-HS... 172
westab plus... 132	XERMELO... 137	YUFLYMA(CF) AUTOINJECTOR... 172
westgel dha... 132	XGEVA... 175	YUFLYMA(CF)... 172
WEZLANA I.V.... 172	XHANCE... 195	YUPELRI... 196
WEZLANA... 171, 172	XIFAXAN... 137	YUSIMRY(CF) PEN... 172
WINLEVI... 126	XIFYRM... 19	YUTREPIA... 196
WINREVAIR... 195	XIGDUO XR... 89	yuvaferm... 156
wixela inhub... 195	XIIDRA... 187	Z
wymzya fe... 156	XIMINO... 31	zafemy... 156
X	XOFLUZA... 81	zafirlukast... 196
XACDURO... 31	XOLAIR... 172	zaleplon... 198
XACIATO... 31	XOLEGEL... 48	ZALTRAP... 66
XADAGO... 70	XOLREMDI... 94	ZANAFLEX... 75
XALATAN... 187	XOPENEX HFA... 195	ZANOSAR... 66
XALKORI... 66	XOSPATA... 66	zarah... 156
XANAX XR... 83	XPOVIO... 66	ZARONTIN... 38
XANAX... 83	XROMI... 182	ZARXIO... 94
xarah fe... 156	XTAMPZA ER... 19	zatean-pn dha... 133
XARELTO DVT-PE TREAT 30D START... 94	XTANDI... 66	zatean-pn plus... 133
XARELTO... 94	xulane... 156	ZAVESCA... 140
XATMEP... 172	XULTOPHY 100/3.6... 89	ZAVZPRET... 50
XCOPRI MAINTENANCE PACK... 38	XYOSTED... 156	ZCORT... 144
XCOPRI TITRATION PACK... 38	XYREM... 198	ZEBUTAL... 182
XCOPRI... 38	XYWAV... 198	ZEGALOGUE AUTOINJECTOR... 89
XDEMVI... 182	Y	ZEGALOGUE SYRINGE... 89
XELJANZ XR... 172	yargesa... 140	ZEGERID... 137
XELJANZ... 172	YASMIN (28)... 156	ZEJULA... 66
XELPROS... 187	YAZ (28)... 156	ZELAPAR... 70
xelria fe... 156	YCANTH... 182	ZELBORAF... 66
XELSTRYM... 116	YERVOY... 66	ZELSUVMI... 126
	YESINTEK... 172	

ZEMAIRA... 140	ZINPLAVA... 137	ZOVIRAX... 81
ZEMBRACE SYMTOUCH... 50	ZIOPTAN (PF)... 187	ZTALMY... 38
ZEMDRI... 32	ziprasidone hcl... 74	ZTLIDO... 21
ZEMPLAR... 175	ziprasidone mesylate... 74	ZUBSOLV... 22
zenatane... 126	ZIPSOR... 19	ZULRESSO... 43
ZENPEP... 140	ZIRABEV... 67	zumandimine (28)... 156
zenzedi... 116	ZIRGAN... 81	ZUNVEYL... 39
ZEPATIER... 81	ZITHROMAX TRI-PAK... 32	ZURZUVAE... 43
ZEPBOUND... 182, 183	ZITHROMAX Z-PAK... 32	ZYCLARA... 126
ZEPOSIA STARTER KIT (28-DAY)... 116	ZITHROMAX... 32	ZYDELIG... 67
ZEPOSIA STARTER PACK (7-DAY)... 116	ZITUVIMET XR... 89	ZYFLO... 196
ZEPOSIA... 116	ZITUVIMET... 89	ZYKADIA... 67
ZEPZELCA... 66	ZITUVIO... 89	ZYLET... 187
ZERBAXA... 32	ZOCOR... 109	ZYLOPRIM... 49
ZERVIA... 187	ZOLADEX... 159	ZYMFENTRA... 172
ZESTORETIC... 109	zoledronic ac-mannitol-0.9nacl... 175	ZYNLONTA... 67
ZESTRIL... 109	zoledronic acid-mannitol-water... 175	ZYNRELEF... 183
ZETIA... 109	zoledronic acid... 175	ZYNYZ... 67
ZETONNA... 196	ZOLINZA... 67	ZYPITAMAG... 109
ZEVALIN (Y-90)... 183	zolmitriptan... 50	ZYPREXA RELPREVV... 74
ZEVTERA... 32	ZOLOFT... 43	ZYPREXA ZYDIS... 75
ZIAC... 109	zolpidem... 198	ZYPREXA... 74
ZIAGEN... 81	ZOMACTON... 146	ZYTIGA... 67
ZIANA... 126	zomig... 50	ZYVOX... 32
zidovudine... 81	ZONALON... 126	
ZIEXTENZO... 94	ZONEGRAN... 38	
ZIIHERA... 66	ZONISADE... 38	
ZILBRYSQ... 172	zonisamide... 38	
zileuton... 196	ZORTRESS... 172	
ZILRETTA... 144	ZORVOLEX... 19	
ZILXI... 126	ZORYVE... 126	
ZIMHI... 22	ZOSYN IN DEXTROSE (ISO-OSM)... 32	
zingiber... 183	zovia 1-35 (28)... 156	

Multi-Language Insert

Multi-language Interpreter Services

English: We have free interpreter services to answer any questions you may have about our health or drug plan. To get an interpreter, just call us at 1-877-320-1235 (TTY: 711). Someone who speaks English can help you. This is a free service.

Spanish: Tenemos servicios de intérprete sin costo alguno para responder cualquier pregunta que pueda tener sobre nuestro plan de salud o medicamentos. Para hablar con un intérprete, por favor llame al 1-877-320-1235 (TTY: 711). Alguien que hable español le podrá ayudar. Este es un servicio gratuito.

Chinese Mandarin: 我们提供免费的翻译服务，帮助您解答关于健康或药物保险的任何疑问。如果您需要此翻译服务，请致电 1-877-320-1235 (听障专线：711)。我们的中文工作人员很乐意帮助您。这是一项免费服务。

Chinese Cantonese: 您對我們的健康或藥物保險可能存有疑問，為此我們提供免費的翻譯服務。如需翻譯服務，請致電 1-877-320-1235 (聽障專線：711)。我們講中文的人員將樂意為您提供幫助。這是一項免費服務。

Tagalog: Mayroon kaming libreng serbisyo sa pagsasaling-wika upang masagot ang anumang mga katanungan ninyo hinggil sa aming planong pangkalusugan o panggagamot. Upang makakuha ng tagasaling-wika, tawagan lamang kami sa 1-877-320-1235 (TTY: 711). Maaari kayong tulungan ng isang nakakapagsalita ng Tagalog. Ito ay libreng serbisyo.

French: Nous proposons des services gratuits d'interprétation pour répondre à toutes vos questions relatives à notre régime de santé ou d'assurance-médicaments. Pour accéder au service d'interprétation, il vous suffit de nous appeler au 1-877-320-1235 (TTY: 711). Un interlocuteur parlant Français pourra vous aider. Ce service est gratuit.

Vietnamese: Chúng tôi có dịch vụ thông dịch miễn phí để trả lời các câu hỏi về chương sức khỏe và chương trình thuốc men. Nếu quý vị cần thông dịch viên xin gọi 1-877-320-1235 (TTY: 711) sẽ có nhân viên nói tiếng Việt giúp đỡ quý vị. Đây là dịch vụ miễn phí.

German: Unser kostenloser Dolmetscherservice beantwortet Ihren Fragen zu unserem Gesundheits- und Arzneimittelplan. Unsere Dolmetscher erreichen Sie unter 1-877-320-1235 (TTY: 711). Man wird Ihnen dort auf Deutsch weiterhelfen. Dieser Service ist kostenlos.

Korean: 당사는 의료 보험 또는 약품 보험에 관한 질문에 대해 드리고자 무료 통역 서비스를 제공하고 있습니다. 통역 서비스를 이용하려면 전화 1-877-320-1235 (TTY: 711) 번으로 문의해 주십시오. 한국어를 하는 담당자가 도와 드릴 것입니다. 이 서비스는 무료로 운영됩니다.

Russian: Если у вас возникнут вопросы относительно страхового или медикаментного плана, вы можете воспользоваться нашими бесплатными услугами переводчиков. Чтобы воспользоваться услугами переводчика, позвоните нам по телефону 1-877-320-1235 (TTY: 711). Вам окажет помощь сотрудник, который говорит по-русски. Данная услуга бесплатная.

Arabic: إننا نقدم خدمات المترجم الفوري المجانية للإجابة عن أي أسئلة تتعلق بخططنا الصحية أو خطة الأدوية الموصوفة لدينا. للحصول على مترجم فوري، ليس عليك سوى الاتصال بنا على (TTY: 711) 1-877-320-1235. سيقوم شخص ما يتحدث العربية بمساعدتك. هذه خدمة مجانية.

Hindi: हमारे स्वास्थ्य या दवा की योजना के बारे में आपके किसी भी प्रश्न के जवाब देने के लिए हमारे पास मुफ्त दुभाषिया सेवाएँ उपलब्ध हैं. एक दुभाषिया प्राप्त करने के लिए, बस हमें 1-877-320-1235 (TTY: 711) पर फोन करें. कोई व्यक्ति जो हिन्दी बोलता है आपकी मदद कर सकता है. यह एक मुफ्त सेवा है.

Italian: È disponibile un servizio di interpretariato gratuito per rispondere a eventuali domande sul nostro piano sanitario e farmaceutico. Per un interprete, contattare il numero 1-877-320-1235 (TTY: 711). Un nostro incaricato che parla Italiano fornirà l'assistenza necessaria. È un servizio gratuito.

Portuguese: Dispomos de serviços de interpretação gratuitos para responder a qualquer questão que tenha acerca do nosso plano de saúde ou de medicação. Para obter um intérprete, contacte-nos através do número 1-877-320-1235 (TTY: 711). Irá encontrar alguém que fale o idioma Português para o ajudar. Este serviço é gratuito.

French Creole: Nou genyen sèvis entèprèt gratis pou reponn tout kesyon ou ta genyen konsènan plan medikal oswa dwòg nou an. Pou jwenn yon entèprèt, jis rele nou nan 1-877-320-1235 (TTY: 711). Yon moun ki pale Kreyòl kapab ede w. Sa a se yon sèvis ki gratis.

Polish: Umożliwiamy bezpłatne skorzystanie z usług tłumacza ustnego, który pomoże w uzyskaniu odpowiedzi na temat planu zdrowotnego lub dawkowania leków. Aby skorzystać z pomocy tłumacza znającego język polski, należy zadzwonić pod numer 1-877-320-1235 (TTY: 711). Ta usługa jest bezpłatna.

Japanese: 当社の健康保険と処方薬プランに関するご質問にお答えするために、無料の通訳サービスをご用意しています。通訳をご用命になるには、1-877-320-1235 (TTY:711) にお電話ください。日本語を話す者が支援いたします。これは無料のサービスです。



This formulary was updated on 08/01/2025. For more recent information or other questions, please contact the NC State Health Plan Humana Customer Care Team with any questions at 1-888-700-2263 or, for TTY users, 711, or visit your.humana.com/ncshp.

GRP042PDG2580025C_v1

